

# BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2025 interim update)

## Writing group members

|                            |   |
|----------------------------|---|
| Laura Waters*              | Central and North West London NHS Foundation Trust                        |
| Alan Winston (Vice-chair)* | Imperial College London and Imperial College Healthcare NHS Trust, London |
| Iain Reeves*               | Homerton Hospital NHS Trust, London                                       |
| Marta Boffito*             | Chelsea and Westminster Hospital NHS Foundation Trust, London             |
| Duncan Churchill*          | University Hospitals Sussex NHS Foundation Trust                          |
| Ben Cromarty*              | UK Community Advisory Board and Yorkshire Mesmac                          |
| David Dunn                 | University College London   |
| Douglas Fink               | University College London   |
| Sarah Fidler*              | Imperial College London and Imperial College Healthcare NHS Trust, London |
| Caroline Foster*           | Imperial College Healthcare NHS Trust, London                             |
| Julie Fox*                 | Guys and St Thomas' NHS Foundation Trust and Kings College London         |
| Anna Maria Geretti*        | Royal Free London NHS Foundation Trust                                    |
| Ravi Gupta*                | University of Cambridge   |
| Andy Hilton                | UK Community Advisory Board and HiVitality                                |
| Saye Khoo*                 | University of Liverpool   |
| Clifford Leen              | NHS Lothian   |
| Nicola Mackie*             | Imperial College Healthcare NHS Trust, London                             |
| Nadia Naous                | Chelsea and Westminster Hospital NHS Foundation Trust, London             |
| Daisy Ogbonmwan            | University Hospital North Durham, Durham                                  |
| Chloe Orkin*               | Queen Mary University of London   |
| Linda Panton               | Western General Hospital, Edinburgh                                       |
| Frank Post*                | King's College Hospital NHS Foundation Trust, London                      |
| Anton Pozniak*             | Chelsea and Westminster Hospital NHS Foundation Trust, London             |
| Caroline Sabin*            | University College London   |
| John Walsh (Chair)         | Imperial College Healthcare NHS Trust, London                             |

\*Were involved in the 2025 interim update.

# Contents

|  |           |
|--|-----------|
| <b>1 Introduction</b> .....  | <b>6</b>  |
| 1.1 <i>Scope and purpose</i> .....   | 6         |
| 1.2 <i>Methodology</i> .....   | 6         |
| 1.2.1 <i>Guideline development process</i> .....   | 6         |
| 1.2.2 <i>Involvement of people living with HIV</i> .....   | 7         |
| 1.2.3 <i>GRADE</i> .....   | 7         |
| 1.2.4 <i>Good practice points</i> .....  | 8         |
| 1.2.5 <i>Dissemination and implementation</i> .....  | 9         |
| 1.2.6 <i>Guideline updates and date of next review</i> .....   | 9         |
| 1.3 <i>Treatment aims</i> .....  | 9         |
| 1.4 <i>Resource use</i> .....  | 10        |
| 1.5 <i>Implications for research</i> .....   | 11        |
| 1.6 <i>References</i> .....  | 12        |
| <b>2 Summary of recommendations</b> .....  | <b>14</b> |
| <b>3 Active involvement of people living with HIV in decision-making</b> .....   | <b>14</b> |
| <b>4 When to start</b> .....   | <b>14</b> |
| 4.1 <i>Established infection</i> .....   | 14        |
| 4.2 <i>Same-day ART initiation</i> .....   | 14        |
| 4.3 <i>Individuals presenting with AIDS or a major infection</i> .....   | 15        |
| 4.4 <i>Treatment of primary HIV infection</i> .....  | 15        |
| 4.5 <i>Impact of treatment on prevention of onward transmission</i> .....  | 15        |
| 4.6 <i>Persons choosing not to commence ART</i> .....  | 15        |
| 4.7 <i>Considerations when managing people with spontaneous HIV viral control</i> .....  | 15        |
| 4.8 <i>Stopping therapy</i> .....  | 16        |
| <b>5 What to start</b> .....   | <b>16</b> |
| 5.5 <i>What to start in the context of TDR</i> .....   | 18        |
| 5.6 <i>What to start in the context of rapid ART initiation</i> .....  | 18        |
| 5.7 <i>What to start in the context of very high viral load</i> .....  | 18        |
| 5.9 <i>Switching ART in virological suppression</i> .....  | 18        |
| 5.10 <i>Suppressed switch or maintenance</i> .....   | 19        |
| 5.11 <i>Two-drug injectable regimens: switching in virological suppression</i> .....   | 22        |
| 5.12 <i>PI monotherapy</i> .....   | 24        |
| <b>6 Supporting individuals on therapy</b> .....   | <b>24</b> |
| 6.1 <i>Adherence</i> .....   | 24        |
| 6.2 <i>Pharmacology</i> .....  | 24        |
| <b>7 Managing virological failure</b> .....  | <b>26</b> |
| 7.2 <i>Blips</i> .....   | 26        |
| 7.3 <i>Low-level viraemia on ART</i> .....   | 26        |
| 7.4 <i>Virological failure on ART</i> .....  | 26        |
| 7.5 <i>Individuals with no or limited drug resistance</i> .....  | 26        |
| 7.6 <i>Individuals with multi-class virological failure with or without extensive drug resistance</i> .....                      | 27        |
| 7.7 <i>Individuals with limited or no therapeutic options when a fully viral suppressive regimen cannot be constructed</i> ..... | 27        |
| <b>8 Specific populations</b> .....  | <b>28</b> |
| 8.1 <i>Adolescents</i> .....   | 28        |
| 8.2 <i>Bone disease</i> .....  | 29        |

|  |           |
|--|-----------|
| 8.3 Cardiovascular and metabolic disease .....                                   | 29        |
| 8.4 Chronic kidney disease .....   | 29        |
| 8.5 Chronic liver disease .....  | 30        |
| 8.6 Cognitive impairment associated with HIV .....                               | 30        |
| 8.7 Later life and ageing with HIV .....   | 31        |
| 8.8 Mental health .....  | 31        |
| 8.9 Transgender people .....   | 31        |
| 8.10 Women .....   | 32        |
| <b>3 Active involvement of people living with HIV in decision-making .....</b>   | <b>33</b> |
| 3.1 References .....   | 34        |
| <b>4 When to start .....</b>   | <b>36</b> |
| 4.1 Established infection .....  | 36        |
| 4.2 Same-day ART initiation .....  | 37        |
| 4.3 Individuals presenting with AIDS or a major infection .....                  | 39        |
| 4.4 Treatment of primary HIV infection .....                                     | 40        |
| 4.5 Impact of treatment on prevention of onward transmission .....               | 43        |
| 4.6 Persons choosing not to commence ART .....                                   | 45        |
| 4.7 Considerations when managing people with spontaneous HIV viral control ..... | 46        |
| 4.7.1 Definition of viral controllers (also known as elite controllers) .....    | 47        |
| 4.7.2 Risks versus benefits of ART in viral controllers .....                    | 48        |
| 4.7.3 Summary .....  | 49        |
| 4.8 Stopping therapy .....   | 49        |
| 4.9 References .....   | 50        |
| <b>5 What to start .....</b>   | <b>57</b> |
| 5.1 Introduction .....   | 57        |
| 5.2 Regimens recommended for most people .....                                   | 60        |
| 5.2.1 Dolutegravir versus efavirenz .....  | 60        |
| 5.2.2 Dolutegravir versus bictegravir .....                                      | 61        |
| 5.2.3 Dolutegravir/lamivudine .....  | 62        |
| 5.3 Regimens recommended in certain clinical situations .....                    | 63        |
| 5.3.1 Doravirine .....   | 63        |
| 5.3.2 Raltegravir .....  | 64        |
| 5.3.3 Darunavir/ritonavir .....  | 65        |
| 5.3.4 Atazanavir/ritonavir .....   | 66        |
| 5.3.5 Tenofovir DF/emtricitabine compared with tenofovir AF/emtricitabine .....  | 66        |
| 5.3.6 Use of abacavir in people with CVD risk factors .....                      | 67        |
| 5.3.7 Lamivudine versus emtricitabine in combination with tenofovir DX .....     | 68        |
| 5.4 Regimens not recommended first line compared to 2015 guidelines .....        | 69        |
| 5.4.1 Abacavir/lamivudine other than in combination with dolutegravir .....      | 69        |
| 5.4.2. Atazanavir/ritonavir .....  | 69        |
| 5.4.3 Efavirenz .....  | 69        |
| 5.4.4 Rilpivirine .....  | 69        |
| 5.4.5 Elvitegravir/cobicistat .....  | 69        |
| 5.5 What to start in the context of TDR .....                                    | 70        |
| 5.6 What to start in the context of rapid ART initiation .....                   | 72        |
| 5.7 What to start in the context of very high viral load .....                   | 73        |
| 5.8 What to start in people diagnosed with HIV on PrEP .....                     | 74        |
| 5.9 Switching ART in virological suppression .....                               | 74        |
| 5.10 Suppressed switch or maintenance .....                                      | 76        |

|  |     |
|--|-----|
| 5.10.1 NRTI switch .....   | 79  |
| 5.10.2 PI switch.....  | 80  |
| 5.10.3 NNRTI switch .....  | 82  |
| 5.10.4 Integrase switch.....   | 83  |
| 5.10.5 Two-drug oral regimens: switching in virological suppression .....  | 83  |
| 5.11 <i>Two-drug injectable regimens</i> .....   | 87  |
| 5.11.1 Hepatitis B reactivation .....  | 91  |
| 5.11.2 Oral lead-in and oral bridging.....   | 92  |
| 5.11.3 Offering long-acting cabotegravir/rilpivirine.....  | 92  |
| 5.11.4 Service capacity .....  | 93  |
| 5.11.5 Long-acting cabotegravir/rilpivirine in pregnancy .....   | 94  |
| 5.11.6 Prescribing long-acting cabotegravir/rilpivirine in people who are not virally suppressed.....                              | 94  |
| 5.12 <i>PI monotherapy</i> .....   | 96  |
| 5.13 <i>References</i> .....   | 97  |
| 6 Supporting individuals on therapy.....   | 111 |
| 6.1 <i>Adherence</i> .....   | 111 |
| 6.1.1 Barriers to adherence .....  | 112 |
| 6.1.2 Interventions to increase adherence to treatment.....  | 114 |
| 6.1.3 Should the choice of first-line ART combination be affected by risk of non-adherence?.....                                   | 117 |
| 6.2 <i>Pharmacology</i> .....  | 120 |
| 6.2.1 Drug interactions .....  | 120 |
| 6.2.2 Stopping therapy: pharmacological considerations .....   | 123 |
| 6.2.3 Switching therapy: pharmacological considerations.....   | 124 |
| 6.2.4 TDM .....  | 127 |
| 6.3 <i>References</i> .....  | 128 |
| 7 Managing virological failure.....  | 136 |
| 7.1 <i>Introduction</i> .....  | 136 |
| 7.2 <i>Blips</i> .....   | 137 |
| 7.3 <i>Low-level viraemia on ART</i> .....   | 139 |
| 7.4 <i>Virological failure on ART</i> .....  | 140 |
| 7.5 <i>Individuals with no or limited drug resistance</i> .....  | 142 |
| 7.5.1 PI-based and INSTI-based regimens in people with NRTI resistance .....   | 142 |
| 7.5.2 First-line treatment failure with no resistance.....   | 146 |
| 7.5.3 First-line treatment failure with NNRTI resistance.....  | 147 |
| 7.5.4 First-line treatment failure on a ritonavir-boosted PI-based two-NRTI regimen with or without PI resistance.....             | 148 |
| 7.5.5 First-line treatment failure with first- and second-generation INSTI-based resistance.....                                   | 148 |
| 7.6 <i>Individuals with multi-class virological failure with or without extensive drug resistance</i> .....                        | 149 |
| 7.7 <i>Individuals with limited or no therapeutic options when a fully viral suppressive regimen cannot be constructed</i> .....   | 152 |
| 7.8 <i>References</i> .....  | 155 |
| 8 Specific populations .....   | 163 |
| 8.1 <i>Adolescents</i> .....   | 163 |
| 8.1.1 Management of HIV, ART and sexual and reproductive health specifically for young adults and adolescents living with HIV..... | 164 |
| 8.1.2 Youth-focused HIV and sexual and reproductive health services .....  | 164 |
| 8.1.3 UK Epidemiology for young adults and adolescents living with HIV .....   | 164 |
| 8.1.4 Transition of clinical care from paediatric to adult services: a process for young adults and adolescents with PaHIV .....   | 165 |

|  |            |
|--|------------|
| 8.1.5 Cognitive and mental health impact of HIV in young adults and adolescents with PaHIV .....   | 166        |
| 8.1.6 ART.....   | 166        |
| <b>8.2 Bone disease .....</b>  | <b>168</b> |
| 8.2.1 What to start .....  | 168        |
| 8.2.2 Switching treatment.....   | 169        |
| <b>8.3 Cardiovascular and metabolic disease .....</b>  | <b>170</b> |
| 8.3.1 Cardiovascular considerations.....   | 170        |
| 8.3.2 Lipid considerations.....  | 172        |
| 8.3.3 Weight gain considerations.....  | 173        |
| <b>8.4 Chronic kidney disease.....</b>   | <b>174</b> |
| 8.4.1 What to start .....  | 174        |
| 8.4.2 Need to switch.....  | 175        |
| 8.4.3 Dose adjustment of ART in the setting of renal impairment .....                              | 177        |
| 8.4.4 Assessment of renal function in the presence of agents that reduce creatinine clearance..... | 177        |
| <b>8.5 Chronic liver disease .....</b>   | <b>178</b> |
| <b>8.6 Cognitive impairment associated with HIV .....</b>  | <b>179</b> |
| 8.6.1 Introduction.....  | 179        |
| 8.6.2 When to start ART .....  | 179        |
| 8.6.3 What to start .....  | 180        |
| 8.6.4 Simplification strategies .....  | 182        |
| 8.6.5 Continuing or worsening cognitive impairment despite ART.....                                | 183        |
| <b>8.7 Later life and ageing with HIV .....</b>  | <b>184</b> |
| 8.7.1 Introduction.....  | 184        |
| 8.7.2 When to start ART .....  | 184        |
| 8.7.3 What to start .....  | 185        |
| <b>8.8 Mental health .....</b>   | <b>186</b> |
| <b>8.9 Transgender people.....</b>   | <b>188</b> |
| 8.9.1 Accessing care .....   | 189        |
| 8.9.2 Peer support .....   | 190        |
| 8.9.3 ART outcomes.....  | 190        |
| 8.9.4 Drug–drug interactions.....  | 190        |
| 8.9.5 CVD risk.....  | 190        |
| 8.9.6 Bone health .....  | 191        |
| 8.9.7 Renal function.....  | 191        |
| <b>8.10 Women .....</b>  | <b>192</b> |
| 8.10.1 Introduction.....   | 192        |
| 8.10.2 What to start .....   | 192        |
| 8.10.3 Women living with HIV experiencing virological failure.....                                 | 195        |
| 8.10.4 Psychosocial issues .....   | 195        |
| <b>8.11 References .....</b>   | <b>196</b> |
| <b>9 Acknowledgements.....</b>   | <b>216</b> |
| <b>10 List of abbreviations.....</b>   | <b>217</b> |
| <b>11 List of appendices .....</b>   | <b>220</b> |

# 1 Introduction

## 1.1 Scope and purpose

The overall purpose of these guidelines is to provide guidance on best clinical practice for antiretroviral therapy (ART) and management of adults living with human immunodeficiency virus (HIV). The scope includes: (i) guidance on the initiation of ART in those previously naïve to therapy; (ii) support of people living with HIV on treatment; (iii) management of individuals experiencing virological failure; (iv) switch for tolerability and/or toxicity issues; and (v) recommendations for specific populations where other factors need to be taken into consideration. The guidelines are written for clinical professionals directly involved with and responsible for the care of adults living with HIV, community advocates responsible for promoting the best interests and care of adults living with HIV, and people living with HIV for whom a non-technical summary will also be available, if preferred. They should be read in conjunction with other published British HIV Association (BHIVA) guidelines. Of note, the term ‘HIV’ refers to HIV-1 throughout these guidelines.

## 1.2 Methodology

### 1.2.1 Guideline development process

BHIVA fully revised and updated the Association’s guideline development manual in 2021 [1]. Full details of the guideline development process, including conflict of interest policy, are outlined in the manual. BHIVA has adopted the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for the assessment, evaluation and grading of evidence and development of recommendations (see below and Appendix 1) [2,3].

The scope, purpose and guideline topics were agreed by the writing group. Questions concerning each guideline topic were drafted and a systematic literature search was undertaken. Details of the search questions and strategy (including the definitions of populations, interventions, comparisons and outcomes) are outlined in Appendix 2. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy were last published in 2015 [4] with a subsequent interim update in 2016 to include tenofovir alafenamide (AF), and interim statements in 2019 and 2022, to cover two-drug regimens and long-acting cabotegravir/rilpivirine respectively. For the 2022 guidelines Medline, Embase and the Cochrane library were searched between January 2014 (August 2014 for Virological failure/Transmitted drug resistance) and March 2021. Abstracts from selected conferences were searched between January 2017 and March 2021. For the narrative, authors could add publications of major importance at their discretion. For further details see Appendix 2.

For each topic and healthcare question, evidence was identified and evaluated by writing group members with expertise in the field. Using the modified GRADE system, writing group members were responsible for assessing and grading the quality of evidence for predefined outcomes across studies and developing and grading the strength of recommendations. An important aspect of evaluating evidence is an understanding of the design and analysis of clinical trials, including the use of surrogate marker data. Decisions regarding the clinical importance of difference in outcomes were made by the writing group.

For a number of questions, GRADE evidence profile and summary of findings tables were constructed, using predefined and rated treatment outcomes (Appendix 3), to help achieve consensus for key recommendations and aid transparency of the process. Before final approval by the writing group, the guidelines were published online for public consultation and external peer reviews were commissioned.

### **1.2.2 Involvement of people living with HIV**

BHIVA views the involvement of people living with HIV and community representatives in the guideline development process as essential. The writing group included two representatives appointed through the UK Community Advisory Board (UK-CAB) who were involved in all aspects of the guideline development process. Community groups were invited to participate in the draft guideline consultation process and have reviewed and commented on the guidelines. A community question and answer session was held on 11 August 2022 with members of UK-CAB.

### **1.2.3 GRADE**

The GRADE Working Group [5] has developed an approach to grading evidence that moves away from initial reliance on study design to consider the overall quality of evidence across outcomes. BHIVA has adopted the modified GRADE system for its guideline development.

The advantages of the modified GRADE system are (i) the grading system provides an informative, transparent summary for clinicians, people living with HIV and policy makers by combining an explicit evaluation of the strength of the recommendation with a judgement of the quality of the evidence for each recommendation, and (ii) the two-level grading system of recommendations has the merit of simplicity and provides clear direction to clinicians, people living with HIV and policy makers.

The strength of recommendation is graded as 1 or 2 as follows:

- A Grade 1 recommendation is a strong recommendation to do (or not do) something, where the benefits clearly outweigh the risks (or vice versa) for most if not all people living with HIV. Most clinicians and individuals living with HIV should and would want to follow a strong recommendation

unless there is a clear rationale for an alternative approach. A strong recommendation usually starts with the standard wording 'we recommend'.

- A Grade 2 recommendation is a weaker or conditional recommendation, where the risks and benefits are more closely balanced or are more uncertain. Most clinicians and people living with HIV would want to follow a weak or conditional recommendation but many would not. Alternative approaches or strategies may be reasonable depending on the individual circumstances, preferences and values of the person living with HIV. A weak or conditional recommendation usually starts with the standard wording 'we suggest'.

The strength of a recommendation is determined not only by the quality of evidence for defined outcomes but also by the balance between desirable and undesirable effects of a treatment or intervention, differences in values and preferences and, where appropriate, resource use. Each recommendation concerns a defined target population and is actionable.

The quality of evidence is graded from A to D and for the purpose of these guidelines is defined as the following:

- Grade A evidence is high-quality evidence from consistent results from well-performed randomised controlled trials, or overwhelming evidence of some other sort (such as well-executed observational studies with consistent strong effects and a low likelihood of uncorrected bias). Grade A implies confidence that the true effect lies close to the estimate of the effect.
- Grade B evidence is moderate-quality evidence from randomised trials that suffer from serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some combination of these limitations, or from other study designs with special strengths such as observational studies with consistent effects and exclusion of most potential sources of bias.
- Grade C evidence is low-quality evidence from controlled trials with several very serious limitations or observational studies with limited evidence on effects and exclusion of most potential sources of bias.
- Grade D evidence is based only on case studies, expert judgement or observational studies with inconsistent effects and a potential for substantial bias, such that there is likely to be little confidence in the effect estimate.

#### **1.2.4 Good practice points**

In addition to graded recommendations, the BHIVA writing group has also included good practice points (GPPs), which are recommendations based on the clinical judgement and experience of the writing group.

GPPs emphasise an area of important clinical practice for which there is no significant research evidence, nor is there likely to be any. They address an aspect of treatment and care that is regarded as such sound clinical practice that healthcare professionals are unlikely to question it and where the alternative is deemed unacceptable. It must be noted that GPPs are not an alternative to evidence-based recommendations.

### 1.2.5 Dissemination and implementation

The following measures have been or will be undertaken to disseminate and aid implementation of the guidelines:

- E-publication on the BHIVA website and in the journal *HIV Medicine*;
- Shortened version detailing concise summary of recommendations;
- Shortened version for BHIVA guidelines app;
- Non-technical summary;
- E-learning module for continuing professional development;
- Educational slide set to support local and regional educational meetings;
- National BHIVA audit programme.

### 1.2.6 Guideline updates and date of next review

The guidelines will be fully updated and revised in 2027. However, the writing group will continue to meet regularly to consider new information from high-quality studies and publish amendments and addendums to the current recommendations before the full revision date where this is thought to be clinically important to ensure continued best clinical practice.

## 1.3 Treatment aims

The primary aim of ART is to achieve viral suppression (to less than 50 copies/mL), thus reducing HIV-associated mortality and morbidity, with a low level of drug toxicity. Treatment should improve the physical and psychological well-being of people living with HIV. The effectiveness and tolerability of ART has improved significantly over time. The overwhelming majority of people attending HIV services in the UK and receiving ART experience long-term virological suppression and good treatment outcomes [6], which compare very favourably with other high-income countries. Of note, in 2020 around 99% of those diagnosed with HIV in the UK had initiated ART, with 97% of those on ART having a suppressed viral load [6].

A UK analysis of individuals commencing ART between 2000 and 2010 demonstrated that life expectancy in men and women with an undetectable viral load and CD4 count greater than 350 cells/mm<sup>3</sup> is the same as, or slightly better than, that of the general population (of note, a small group of people who acquired HIV

vertically or through injection drug use were excluded from these analyses) [7]. Decreasing late diagnosis (and consequently starting ART earlier), maintaining individuals in care, reducing long-term drug toxicity and optimal management of comorbidities are crucial to ensure optimal outcomes for all people living with HIV.

A further benefit of ART is the reduction in HIV transmission. There is no risk of sexual transmission in the context of suppressive ART [8-10]. The use of ART to prevent vertical transmission is universally accepted and best practice is addressed in the BHIVA guidelines for the management of HIV in pregnancy and postpartum [11].

## 1.4 Resource use

ART is extremely cost-effective and is one of the most cost-effective medical interventions for long-term conditions [12-15].

There has been a steady decline in annual diagnoses of HIV since 2005 and the number of people living with HIV in the UK by the end of 2020 was estimated to be 106,890 (95% credible interval 105,460–109,510), of whom 5% were undiagnosed [6]. Data on total ART spend are scant. It was estimated that the annual population treatment and care costs rose from £104 million in 1997 to £483 million in 2006, with a projected annual cost of £721 million in 2013 [16]. However, data for England showed an antiretroviral (ARV) spend of £413.7 million in 2016/2017, a more than 3.5% saving compared to the previous year, despite higher numbers on treatment [17]. This was driven by routine switching of branded to generic drugs, targeted value schemes and a relative reduction in the price of some branded products following the availability of generic drugs. Since then, costs in England have continued to decline further, to a predicted £270 million for 2022/2023 [18], and it is likely that relative cost reductions have been similar in other UK nations. Balancing cost efficiency against the preferences of people living with HIV will continue to be a challenge and a continued collaborative approach between commissioners, healthcare professionals and people living with HIV is required.

In the UK, higher annual treatment and care costs have been associated with late diagnosis and initiation of ART at lower CD4 cell counts [19,20]. In addition to earlier diagnosis and initiation of ART, reducing inpatient episodes, decreasing drug toxicity, preventing HIV-associated comorbidities, streamlined monitoring and innovations in models of care are likely to have a beneficial effect on costs. However, the cost of ARV drugs remains the major factor contributing to treatment and care costs [21]. With the increasing availability of generic drugs, commissioners and the NHS must continuously review the value and relative benefit of different drugs.

The writing group recognises that price of drugs is an important ethical consideration in ART choice within a resource-constrained health economy which is free at the point of access. In addition to drug acquisition costs there are costs associated with, for example, multidisciplinary team meetings, switching ART, comorbidities and management of drug–drug interactions. There are limited cost-effectiveness data in the UK comparing different ART options, and each nation undertakes separate drug procurement processes (securing different prices); for this reason, we did not include cost-effectiveness as an outcome in ART comparisons. In the setting of similar virological efficacy, determining the acceptable threshold at which differences in the risk of toxicity, tolerability and convenience outweigh differences in resource use and cost will be important. These thresholds may differ among both clinicians and people living with HIV.

In developing the recommendations in these guidelines, we have considered differences in critical treatment outcomes between different drug regimens in determining recommended treatment regimens. Regimens no longer recommended for first-line therapy still have a role in terms of switching in virologically suppressed people and/or maintenance treatment in people already established on ART. We recognise that commissioning arrangements and local drug costs will influence ART choice where outcomes, across a range of clinical measures, are similar between individual drugs in the treatment of defined populations. We support prescribing algorithms based on cost where preferred options are recommended by BHIVA. However, we believe that optimal treatment outcomes and quality of care should be the primary drivers of prescribing decisions, with cost a secondary consideration where more than one treatment option is considered clinically appropriate.

## 1.5 Implications for research

In reviewing quality of evidence, guidelines will identify areas of treatment and care where there is an absence of evidence or limited confidence in the size of effect to influence choice of treatments or determine treatment and management strategies. For this reason, it is not the intention of these guidelines to stifle clinical research but rather to help promote continued research with the aim to further improve clinical care and treatment outcomes. BHIVA is highly committed to the development and provision of HIV clinical trials to further improve ART options, and access to and participation in a clinical trial should be offered to people living with HIV where appropriate, considering the need to offer trials to women and racial minority groups. BHIVA strongly supports broader representation of under-studied populations in clinical trials with better inclusion of women, pregnant or breastfeeding people, people of non-white ethnicity, transgender people and children.

## 1.6 References

1. British HIV Association. *British HIV Association (BHIVA) Guideline Development Manual*. 2021. Available at: <https://www.bhiva.org/file/jgCacHqmuxZFL/GuidelineDevelopmentManual.pdf> (accessed July 2022).
2. Guyatt GH, Oxman AD, Kunz R *et al*. Going from evidence to recommendations. *BMJ* 2008; **336**: 1049–1051.
3. GRADE Working Group. *Publications about the GRADE approach*. Available at: <https://www.gradepro.org/resources> (accessed April 2022).
4. Churchill D, Waters L, Ahmed N *et al*. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. *HIV Med* 2016; **17 Suppl 4**: s2–s104.
5. GRADE Working Group. *GRADE*. Available at: <https://www.gradeworkinggroup.org/> (accessed April 2022).
6. UK Health Security Agency. *HIV testing, PrEP, new HIV diagnoses, and care outcomes for people accessing HIV services: 2022 report*. Available at: <https://www.gov.uk/government/statistics/hiv-annual-data-tables/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2022-report> (accessed October 2022).
7. May MT, Gompels M, Delpech V *et al*.; UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. *AIDS* 2014; **28**: 1193–1202.
8. Rodger AJ, Cambiano V, Bruun T *et al*.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. *JAMA* 2016; **316**: 171–181.
9. Rodger AJ, Cambiano V, Bruun T *et al*.; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet* 2019; **393**: 2428–2438.
10. Bavinton BR, Pinto AN, Phanuphak N *et al*.; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. *Lancet HIV* 2018; **5**: e438–e447.
11. Gilleece Y, Tariq S, Bamford A *et al*. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. *HIV Med* 2019; **20 Suppl 3**: s2–s85.
12. Sendi PP, Bucher HC, Harr T *et al*. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. *AIDS* 1999; **13**: 1115–1122.
13. Miners AH, Sabin CA, Trueman P *et al*. Assessing the cost-effectiveness of HAART for adults with HIV in England. *HIV Med* 2001; **2**: 52–58.
14. Freedberg KA, Losina E, Weinstein MC *et al*. The cost effectiveness of combination antiretroviral therapy for HIV disease. *N Engl J Med* 2001; **344**: 824–831.

15. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. *J Antimicrob Chemother* 2004; **53**: 558–561.
16. Mandalia S, Mandalia R, Lo G *et al*. Rising population cost for treating people living with HIV in the UK, 1997–2013. *PLoS One* 2010; **5**: e15677.
17. Waters L, Aubrey P, Harper J *et al*. Was the pain worth the gain? Antiretroviral savings from the ‘Improving value’ project and generics use in England. *Clin Med (Lond)* 2019; **19 Suppl 2**: 76. doi:10.7861/clinmedicine.19-2-s76.
18. NHS England. *National procurement for HIV and preventative treatments*. Available at: <https://www.find-tender.service.gov.uk/Notice/006329-2022> (accessed April 2022).
19. Beck EJ, Mandalia S, Sangha R *et al*. The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. *PLoS One* 2011; **6**: e27830.
20. Beck EJ, Mandalia S, Lo G *et al*. Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996–2006. *PLoS One* 2011; **6**: e20200.
21. Beck EJ, Mandalia S, Yfantopoulos P *et al*. The efficiency of the EmERGE pathway of care for people living with HIV in England. *AIDS Care* 2022: 1-10. doi: 10.1080/09540121.2022.2040723.

## 2 Summary of recommendations

### 3 Active involvement of people living with HIV in decision-making

- We recommend that people living with HIV are given the opportunity to contribute actively to decisions about their treatment (GPP).
- Provision of treatment-support resources should include in-house, independent and community information providers and peer-support resources (GPP).
- We recommend following the European AIDS Clinical Society (EACS) guidance on 'assessing readiness to start and maintain ART' [1] (GPP).
- We recommend that HIV services have clear pathways for referral to peer support (GPP).
- We recommend that people living with HIV share their status with general practitioners (GPs) and other healthcare professionals; where an individual declines to do so the benefits and potential harm should be reviewed regularly (GPP).

### 4 When to start

#### 4.1 Established infection

- We recommend that all people living with HIV should be on ART (Grade 1A).
- We recommend that all people living with HIV are offered the opportunity to start ART within 2–4 weeks of diagnosis (GPP).
- We recommend that readiness to start is assessed and decisions about starting ART tailored accordingly (GPP).

#### 4.2 Same-day ART initiation

- We recommend that the advantages and disadvantages of starting ART the same day as diagnosis are discussed with each person, including the lack of proven benefit or harm of same-day ART in a UK or similar setting (GPP).
- We recommend same-day ART in the following situations (GPP):
  - Primary HIV (see below);
  - Where an individual wishes to and is ready to start same-day ART and has no clinical contraindications.

### **4.3 Individuals presenting with AIDS or a major infection**

- We recommend that most individuals presenting with an AIDS-defining infection, or with a serious bacterial infection and a CD4 count  $<200$  cells/mm<sup>3</sup>, start ART within 2 weeks of initiation of specific antimicrobial chemotherapy (Grade 1B).

### **4.4 Treatment of primary HIV infection**

- We recommend that all individuals with suspected or diagnosed primary HIV infection (PHI) are reviewed promptly by an HIV specialist and offered immediate ART (Grade 1B).

### **4.5 Impact of treatment on prevention of onward transmission**

- An assessment of the risk of transmission to others should be made at diagnosis and subsequent visits with signposting to relevant interventions (GPP).
- We recommend that the evidence that treatment with suppressive ART reduces the risk of sexual transmission to zero is discussed where relevant (GPP).
- We recommend that the major impact of suppressive ART on the risk of vertical transmission and transmission through breastfeeding is discussed with all people living with HIV where relevant (GPP).
- We recommend condoms, both male and female, to reduce the risk of other sexually transmitted infections and unplanned pregnancy, where appropriate (GPP).

### **4.6 Persons choosing not to commence ART**

- We recommend that all people living with HIV choosing not to commence ART should be counselled about the risk to their own health and the risk of onward sexual transmission of HIV (Grade 1A).
- We recommend that in all people living with HIV choosing not to commence ART, capacity to make this decision is assessed and psychological support offered (GPP).
- We recommend that where people with HIV have chosen to not commence ART, their sexual partners (with the consent of the person with HIV) should be signposted to prevention interventions including PrEP (GPP).

### **4.7 Considerations when managing people with spontaneous HIV viral control**

- Given that there is evidence of ongoing HIV replication even at a low level in some viral controllers, ART is strongly recommended for viral controllers with evidence of HIV disease progression, defined by declining CD4 counts, inverted CD4:CD8 ratio ( $<1$ ) or the development of HIV-related complications (Grade 2A).

- In specific situations there may be a case to continue regular HIV viral load and CD4 count monitoring while remaining off ART; we recommend this only where the following have been excluded (GPP):
- Chronic co-infection with hepatitis B or C, or human T-cell lymphotropic virus (HTLV);
- Significant past or present comorbidities such as cancer, autoimmune disease and cardiovascular disease (CVD; myocardial infarction and cerebrovascular accident);
- Indication for current or planned immune suppressive or chemotherapy treatment;
- Pregnancy or planned pregnancy and breastfeeding; this is due to the relative immune suppression of pregnancy plus uncertainty of viral rebound and potential risk of transmission. Stopping ART post-delivery must be discussed with a specialist team.

Recommendations for monitoring of viral controllers off ART (GPP):

- Six- to 12-monthly measurement of HIV viral load;
- At least 6-monthly measurement of CD4 count and CD4:CD8 ratio;
- At least 6-monthly clinical assessment for CVD, malignancy, any comorbidity, pregnancy and hepatitis co-infection.

#### 4.8 Stopping therapy

- We recommend against treatment interruption or intermittent therapy in individuals stable on a virally suppressive ART regimen except in the context of clinical trials (Grade 1A).

## 5 What to start

Recommendations for choice of first-line ART are summarised in Table 5.1. Where clinically appropriate, lamivudine and emtricitabine can be considered interchangeable (see Section 5.3.6 Use of abacavir in people with CVD risk factors).

**Table 5.1** Recommendations for choice of first-line ART (in alphabetical order by core agent)

| Recommended as initial treatment for most people living with HIV  |   |
|---|---|
| <i>Abacavir should only be used for people who are HLA B*5701 negative and where a three-drug regimen is necessary, but tenofovir DX and tenofovir AF are not suitable and abacavir is the most clinically appropriate option</i> |   |
| Regimen   | Specific details  |
| Bictegravir/emtricitabine/tenofovir AF  |   |
| Dolutegravir plus emtricitabine/tenofovir AF or emtricitabine/tenofovir DX  | Bone/renal caveats for tenofovir DX   |
| Dolutegravir/lamivudine   | No baseline lamivudine resistance<br>Baseline viral load <500,000 copies/mL |

|   |   |
|---|---|
|   | No requirement for tenofovir for hepatitis B treatment or prevention  |
| <b>Recommended as initial treatment in certain clinical situations (Grade 2A)</b>           |   |
| <b>Regimen</b>  | <b>Specific details</b>   |
| Darunavir plus cobicistat or ritonavir plus emtricitabine plus tenofovir AF or tenofovir DX | Bone/renal caveats for tenofovir DX   |
| Doravirine plus emtricitabine or lamivudine plus tenofovir AF or tenofovir DX               | Bone/renal caveats for tenofovir DX   |
| Efavirenz plus emtricitabine or lamivudine plus abacavir or tenofovir AF or tenofovir DX    | May be a first-line choice in pregnancy and for people on TB treatment but not recommended outside these scenarios<br><br>No requirement for tenofovir for hepatitis B treatment or prevention (abacavir/lamivudine only) |
| Raltegravir plus emtricitabine plus tenofovir AF or tenofovir DX                            | Baseline viral load less than 100,000 copies/mL<br>Bone/renal caveats for tenofovir DX  |
| <b>Dolutegravir plus abacavir plus lamivudine</b>   | Where a three-drug regimen is necessary and abacavir is the most clinically appropriate option (see below)<br><br>No requirement for tenofovir for hepatitis B treatment or prevention (abacavir/lamivudine only)         |

Tenofovir DX, tenofovir disoproxil.

Where a woman living with HIV is pregnant, or planning to conceive, the BHIVA pregnancy guidelines should be followed [3].

It may be necessary to use abacavir when a second NRTI is needed (e.g. because of NRTI resistance or HIV-related CNS disease) but tenofovir DX and tenofovir AF are contraindicated (e.g. in the presence of severe acute kidney injury) or where abacavir is considered the most clinically appropriate option (e.g. in pregnancy). While tenofovir AF demonstrates less renal toxicity than tenofovir DF, tenofovir AF has been associated with kidney injury in rare cases [4]. Drugs from other classes can be considered where tenofovir cannot be used to construct an appropriate regimen with the caveat that there may be a paucity of supportive evidence.

## 5.5 What to start in the context of TDR

- Standard genotypic resistance testing (of reverse transcriptase and protease) is recommended in ART-naïve individuals (GPP).
- Baseline integrase resistance testing should be considered in addition (GPP) if:
  - Any major mutations to other drug classes are detected *or*
  - If diagnosis is made in pregnancy *or*
  - If there are other reasons to suspect transmitted integrase resistance (e.g. likely acquisition from a source with suspected or known integrase resistance).
- We recommend that ART-naïve people living with HIV and evidence of TDR should start ART containing tenofovir DX or tenofovir AF with lamivudine or emtricitabine plus one of the following: dolutegravir, bictegravir or boosted darunavir (GPP).

## 5.6 What to start in the context of rapid ART initiation

- We recommend that where ART is commenced prior to baseline resistance testing, a regimen containing tenofovir DX or tenofovir AF with lamivudine or emtricitabine plus one of the following should be used: dolutegravir, bictegravir or boosted darunavir (GPP).

## 5.7 What to start in the context of very high viral load

- We suggest that three-drug ART combinations characterised by a high barrier to resistance are initiated or re-initiated in people with very high viral loads (>500,000 copies/mL) (Grade 2B).
- We suggest tenofovir DX or tenofovir AF plus lamivudine or emtricitabine plus dolutegravir or bictegravir or boosted darunavir are used (GPP).

## 5.9 Switching ART in virological suppression

- We recommend that most people should be on a regimen that is preferred for first-line therapy or considered acceptable for switch/maintenance (GPP).
- We recommend that, in individuals on suppressive ART regimens, consideration is given to differences in side effect profile, drug–drug interactions, dosing requirements and known/suspected drug resistance before switching any ART component (GPP).
- We recommend particular caution when switching from a high-genetic barrier to a low-genetic barrier regimen in the presence of known or suspected resistance (Grade 1B).

- When switching from an NNRTI there may be pharmacological considerations (see Section 6.2 Pharmacology) (GPP).
- In individuals with previous NRTI resistance mutations, we recommend against switching from a boosted PI to an NNRTI or first-generation INSTI as the core agent (Grade 1B).
- In individuals with any NNRTI resistance, we recommend not switching to NNRTI-based ART\* (GPP).
- We recommend review of ART at least annually (GPP).
- Where an individual is on a non-recommended regimen, we recommend regular review and clear documentation of rationale (GPP).
- We recommend people are advised that they may be able to switch back to their original regimen, if preferred and clinically appropriate, depending on the reasons for switching (GPP).
- Abacavir should only be considered for people who are HLA B\*5701 negative (Grade 1A); where a three-drug regimen is necessary, tenofovir DX and tenofovir AF are not suitable and abacavir is the most clinically appropriate option (GPP).
- We recommend that all individuals on abacavir be considered for switching to a non-abacavir-based regimen where clinically appropriate, regardless of CVD risk (GPP).
- We recommend proactively switching all individuals on abacavir/lamivudine/dolutegravir to dolutegravir/lamivudine if eligible (see Section 5.10.5.1 Dolutegravir with lamivudine) (GPP).
- Due to associations with long-term toxicity and potential harm of drug–drug interactions, switching from a PI to an INSTI or NNRTI is advised where clinically appropriate (GPP).

\*For situations where an NNRTI might be considered, see Section 7.5.3 First-line treatment failure with NNRTI resistance.

### 5.10 Suppressed switch or maintenance

- We recommend that all adults on abacavir-containing ART are offered a switch to a non-abacavir-based regimen where clinically appropriate, regardless of CVD risk (GPP).

All regimens recommended for first-line ART are also recommended for suppressed switch or maintenance. In addition, the following regimens are also acceptable (see Table 5.2).

**Table 5.2** Recommendations for choice of ART for suppressed switch or maintenance

**Acceptable for switch or to continue where clinically appropriate**  
*Where feasible, lamivudine and emtricitabine are considered interchangeable*

|   |  |
|---|--|
| <i>Abacavir should only be used for people who are HLA B*5701 negative and where a three-drug regimen is necessary, but tenofovir DX and tenofovir AF are not suitable and abacavir is the most clinically appropriate option</i> |  |
| <b>NNRTI-based three-drug regimens</b>  |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus doravirine   |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus rilpivirine  |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus efavirenz  | Maintenance only; not recommended routinely for switch due to risk of neuropsychiatric toxicity, unless considered most clinically appropriate option  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus nevirapine   | Maintenance only; not recommended routinely for switch due to small risk of severe toxicity  |
| <b>INSTI-based three-drug regimens</b>  |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with dolutegravir   |  |
| Tenofovir AF/emtricitabine/bictegravir  |  |
| Tenofovir DX/emtricitabine/elvitegravir/cobicistat or tenofovir AF/emtricitabine/elvitegravir/cobicistat  | Improvements in renal/bone biomarkers for tenofovir AF compared to tenofovir DF are most evident in the context of boosted ART   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with raltegravir  |  |
| <b>PI-based regimens</b>  |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with atazanavir/ritonavir or atazanavir/cobicistat  | Where resistance necessitates a PI; improvements in renal/bone biomarkers for tenofovir AF over tenofovir DF are most evident in the context of boosted ART. Atazanavir and tenofovir DX are both associated with renal toxicity |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with darunavir/ritonavir or darunavir/cobicistat  |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with lopinavir/ritonavir  |  |
| <b>Two-drug regimens</b>  |  |

|  |  |
|--|--|
| Dolutegravir/lamivudine  |  |
| Dolutegravir/rilpivirine   | Studied only in suppressed switch; high risk of NNRTI resistance at virological failure  |
| Cabotegravir plus rilpivirine injectable   | Studied only in suppressed switch; high risk of NNRTI and INSTI resistance at virological failure  |
| Raltegravir with darunavir/ritonavir or darunavir/cobicistat   | Underperformed at viral load >100,000 copies/mL and CD4 count <200 cells/mm <sup>3</sup> when used first line  |
| Dolutegravir with darunavir/ritonavir or darunavir/cobicistat  | Studied only in suppressed switch  |
| Lamivudine or emtricitabine with darunavir/ritonavir or darunavir/cobicistat or atazanavir/ritonavir or atazanavir/cobicistat or lopinavir/ritonavir   | In the absence of known or suspected M184V/I. Several studies demonstrate non-inferiority of lamivudine with a boosted PI. ATLAS-M demonstrated switch to lamivudine plus atazanavir/ritonavir was superior to continuing tenofovir DX/emtricitabine plus atazanavir/ritonavir in people with viral suppression and no NRTI resistance |
| <b>ARVs that may play a role in specific circumstances</b>   |  |
| <p>Though not recommended routinely, there are some agents that may be used based on a need to deliver ART parenterally or an inability to otherwise create a suppressive regimen:</p> <ul style="list-style-type: none"> <li>• Zidovudine</li> <li>• Etravirine</li> <li>• Maraviroc</li> <li>• Enfuvirtide</li> <li>• Fostemsavir</li> <li>• <b>Lenacapavir</b></li> </ul> |  |

It may be necessary to continue or switch to abacavir when a second NRTI is needed (e.g. because of NRTI resistance or HIV-related CNS disease) but tenofovir DX and tenofovir AF are contraindicated (e.g. in the presence of severe acute kidney injury) or where abacavir is considered the most clinically appropriate option (e.g. in pregnancy). While tenofovir AF demonstrates less renal toxicity than tenofovir DF, tenofovir AF has been associated with kidney injury in rare cases [4]. Drugs from other classes can be considered

where tenofovir cannot be used to construct an appropriate regimen with the caveat that there may be a paucity of supportive evidence.

Where individuals have been stable on abacavir-containing therapy and, after discussion about the potential CVD risks, choose not to switch, this should be respected and the decision reviewed regularly thereafter.

- We recommend that ART can be switched to dolutegravir with lamivudine in people with virological suppression (Grade 1A) but this regimen is not suitable for those:
  - Who need a tenofovir-containing regimen for the treatment or prevention of hepatitis B (Grade 1A).
  - With known or suspected resistance to lamivudine or INSTIs (Grade 1A); where lamivudine resistance is historical, dolutegravir/lamivudine may be used exceptionally in virally suppressed people on a case-by-case basis (Grade 2B).
- We recommend proactively switching all individuals on abacavir/lamivudine/dolutegravir to dolutegravir/lamivudine if eligible (GPP).
- We suggest that ART can be switched to dolutegravir with rilpivirine in people with virological suppression (Grade 2A) but this regimen is **not** suitable for those:
  - With a history of previous virological failure or resistance emergence to any NNRTI or INSTI (Grade 1A);
  - Who need a tenofovir-containing regimen for hepatitis B treatment (Grade 1A) or prevention (GPP);
  - Who are considered at risk of hepatitis B reactivation\* (GPP).

\*See Section 5.11 Two-drug injectable regimens: switching in virological suppression.

- We suggest that three-drug boosted PI-based ART can be switched to two-drug boosted PI with lamivudine in people with virological suppression while taking into consideration that this regimen is **not** suitable for those who need tenofovir for hepatitis B treatment or prevention (Grade 1A).
- Other than the regimens listed, we do not recommend other oral two-drug regimens as routine switch strategies (GPP).

### 5.11 Two-drug injectable regimens: switching in virological suppression

- We recommend that long-acting cabotegravir/rilpivirine can be used in people who:
  - Are motivated to use injectable treatment (Grade 1B) *and*
  - Have been on ART for at least 3–6 months and are virally suppressed typically to <50 copies/mL (Grade 1A) *and*
  - Have no known or suspected NNRTI or INSTI resistance (Grade 1A) *and*

- Have no history of virological failure on NNRTI- or INSTI-containing ART (Grade 1A) *and*
- Can commit to 2-monthly attendance for injections (GPP) *and*
- Have engaged in shared decision-making and are aware of the small risk of virological failure, often with resistance, despite complete adherence and the potential implications for U=U (GPP) *and*
- Do not have a combination of body mass index (BMI) >30 kg/m<sup>2</sup> and subtype A6\* (Grade 1A) *and*
- Do not need a tenofovir-containing regimen for the treatment or prevention of hepatitis B (Grade 1A) *and*
- Are not considered at significant risk of hepatitis B reactivation or re-infection (Grade 1C).

\*Based on a multifactorial analysis of clinical trial data and real-world evidence, a high BMI alone has no impact on efficacy, but we advise caution in people with a high BMI and subtype A6 (see below).

- We recommend that long-acting cabotegravir/rilpivirine can be continued in people who may not meet the criteria above but are already virally suppressed on long-acting cabotegravir/rilpivirine:
  - Via a clinical trial (GPP);
  - As part of a compassionate access or named patient programme (GPP).
- We suggest that long-acting cabotegravir/rilpivirine can be used with caution in people with non-suppressed viral load (Grade 2C) who:
  - Continue to have a detectable viral load on oral ART despite extensive support *and*
  - Are at high risk of disease progression based on CD4 count and/or HIV-related conditions *and*
  - Are able to commit to regular appointments *and*
  - Do not have resistance to cabotegravir and/or rilpivirine *and*
  - Are willing to accept the possibility of resistance emergence and limitation of treatment options.
- We recommend the following viral load monitoring:
  - Two-monthly HIV RNA quantification for the first 6–12 months of injectable therapy (Grade 1B);
  - Thereafter, 4- to 6-monthly HIV RNA quantification in people without indicators of risk\*, taking patient preference into account (GPP).

\*We recommend 2-monthly HIV RNA quantification in the case of one or more of the following: subtype A6, history of viraemia on NNRTIs or INSTIs without resistance, starting long-acting cabotegravir/rilpivirine with detectable or recently detectable viral load, receipt of last injection at the end of the 7-day window period and, potentially, NNRTI polymorphisms (i.e. V106I and V179D/E) that are not recognised rilpivirine RAMs (i.e. L100I, K101E/P, E138A/G/K/Q/R, V179L/F, Y181C/I/V, Y188L, H221Y, F227C/L and M230I/L).

## 5.12 PI monotherapy

- We recommend against the use of PI monotherapy for routine ART (Grade 1A).

# 6 Supporting individuals on therapy

## 6.1 Adherence

- We recommend that adherence and potential barriers to it are assessed and discussed with people living with HIV whenever ART is discussed, prescribed or dispensed (GPP).
- Detailed adherence discussion is recommended when virological failure occurs (GPP).
- We recommend that adherence support should address both perceptual and practical barriers to adherence (GPP).
- Individuals experiencing difficulties with adherence should be offered additional support from staff within the multidisciplinary team with experience in adherence support and/or from organisations offering peer support (GPP).

### 6.1.3 Should the choice of first-line ART combination be affected by risk of non-adherence?

- Where there is clinical concern that doses may be missed intermittently, there is insufficient evidence to guide specific recommendations about ART choice. However, where there is a risk of frequent treatment interruptions, higher barrier regimens may be associated with less frequent selection for drug resistance (Grade 2C).

## 6.2 Pharmacology

### 6.2.1 Drug interactions

- Drug histories should be taken at each clinic visit, and a full medication history (including herbal medicines, recreational drugs and other non-prescribed medications) should be taken at least annually (GPP).
- All potential adverse pharmacokinetic interactions between ARV drugs and other concomitant medications should be checked before administration (GPP).
- Wherever feasible, people living with HIV should be counselled about the risks of drug interactions, and advised to use resources such as the University of Liverpool HIV Drug Interactions app (iOS or Android) (GPP).

### 6.2.2 Stopping therapy: pharmacological considerations

- For individuals discontinuing ART containing efavirenz, nevirapine or etravirine in combination with an NRTI backbone, we recommend that all drugs are replaced with a PI (darunavir/ritonavir once daily) for 4 weeks (Grade 1C).
- We strongly recommend against abrupt cessation of long-acting cabotegravir/rilpivirine due to a high risk of resistance emergence (Grade 1D).
- For individuals stopping any other regimen, we recommend that all drugs are stopped simultaneously, and no replacement is required (Grade 1C).

### 6.2.3 Switching therapy: pharmacological considerations

- Despite the potential for altered concentrations of the replacement drug when switching from efavirenz or nevirapine, in the context of viral suppression we recommend a direct switch without dose adjustment (Grade 1D).
- If switching from etravirine to dolutegravir, we recommend increasing the dolutegravir dose to 50 mg twice daily for the first 14 days (GPP).
- We recommend against omitting the oral lead-in when switching from efavirenz, nevirapine or etravirine to long-acting cabotegravir/rilpivirine (GPP).
- We recommend careful consideration of the impact on concomitant non-ARV medications if switching from a boosted to an unboosted regimen (GPP).

#### 6.2.3.3 Switching from efavirenz, etravirine or nevirapine to long-acting cabotegravir/rilpivirine

- We recommend against omitting the oral lead-in (in the absence of pharmacokinetic data) when switching from efavirenz or etravirine (GPP). An oral lead-in period of 4 weeks is recommended for patients switching from efavirenz/etravirine (GPP), comprising:
  - Oral cabotegravir and higher-dose oral rilpivirine (50 mg) for 2 weeks followed by 2 weeks of standard dosing *or*
  - Standard-dose oral cabotegravir and rilpivirine with additional two-NRTI cover from tenofovir DF (or tenofovir AF) plus emtricitabine or lamivudine.
- Although no significant drug–drug interaction is anticipated, we also recommend a 4-week oral cabotegravir/rilpivirine lead-in period when switching from nevirapine (GPP).

### 6.2.4 TDM

- We recommend against the non-selective use of TDM (GPP).

- TDM may be of clinical value in specific populations (e.g. children and pregnant women) or selected clinical scenarios (e.g. malabsorption, drug interactions and suspected non-adherence to therapy) (Grade 2C).

## 7 Managing virological failure

### 7.2 Blips

- In individuals on ART, a single viral load of 50–200 copies/mL preceded and followed by an undetectable viral load is usually not a cause for clinical concern (GPP). It should necessitate clinical vigilance, adherence reinforcement, a search for possible interactions and repeat testing within 2–6 weeks depending on ARV regimen.

### 7.3 Low-level viraemia on ART

- We recommend that in the context of low-level viraemia or repeated viral blips, resistance testing should be attempted (Grade 1D).
- We recommend that in the context of low-level viraemia or repeated blips a high genetic barrier regimen should be used (GPP).

### 7.4 Virological failure on ART

- We recommend that a single viral load of >200 copies/mL is investigated further, including a rapid re-test with/without genotypic resistance testing, as it may be indicative of virological failure (Grade 1C).

### 7.5 Individuals with no or limited drug resistance

- We recommend that factors associated with suboptimal adherence are considered for individuals experiencing virological failure on first-line ART with wild-type virus at baseline and without emergent resistance mutations at failure (GPP).
- If the current regimen is well tolerated and there are no concerning drug–drug interactions, it may be reasonable to continue the same regimen (GPP).
- If there are tolerability issues or significant drug–drug interactions, a switch in regimen should be considered (GPP).
- We suggest in exceptional circumstances that long-acting cabotegravir/rilpivirine can be used in non-virally suppressed people (see Section 5.11.5 Long-acting cabotegravir/rilpivirine in pregnancy) (Grade 2C).

## **7.6 Individuals with multi-class virological failure with or without extensive drug resistance**

- We recommend discussion within a multidisciplinary team or referral for expert advice for individuals with persistent viraemia and with limited options to construct a fully suppressive regimen (GPP).
- We recommend that all past and current genotypic resistance test results and treatment history are reviewed in order to guide therapy decisions (GPP).
- We recommend that individuals with extensive drug resistance are switched to a new ART regimen containing at least two and preferably three fully active agents (Grade 1C).
- We suggest that consideration on an individual basis should be given to whether inclusion of NRTIs with predicted reduced activity on genotypic testing will provide additional antiviral activity (Grade 2A).
- Where there is extensive drug resistance, we recommend consideration of agents with novel mechanisms of action if available (Grade 2B).
- We recommend consideration of clinical trials or expanded access programmes to facilitate the previous recommendation (GPP).
- We recommend that all individuals receive intensive adherence support at the start and at regular intervals to support them on their new ART combination (GPP).

## **7.7 Individuals with limited or no therapeutic options when a fully viral suppressive regimen cannot be constructed**

- We recommend accessing newer agents through research trials, expanded access and named individual programmes (GPP).
- We suggest that consideration, on an individual basis, should be given to whether inclusion of NRTIs with reduced activity on genotypic testing will provide additional antiviral activity; this may be the case where it is difficult to construct a regimen with fully active drugs including a boosted PI (Grade 2A).
- We recommend against discontinuing or interrupting ART (Grade 1B).
- We recommend against adding a single, fully active ARV because of the risk of further resistance (Grade 1D).
- We recommend against the use of maraviroc to increase the CD4 cell count where there is evidence for X4- or dual-tropic virus (Grade 1C).
- We recommend that in the context of triple-class failure and raltegravir-/elvitegravir-selected integrase resistance, twice-daily dolutegravir should be included as part of a new regimen where there is at least one fully active agent in the background regimen (Grade 1C).

## 8 Specific populations

### 8.1 Adolescents

#### 8.1.1 Management of HIV, ART and sexual and reproductive health specifically for young adults and adolescents living with HIV

- We recommend avoiding tenofovir DF in adolescents and young adults under the age of 25 years, prior to peak bone mass accrual (Grade 2B).

#### 8.1.4 Transition of clinical care from paediatric to adult services: a process for young adults and adolescents with PaHIV

- We recommend a robust transition process that includes a written pathway and a designated lead for transitional care within each trust to ensure that linkage of care is maintained following transition to adult services (GPP).
- We suggest that young adults continue in specialised services until 23–25 years of age and then transition to adult care (GPP).

#### 8.1.5 Cognitive and mental health impact of HIV in young adults and adolescents with PaHIV

- Optimising virological control with further investigation and referral to expert HIV neurology clinics for symptomatic individuals is recommended (GPP).

### 8.1.6 ART

#### 8.1.6.1 Adherence

- We suggest that ideally ART should be started with a once-daily regimen with a low pill burden and a high-genetic barrier to resistance based on a second-generation INSTI plus two NRTIs (GPP).

#### 8.1.6.4 Clinical monitoring for young adults and adolescents

- We suggest regular rigorous monitoring for hepatic malignancy for adolescents and young adults living with HIV and co-infected with hepatitis B and C (Grade 1C).
- We suggest a high index of suspicion to exclude cervical, anal and vulval intraepithelial neoplasia and lymphoma (Grade 1C).
- We suggest reviewing bone health including DEXA scanning where clinically indicated (Grade 1C).
- We suggest increasing viral load monitoring for pregnant women with PaHIV. Increasing numbers of young adults and adolescents are having children of their own and, although HIV transmission rates in infants are reassuringly low, women with PaHIV are more likely to have detectable viraemia at the time of the birth than women with BaHIV [38] (Grade 1C).

- We suggest early specialist referral for those struggling to conceive irrespective of age due to preliminary data suggesting a possible reduction in fertility [39] (Grade 1C).

## 8.2 Bone disease

### 8.2.1 What to start

- We recommend against the use of tenofovir DF in individuals with osteoporosis, severe osteopenia ( $T < -2.0$ ), a history of fragility fracture, a 10-year probability of a major osteoporotic fracture  $>5\%$  and/or a 10-year probability of a hip fracture  $>1\%$  (Grade 1D).

### 8.2.2 Switching treatment

- We recommend against continued use of tenofovir DF in individuals with osteoporosis, severe osteopenia ( $T < -2.0$ ), a history of fragility fracture, a 10-year probability of a major osteoporotic fracture  $>5\%$  and/or a 10-year probability of a hip fracture  $>1\%$  (Grade 1D).

## 8.3 Cardiovascular and metabolic disease

### 8.3.1 Cardiovascular considerations

In individuals with high CVD risk:

- We recommend avoiding lopinavir/ritonavir-based regimens (Grade 1C).
- If a boosted PI is the desired option, an atazanavir-based regimen may have advantages over a darunavir-based regimen (GPP).

### 8.3.2 Lipid considerations

- We recommend that the adverse effects on lipid parameters should be considered when selecting ART (GPP).

### 8.3.3 Weight gain considerations

- We recommend that the impact of weight gain should be considered when selecting ART (GPP).

## 8.4 Chronic kidney disease

### 8.4.1 What to start

- We recommend darunavir/ritonavir or darunavir/cobicistat in individuals with an eGFR of  $<60$  mL/min/1.73 m<sup>2</sup> if a PI is required (Grade 1C).
- We recommend tenofovir AF in individuals with an eGFR of 30–60 mL/min/1.73 m<sup>2</sup> who require tenofovir (Grade 1B).

#### **8.4.2 Need to switch**

- We recommend against continued use of tenofovir DF, lopinavir/ritonavir or atazanavir in individuals with worsening renal function who have developed or are approaching an eGFR of  $<60$  mL/min/1.73 m<sup>2</sup> or who have developed moderate-to-severe proteinuria, if acceptable alternatives are available (Grade 1C).

#### **8.4.3 Dose adjustment of ART in the setting of renal impairment**

- We suggest that lamivudine and emtricitabine are dose adjusted in people with a confirmed eGFR of  $<30$  mL/min/1.73 m<sup>2</sup> (GPP).

#### **8.4.4 Assessment of renal function in the presence of agents that reduce creatinine clearance**

- We suggest that repeat and additional measures of kidney function (eGFR and urine protein-to-creatinine ratio) are obtained if large reductions in eGFR are observed following the introduction of drugs that inhibit tubular creatinine secretion (GPP).
- We suggest that an alternative estimate of eGFR (e.g. based on cystatin C) is obtained in individuals in whom reductions in creatinine-based eGFR on drugs that inhibit tubular creatinine secretion may affect decisions about dose reduction or substitution of medications (GPP).

### **8.5 Chronic liver disease**

- People found to have non-alcoholic fatty liver disease (NAFLD) should be actively involved in the choice of ART to attempt to minimise the risks not only of progression of liver disease and CVD but also of weight gain and diabetes (GPP).

### **8.6 Cognitive impairment associated with HIV**

#### **8.6.2 When to start ART**

- Along with the general recommendation to offer ART to all persons with HIV, we recommend that symptomatic HIV-associated cognitive disorders is considered a further indication to commence ART (Grade 1C).

#### **8.6.3 What to start**

- We recommend that individuals with HIV-associated cognitive disorders start standard combination ART regimens (Grade 1C).
- We recommend avoiding efavirenz-containing regimens in individuals with HIV-associated cognitive disorders (Grade 1C).

#### **8.6.4 Simplification strategies**

- We recommend avoiding dual therapy regimens in individuals with HIV-associated cognitive disorders (Grade 1C).

#### **8.6.5 Continuing or worsening cognitive impairment despite ART**

Best practice management should include (GPP):

- Reassessment and management of confounding conditions.
- Assessment and genotyping of CSF HIV RNA.
- Modifications to ART based on paired plasma and CSF genotypic results in subjects with detectable CSF HIV RNA.

### **8.7 Later life and ageing with HIV**

#### **8.7.2 When to start ART**

- We recommend that standard criteria are used to determine when to commence ART in older people with HIV (Grade 1C).

#### **8.7.3 What to start**

- We recommend that standard ART regimens are commenced in older people with HIV (Grade 1C).

### **8.8 Mental health**

- We recommend that efavirenz-containing regimens should be avoided in individuals with a current or past history of depression, psychosis, suicidal ideation or attempted suicide, or at risk of self-harm (Grade 1C).
- We recommend that INSTI-containing regimens should be used with caution in patients with a pre-existing history of any psychiatric illness including depression (GPP).

### **8.9 Transgender people**

- Transgender people living with HIV may be impacted disproportionately by some of the key considerations around ART choice (e.g. drug–drug interactions, mental health concerns, stigma, CVD and low BMD); holistic assessment is advised when selecting optimal ART (GPP).
- We recommend that clinics collect accurate data on gender identity so that data on the outcomes and experiences of transgender people living with HIV can be used to better tailor services (GPP).
- We recommend individualised interpretation of gender-influenced laboratory and other assessments that may impact ART choice (GPP).

## **8.10 Women**

### **8.10.2 What to start**

- There are insufficient data to support specific recommendations for non-pregnant women with HIV. We therefore recommend that therapy-naïve women with HIV start ART as per general guidelines (Grade 1A).
- We recommend that both women with HIV of childbearing potential and healthcare professionals who prescribe ART are familiar with the benefits and risks of ARV agents for the health of the woman as well as for that of the unborn child (GPP).
- We recommend that potential pharmacokinetic interactions between ARV drugs, hormonal contraceptive agents and hormone-replacement therapy are considered before administration (GPP).

## 3 Active involvement of people living with HIV in decision-making

### Recommendations

- We recommend that people living with HIV are given the opportunity to contribute actively to decisions about their treatment (GPP).
- Provision of treatment-support resources should include in-house, independent and community information providers and peer-support resources (GPP).
- We recommend following the European AIDS Clinical Society (EACS) guidance on 'assessing readiness to start and maintain ART' [1] (GPP).
- We recommend that HIV services have clear pathways for referral to peer support (GPP).
- We recommend that people living with HIV share their status with general practitioners (GPs) and other healthcare professionals; where an individual declines to do so the benefits and potential harm should be reviewed regularly (GPP).

### Auditable outcomes

- Percentage of people living with HIV who confirm they have been given the opportunity to contribute to decisions about their treatment.
- Percentage of people living with HIV who have been offered signposting or referral to peer support or treatment advocacy services.
- Evidence of signposting and/or referral to HIV peer support or treatment advocacy services.

### Rationale

People living with HIV should be given the opportunity to consider and contribute to decisions about their treatment and the Medicines and Healthcare products Regulatory Agency now asks applicants to include evidence for patient involvement activities when submitting applications for selected new medicines [2]. Studies show that trust in providers improves linkage to and retention in care and ART adherence [3-5], that patient-provider relationship quality is associated with HIV-related and psychosocial outcomes [6] and that trust transfers from offline to online health services [7]. Having a consistent healthcare provider has been associated with better rates of viral suppression [8].

Clinicians should establish what level of involvement the individual living with HIV would like and carry out an informed clinical and psychosocial assessment to choose the best treatment options. The individual should be able to access and understand relevant information relative to different languages and literacy levels in line with BHIVA standards [9]. If there is a question about an individual's capacity to make an informed decision, this should be assessed in line with General Medical Council guidance [10].

A 'perceptions and practicalities' approach should be used to tailor support to meet the needs of the individual, to identify both the perceptual factors (such as beliefs about ART) and practical factors (such as capacity and resources) influencing adherence [11]. The following should be discussed:

- Rationale for ART;
- Potential adverse effects;
- Importance of adherence and the implications of missed/stopped ART;
- Social circumstances, options to store ART and ability to follow any necessary food requirements;
- Drug–drug interactions and where to seek advice.

Good care requires good communication with the GP and any clinicians involved in management of comorbid conditions. People living with HIV should be offered copies of any correspondence about them. Disclosure of their HIV status to the GP by people living with HIV should be considered best practice and the benefits of sharing HIV status with GPs and the potential risks of not doing so (such as drug–drug interactions) should be explained. However an individual's decision not to share their status with their GP should be respected but revisited regularly.

A systematic review of 20 randomised controlled trials showed that peer-support with routine medical care was superior to routine clinic follow-up, yielding better retention in care, ART adherence and viral suppression [12]. Benefits for other outcomes such as mental health and quality of life were 'promising' but too uncertain to draw firm conclusions.

We recommend following the EACS guidance on assessing the readiness of people living with HIV to start and maintain ART [1].

## 3.1 References

1. European AIDS Clinical Society. *EACS Readiness to Start/Maintain ART*. Available at: <https://eacs.sanfordguide.com/art/readiness-to-start-maintain-art> (accessed July 2022).
2. Medicines and Healthcare products Regulatory Agency. *MHRA pilots patient involvement in new applications*. Available at: <https://www.gov.uk/government/news/mhra-pilots-patient-involvement-in-new-applications> (accessed April 2022).

3. Michel KG, Ocampo JMF, Spence AB *et al.* High provider trust associates with high HIV antiretroviral adherence among women living with HIV in a metropolitan Washington, DC cohort. *AIDS Patient Care STDS* 2022; **36**: 17–25.
4. Graham JL, Shahani L, Grimes RM *et al.* The influence of trust in physicians and trust in the healthcare system on linkage, retention, and adherence to HIV care. *AIDS Patient Care STDS* 2015; **29**: 661–667.
5. Mitchell BD, Utterback L, Hibbeler P *et al.* Patient-identified markers of quality care: improving HIV service delivery for older African Americans. *J Racial Ethn Health Disparities* 2022: 1–12. doi: 10.1007/s40615-022-01237-2.
6. Zhang C, McMahon J, Leblanc N *et al.* Association of medical mistrust and poor communication with HIV-related health outcomes and psychosocial wellbeing among heterosexual men living with HIV. *AIDS Patient Care STDS* 2020; **34**: 27–37.
7. van Velsen L, Flierman I, Tabak M. The formation of patient trust and its transference to online health services: the case of a Dutch online patient portal for rehabilitation care. *BMC Med Inform Decis Mak* 2021; **21**: 188.
8. Wang Z, Lin HC. Having a consistent HIV health care provider and HIV-related clinical outcomes. *Am J Manag Care* 2020; **26**: 288–294.
9. British HIV Association. *British HIV Association standards of care for people living with HIV 2018*. Available at: <https://www.bhiva.org/standards-of-care-2018> (accessed July 2022).
10. General Medical Council. *Decision making and consent*. 2020. Available at: [https://www.gmc-uk.org/-/media/documents/gmc-guidance-for-doctors---decision-making-and-consent-english\\_pdf-84191055.pdf](https://www.gmc-uk.org/-/media/documents/gmc-guidance-for-doctors---decision-making-and-consent-english_pdf-84191055.pdf) (accessed April 2022).
11. Horne R, Chapman SC, Parham R *et al.* Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. *PLoS One* 2013; **8**: e80633.
12. Berg RC, Page S, Øgård-Repål A. The effectiveness of peer-support for people living with HIV: a systematic review and meta-analysis. *PLoS One* 2021; **16**: e0252623.

## 4 When to start

### 4.1 Established infection

#### Recommendations

- We recommend that all people living with HIV should be on ART (Grade 1A).
- We recommend that all people living with HIV are offered the opportunity to start ART within 2–4 weeks of diagnosis (GPP).
- We recommend that readiness to start is assessed and decisions about starting ART tailored accordingly (GPP).

#### Auditable outcomes

- Proportion of diagnosed people living with HIV on ART.
- Proportion of people living with HIV not on ART where the rationale for this, and a discussion of the benefits of ART, has been documented at each visit.

#### Rationale

All consensus HIV treatment guidelines recommend immediate ART initiation, regardless of CD4 count, for people living with HIV based on:

- Randomised controlled trial evidence of benefit in terms of both HIV-related and non-HIV-related morbidity and mortality [1,2];
- Zero risk of sexual transmission of HIV in the context of sustained viral suppression [3-5].

The definition of immediate ART differs across trials; in START, for example, participants in the ‘immediate’ arm had been diagnosed for approximately 1 year. For the purposes of these guidelines, we suggest that all people with HIV should be offered the opportunity to start ART within 2 to 4 weeks of diagnosis. It is important to recognise that despite the significant reduction in relative risk of disease progression associated with early ART, the absolute risk associated with deferring ART will be low if the person has a high CD4 count. In START, for example, the risk of a serious illness over 3 years of follow-up was 1.5% among people in the immediate treatment arm versus 4.1% among those who deferred ART until their CD4 count fell below 350 cells/mm<sup>3</sup> [1]. However, among those diagnosed with a lower CD4 count, the absolute risk associated with deferring for longer periods will be more substantial. The absolute risk of deferring therapy should therefore be considered when making individual decisions.

People living with HIV should be counselled about the risks of interrupting treatment, in terms of individual health [6], emergent drug resistance and risk of onward transmission.

## 4.2 Same-day ART initiation

### Recommendations

- We recommend that the advantages and disadvantages of starting ART the same day as diagnosis are discussed with each person, including the lack of proven benefit or harm of same-day ART in a UK or similar setting (GPP).
- We recommend same-day ART in the following situations (GPP):
- Primary HIV (see below);
- Where an individual wishes to and is ready to start same-day ART and has no clinical contraindications.

### Rationale

With consensus established that ART should be offered immediately, the debate has shifted to how rapidly immediate ART should be commenced. In recent years, there has been increasing interest in the policy of starting ART very soon after diagnosis [7]. The definition of rapid ART varies between studies, from the day of diagnosis to up to 2 weeks after diagnosis; additionally, even 'same day' may differ between studies depending on whether testing takes place at the same facility as treatment initiation. Furthermore, to date, the majority of evidence cited to support 'same day' ART comes from settings with very different healthcare systems compared to the UK. An analysis of four randomised controlled trials in low- and middle-income country settings concluded that same-day ART was associated with higher rates of viral suppression and retention in care at 12 months with a trend to lower mortality [8]. The authors concluded 'Accelerated ART initiation can lead to improved clinical outcomes and is likely to be of particular benefit in those settings where extensive patient preparation prior to starting ART results in long delays'. It is important to note that many screened participants were excluded from the trials included in the Ford analysis: a study conducted in Haiti [9] excluded about half of screened participants, mainly for having World Health Organization (WHO) stage 3 or 4 disease. The results of randomised controlled trials may not translate to real-world settings. A cohort study conducted in Eswatini showed a higher risk of unfavourable outcomes among people who started ART the same day compared to those who started within 1 to 14 days [10] and cohorts from South Africa [11] and Ethiopia [12] showed worse retention in care among people who started ART on the same day compared to later; despite this, the South African cohort [11] showed lower mortality in people who started same-day ART.

Other potential benefits of rapid ART initiation include:

- Earlier reduction in viral load (and thus reduction in the potential risk of transmission of HIV) [13];

- The potential empowerment of individuals, and reduction in anxiety related to waiting to start ART or achieving viral suppression to eliminate the risk of sexual transmission, through supporting them to start ART immediately if they choose to do so;
- Reduced mortality in low- and middle-income countries at 12 months was demonstrated in a meta-analysis of four same-day ART trials [8] but a Cochrane review of seven studies including more than 18,000 patients showed no clear reduction in mortality [14].

However, some studies have shown no clear benefit of immediate ART initiation, and the applicability of results of studies conducted in very different settings to the UK, where engagement and retention in care is generally very high, is unclear. Data for same-day ART in the UK are lacking and a cohort study from London, often quoted as supporting this approach, which showed that rapid ART initiation was popular and feasible, did not examine same-day ART but rapid (within 8 days) versus less rapid (within 21 days) ART initiation [15]. An additional cohort analysis from the same London group described a subset of people with early HIV who started ART within a median of 6 days post-diagnosis, including 26 starting same-day ART [16]. All those starting same-day ART were retained in care and virally suppressed at week 24 and the 22% starting tenofovir disoproxil fumarate (DF)/emtricitabine plus an integrase inhibitor (INSTI) achieved viral suppression faster than the remainder, who commenced tenofovir DF/emtricitabine plus boosted darunavir. Of note, a French cohort study demonstrated worse retention in care at 1 year among people who started treatment earlier [17]. Although this study did not specifically address same-day ART, and the results could be impacted by several confounders, such as the fact that people who started ART earlier may have been more likely to have symptomatic or advanced HIV, more studies are warranted.

Some individuals may be overwhelmed by an HIV diagnosis and while they process this information are unable to contemplate starting therapy immediately; it is important that they do not feel under pressure to start treatment if they are unprepared. A qualitative study among newly diagnosed people in Rwanda revealed that while participants supported a same-day approach, they described logistical and emotional challenges despite the perceived benefits [18]. These challenges included trauma related to, and difficulty accepting, HIV diagnosis and feeling intimidated at the prospect of lifelong ART. Many reported significant side effects in the first days and weeks after initiating ART, 'likely reflecting either physiologic or psychosomatic adjustment to their medications' the authors concluded. It may not be possible to extrapolate these findings to UK care settings, but it is important to acknowledge that same-day ART may not suit all people newly diagnosed with HIV.

Rapid ART initiation is not recommended in the context of some opportunistic illnesses including cryptococcal meningitis [19] and central nervous system (CNS) tuberculosis (TB) [20]. There is insufficient evidence to establish whether same-day ART is appropriate in the context of TB symptoms [21].

There are also potential benefits to deferring starting therapy until the results of baseline tests (including resistance test, baseline biochemistry, CD4 count and hepatitis B serology) are available; this can allow for a more tailored choice of ART regimen. A delay may also offer newly diagnosed individuals the opportunity to explore treatment options, access peer support, and prepare for starting a treatment where adherence is of paramount importance. Finally, the ability to offer same-day ART will depend on clinic facilities, staffing and capacity to offer the recommended support and assessments at the first visit.

## 4.3 Individuals presenting with AIDS or a major infection

### Recommendation

- We recommend that most individuals presenting with an AIDS-defining infection, or with a serious bacterial infection and a CD4 count  $<200$  cells/mm<sup>3</sup>, start ART within 2 weeks of initiation of specific antimicrobial chemotherapy (Grade 1B).

### Auditable outcome

- Proportion of individuals living with HIV presenting with an AIDS-defining infection or with a serious bacterial infection and a CD4 count  $<200$  cells/mm<sup>3</sup> who are started on ART within 2–4 weeks of initiation of specific antimicrobial chemotherapy.

### Rationale

This recommendation is largely based on the ACTG 5164 study that demonstrated fewer AIDS progressions/deaths and improved cost-effectiveness when ART was commenced within 14 days (median 12 days, interquartile range [IQR] 9–13 days) compared with initiation after completion of treatment for the acute infection (median 45 days, IQR 41–55 days) [22,23]. Those with TB as the primary infection were excluded from this study, and the majority of individuals enrolled had *Pneumocystis pneumonia*. All patients were well enough to give informed consent and to take oral medications, and therefore the findings may not be generalisable to those who are severely unwell or who require intensive care. Previous observational data suggest a survival benefit for patients with HIV who are started on ART while in the intensive care unit [24,25], but the data are insufficient to make a recommendation for this group [24,25].

There was no increase in the incidence of immune reconstitution disorders or adverse events generally with early ART initiation in ACTG 5164 [22,26]. However, those with intracranial opportunistic infections may be

more prone to severe immune reconstitution disorders with early ART initiation. Some data suggest that particular caution is warranted with cryptococcal meningitis: two studies from sub-Saharan Africa have demonstrated an increased mortality with early ART initiation; however, both were in very different healthcare settings from the UK and one utilised antifungal regimens that would not be preferred [27,28]. The COAT study highlighted that those with an acellular cerebrospinal fluid (CSF) or with decreased levels of consciousness were at higher risk of death with early ART initiation [28]. It is important to note that immune reconstitution disorders can be difficult to diagnose and case definitions vary across studies.

While most studies in all settings favour deferred (after 2 weeks) initiation of ART during treatment of cryptococcal meningitis, timing of ART initiation after 2 weeks should be tailored to individual cases supported by careful clinical and CSF assessments.

## 4.4 Treatment of primary HIV infection

### Recommendation

- We recommend that all individuals with suspected or diagnosed primary HIV infection (PHI) are reviewed promptly by an HIV specialist and offered immediate ART (Grade 1B).

### Auditable outcomes

- Proportion of individuals with PHI assessed by an HIV specialist within 2 weeks.
- Proportion of individuals with PHI offered ART as soon as possible after confirmed HIV status.

### Rationale

PHI is defined as HIV infection within a maximum of 6 months from the estimated time of HIV acquisition. It can be diagnosed based on laboratory test results in the setting of a clinical sexual history [29]. In the setting of the results from the START, TEMPRANO and HPTN052 trials, there is now no longer equipoise when counselling all individuals diagnosed with HIV; these studies showed clinical benefit to starting immediate ART over deferral [1,2,30,31]. However, these studies were not powered to determine specifically the outcome of those starting ART at the time of PHI diagnosis versus deferral.

While immediate ART is recommended for all people with HIV, PHI is a unique situation in which starting ART as soon as possible may confer benefit over deferring ART for even a short period of time, such as within 2 weeks. This should therefore influence advice when counselling someone with newly diagnosed PHI, which should reflect that the risk of harm if deferring ART is likely to be greater than for established infection. HIV services should ensure that there are pathways for rapid assessment of people with PHI.

In the context of PHI there are additional issues to take into account when considering best management. PHI is a distinct situation in which often-significant symptoms consistent with seroconversion occur at a time of the stress of coming to terms with a new HIV diagnosis. Individuals diagnosed with PHI with low initial CD4 cell counts [32,33], high plasma viral loads (>100,000 copies/mL) [34] and short test intervals (diagnosis within 12 weeks of a previous negative test) [35,36] have a more rapid rate of disease progression than others without these features at diagnosis of PHI, and hence early ART initiation should be prioritised. A recent Italian study identified enhanced clinical outcome among a cohort of participants recently diagnosed with HIV [37]. Early ART emerged as an independent predictor of optimal immunological recovery after adjustment for baseline CD4 (absolute and percentage count) and CD4/CD8 ratio.

ART should be started only when the individual feels ready. Certain ART combinations may be better tolerated in association with symptoms of PHI. The only independent predictor of first-line ART discontinuation was an initial ART regimen including more than three drugs [37], and complex ART regimens were associated with worse virological responses [38]. However, there are certain clinical presentations of PHI where expedited ART initiation should be recommended. We recommend starting ART as soon as possible for patients presenting with PHI meeting any one of the following criteria known to be associated with morbidity or very rapid disease progression:

- Neurological involvement (Grade 1D);
- Any AIDS-defining illness (Grade 1A);
- CD4 count <350 cells/mm<sup>3</sup> (Grade 1C);
- PHI diagnosed within 12 weeks of a previous negative test (Grade 1C).

The advantages and disadvantages of early ART initiation with a view to long-term therapy should be clearly and sensitively presented to any individual diagnosed with PHI (see Table 4.1). Once started, ART should be considered as potentially lifelong due to the increased all-cause mortality observed from treatment interruption in the SMART study [6], which was seen regardless of nadir CD4 cell count. The recent global use of INSTI-containing ART regimens has limited the prevalence of transmitted drug-resistant HIV variants among individuals with PHI, however baseline viral sequencing is recommended at the time of diagnosis [39].

**Table 4.1** Advantages and disadvantages of starting ART immediately in PHI

| Advantages of starting ART in PHI  | Disadvantages of starting ART in PHI   |
|--|--|
| Enhanced probability of immunological recovery to normal levels [40-44,48]   | Ambivalence to ART at a time of emotional challenges can risk poor adherence and the development of drug resistance  |
| Individuals with recent HIV diagnosis may feel comforted to know that they are taking immediate control of their infection with evidence to support enhanced immunological and virological benefits [45] | Individuals with recently diagnosed PHI may be in a particularly vulnerable psychological state, and thus ill-prepared to commit to starting long-term treatment |
| Reduced risk of onward viral transmission at a time of very high viral load and consequent high risk of transmission [45,54,90-93]   | Consider choice of ART regimen in the context of same-day ART initiation and side effects that overlap with PHI symptoms   |
| Reduction in morbidity and more rapid disease progression associated with high viraemia [34]   |  |
| Data from the START, TEMPRANO and HPTN052 trials showed clinical benefit from starting ART irrespective of CD4 count [1,2,31]  |  |
| Earlier intervention within the first 12 weeks of diagnosis confers enhanced immune recovery for this group of individuals who progress more rapidly if ART is deferred [40-43,48]                       |  |
| Limitation of viral reservoir to significantly below that seen when treatment is deferred [94]   |  |

The rationale for immediate ART initiation among individuals diagnosed with PHI include:

- Preservation of immune function, in terms of both total CD4 counts and the ratio of CD4:CD8 T cells (which reflects immune activation and is associated with increased all-cause mortality), is associated with survival in untreated individuals [40-45];
- Reduction in morbidity associated with high viraemia and profound CD4 cell depletion during acute infection [6,33-36];
- Reduction in the enhanced risk of onward transmission of HIV associated with the high viral load of PHI [46].

There is never likely to be a randomised controlled trial in PHI comparing immediate versus deferred ART that is powered to a survival outcome, as such a study would require decades to accrue endpoints and given the level of evidence supporting ART initiation would not be ethical. Hence recommendations of best management of PHI are based on surrogate markers of mortality and CD4 count. Increasing evidence has identified both rapid and enhanced recovery of surrogate markers of the immune system [47] in terms of

CD4 cell count [36] and CD4:CD8 ratio [6,48] for individuals initiating ART close to the time of HIV transmission compared to deferred ART initiation. A recent analysis demonstrated lower likelihood of achieving a normal CD4 cell count if treatment initiation was delayed more than 12 months after diagnosis of PHI; therefore, even outside the circumstances where prompt ART is advised, starting within 1 year of PHI diagnosis is advisable [44].

Immediate or expedited ART initiation for symptomatic seroconversion and for those with very high plasma viral loads will additionally resolve clinical symptoms and limit the enhanced risk of onward viral transmission [40-44,48]. Furthermore, earlier ART initiation has been shown to correspond with reduced measures of the latent pool of infected cells (viral reservoir) [49-51], the current barrier to HIV remission or cure [52,53]. We therefore recommend an expedited pathway of care for individuals diagnosed with PHI to ensure that a clear and informed discussion of the advantages and disadvantages of immediate ART is provided to all individuals to support them making the optimal treatment decision. An individual's readiness to start ART should be explored prior to commencing treatment (see Section 3 Active involvement of people living with HIV in decision-making).

## 4.5 Impact of treatment on prevention of onward transmission

### Recommendations

- An assessment of the risk of transmission to others should be made at diagnosis and subsequent visits with signposting to relevant interventions (GPP).
- We recommend that the evidence that treatment with suppressive ART reduces the risk of sexual transmission to zero is discussed where relevant (GPP).
- We recommend that the major impact of suppressive ART on the risk of vertical transmission and transmission through breastfeeding is discussed with all people living with HIV where relevant (GPP).
- We recommend condoms, both male and female, to reduce the risk of other sexually transmitted infections and unplanned pregnancy, where appropriate (GPP).

### Auditable outcomes

- Proportion of people for whom the risk of transmission has been assessed at diagnosis and regularly thereafter.

- Proportion of people who have a discussion that suppressive ART means a zero risk of onward sexual transmission (undetectable=untransmittable [U=U]) and, where relevant, a very low risk of vertical transmission or transmission through breast milk is documented in the medical notes.
- Proportion of people for whom a discussion about the benefits of condoms and other modalities to prevent sexually transmitted infections and unintended pregnancy has been documented.
- Proportion of people for whom advice that viral suppression should be confirmed after initiation and that high and consistent adherence to ART is required to maintain viral suppression has been documented.

## Rationale

The potential effect of HIV treatment to reduce the risk of onward sexual transmission should be discussed with all people living with HIV as a part of combination prevention. For the purposes of U=U, a viral load that is durably less than 200 copies/mL is considered undetectable.

Cohort studies provided the initial evidence base for treatment to reduce transmission with no, or very rare, transmission events within heterosexual, serodifferent couples where the HIV-positive partner had an undetectable viral load on treatment [54-59].

This was followed by good evidence from one randomised controlled trial (HPTN 052) [60] which showed that ART yielded a 96% reduction in transmission to HIV-negative partners and zero transmissions when the HIV-positive partner had an undetectable viral load. Secondary outcomes of the Partners in Prevention trial [61] demonstrated similar findings. Of note, 97% of couples participating in HPTN 052 and all couples participating in Partner in Prevention were heterosexual, and condom use was high in both studies.

Three large prospective cohort studies have also investigated the risk of sexual HIV transmission in the context of suppressive ART: PARTNER (heterosexual people and men who have sex with men [MSM]), PARTNER2 (MSM) and Opposites Attract (MSM) [3-5]. These three studies demonstrated no sexual transmission to HIV-negative partners when the HIV-positive person was on suppressive ART. These studies provide sufficient evidence, after more than 100,000 condomless sex acts among MSM, to conclude that there is zero risk of onward sexual transmission of HIV in the context of viral suppression.

Condoms should still be recommended to reduce the risk of other sexually transmitted infections and unwanted pregnancy.

People living with HIV should be informed that taking ART does not result in immediate viral suppression. INSTI-based ART achieves more rapid viral suppression than non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based therapy, with most individuals achieving an undetectable viral load

by 1–3 months [62-64]. People living with HIV should also be informed that the risk of virological rebound, when medication is taken as recommended, is very low.

People wishing to conceive can be reassured that there is zero risk of transmission if the HIV-positive person has suppressed viral load. Sperm washing is not recommended in the context of viral suppression [65].

Pre-exposure prophylaxis (PrEP) is not recommended for HIV-negative people with an HIV-positive sexual partner on suppressive ART unless they have other sexual partners who may have HIV with a detectable viral load [66]. The use of ART to prevent vertical transmission is discussed in the BHIVA guidelines for the management of HIV in pregnancy and postpartum [67].

## 4.6 Persons choosing not to commence ART

### Recommendations

- We recommend that all people living with HIV choosing not to commence ART should be counselled about the risk to their own health and the risk of onward sexual transmission of HIV (Grade 1A).
- We recommend that in all people living with HIV choosing not to commence ART, capacity to make this decision is assessed and psychological support offered (GPP).
- We recommend that where people with HIV have chosen to not commence ART, their sexual partners (with the consent of the person with HIV) should be signposted to prevention interventions including PrEP (GPP).

### Rationale

The advantages of commencing ART in all people living with HIV are outlined above. In people living with HIV who choose not to commence ART, healthcare providers should assess the rationale for this choice. Such assessments should include exploring the underlying reasons and ensuring the individual is aware of the risks of this choice to their own health, and to the health of others with regard to onward sexual transmission of HIV in those who are sexually active.

Assessment of capacity should be undertaken to ensure that the individual understands the risks of not commencing ART and psychological support offered if deemed required.

The START study results can be used to counsel people choosing not to take ART [1]. For people with a CD4 count greater than 500 cells/mm<sup>3</sup>, early ART was associated with significant reduction in relative risk of disease progression but the absolute risk of deferring ART was relatively small; 4.1% of individuals in the

deferred arm versus 1.8% in the immediate treatment arm experienced a serious illness over 3 years of follow-up. The absolute risk of deferring therapy can help guide individual decisions. Although our recommendation is that all should start ART soon after diagnosis, some people who are at low short-term risk of disease progression may make an informed choice to defer treatment, and should be supported in their decision.

It is important that all people living with HIV who choose not to commence ART should be offered regular follow-up appointments at approximately 3-monthly intervals, or at shorter intervals if deemed clinically appropriate. This is to ensure that discussions about commencing ART are ongoing, and also to monitor for HIV-disease progression.

## 4.7 Considerations when managing people with spontaneous HIV viral control

### Recommendations

- Given that there is evidence of ongoing HIV replication even at a low level in some viral controllers, ART is strongly recommended for viral controllers with evidence of HIV disease progression, defined by declining CD4 counts, inverted CD4:CD8 ratio (<1) or the development of HIV-related complications (Grade 2A).
- In specific situations there may be a case to continue regular HIV viral load and CD4 count monitoring while remaining off ART; we recommend this only where the following have been excluded (GPP):
  - Chronic co-infection with hepatitis B or C, or human T-cell lymphotropic virus (HTLV);
  - Significant past or present comorbidities such as cancer, autoimmune disease and cardiovascular disease (CVD; myocardial infarction and cerebrovascular accident);
  - Indication for current or planned immune suppressive or chemotherapy treatment;
  - Pregnancy or planned pregnancy and breastfeeding; this is due to the relative immune suppression of pregnancy plus uncertainty of viral rebound and potential risk of transmission. Stopping ART post-delivery must be discussed with a specialist team.

### Recommendations for monitoring of viral controllers off ART (GPP):

- Six- to 12-monthly measurement of HIV viral load;
- At least 6-monthly measurement of CD4 count and CD4:CD8 ratio;
- At least 6-monthly clinical assessment for CVD, malignancy, any comorbidity, pregnancy and hepatitis co-infection.

#### 4.7.1 Definition of viral controllers (also known as elite controllers)

Viral controllers are defined as:

- Individuals with confirmed HIV infection by positive HIV antibody test (western blot), or HIV RNA or DNA detected through routine NHS or referral centre testing *and*
- Individuals with confirmed HIV-1 infection not taking ART with undetectable HIV viral load <50 copies/mL on more than one occasion *and*
- Individuals with confirmed HIV infection not on ART with CD4 count in the normal range and/or CD4:CD8 ratio >1.0.

Starting ART should be discussed with all people living with HIV and should be commenced for anyone wishing to start treatment irrespective of their HIV viral load and CD4 count. This section refers only to those rare individuals who spontaneously control HIV viral load to undetectable levels (<50 copies/mL) without ART and have repeated CD4 counts in the normal range where the benefits of ART remain uncertain. Specialist consultation through referral to a national NHS clinical service (IDRIS; clinic run at Imperial College NHS Trust, London: [imperial.idris@nhs.net](mailto:imperial.idris@nhs.net)) via the UK Health Security Agency ([csuqueries@ukhsa.gov.uk](mailto:csuqueries@ukhsa.gov.uk)) is recommended.

#### Rationale

In a rare group of people living with HIV, estimated to represent approximately 1–5% of all those with HIV depending on the definition [68,69], HIV viral control to undetectable levels can be achieved without ART. The START [1] and TEMPRANO [2] studies demonstrated that initiating ART confers survival benefit for all people living with HIV regardless of CD4 count; therefore, delaying ART to see if an individual becomes a viral controller is **strongly discouraged**. The START study did include several participants with viral loads less than 3000 copies/mL, including 93 with undetectable viraemia. A separate analysis of this population demonstrated higher CD4 counts, greater proportion with suppressed viremia, and decreases in D-dimer levels on immediate ART but a lack of difference in serious clinical outcomes [70]. These data support immediate ART in people with low-level viraemia, although equipoise remains for suppressors. There remains uncertainty as to the best management of long-term viral controllers. We recommend that ART is discussed with all people, but for those with spontaneous viral control and normal immune markers off ART, there is a lack of high-quality, long-term, clinical outcome data on or off ART. Other benefits of ART include confidence in durable viral suppression (and zero risk of sexual transmission) and reassurance that ART will prevent disease progression.

#### 4.7.2 Risks versus benefits of ART in viral controllers

The risk of HIV clinical progression among viral controllers has been estimated from observational studies. A French longitudinal study of 302 viral controllers over a median of 14.8 years demonstrated that 30% clinically progressed and started ART [71-73]. Whether viral controllers are still at risk of HIV-associated comorbidities and could potentially benefit from ART is still debated, although studies have demonstrated an increased risk of hospitalisation among viral controllers compared with matched uninfected individuals [74]. Depending on the definition of viral control, long-term studies have demonstrated that ultimately people living with HIV will experience progression [75].

There is an established relationship between clinical outcomes and excessive immune activation, reversal of CD4:CD8 ratio and age, in particular in CVD and malignancy [76]. Some viral controllers with normal CD4 counts show evidence of abnormally high immune activation and surrogate markers of atherosclerosis [77,78], which may contribute to an increased risk of non-AIDS-related diseases. In a study of 30 viral controllers and 187 ART-treated people living with HIV, all of whom had undetectable HIV viral load measurements, viral controllers had higher levels of CD4+ and CD8+ immune activation ( $P<0.001$  for both) compared with ART-treated people living with HIV which could contribute to progressive CD4 cell loss and comorbidities despite undetectable plasma viral load. Among viral controllers with elevated T cell activation, ART has been demonstrated to normalise these parameters [79]. Moreover, viral controllers with preserved CD4 counts appear to experience a decline in immune activation after ART initiation, suggesting that treatment may be beneficial [80,81], although all studies have been small and long-term outcomes are not yet known. In a prospective observational study among 3106 subjects followed from 2000 to 2013, 221 were HIV controllers, including 33 elite (1.1%) and 188 viraemic (6.0%) controllers, who contributed 882 person-years (PY) of observation time. An additional 870 subjects living with HIV on ART contributed 4217 PY. Mean hospitalisation rates were 9.4/100 PY among HIV controllers and 8.8/100 PY among medically controlled subjects. Non-AIDS-defining infections were the most common reason for hospitalisation (2.95/100 PY and 2.70/100 PY, respectively) and rates of cardiovascular hospitalisation were similar in both groups (0.45/100 PY and 0.76/100 PY, respectively). This study demonstrated that all-cause and cardiovascular hospitalisation rates did not differ between HIV controllers and people living with HIV on ART [82].

Whether a potential immunological benefit of ART in viral controllers outweighs the potential risks of ART toxicity and results in clinical benefit is unclear and the US Department of Health and Human Services (DHHS) guidelines state that there is insufficient evidence to adequately compare risks and benefits of ART in viral controllers [83]. It is unlikely that randomised controlled trials will be conducted, given the very low

prevalence of viral controllers [73]. It is well established that there is no risk of sexual transmission from a person living with HIV receiving ART with an undetectable plasma HIV viral load for >6 months. Although the risk of transmission of HIV from a viral controller not receiving ART to a sexual partner is therefore likely to be very low or zero, there are no robust data in this setting. No transmission has ever been confirmed, with only one possible transmission reported in this context [84]. Further, to date there are no validated markers that can predict loss of viral control.

### 4.7.3 Summary

There is a clear rationale for offering ART even in the absence of detectable plasma HIV RNA levels among viral controllers. If a decision to defer ART is made, people with spontaneous viral control should be followed closely as some may experience CD4 cell count decline, loss of viral control or complications related to HIV infection. Monitoring for comorbidities should be in line with BHIVA monitoring guidelines [85], national screening guidelines (e.g. population bowel cancer screening) or as indicated based on symptoms and/or laboratory abnormalities. We do not recommend enhanced screening in people with spontaneous viral control off ART.

Overall the quality of evidence remains low and current recommendations are based on expert opinion. Enrolment in cohort studies or clinical trials for people with spontaneous viral control should be offered where available. People with spontaneous viral control, including those reluctant to start ART, may particularly benefit from signposting to peer support and third sector organisations. The lack of high-quality data to guide recommendations for people with spontaneous viral control may result in anxiety; people should be signposted or referred to appropriate psychological support in line with BHIVA standards [86].

## 4.8 Stopping therapy

### Recommendation

- We recommend against treatment interruption or intermittent therapy in individuals stable on a virally suppressive ART regimen except in the context of clinical trials (Grade 1A).

### Auditable outcomes

- Proportion of individuals not on ART having previously been on ART.
- Documentation of reasons for stopping in those who stopped.

### Rationale

Several randomised controlled trials have investigated the efficacy of CD4 cell count-guided intermittent therapy as a potential strategy to reduce long-term risk of drug toxicity and drug resistance [6,87-89]. In the

largest of these trials, subjects were randomly allocated to either CD4 cell count-guided intermittent therapy (stopping ART once CD4 count  $>350$  cells/mm<sup>3</sup>, restarting when CD4 count falls to 250 cells/mm<sup>3</sup>) or continuous ART [6]. The trial showed that intermittent therapy was associated with a significantly higher rate of opportunistic disease and all-cause mortality and a higher rate of major CVD or renal or hepatic disease. The effect was seen at all CD4 cell count levels. The study showed for the first time that continuous ART with virological suppression is associated with a reduction in the risk of non-AIDS comorbidities and all-cause mortality as well as HIV disease progression. For this reason, treatment interruption or intermittent therapy is not recommended.

Once ART has been started in a person with HIV, it should be continued. Interruptions of ART should only be considered in exceptional circumstances. These may include:

- Severe drug toxicity (e.g. hepatotoxicity);
- Severe psychological distress;
- Severe intercurrent illness or major organ dysfunction;
- Participation in a clinical trial investigating treatment interruption.

For guidance on pharmacokinetic considerations when stopping ART (see Section 6.2.2 Stopping therapy: pharmacological considerations).

## 4.9 References

1. Lundgren JD, Babiker AG, Gordin F *et al.*; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med* 2015; **373**: 795–807.
2. Danel C, Moh R, Gabillard D *et al.* TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med* 2015; **373**: 808–822.
3. Rodger AJ, Cambiano V, Bruun T *et al.*; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. *JAMA* 2016; **316**: 171–181.
4. Rodger AJ, Cambiano V, Bruun T *et al.*; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet* 2019; **393**: 2428–2438.
5. Bavinton BR, Pinto AN, Phanuphak N *et al.*; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. *Lancet HIV* 2018; **5**: e438–e447.

6. El-Sadr WM, Lundgren J, Neaton JD *et al.* CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006; **355**: 2283–2296.
7. Coffey S, Bacchetti P, Sachdev D *et al.* RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. *AIDS* 2019; **33**: 825–832.
8. Ford N, Migone C, Calmy A *et al.* Benefits and risks of rapid initiation of antiretroviral therapy. *AIDS* 2018; **32**: 17–23.
9. Koenig SP, Dorvil N, Dévieux JG *et al.* Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. *PLoS Med* 2017; **14**: e1002357.
10. Kerschberger B, Aung A, Mpala Q *et al.* Predicting, diagnosing, and treating acute and early HIV infection in a public sector facility in Eswatini. *J Acquir Immune Defic Syndr* 2021; **88**: 506–517.
11. Lilian RR, Rees K, McIntyre JA *et al.* Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa: analysis of routine data. *PLoS One* 2020; **15**: e0227572.
12. Ahmed I, Demissie M, Worku A *et al.* Effectiveness of same-day antiretroviral therapy initiation in retention outcomes among people living with human immunodeficiency virus in Ethiopia: empirical evidence. *BMC Public Health* 2020; **20**: 1802.
13. Berenguer, J, Parrondo J, Landovitz RJ. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: a mathematical model. *PLoS One* 2020; **15**: e0236032.
14. Mateo-Urdiales A, Johnson S, Smith R *et al.* Rapid initiation of antiretroviral therapy for people living with HIV. *Cochrane Database Syst Rev* 2019; **6**: CD012962.
15. Whitlock G, Carbonell M, Blackwell S, Nwokolo N; Dean Street Collaborative Group. Rapid initiation of antiretroviral therapy in those with newly diagnosed HIV infection in London, UK. *HIV Med* 2019; **20**: 699–703.
16. Girometti N, Lander F, McOwan A *et al.*; Dean Street Collaborative Group. Rapid ART start in early HIV infection: time to viral load suppression and retention in care in a London cohort. *HIV Med* 2020; **21**: 613–615.
17. Cuzin L, Cotte L, Delpierre C *et al.* Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort. *PLoS One* 2019; **14**: e0222067.
18. Ross J, Ingabire C, Umwiza F *et al.* How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda—a qualitative study. *PLoS One* 2021; **16**: e0251645.
19. Nelson M, Dockrell D, Edwards S *et al.*; BHIVA Guidelines Subcommittee. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. *HIV Med* 2011; **12 Suppl 2**: 1–140.
20. Bracchi M, van Halsema C, Post F *et al.* British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. *HIV Med* 2019; **20 Suppl 6**: s2-s83.

21. Burke RM, Rickman HM, Singh V *et al.* Same-day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review. *HIV Med* 2022; **23**: 4–15.
22. Zolopa A, Andersen J, Powderly W *et al.* Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. *PLoS One* 2009; **4**: e5575.
23. Sax PE, Sloan CE, Schackman BR *et al.* Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. *HIV Clin Trials* 2010; **11**: 248–259.
24. Morris A, Wachter RM, Luce J *et al.* Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe *Pneumocystis carinii* pneumonia. *AIDS* 2003; **17**: 73–80.
25. Croda J, Croda MG, Neves A, De Sousa dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. *Crit Care Med* 2009; **37**: 1605–1611.
26. Grant PM, Komarow L, Andersen J *et al.* Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. *PLoS One* 2010; **5**: e11416.
27. Makadzange AT, Ndhlovu CE, Takarinda K *et al.* Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. *Clin Infect Dis* 2010; **50**: 1532–1538.
28. Boulware DR, Meya DB, Muzoora C *et al.* Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. *N Engl J Med* 2014; **370**: 2487–2498.
29. Rosenberg NE, Pilcher CD, Busch MP, Cohen MS. How can we better identify early HIV infections? *Curr Opin HIV AIDS* 2015; **10**: 61–68.
30. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. *N Engl J Med* 2011; **364**: 1943–1954.
31. Cohen MS, Chen YQ, McCauley M *et al.*; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med* 2016; **375**: 830–839.
32. Goujard C, Bonarek M, Meyer L *et al.* CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. *Clin Infect Dis* 2006; **42**: 709–715.
33. Lodi S, Phillips A, Touloumi G *et al.* Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm<sup>3</sup>: assessment of need following changes in treatment guidelines. *Clin Infect Dis* 2011; **53**: 817–825.
34. Socias ME, Sued O, Laufer N *et al.* Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. *J Int AIDS Soc* 2011; **14**: 40.
35. CASCADE Collaboration. The relationships between the HIV test interval, demographic factors and HIV disease progression. *Epidemiol Infect* 2001; **127**: 91–100.

36. Tyrer F, Walker AS, Gillett J, Porter K. The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohort. *Epidemiol Infect* 2003; **131**: 1117–1123.
37. Muscatello A, Nozza S, Fabbiani M *et al.*; Inaction Study Group. Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection—results of Italian Network of ACuTe HIV Infection (IN ACTION) Retrospective Study. *Pathog Immun* 2020; **5**: 8–33.
38. Taramasso L, Fabbiani M, Nozza S *et al.*; IN ACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV Infection (IN ACTION) cohort. *HIV Med* 2020; **21**: 523–535.
39. Guo C, Wu Y, Zhang Y *et al.* Transmitted drug resistance in antiretroviral therapy-naive persons with acute/early/primary HIV infection: a systematic review and meta-analysis. *Front Pharmacol* 2021; **12**: 718763.
40. Macatangay BJ, Rinaldo CR. Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help? *Curr Opin HIV AIDS* 2015; **10**: 55–60.
41. Ananworanich J, Dube K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? *Curr Opin HIV AIDS* 2015; **10**: 18–28.
42. Le T, Wright EJ, Smith DM *et al.* Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. *N Engl J Med* 2013; **368**: 218–230.
43. Thornhill J, Inshaw J, Oomeer S *et al.* Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. *J Int AIDS Soc* 2014; **17**: 19480.
44. Okulicz JF, Le TD, Agan BK *et al.* Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. *JAMA Intern Med* 2015; **175**: 88–99.
45. Parsons V, Porter K, Gilson R, Hart G. Attitudes and beliefs towards early ART initiation in MSM with primary HIV infection. *J Int AIDS Soc* 2014; **17**: 19732.
46. Rutstein SE, Ananworanich J, Fidler S *et al.* Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. *J Int AIDS Soc* 2017; **20**: 21579.
47. Kazer SW, Walker BD, Shalek AK. Evolution and diversity of immune responses during acute HIV infection. *Immunity* 2020; **53**: 908–924.
48. Rosenberg ES, Altfeld M, Pooh SH *et al.* Immune control of HIV-1 after early treatment of acute infection. *Nature* 2000; **407**: 523–526.
49. Williams JP, Hurst J, Stohr W *et al.* HIV-1 DNA predicts disease progression and post-treatment virological control. *Elife* 2014; **3**: e03821.
50. Cheret A, Bacchus-Souffan C, Avettand-Fenoel V *et al.* Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. *J Antimicrob Chemother* 2015; **70**: 2108–2120.

51. Laanani M, Ghosn J, Essat A *et al.* Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. *Clin Infect Dis* 2015; **60**: 1715–1721.
52. Thornhill J, Fidler S, Frater J. Advancing the HIV cure agenda: the next 5 years. *Curr Opin Infect Dis* 2015; **28**: 1–9.
53. Katlama C, Deeks SG, Autran B *et al.* Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. *Lancet* 2013; **381**: 2109–2117.
54. Quinn TC, Wawer MJ, Sewankambo N *et al.* Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med* 2000; **342**: 921–929.
55. Castilla J, Del Romero J, Hernando V *et al.* Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. *J Acquir Immune Defic Syndr* 2005; **40**: 96–101.
56. Del Romero J, Castilla J, Hernando V *et al.* Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. *BMJ* 2010; **340**: c2205.
57. Melo MG, Santos BR, De Cassia Lira R *et al.* Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. *Sex Transm Dis* 2008; **35**: 912–915.
58. Attia S, Egger M, Muller M *et al.* Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS* 2009; **23**: 1397–1404.
59. Barreiro P, del Romero J, Leal M *et al.* Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. *J Acquir Immune Defic Syndr* 2006; **43**: 324–326.
60. Cohen MS, Chen YQ, McCauley M *et al.* Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; **365**: 493–505.
61. Donnell D, Baeten JM, Kiarie J *et al.* Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet* 2010; **375**: 2092–2098.
62. Walmsley SL, Antela A, Clumeck N *et al.*; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med* 2013; **369**: 1807–1818.
63. Cahn P, Madero JS, Arribas JR *et al.* Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naïve adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr* 2020; **83**: 310–318.
64. Sax PE, DeJesus E, Crofoot G *et al.* Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. *AIDS* 2018; **32**: 1723–1725.
65. National Institute for Health and Care Excellence. *Fertility problems: assessment and treatment. Clinical guideline [CG156]*. Updated 2017. Available at: <https://www.nice.org.uk/guidance/cg156/ifp/chapter/hiv-hepatitis-b-and-hepatitis-c> (accessed July 2022).

66. Brady M, Rodger A, Asboe D *et al.* BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. *HIV Med* 2019; **20 Suppl 2**: s2–s80.
67. Gilleece Y, Tariq S, Bamford A *et al.* British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. *HIV Med* 2019; **20 Suppl 3**: s2–s85.
68. Grabar S, Selinger-Leneman H, Abgrall S. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. *AIDS* 2009; **23**: 1163–1169.
69. Sajadi MM, Constantine N, Abgrall S *et al.* Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. *J Acquir Immune Defic Syndr* 2009; **50**: 403–408.
70. Sereti I, Gulick RM, Krishnan S *et al.*; INSIGHT START Study Group. ART in HIV-positive persons with low pretreatment viremia: results from the START Trial. *J Acquir Immune Defic Syndr* 2019; **81**: 456–462.
71. Leon A, Perez I, Ruiz-Mateos E *et al.*; EC and Immune Pathogenesis Working group of the Spanish AIDS Research Network. Rate and predictors of progression in elite and viremic HIV-1 controllers. *AIDS* 2016; **30**: 1209–1220.
72. Okulicz JF, Marconi VC, Ladrum ML *et al.* Clinical outcomes of elite controllers, viremic controllers and long term non-progressors in the US Department of Defense natural history study. *J Infect Dis* 2009; **200**: 1714–1723.
73. Plaçais L, Boufassa F, Lécuroux C *et al.*; ANRS CO21 study group. Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. *EClinicalMedicine* 2021; **37**: 100963.
74. Crowell TA, Gebo KA, Blankson JN *et al.*; HIV Research Network. Hospitalization rates among HIV elite controllers and persons with medically controlled HIV infection. *J Infect Dis* 2015; **211**: 1692–1702.
75. Borrell M, Fernández I, Etcheverry F *et al.* High rates of long-term progression in HIV-1-positive elite controllers. *J Int AIDS Soc* 2021; **24**: e25675.
76. Serrano-Villar S, Pérez-Elías MJ, Drona F *et al.* Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. *PLoS One* 2014; **9**: e85798.
77. Hunt PW, Benchley J, Sinclair E *et al.* Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable HIV RNA levels in the absence of therapy. *J Infect Dis* 2008; **197**: 126–133.
78. Pereyra F, Lo J, Triant VA *et al.* Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. *AIDS* 2012; **26**: 2409–2412.
79. Hatano H, Yukl SA, Ferre AL *et al.* Prospective antiretroviral treatment of asymptomatic, HIV-1-infected controllers. *PLoS Pathog* 2013; **9**: e1003691.
80. Li JZ, Segal FP, Bosch RJ *et al.*; AIDS Clinical Trials Group Study A5308 Team. Antiretroviral therapy reduces T-cell activation and immune exhaustion markers in human immunodeficiency virus controllers. *Clin Infect Dis* 2020; **70**: 1636–1642.

81. Karris MY, Haubrich RH. Antiretroviral therapy in the elite controller: justified or premature? *J Infect Dis* 2015; **211**: 1689–1691.
82. Crowell TA, Ganesan A, Berry SA *et al.*; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group. Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study. *J Int AIDS Soc* 2016; **19**: 20524.
83. US Department of Health and Human Services. *Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV*. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines> (accessed April 2022).
84. Killian MS, Vyas GN, Mehta R *et al.* Possible transmission of human immunodeficiency virus-1 infection from an elite controller to a patient who progressed to acquired immunodeficiency syndrome: a case report. *J Med Case Rep* 2012 **6**: 291.
85. Angus B, Brook G, Awosusi F *et al.* *BHIVA guidelines for the routine investigation and monitoring of adult HIV-1 positive individuals 2016 (2019 interim update)*. Available at: <https://www.bhiva.org/monitoring-guidelines> (accessed September 2022).
86. British HIV Association. *British HIV Association standards of care for people living with HIV 2018*. Available at: <https://www.bhiva.org/standards-of-care-2018> (accessed July 2022).
87. Ananworanich J, Gayet-Ageron A, Le Braz M *et al.* CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet* 2006; **368**: 459–465.
88. Cardiello PG, Hassink E, Ananworanich J *et al.* A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. *Clin Infect Dis* 2005; **40**: 594–600.
89. Danel C, Moh R, Minga A *et al.* CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. *Lancet* 2006; **367**: 1981–1989.
90. Powers KA, Ghani AC, Miller WC *et al.* The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. *Lancet* 2011; **378**: 256–268.
91. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. *AIDS Behav* 2008; **12**: 677–684.
92. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. *J Infect Dis* 2008; **198**: 687–693.
93. Pao D, Fisher M, Hue S *et al.* Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. *AIDS* 2005; **19**: 85–90.
94. De Clercq J, Rutsaert S, De Scheerder MA *et al.* Benefits of antiretroviral therapy initiation during acute HIV infection. *Acta Clin Belg* 2022; **77**: 168–176.

## 5 What to start

### 5.1 Introduction

Following the GRADE process, as in the previous 2015 BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy [1], clinical outcomes were discussed and ranked according to importance by the writing group (critical, important and not important). A list of 10 outcomes, broadly reflecting virological outcomes and adverse events, were considered for these guidelines. In the previous guidelines [1], virological success outcomes were ranked the highest, but in developing the present guidelines, virological failure and resistance were considered to be more important, given the high rates of virological success of most of the recommended regimens, as well as the impact of these outcomes on subsequent treatment. Adverse event outcomes also moved higher up in the ranking, owing to the importance of tolerability for long-term treatment. The outcomes and ranking were as follows:

Critical outcomes:

1. Proportion with virological failure at week 48
2. Proportion developing resistance at virological failure
3. Proportion discontinuing treatment due to an adverse event
4. Proportion with virological success at week 48
5. Proportion with virological success at week 96

Important outcomes:

6. Proportion with a drug-related serious adverse event
7. Proportion with any serious adverse event
8. Proportion with drug-related grade 3/4 adverse events
9. Proportion with virological failure at week 96
10. Proportion with any grade 3/4 adverse event

Relevant randomised clinical trials identified from the literature search were evaluated according to these outcomes with a meta-analysis, forest plots and GRADE tables (see Appendix 3). This evaluation is referred to as the 'GRADE analysis' in the rationale for the treatment recommendations.

Of note, the recommendations in this section are for first-line therapy; there are several regimens not recommended first line but which are suitable for switch or to continue when clinically appropriate. For further details, see Section 5.10 Suppressed switch or maintenance.

The BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals should be consulted for guidance on assessment of people living with HIV before initiation of ART and monitoring individuals on ART [2]. The monitoring guidelines recommend that all newly diagnosed individuals should have a baseline genotypic resistance test. Implications on the selection of first-line ART if baseline viral resistance is detected are discussed in Section 6.2.4 TDM.

## Recommendations

Recommendations for choice of first-line ART are summarised in Table 5.1. Where clinically appropriate, lamivudine and emtricitabine can be considered interchangeable (see Section 5.3.6 Use of abacavir in people with CVD risk factors).

**Table 5.1** Recommendations for choice of first-line ART (in alphabetical order by core agent)

| <b>Recommended as initial treatment for most people living with HIV</b>   |  |
|---|--|
| <i>Abacavir should only be used for people who are HLA B*5701 negative and where a three-drug regimen is necessary, but tenofovir DX and tenofovir AF are not suitable and abacavir is the most clinically appropriate option</i> |  |
| <b>Regimen</b>  | <b>Specific details</b>  |
| Bictegravir/emtricitabine/tenofovir AF  |  |
| Dolutegravir plus emtricitabine/tenofovir AF or emtricitabine/tenofovir DX  | Bone/renal caveats for tenofovir DX  |
| Dolutegravir/lamivudine   | No baseline lamivudine resistance<br>Baseline viral load <500,000 copies/mL<br><b>No requirement for tenofovir for hepatitis B treatment or prevention</b> |
| <b>Recommended as initial treatment in certain clinical situations (Grade 2A)</b>   |  |
| <b>Regimen</b>  | <b>Specific details</b>  |
| Darunavir plus cobicistat or ritonavir plus emtricitabine plus tenofovir AF or tenofovir DX   | Bone/renal caveats for tenofovir DX  |
| Doravirine plus emtricitabine or lamivudine plus tenofovir AF or tenofovir DX   | Bone/renal caveats for tenofovir DX  |
| Efavirenz plus emtricitabine or lamivudine plus abacavir or tenofovir AF or tenofovir DX  | May be a first-line choice in pregnancy and for people on TB treatment but not recommended outside these scenarios   |

|  |   |
|--|---|
|  | No requirement for tenofovir for hepatitis B treatment or prevention (abacavir/lamivudine only)   |
| Raltegravir plus emtricitabine plus tenofovir AF or tenofovir DX | Baseline viral load less than 100,000 copies/mL<br>Bone/renal caveats for tenofovir DX  |
| Dolutegravir plus abacavir plus lamivudine                       | Where a three-drug regimen is necessary and abacavir is the most clinically appropriate option (see below)<br><br>No requirement for tenofovir for hepatitis B treatment or prevention (abacavir/lamivudine only) |

Tenofovir DX, tenofovir disoproxil.

Where a woman living with HIV is pregnant, or planning to conceive, the BHIVA pregnancy guidelines should be followed [3].

It may be necessary to use abacavir when a second NRTI is needed (e.g. because of NRTI resistance or HIV-related CNS disease) but tenofovir DX and tenofovir AF are contraindicated (e.g. in the presence of severe acute kidney injury) or where abacavir is considered the most clinically appropriate option (e.g. in pregnancy). While tenofovir AF demonstrates less renal toxicity than tenofovir DF, tenofovir AF has been associated with kidney injury in rare cases [4]. Drugs from other classes can be considered where tenofovir cannot be used to construct an appropriate regimen with the caveat that there may be a paucity of supportive evidence.

We have removed the previous CD4 count caveat for dolutegravir/lamivudine based on the DOLCE study [5]. In the DOLCE study, 230 ART-naïve adults with CD4 counts <200 cells/mm<sup>3</sup> were randomly assigned to open-label dolutegravir/lamivudine or dolutegravir plus tenofovir DX with lamivudine or emtricitabine. Median baseline CD4 cell count was 116 cells/mm<sup>3</sup> (43% had a baseline CD4 count >100 cells/mm<sup>3</sup>) and median baseline viral load was 151,000 copies/mL (baseline viral load was >100,000 copies/mL in 61%, >500,000 copies/mL in 23% and >1,000,000 copies/mL in 10%). Week 48 viral suppression by intention-to-treat analysis in the whole population was 82.2% on dual ART and 80.5% on triple ART, and 80.9% and 76.6%, respectively, in the subpopulation with baseline viral load >100,000 copies/mL. The proportion meeting virological non-response criteria was identical in each arm (11.8%) and no emergent resistance was identified among the successfully amplified samples (11/27).

### Auditable outcome

- Proportion of individuals commencing an ART regimen recommended as initial treatment for most people living with HIV.

## 5.2 Regimens recommended for most people

The INSTI-based three-drug combinations recommended first line have been compared in large, high-quality randomised controlled trials with at least one other preferred regimen, or with efavirenz or boosted darunavir-based treatment.

- Dolutegravir with abacavir/lamivudine or tenofovir DX/emtricitabine has compared favourably on a number of critical outcomes when compared with efavirenz-based [6-8] or boosted darunavir-based regimens [9].
- Tenofovir AF/emtricitabine/bictegravir has been compared with abacavir/lamivudine/dolutegravir [10] and with tenofovir AF/emtricitabine with dolutegravir [11]. No significant differences for any critical outcome were demonstrated in either of these comparisons.
- Tenofovir DF/emtricitabine with dolutegravir has been compared with the novel two-drug combination of dolutegravir/lamivudine, demonstrating comparable results for critical outcomes [12].

### 5.2.1 Dolutegravir versus efavirenz

Dolutegravir with two nucleoside reverse transcriptase inhibitors (NRTIs) has been compared with efavirenz with two NRTIs for first-line treatment in the ADVANCE, NAMSAL and SINGLE studies [6-8]. In the meta-analysis conducted for these guidelines there were overall differences in favour of dolutegravir for virological success, adverse event-driven discontinuation, and both overall and drug-related grade 3 and 4 adverse events. Virological failure was not significantly different, but in the meta-analysis there was significantly more development of resistance at failure for the efavirenz-based combinations at week 48 (odds ratio [OR] 0.11, 95% confidence interval [CI] 0.02–0.61;  $P=0.01$ ).

The ADVANCE study was a large, open-label, randomised comparison of two dolutegravir-based regimens, with either tenofovir DF/emtricitabine or tenofovir AF/emtricitabine, and a third arm comprising tenofovir DF/emtricitabine/efavirenz [6]. At week 48, this trial demonstrated non-inferiority of each arm, according to a pre-specified significance level. However, 85% of those taking tenofovir DF/emtricitabine/dolutegravir had a viral load <50 copies/mL, compared with 79% of those taking tenofovir DF/emtricitabine/efavirenz, and adverse event-related discontinuation was an important factor accounting for this difference.

NAMSAL was an open-label randomised comparison of dolutegravir-based treatment with lower-dose efavirenz (400 mg) [7]. Viral suppression at week 48 was non-inferior with a numerical advantage for dolutegravir (74.5% vs 69%).

The SINGLE study was a large, double-blind randomised comparison of abacavir/lamivudine/dolutegravir and tenofovir DF/emtricitabine/efavirenz [8]. In this study, at week 48, there was clear superiority for viral load outcomes favouring dolutegravir and again there were significantly more adverse event-related discontinuations in those taking efavirenz.

The week 96 results of the above studies were in accord with the week 48 results. However, the ADVANCE study also reported more failure with resistance at week 96 in those taking efavirenz-based regimens (13 of 21 participants taking efavirenz with virological failure and resistance data, vs 2 of 28 taking dolutegravir: OR for dolutegravir vs efavirenz 0.05, 95% CI 0.01–0.26;  $P=0.0004$ ).

### 5.2.2 Dolutegravir versus bictegravir

The fixed-dose combination tenofovir AF/emtricitabine/bictegravir has been compared in large, high-quality, randomised controlled trials with tenofovir AF/emtricitabine/dolutegravir (GS-1490) [11], as well as with abacavir/lamivudine/dolutegravir (GS-1489) [10]. Both these double-blind studies established non-inferiority for virological success (viral load <50 copies/mL for tenofovir AF/emtricitabine/bictegravir vs abacavir/lamivudine/dolutegravir at week 48 = 92.4% vs 93.0%, and at week 96 = 88% vs 90%; viral load <50 copies/mL for tenofovir AF/emtricitabine/bictegravir vs tenofovir AF/emtricitabine/dolutegravir at week 48 = 89% vs 93% and at week 96 = 84% vs 86%). In GS-1490, at week 48, there were 14 cases of virological failure among those taking bictegravir and four among those taking dolutegravir; this difference reached statistical significance in our analysis (OR 0.27, 95% CI 0.09–0.84). However, virological failure in 11 of the participants on bictegravir was due to reasons not related to drug efficacy. In our analysis, considering the results of both studies at week 48, there was no significant difference in virological failure, and this was also true for both studies considered separately and together at week 96. Among those who experienced virological failure, no resistance was detected in any arm through to week 96. With respect to adverse events, in GS-1490, there was a difference in serious adverse events favouring dolutegravir at week 96 (bictegravir,  $n=55$  [17%] vs dolutegravir,  $n=33$  [10%]; OR 0.54, 95% CI 0.34–0.86). However, in the same study there was no difference in serious adverse events judged to be related to study drug and no significant differences were seen at any other timepoint in either study. No differences were seen in any other adverse event outcome chosen for our analysis.

**Despite non-inferior efficacy to tenofovir AF/emtricitabine/bictegravir, we no longer recommend abacavir/lamivudine/dolutegravir for initial therapy based on the following:**

- **No difference in efficacy compared to dolutegravir/lamivudine (see Section 5.2.3 Dolutegravir/lamivudine);**

- Association with CVD;
- Requirement for HLA B\*5701 screening.

A huge amount of evidence has accrued regarding the association between abacavir and CVD (see Section 8.3 Cardiovascular and metabolic disease); each study has its own strengths and limitations but most show consistent findings, i.e. an association between abacavir use and increased CVD risk, with data from the REPRIEVE trial (randomised comparison of pitavastatin vs placebo for primary prevention of CVD in virally suppressed people) confirming this association [13] (see Section 5.3.6 Use of abacavir in people with CVD risk factors).

The writing group therefore concludes that abacavir is not a preferred option in initial therapy, in line with European and US guidelines.

### 5.2.3 Dolutegravir/lamivudine

Once-daily dolutegravir in combination with lamivudine as first-line treatment has been compared with standard triple therapy in two Phase 3 randomised clinical trials (GEMINI 1 and 2) [12]. Both studies compared dolutegravir/lamivudine with dolutegravir and tenofovir DF/emtricitabine. Investigators and participants were blinded to study drug allocation as the lamivudine and tenofovir DF/emtricitabine were over-encapsulated to be visually similar. Across the two studies, 1441 participants were randomly assigned to treatment. Non-inferiority of the two-drug regimen to the three-drug regimen was demonstrated in both studies at both week 48 and week 96 (viral load <50 copies/mL at week 48 by intention-to-treat analysis, for two-drug vs three-drug: GEMINI 1, 90% vs 93%; GEMINI 2, 93% vs 94%). People with a pre-treatment viral load >500,000 copies/mL were excluded, as were those with hepatitis B co-infection, pre-existing antiretroviral resistance to lamivudine and opportunistic disease (other than cutaneous Kaposi's sarcoma with a CD4 count >200 cells/mm<sup>3</sup>) and pregnant women. Baseline INSTI resistance testing was not undertaken. The viral load exclusion may limit the generalisability of the findings, although a small number of individuals did have a viral load >500,000 copies/mL at the baseline visit. The proportion of people with viral loads >500,000 copies/mL in recent clinical trials is generally small. For example, in the ADVANCE study [6], where participants had relatively advanced HIV with a median CD4 count <350 cells/mm<sup>3</sup> in all arms, the proportion with a baseline viral load above 500,000 copies/mL was 2.7% (28 or 1053 participants) compared with 2% (n=28) in the GEMINI studies [12]. Virological success at week 48 and week 96 in those with a baseline CD4 count <200 cells/mm<sup>3</sup> was lower among those on the two-drug regimen versus the three-drug regimen (week 48: 50/63 [79.4%] on the two-drug regimen vs 51/55 [92.7%] on the three-drug regimen; week 96: 43/63 [68.3%] vs 48/55 [87.3%], respectively). Treatment failures were largely because of reasons not related to study drug efficacy. There were no significant differences in virological failure at either week

48 (two-drug regimen:  $n=20$  [3%] vs three-drug regimen:  $n=13$  [2%]; OR 1.56, 95% CI 0.77–3.15) or week 96 (two-drug regimen:  $n=22$  [3%] vs three-drug regimen:  $n=14$  [2%]; OR 1.59, 95% CI 0.77–3.15). There were no failures with resistance through to week 96. The writing group has considered these results and come to the view that there remains uncertainty regarding comparisons stratified by HIV-1 RNA  $>500,000$  versus  $\leq 500,000$  copies/mL which were not included in the original GEMINI studies analysis plans. Therefore we recommend that clinicians are cautious in the use of this regimen in certain people living with HIV. With respect to adverse events outcomes, there were no differences in adverse event driven discontinuation, serious adverse events, drug-related serious adverse events and either of the grade 3 and 4 adverse event outcomes.

In summary, dolutegravir/lamivudine is recommended as initial treatment for most people living with HIV with the following caveats:

- It is not recommended for those with pre-treatment viral load  $>500,000$  copies/mL;
- It is not recommended for those who require tenofovir for hepatitis B treatment or prevention;
- It is not recommended in the context of transmitted drug resistance (TDR);
- It is not routinely recommended for those with documented/archived/suspected M184IV mutation;
- It is not recommended for those with HIV-associated cognitive impairment;
- It should be considered with caution in specific populations such as those with PHI, opportunistic diseases or renal impairment.

## 5.3 Regimens recommended in certain clinical situations

### 5.3.1 Doravirine

Doravirine has been evaluated with a two-NRTI backbone in two large randomised controlled trials:

- DRIVE-AHEAD: a double-blind, non-inferiority trial comparing the fixed-dose combination of doravirine/lamivudine/tenofovir DF with efavirenz/emtricitabine/tenofovir DF, both given once daily [14];
- DRIVE-FORWARD: a double-blind, non-inferiority trial comparing once-daily doravirine with once-daily darunavir/ritonavir, both given with investigator-selected tenofovir DF/emtricitabine (87%) or abacavir/lamivudine (13%) [15].

In the comparison with efavirenz-based treatment, non-inferiority was demonstrated at week 48. The comparison was similar on all critical outcomes, other than for adverse events. There were generally fewer adverse events with doravirine; in the GRADE analysis there were significantly fewer discontinuations for

adverse events in the doravirine arm (OR 0.44, 95% CI 0.21–0.92). This difference was mainly due to well-recognised neuropsychiatric side effects of efavirenz. There were no changes in these comparisons from week 48 to week 96. At week 48, genotypes were obtained for 22 (doravirine) and 23 (efavirenz) participants with virological failure or those who discontinued without protocol-defined virological failure. NNRTI resistance was detected in 1.9% of participants taking doravirine versus 3.3% taking efavirenz, while NRTI resistance was detected in 1.4% of participants for both treatment options. At week 96, for each regimen, resistance was detected in similar proportions compared to week 48.

In the comparison with darunavir/ritonavir, non-inferiority was demonstrated at week 48. The proportion with virological success at week 96 favoured doravirine: viral load <50 copies/mL was 277/379 (73%) in the doravirine group and 248/376 (66%) in the darunavir group (OR 1.40, 95% CI 1.03–1.91). A Kaplan–Meier analysis showed a greater risk over time of discontinuation of darunavir due to adverse events; these were largely related to gastrointestinal and lipid side effects. No significant differences in the other GRADE outcomes were seen. Treatment-emergent resistance to any drug was seen in 2/383 participants in the doravirine arm, and 1/383 in the darunavir arm through to week 96. The virus from the participant in the darunavir arm was noted to have phenotypic resistance to emtricitabine and lamivudine, though genotyping failed.

The rationale for recommending doravirine-based ART only for certain clinical scenarios is the current lack of comparison with INSTIs. Doravirine has shown broadly similar outcomes to efavirenz and boosted darunavir, whereas recommended INSTIs have shown superior outcomes to these agents. There is limited experience with abacavir/lamivudine with doravirine.

### 5.3.2 Raltegravir

SPRING-2 [16] was a double-blind randomised controlled trial of tenofovir DF/emtricitabine or abacavir/lamivudine plus raltegravir versus tenofovir DF/emtricitabine or abacavir/lamivudine plus dolutegravir. In SPRING-2, dolutegravir was non-inferior to raltegravir at weeks 48 and 96 in terms of virological success [16]. When analysed by baseline viral load (participants were stratified by baseline viral load at randomisation) there was no significant difference in virological response at baseline viral load >100,000 copies/mL at 48 weeks (OR for success on dolutegravir 1.57, 95% CI 0.83–2.97;  $P=0.17$ ) but by week 96 there was a significant difference favouring dolutegravir (OR for success on dolutegravir 2.10, 95% CI 1.17–3.75;  $P=0.01$ ).

SPRING-2 was not powered for a stratified viral load comparison but our analysis of the data showed a trend towards less virological failure on dolutegravir (OR 0.63, 95% CI 0.35–1.12) which was statistically significant

at week 96 (OR 0.48, 95% CI 0.28–0.82). We were unable to analyse virological failure by baseline viral load as these data were not available. There was a trend towards less virological failure with resistance on dolutegravir but confidence intervals were wide (at week 48: OR 0.13, 95% CI 0.01–2.61; at week 96: OR 0.13, 95% CI 0.01–2.47). Other critical outcomes were similar between raltegravir and dolutegravir.

In summary, raltegravir is recommended only in certain clinical scenarios based on the underperformance in terms of virological success for raltegravir compared to dolutegravir among people with a baseline viral load >100,000 copies/mL and the higher risk of virological failure at week 96, along with a numerically higher risk of resistance development which related to its demonstrably low genetic barrier [17].

### 5.3.3 Darunavir/ritonavir

In the randomised open-label Phase 3b FLAMINGO study, darunavir/ritonavir was compared with dolutegravir given in combination with investigator-selected tenofovir DF/emtricitabine or abacavir/lamivudine [9].

Dolutegravir demonstrated superior overall efficacy compared with darunavir/ritonavir in FLAMINGO (OR for success at 48 weeks 1.08, 95% CI 1.01–1.17;  $P=0.03$ ) [9]. Superiority for virological success was maintained at week 96 (OR 1.92, 95% CI 1.27–2.91) [15]. The superior outcome related to a combination of fewer overall discontinuations and fewer discontinuations related to adverse events, however there was no difference in rates of virological failure and no instance of drug resistance in either arm. There were fewer discontinuations because of adverse events in those taking dolutegravir versus boosted darunavir at week 48 ( $n=3$  [1%] vs  $n=9$  [4%]) and at week 96 ( $n=5$  [2%] vs  $n=13$  [5%]). However, in our analysis these numerical differences did not reach statistical significance at either timepoint. There were significantly more clinically serious adverse events in the dolutegravir arm (OR 2.00, 95% CI 1.05–3.80;  $P=0.03$ ) at week 96. Three serious adverse events were deemed possibly drug related in the dolutegravir arm (tendon rupture, polyarthrititis and suicide attempt) versus none in the darunavir arm. This numerical difference did not reach statistical significance in our analysis (OR 7.09, 95% CI 0.36–137.95;  $P=0.20$ ).

For the comparison between darunavir/ritonavir and raltegravir in the three-arm ACTG 5257 study [18], overall response was significantly higher for raltegravir (OR 1.83, 95% CI 1.16–2.89 at 96 weeks in favour of raltegravir;  $P=0.009$ ). The corresponding proportion of people with an undetectable HIV RNA at 96 weeks by intention-to-treat analysis was 88.3% for atazanavir/ritonavir, 93.9% for raltegravir and 89.4% for darunavir/ritonavir. Although a higher proportion of people experienced virological failure on darunavir/ritonavir (OR 0.69 favouring raltegravir, 95% CI 0.51–0.94;  $P=0.02$ ), individuals on raltegravir were more likely to develop resistance (OR 4.59, 95% CI 1.54–13.65;  $P=0.006$ ) favouring darunavir/ritonavir for

percentage of the total population with resistance. There were fewer discontinuations for toxicity in the raltegravir arm (8/603 vs 32/601 in the darunavir/ritonavir arm: OR 0.24, 95% CI 0.11–0.52); however, there were no significant differences for the critical outcomes of grade 3/4 clinical or laboratory adverse events, headache and diarrhoea.

In summary, darunavir/ritonavir was inferior to dolutegravir in FLAMINGO, inferior to raltegravir in ACTG 5257, has a high propensity for drug–drug interactions and was associated with a higher risk of CVD in one cohort study, although this has not been observed in other studies [19-21]. Based in this, boosted darunavir is only recommended in certain clinical scenarios, such as TDR, same-day ART initiation or high risk of suboptimal adherence where a higher barrier to resistance is desired.

#### **5.3.4 Atazanavir/ritonavir**

ARIA was a randomised, open-label, Phase 3b non-inferiority study comparing atazanavir/ritonavir with dolutegravir conducted in women only [22]. Dolutegravir was administered as a fixed-dose combination with abacavir/lamivudine, while the PI was given with tenofovir DF/emtricitabine. This study demonstrated superiority of dolutegravir/abacavir/lamivudine with viral load <50 copies/mL at week 48 demonstrated in 82% of participants taking the dolutegravir-based regimen versus 71% taking atazanavir/ritonavir (mean difference 10.5%, 95% CI 3.1–17.8;  $P=0.005$ ). This difference was mainly driven by lower rates of adverse event-related discontinuation (4% vs 7%) and virological non-response in the dolutegravir arm (16 vs 35 events, OR 0.42, 95% CI 0.22–0.78). In our analysis, there were significantly fewer grade 3/4 events in those taking dolutegravir.

Given the higher rates of virological failure and grade 3/4 adverse events along with the lower virological success, the use of atazanavir/ritonavir can be considered only in those where a boosted PI is required and who cannot take darunavir/ritonavir.

#### **5.3.5 Tenofovir DF/emtricitabine compared with tenofovir AF/emtricitabine**

In this analysis we considered Phase 3 randomised clinical trials. Two of the studies compared tenofovir DF/emtricitabine with tenofovir AF/emtricitabine in combination with elvitegravir/cobicistat, and one compared tenofovir DF/emtricitabine with tenofovir AF/emtricitabine in combination with darunavir/cobicistat; all three were double-blind trials [23,24]. The open-label ADVANCE study also included a comparison of tenofovir DF with tenofovir AF. However, efavirenz was given with tenofovir DF only, meaning that adverse events in particular were significantly affected by the efavirenz component. As a result, ADVANCE was excluded from the GRADE analysis.

In the GRADE analysis, a significant difference was seen only for the outcome of discontinuation for adverse events at week 48 (OR 1.97, 95% CI 1.08–3.59) and at week 96 (OR 1.88, 95% CI 1.08–3.26). In the trials in which elvitegravir/cobicistat was the third agent, discontinuation due to adverse events considered to be related to the study drug were very similar (tenofovir AF vs tenofovir DF: 7 [0.8%] vs 11 [1.3%] at week 48). However, a small number of participants discontinued tenofovir DF because of renal and bone events (four participants at week 48 and a further four at week 96) compared with none taking tenofovir AF. In the study in which darunavir/cobicistat was used as the third agent, adverse event-driven discontinuation was seen in 2% of those taking tenofovir AF versus 4% of those taking tenofovir DF at week 48. Renal adverse events were more common in those taking tenofovir DF (2% vs 6%) but none resulted in study drug discontinuation.

Decreases in bone mineral density (BMD), increases in markers of renal tubular dysfunction and changes in estimated glomerular filtration rate (eGFR) are generally seen in all these trials, favouring tenofovir AF. These changes are small and of uncertain clinical significance for the majority of people living with HIV.

Randomised trial data comparing continued tenofovir DF with switch to tenofovir AF/emtricitabine/elvitegravir/cobicistat showed greater improvement in renal biomarkers in people at higher risk of chronic kidney disease (CKD) than those at lower risk [25].

In conclusion, these differences between tenofovir AF and tenofovir DX are likely to have more clinical importance in people with established bone and/or renal disease, or in those with risk factors for these conditions where there is a desire to remove the risk of further drug-related deterioration.

### **5.3.6 Use of abacavir in people with CVD risk factors**

An association between abacavir use and increased risk of myocardial infarction/CVD has been found in many, although not all, observational studies and some randomised controlled trials. The findings from observational studies have been most consistent for increased risk of CVD with recent exposure to abacavir. A systematic review and meta-analysis of 17 studies found overall relative risks of 1.54 (95% CI 1.37–1.73) for acute myocardial infarction and 1.61 (95% CI 1.48–1.75) for all CVD from recent exposure to abacavir [26]. The findings for cumulative exposure in this study were less clear. The populations included in the randomised controlled trials used to make recommendations for initial treatment in people living with HIV are too small, and with too low a risk for CVD, to draw conclusions about CVD outcomes compared with any other adverse event.

More recently, the REPRIEVE trial (randomised comparison of pitavastatin vs placebo for primary prevention of CVD in virally suppressed people) confirmed an association between abacavir and CVD in a population at low to intermediate risk of CVD [13]. Although ART was not randomised, REPRIEVE was a prospective study,

and all cardiovascular events were adjudicated independently. In an adjusted analysis, former (hazard ratio [HR] 1.62, 95% CI 1.14–2.30) and current (HR 1.41, 95% CI 1.01–1.96) abacavir use were associated with an increased risk of major adverse cardiovascular events.

### 5.3.7 Lamivudine versus emtricitabine in combination with tenofovir DX

The 2015 BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy [1] recommended tenofovir DF/emtricitabine rather than tenofovir DF/lamivudine due to a lack of clear evidence and in the absence of tenofovir DF/lamivudine-containing fixed-dose combination. In addition, the longer intracellular half-life [27], more efficient incorporation into proviral DNA [28] and greater *in vitro* potency [29] of emtricitabine provided biological plausibility for this agent being preferred.

Since then, however:

- WHO [30], DHHS [31] and EACS [32] guidelines recommend lamivudine and emtricitabine as interchangeable, where applicable;
- A review of three randomised controlled trials directly comparing the safety and efficacy of lamivudine versus emtricitabine concluded that the two drugs are therapeutically interchangeable [33];
- An ATHENA cohort analysis showed no difference between lamivudine and emtricitabine in terms of virological response on PI-based ART over 5 years [34] and although emtricitabine was associated with better virological outcomes with first-generation NNRTI-based ART in the same cohort [35] this has not been replicated in trials of doravirine [14,15].

Of note, lamivudine may confer some advantages over emtricitabine for some people in terms of tolerability [36], hyperpigmentation [37,38] and mitochondrial toxicity [39].

Fixed-dose combinations may limit choice; tenofovir AF-based products are available only in combination with emtricitabine, and the fixed-dose combination for doravirine is based on tenofovir DF/lamivudine.

In conclusion, where clinically appropriate and feasible, lamivudine and emtricitabine can be considered interchangeable.

## 5.4 Regimens not recommended first line compared to 2015 guidelines

### 5.4.1 Abacavir/lamivudine other than in combination with dolutegravir

Abacavir/lamivudine is associated with higher rates of virological failure compared to tenofovir DF/emtricitabine with efavirenz or atazanavir/ritonavir [40], and is associated with a higher risk of CVD [41]; most modern studies have used tenofovir-based backbones.

Whereas the 2022 guidelines recommended abacavir/lamivudine/dolutegravir for initial therapy for most people, in the 2025 update this option is only recommended in certain clinical situations (see Section 5.2.2 Dolutegravir versus bictegravir).

### 5.4.2. Atazanavir/ritonavir

Ritonavir-boosted atazanavir was inferior to raltegravir for the combined endpoint in ACTG 5257, with a higher risk of adverse event-driven discontinuation in the same study [18]. Atazanavir/ritonavir was also inferior to tenofovir DF/emtricitabine/elvitegravir/cobicistat in WAVES [42], inferior to dolutegravir in ARIA [22] and associated with a higher risk of emergent CKD in D:A:D [43]. In addition, boosted ART is associated with a high risk of drug–drug interactions [44].

### 5.4.3 Efavirenz

Efavirenz was inferior to dolutegravir in SINGLE [8], with higher rates of suicidality [45,46] and more adverse events and adverse event-driven discontinuations than other recommended agents [8,14,47,48].

### 5.4.4 Rilpivirine

Rilpivirine is non-inferior to efavirenz first line with lower rates of toxicity [49,50] but higher risk of resistance emergence at virological failure; food requirement and interaction with acid-reducing agents are considerations.

### 5.4.5 Elvitegravir/cobicistat

Cobicistat-boosted elvitegravir is non-inferior to efavirenz [51] and atazanavir/ritonavir [52], and superior to atazanavir/ritonavir in women [42]. Complexity of drug–drug interactions with relatively high risk of resistance emergence at virological failure are considerations [51].

## 5.5 What to start in the context of TDR

### Recommendations

- Standard genotypic resistance testing (of reverse transcriptase and protease) is recommended in ART-naïve individuals (GPP).
- Baseline integrase resistance testing should be considered in addition (GPP) if:
  - Any major mutations to other drug classes are detected *or*
  - If diagnosis is made in pregnancy *or*
  - If there are other reasons to suspect transmitted integrase resistance (e.g. likely acquisition from a source with suspected or known integrase resistance).
- We recommend that ART-naïve people living with HIV and evidence of TDR should start ART containing tenofovir DX or tenofovir AF with lamivudine or emtricitabine plus one of the following: dolutegravir, bictegravir or boosted darunavir (GPP).

### Auditable outcome

- Proportion of individuals with TDR commencing an ART regimen containing dolutegravir, bictegravir or boosted darunavir.

### Rationale

Transmission of drug-resistant HIV has historically been associated with suboptimal virological responses to ART [53]. Genotypic resistance testing is therefore recommended prior to starting ART, ideally at the time of HIV diagnosis. The BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals recommend genotypic sequencing of the reverse transcriptase and protease genes but not, at the time of writing, the integrase gene [2]. If transmitted integrase resistance is a concern, for example where there is major drug resistance to other classes of ARV agents, then sequencing of the integrase gene should also be considered at baseline.

The rationale for these recommendations comes from the TDR prevalence in 2016 in the UK [54]. Of 3182 baseline tests, 9.6% had at least one mutation; 4.2%, 4.1% and 2.2% of samples had at least one mutation that conferred resistance to NRTI (mainly single thymidine analogue mutations [TAMs]), NNRTI (most commonly K103N [2.7%] and G190A [0.5%]) and PI (most commonly L90M [0.8%] and M46L [0.5%]) respectively. Baseline integrase sequencing is performed infrequently in routine clinical practice in the UK, but informative data come from a study of 655 individuals with recently acquired HIV between 2014 and 2016 [55]. Using ultradeep sequencing, no major integrase resistance mutations were identified at high

variant frequency (>20%), although a few low-frequency variants of doubtful clinical significance were observed [55]. The transmission of multidrug-resistant HIV variants is rare and resistance testing alongside expert opinion can guide treatment choices in such cases.

There are no published prospective clinical trials comparing different ART regimens in the presence of TDR. Thus, recommendations are based on extrapolation from other clinical studies. It was previously considered that TAMs reduced tenofovir DF sensitivity, but accumulating evidence from trials of second-line therapy demonstrate that the use of tenofovir DF as part of a second-line regimen is highly effective even in the presence of multiple TAMs acquired during first-line ART [56-59]. The M184V/I mutation, which confers high-level resistance to emtricitabine/lamivudine, is rarely detected in baseline resistance samples. Where the M184V/I mutation is present (in the absence of compensatory mutations) [60], their high fitness cost results in their rapid disappearance to undetectable levels [61].

The second-generation INSTIs dolutegravir and bictegravir have a high genetic barrier to resistance when compared to raltegravir and elvitegravir [8,10,11,16]. Treatment-emergent resistance has been reported very rarely in individuals receiving dolutegravir- or bictegravir-based initial therapy [62,63]. As noted above, transmitted integrase resistance was rare in 2014–2016 but as the use of INSTIs has increased since that time ongoing surveillance and updated analysis of the prevalence of INSTI TDR is warranted.

Similarly, boosted darunavir has a high genetic barrier to resistance and a low rate of treatment-emergent resistance. Darunavir-based therapy, in combination with NRTIs, was non-inferior to dolutegravir-based ART when used as second-line treatment in patients with extensive resistance following virological failure with an NNRTI-based initial regimen [59].

The lower barrier to development of resistance in the NNRTI class means that an NNRTI-based regimen is not recommended where NRTI or NNRTI TDR is detected.

The evolution of treatment guidelines towards regimens that include two NRTIs and a third agent with a high genetic barrier as first-line ART means that such regimens are likely to be highly active in patients with TDR.

It is therefore recommended that for initiation of therapy for people living with HIV in the presence of TDR, the following regimens should be considered:

- Dolutegravir plus tenofovir DF/tenofovir AF plus emtricitabine/lamivudine
- Boosted darunavir plus tenofovir DF/tenofovir AF plus emtricitabine/lamivudine
- Bictegravir/tenofovir AF/emtricitabine

We do not recommend dolutegravir/lamivudine as initial therapy where there is TDR.

## 5.6 What to start in the context of rapid ART initiation

### Recommendation

- We recommend that where ART is commenced prior to baseline resistance testing, a regimen containing tenofovir DX or tenofovir AF with lamivudine or emtricitabine plus one of the following should be used: dolutegravir, bictegravir or boosted darunavir (GPP).

For the purpose of these guidelines, rapid ART is defined as situations where ART is started without available baseline resistance testing. Where rapid ART is indicated or preferred, we advise a cautious approach by recommending the same regimens as for first-line therapy in the context of TDR (see Section 5.5 What to start in the context of TDR):

- Dolutegravir plus tenofovir DF/tenofovir AF plus emtricitabine/lamivudine or bictegravir/tenofovir AF/emtricitabine
- Boosted darunavir plus tenofovir DF/tenofovir AF plus emtricitabine/lamivudine

There is a paucity of data investigating optimal initial regimens for rapid ART; two single-arm studies conducted in the USA have been published. The DIAMOND study investigated darunavir/cobicistat/emtricitabine/tenofovir AF as an initial regimen within 14 days of diagnosis without baseline results [64]. At week 48, 89% of the 109 participants had a viral load less than 50 copies/mL and none needed to change ART once baseline resistance tests were available. There were no protocol-defined virological failures, no serious adverse events, one adverse event-driven discontinuation and high treatment satisfaction scores. The STAT study investigated dolutegravir/lamivudine in a test-and-treat strategy for newly diagnosed individuals [65], also within 14 days of diagnosis without access to baseline results. Treatment modification was necessary for eight of 131 participants (6%): five due to hepatitis B coinfection and one case of baseline M184V, one case of rash and one due to participant choice. At week 24, 78% of all participants and 92% of the 111 with available data achieved a viral load less than 50 copies/mL. Bictegravir/tenofovir AF/emtricitabine was investigated in the context of rapid ART in the FAST study, a single-arm, open-label trial [66].

INSTIs yield more rapid viral suppression than other antiretroviral classes [9,67].

It is important that when full baseline assessment has been undertaken, ART should be reviewed in line with these guidelines and, where appropriate, other prescribing policies.

## 5.7 What to start in the context of very high viral load

### Recommendations

- We suggest that three-drug ART combinations characterised by a high barrier to resistance are initiated or re-initiated in people with very high viral loads (>500,000 copies/mL) (Grade 2B).
- We suggest tenofovir DX or tenofovir AF plus lamivudine or emtricitabine plus dolutegravir or bictegravir or boosted darunavir are used (GPP).

### Auditable outcome

- Proportion of individuals with a very high viral load commencing an ART regimen containing dolutegravir, bictegravir or boosted darunavir.

### Rationale

The goal of ART in individuals presenting with a very high viral load is to suppress plasma HIV RNA to undetectable levels to minimise the risk of disease progression as soon as possible and realise the benefits in terms of preventing HIV transmission. Hence, individuals should be encouraged to initiate or re-initiate therapy as soon they are ready. It may take longer to reach an undetectable level from a high baseline viral load and a large reservoir is association with slower suppression [68-72]. This should be considered when counselling patients and interpreting results.

Clinical trial data regarding the treatment of HIV infection with very high viral load are limited. However, three-drug ART combinations characterised by a high barrier to resistance because they contain dolutegravir, bictegravir or boosted darunavir have been shown to lead to the achievement and maintenance of an undetectable viral load [9]. A potential advantage of INSTI-based ART is more rapid viral suppression [9] and a lower risk of drug–drug interaction [73].

A cohort analysis from Switzerland demonstrated that a baseline viral load >100,000 copies/mL was associated with a higher risk of treatment failure among individuals commencing first-line INSTI-based ART [70]. About two-thirds of people started dolutegravir-based ART (the study was undertaken before routine use of bictegravir) and among those with baseline viral load >100,000 copies/mL, dolutegravir was associated with faster viral suppression than raltegravir ( $P<0001$ ).

ART combinations containing more than three active drugs have not shown a benefit in terms of achievement and maintenance of viral load <50 copies/mL versus three-drug regimens, though none of the 12 studies in this meta-analysis specifically recruited participants with high baseline viral load [74].

The importance of adherence in people starting or restarting ART with a high viral load needs to be underlined. As for all ART-naïve persons who are starting ART or for individuals who are restarting ART, the results of drug resistance testing should guide selection of the ART combination. However, ART can be initiated while awaiting confirmation of the resistance test result if deemed necessary (see Section 4.2 Same-day ART initiation).

## 5.8 What to start in people diagnosed with HIV on PrEP

Given the increasing use of tenofovir DF/emtricitabine as PrEP, infection may be diagnosed in some individuals while they are taking tenofovir DF/emtricitabine PrEP or after a period of suboptimal PrEP intake. Therefore, in this setting, drug resistance results are particularly important. The ART combinations listed for rapid ART are recommended options while awaiting resistance testing results. If viral load is undetectable or low at the time of HIV diagnosis, one of these same combinations should be used. For more detail, see the British Association for Sexual Health and HIV (BASHH)/BHIVA guidelines on the use of PrEP [75].

In a London cohort, virological outcomes were described after rapid ART initiation (median 8 days) in 47 people with recent or ongoing PrEP exposure [76]. The M184V mutation was common (detected in 30%) and all achieved viral suppression at week 24 with tenofovir DF or AF, plus emtricitabine plus dolutegravir, bictegravir or boosted darunavir.

## 5.9 Switching ART in virological suppression

### Recommendations

- We recommend that most people should be on a regimen that is preferred for first-line therapy or considered acceptable for switch/maintenance (GPP).
- We recommend that, in individuals on suppressive ART regimens, consideration is given to differences in side effect profile, drug–drug interactions, dosing requirements and known/suspected drug resistance before switching any ART component (GPP).
- We recommend particular caution when switching from a high-genetic barrier to a low-genetic barrier regimen in the presence of known or suspected resistance (Grade 1B).
- When switching from an NNRTI there may be pharmacological considerations (see Section 6.2 Pharmacology) (GPP).
- In individuals with previous NRTI resistance mutations, we recommend against switching from a boosted PI to an NNRTI or first-generation INSTI as the core agent (Grade 1B).
- In individuals with any NNRTI resistance, we recommend not switching to NNRTI-based ART\* (GPP).

- We recommend review of ART at least annually (GPP).
- Where an individual is on a non-recommended regimen, we recommend regular review and clear documentation of rationale (GPP).
- We recommend people are advised that they may be able to switch back to their original regimen, if preferred and clinically appropriate, depending on the reasons for switching (GPP).
- Abacavir should only be considered for people who are HLA B\*5701 negative (Grade 1A); where a three-drug regimen is necessary, tenofovir DX and tenofovir AF are not suitable and abacavir is the most clinically appropriate option (GPP).
- We recommend that all individuals on abacavir be considered for switching to a non-abacavir-based regimen where clinically appropriate, regardless of CVD risk (GPP).
- We recommend proactively switching all individuals on abacavir/lamivudine/dolutegravir to dolutegravir/lamivudine if eligible (see Section 5.10.5.1 Dolutegravir with lamivudine) (GPP).
- Due to associations with long-term toxicity and potential harm of drug–drug interactions, switching from a PI to an INSTI or NNRTI is advised where clinically appropriate (GPP).

\*For situations where an NNRTI might be considered, see Section 7.5.3 First-line treatment failure with NNRTI resistance.

### Auditable outcomes

- Proportion of individuals with documented previous NRTI resistance who have remained suppressed after switching ART.
- Proportion of individuals on abacavir/lamivudine/dolutegravir without a clearly documented rationale.

### Rationale

In individuals on fully virally suppressive regimens, switching components of the ART combination may be considered for several reasons, including: management of ARV drug toxicity or intolerance, more convenient dosing, to reduce pill burden, management of potential drug–drug interactions, individual preference and cost [77]. Guidance on the management of drug toxicity of individual ARVs is not within the scope of these guidelines. Guidance on interventions to support adherence, including once-daily dosing and fixed-dose combinations is addressed in Section 6.1 Adherence, and pharmacological considerations on switching ARVs is discussed in Section 6.2 Pharmacology.

Switching ART should not be at the cost of virological efficacy. The following summarises the key principles of switching ART and which regimens are considered acceptable for switching or continuing in people already stable on those regimens. Of note, all options recommended for first-line ART are also suitable

for use in the context of suppressed switch if considered clinically appropriate and acceptable to the individual concerned.

## 5.10 Suppressed switch or maintenance

### Recommendations

- We recommend that all adults on abacavir-containing ART are offered a switch to a non-abacavir-based regimen where clinically appropriate, regardless of CVD risk (GPP).

All regimens recommended for first-line ART are also recommended for suppressed switch or maintenance. In addition, the following regimens are also acceptable (see Table 5.2).

**Table 5.2** Recommendations for choice of ART for suppressed switch or maintenance

| <b>Acceptable for switch or to continue where clinically appropriate</b>  |   |
|---|---|
| <i>Where feasible, lamivudine and emtricitabine are considered interchangeable</i>  |   |
| <i>Abacavir should only be used for people who are HLA B*5701 negative and where a three-drug regimen is necessary, but tenofovir DX and tenofovir AF are not suitable and abacavir is the most clinically appropriate option</i> |   |
| <b>NNRTI-based three-drug regimens</b>  |   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus doravirine   |   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus rilpivirine  |   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus efavirenz  | Maintenance only; not recommended routinely for switch due to risk of neuropsychiatric toxicity, unless considered most clinically appropriate option |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine plus nevirapine   | Maintenance only; not recommended routinely for switch due to small risk of severe toxicity   |
| <b>INSTI-based three-drug regimens</b>  |   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with dolutegravir   |   |
| Tenofovir AF/emtricitabine/bictegravir  |   |

|  |  |
|--|--|
| Tenofovir DX/emtricitabine/elvitegravir/cobicistat or tenofovir AF/emtricitabine/elvitegravir/cobicistat   | Improvements in renal/bone biomarkers for tenofovir AF compared to tenofovir DF are most evident in the context of boosted ART   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with raltegravir   |  |
| <b>PI-based regimens</b>   |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with atazanavir/ritonavir or atazanavir/cobicistat                   | Where resistance necessitates a PI; improvements in renal/bone biomarkers for tenofovir AF over tenofovir DF are most evident in the context of boosted ART. Atazanavir and tenofovir DX are both associated with renal toxicity   |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with darunavir/ritonavir or darunavir/cobicistat                     |  |
| Tenofovir DX/emtricitabine or tenofovir AF/emtricitabine or abacavir/lamivudine with lopinavir/ritonavir   |  |
| <b>Two-drug regimens</b>   |  |
| Dolutegravir/lamivudine  |  |
| Dolutegravir/rilpivirine   | Studied only in suppressed switch; high risk of NNRTI resistance at virological failure  |
| Cabotegravir plus rilpivirine injectable   | Studied only in suppressed switch; high risk of NNRTI and INSTI resistance at virological failure  |
| Raltegravir with darunavir/ritonavir or darunavir/cobicistat   | Underperformed at viral load >100,000 copies/mL and CD4 count <200 cells/mm <sup>3</sup> when used first line  |
| Dolutegravir with darunavir/ritonavir or darunavir/cobicistat  | Studied only in suppressed switch  |
| Lamivudine or emtricitabine with darunavir/ritonavir or darunavir/cobicistat or atazanavir/ritonavir or atazanavir/cobicistat or lopinavir/ritonavir | In the absence of known or suspected M184V/I. Several studies demonstrate non-inferiority of lamivudine with a boosted PI. ATLAS-M demonstrated switch to lamivudine plus atazanavir/ritonavir was superior to continuing tenofovir DX/emtricitabine plus atazanavir/ritonavir in people with viral suppression and no NRTI resistance |
| <b>ARVs that may play a role in specific circumstances</b>   |  |

Though not recommended routinely, there are some agents that may be used based on a need to deliver ART parenterally or an inability to otherwise create a suppressive regimen:

- Zidovudine
- Etravirine
- Maraviroc
- Enfuvirtide
- Fostemsavir
- **Lenacapavir**

It may be necessary to continue or switch to abacavir when a second NRTI is needed (e.g. because of NRTI resistance or HIV-related CNS disease) but tenofovir DX and tenofovir AF are contraindicated (e.g. in the presence of severe acute kidney injury) or where abacavir is considered the most clinically appropriate option (e.g. in pregnancy). While tenofovir AF demonstrates less renal toxicity than tenofovir DF, tenofovir AF has been associated with kidney injury in rare cases [4]. Drugs from other classes can be considered where tenofovir cannot be used to construct an appropriate regimen with the caveat that there may be a paucity of supportive evidence.

Where individuals have been stable on abacavir-containing therapy and, after discussion about the potential CVD risks, choose not to switch, this should be respected and the decision reviewed regularly thereafter.

- We recommend that ART can be switched to dolutegravir with lamivudine in people with virological suppression (Grade 1A) but this regimen is not suitable for those:
  - Who need a tenofovir-containing regimen for the treatment or prevention of hepatitis B (Grade 1A);
  - With known or suspected resistance to lamivudine or INSTIs (Grade 1A); where lamivudine resistance is historical, dolutegravir/lamivudine may be used exceptionally on a case-by-case basis (Grade 2B).
- We recommend proactively switching all individuals on abacavir/lamivudine/dolutegravir to dolutegravir/lamivudine if eligible (GPP).
- We suggest that ART can be switched to dolutegravir with rilpivirine in people with virological suppression (Grade 2A) but this regimen is **not** suitable for those:
  - With a history of previous virological failure or resistance emergence to any NNRTI or INSTI (Grade 1A);
  - Who need a tenofovir-containing regimen for hepatitis B treatment (Grade 1A) or prevention (GPP);

- Who are considered at risk of hepatitis B reactivation\* (GPP).

\*See Section 5.11 Two-drug injectable regimens: switching in virological suppression.

- We suggest that three-drug boosted PI-based ART can be switched to two-drug boosted PI with lamivudine in people with virological suppression while taking into consideration that this regimen is **not** suitable for those **who need tenofovir for hepatitis B treatment or prevention** (Grade 1A).
- **Other than the regimens listed, we do not recommend other oral two-drug regimens as routine switch strategies (GPP).**

## Rationale

### 5.10.1 NRTI switch

In the absence of NRTI resistance, abacavir/lamivudine, tenofovir DX/lamivudine, tenofovir DX/emtricitabine and tenofovir AF/emtricitabine can all be expected to deliver similar virological efficacy. In people who have experienced virological failure, NRTI choice should be guided by resistance testing; there is evidence that tenofovir is more likely to retain activity than abacavir in this context because the M184V mutation reduces abacavir susceptibility but leads to tenofovir hypersusceptibility [78].

In general, switching from tenofovir DF to tenofovir AF is associated with improvements in renal and bone biomarkers and slight increases in triglycerides and total, LDL- and HDL-cholesterol, with minimal change in the total/HDL-cholesterol ratio. In the GS-109 study, 1436 people on one of four suppressive tenofovir DF/emtricitabine-based regimens were randomly assigned to continue or switch to tenofovir AF/emtricitabine/elvitegravir/cobicistat [79]. In terms of baseline ART, 32% were on elvitegravir/cobicistat, 26% on efavirenz and 42% on boosted atazanavir (approximately two-thirds ritonavir-boosted and one-third cobicistat-boosted). Viral suppression at week 96 was significantly higher in the switch arm though as most individuals also switched third agent it is not possible to attribute this to the backbone switch and the difference was not driven by discontinuations for efficacy, adverse events or death. Three of six virological failures in the switch arm developed resistance compared to one of two virological failures in the continued ART arm. Hip and spine BMD remained stable or decreased in the continued ART arm and increased in the switch arm yielding a statistically significant difference at week 96, and a greater proportion of participants saw recovery from osteopenia or osteoporosis in the switch arm. It was difficult to interpret serum creatinine changes in this study as most people in the switch arm switched to cobicistat for the first time which is associated with a rise in serum creatinine due to inhibition of creatinine secretion in the proximal tubule [80]. Excluding those on efavirenz (i.e. unboosted ART) at baseline, there was a small increase in eGFR in the switch group compared with minimal change on continued ART. Urine protein and albumin levels

decreased in those who switched to tenofovir AF, regardless of baseline ART, and increased in the continued ART group with a statistically significant difference favouring switch at week 96. Lipid results were difficult to interpret as efavirenz is associated with a more negative impact on lipids than elvitegravir/cobicistat but first-line trials have demonstrated an advantage of tenofovir DF over tenofovir AF in terms of lipid fractions [81]. A single-arm study switching people with renal impairment (eGFR 30–69 mL/min) to tenofovir AF/emtricitabine/elvitegravir/cobicistat demonstrated maintained viral suppression, stable eGFR and improvements in proteinuria, markers of proximal tubule function and hip and spine BMD [82]. A cohort from the UK demonstrated significant improvement in eGFR slope in 357 patients who switched from tenofovir DX- to tenofovir AF-containing ARV regimens [83].

Switching from tenofovir DF, and to a lesser degree abacavir, to tenofovir AF is associated with an increase in weight. In a pooled analysis of 12 prospective clinical trials, virally suppressed people who switched from tenofovir DF or abacavir to tenofovir AF experienced significant weight gain at week 48 (+1.6 kg for tenofovir DF) [84]. In addition, switching from tenofovir DF to tenofovir AF was associated with a significantly higher risk of experiencing  $\geq 10\%$  weight gain at week 48 (OR 2.58, 95% CI 1.94–3.43). Two other studies demonstrated  $\geq 2$  kg weight gain at week 48 for people switching to tenofovir AF versus those staying on tenofovir DF: the randomised controlled trial GS-4030 [85] and the US OPERA cohort [86]. Most reported changes are likely to have resulted from the removal of the weight-restricting properties of the high tenofovir exposures achieved with tenofovir DF (see Section 8.3.3 Weight gain considerations).

Studies switching from a two-NRTI-based three-drug regimen to dolutegravir or boosted PI with one NRTI are summarised below.

### **5.10.2 PI switch**

Most studies investigating switching within the PI class investigated now non-recommended or unboosted regimens. Due to the association with long-term toxicity [87,88] combined with the complexities and potential harm of drug–drug interactions secondary to ritonavir and cobicistat, switching from a PI to an INSTI or NNRTI is advised where clinically appropriate.

Careful attention should be paid to any likely or known resistance and particular caution is advised when switching to a low-barrier regimen as illustrated by the SWITCHMRK results [17]. In the randomised SWITCHMRK study, switching to raltegravir with at least two NRTIs failed to show non-inferiority to continued PI-based ART in participants who may have experienced prior virological failure. The ODIS study yielded similar results [89]; individuals suppressed on PI-based therapy with prior NRTI resistance experienced much higher rates of virological failure on switching to once- or twice-daily raltegravir than

those with no NRTI resistance (16.2% vs 0.7%;  $P < 0.001$ ). By contrast, the SPIRAL study showed switching to raltegravir to be non-inferior to continued boosted PI with two NRTIs, with significant improvements in lipid parameters; the difference between the results from the SPIRAL, ODIS and SWITCHMRK studies may be explained by risk of NRTI resistance and duration of viral suppression prior to study entry. One randomised controlled trial assessed switching from a PI to cobicistat-boosted elvitegravir in people with viral suppression (excluding individuals with a history of virological failure or resistance to tenofovir DF or emtricitabine) and found that suppression was maintained and the regimen was well tolerated [90].

In STRATEGY-PI, virally suppressed people on a ritonavir-boosted PI with emtricitabine plus tenofovir DF were randomly allocated to switch to coformulated tenofovir DF/emtricitabine/elvitegravir/cobicistat or to continue on their existing regimen [91]. Exclusion criteria included any history of virological failure, and all participants were required to have a pre-ART resistance test demonstrating an absence of NRTI mutations. Around 40% of participants were on atazanavir, 40% on darunavir and the remainder on older PIs; virological efficacy was proven, indeed the switch arm demonstrated statistically superior virological outcomes. Minor improvements in lipids were observed, most notable in those on lopinavir/ritonavir at baseline. Switching from a boosted-darunavir or boosted-atazanavir to tenofovir AF/emtricitabine/bictegravir in virally suppressed, INSTI-naïve people with no documented resistance to abacavir, lamivudine, emtricitabine or tenofovir was investigated in the randomised, open-label GS-1878 trial [92]. Switching to bictegravir-based ART demonstrated non-inferior virological efficacy; lipid improvements were observed in those switching from abacavir-based ART but not those switching from tenofovir DF, presumably because the benefit of switching off a boosted PI was balanced by the lipid increase when switching from tenofovir DF to tenofovir AF. There are limited data to support switching to tenofovir AF/emtricitabine/bictegravir in the context of NRTI resistance [93] but this is only in the context of viral suppression and studies have tended to combine known genotypic resistance with mutations detected on proviral sequencing which may not have the same clinical implications. By contrast, dolutegravir has been studied in people on failing first-line NNRTI-based ART and shown to be superior to lopinavir/ritonavir in DAWNING and non-inferior to darunavir/ritonavir in NADIA. A small proportion (about 8%) of people in the TANGO and SALSA trials (both investigating switch from a suppressive three-drug regimen to dolutegravir/lamivudine) were on a boosted PI at baseline, mainly darunavir, and demonstrated maintained efficacy. There are no published trials specifically investigating switching from a boosted PI to dolutegravir.

Previous treatment failure on an NRTI-containing regimen has also been associated with an increased risk of virological failure when switching from a PI- to an NNRTI-based regimen [94]. One randomised controlled trial has assessed the switch from PI to once-daily etravirine in people with HIV RNA suppression [95] and no participants presented with virological failure through to 48 weeks. In the SPIRIT Study, switching in

virological suppression to rilpivirine from PI-maintained suppression was safe and, with or without K103N, had a high response rate [96]. People on a suppressive boosted PI plus two-NRTI regimen were randomly assigned to continue current ART or switch to a fixed-dose combination of tenofovir DF/emtricitabine/rilpivirine [97]. Importantly, participants were required to have a pre-ART resistance test demonstrating no mutations conferring resistance to study drugs; switching to the NNRTI regimen was non-inferior to continued boosted PI and yielded significant lipid improvements. The randomised DRIVE-SHIFT study investigated continued ART versus switching to doravirine/lamivudine/tenofovir DF in people suppressed on ritonavir- or cobicistat-boosted PI (atazanavir, darunavir or lopinavir), cobicistat-boosted elvitegravir or an NNRTI (efavirenz, nevirapine or rilpivirine), each in combination with two NRTIs [98]. Eligible participants were required to have been virally suppressed for at least 6 months with no history of virological failure and switching to doravirine was non-inferior to continued ART. For individuals without previous NRTI or NNRTI resistance mutations, switching from a boosted PI to any of the currently licensed NNRTIs is likely to maintain virological efficacy and choice of NNRTI will depend on side effect profile, tolerability and individual preference. For individuals with known NNRTI mutations that are not predicted to impact susceptibility to a given NNRTI there are insufficient data to make a recommendation. A total of 24 patients in the SPIRIT trial had a history of the K103N mutation and the majority maintained viral suppression (one experienced virological failure with emergent NNRTI and NRTI resistance and one had no data in the window at week 48) [97]. DRIVE-BEYOND was designed to investigate the efficacy of doravirine/lamivudine/tenofovir DF in virally suppressed people with selected NNRTI resistance mutations (K103N, Y181C or G190A), none of which are predicted to impact doravirine susceptibility [99]. Unfortunately, only 10 people were recruited after more than a year and the trial was terminated early; all eight and seven participants who reached week 48 and week 96, respectively, maintained suppression but the sample size is far too small to draw meaningful conclusions. Therefore, we suggest not switching to NNRTI-based ART in the context of any NNRTI resistance.

### **5.10.3 NNRTI switch**

Small studies investigating switching from efavirenz to alternative NNRTIs have demonstrated maintained virological efficacy with improvements in neuropsychiatric symptoms and lipid parameters [100,101].

STRATEGY-NNRTI investigated a randomised switch to tenofovir DF/emtricitabine/elvitegravir/cobicistat versus continued NNRTI/two-NRTI-based ART, with most participants on efavirenz at baseline [102]. The switch strategy was non-inferior from a virological efficacy perspective and, among people switching off efavirenz, was associated with improvements in CNS symptoms.

The TANGO and SALSA trials (both investigating switching from a suppressive three-drug regimen to dolutegravir/lamivudine) recruited some participants on an NNRTI at baseline: 13–14% in TANGO (12% were on rilpivirine) and 50% in SALSA (31% were on efavirenz). Efficacy was maintained but it is not possible to draw specific conclusions because of the absence of specific subanalyses or switch trials restricted to people on an NNRTI.

#### **5.10.4 Integrase switch**

The majority of TANGO participants (around 75%) were on coformulated tenofovir AF/emtricitabine/elvitegravir/cobicistat at baseline; switch to dolutegravir/lamivudine was associated with maintained virological efficacy and improvements in lipids and insulin sensitivity at week 48. Insulin sensitivity benefits were not maintained at later timepoints.

Approximately 40% of SALSA participants were on an INSTI at baseline: 17% dolutegravir, 10% elvitegravir/cobicistat, 10% bictegravir and 2% raltegravir. Again, virological efficacy was maintained but it is difficult to draw additional conclusions in the absence of specific subgroup analyses.

In GS-4030, people on a suppressive regimen of dolutegravir with tenofovir AF/emtricitabine or tenofovir DF/emtricitabine were randomly allocated to tenofovir AF/emtricitabine/bictegravir or tenofovir AF/emtricitabine plus dolutegravir (i.e. some people remained on the same backbone, some switched from tenofovir DF to tenofovir AF, some continued dolutegravir and some switched to bictegravir) [85].

Maintained viral suppression rates, despite limited historical and proviral DNA evidence of NRTI resistance in some participants, were high and the only notable difference was greater weight gain in those switching from tenofovir DF to tenofovir AF compared to those already on tenofovir AF at baseline. Conversely weight change was similar in virally suppressed people continuing tenofovir AF-based ART compared to those switching to dolutegravir/lamivudine in TANGO at week 48 [103]. In SALSA, a greater increase in weight was observed in those switching from tenofovir DF-based ART to dolutegravir/lamivudine, with no difference in those switching from tenofovir AF [104].

#### **5.10.5 Two-drug oral regimens: switching in virological suppression**

**Note:** at the time of writing, two-drug regimens are not routinely recommended in pregnancy; please refer to the BHIVA guidelines for the management of HIV in pregnancy and postpartum for up-to-date guidance [3].

### 5.10.5.1 Dolutegravir with lamivudine

The TANGO study recruited participants who had a stable, suppressed viral load and were treated with first-line, three-drug ART combinations containing tenofovir AF/emtricitabine as the NRTI backbone [105]. In approximately two-thirds of participants, the third agent was elvitegravir/cobicistat and about three-quarters were on a boosted regimen.

Exclusions included any history of major NRTI or INSTI resistance, hepatitis B infection, opportunistic disease other than cutaneous Kaposi's sarcoma with a CD4 count  $>200$  cells/mm<sup>3</sup> and severe hepatic impairment.

Participants were randomly assigned to continue their standard regimen or to switch to dolutegravir/lamivudine. Non-inferiority of the two-drug regimen was demonstrated at week 48. There was only one virological failure (in the tenofovir AF/emtricitabine-based regimen group), and no emergent resistance was detected. Pro-viral DNA sequencing from baseline samples was undertaken and M184V was detected in four patients in the dolutegravir/lamivudine group (all of whom maintained viral suppression), but the clinical significance of proviral DNA detection is unclear. A slightly higher proportion of participants taking the two-drug regimen discontinued treatment because of adverse events, but the total number of these discontinuations was small.

Small but significantly different changes in metabolic parameters, such as lipids, were seen from baseline to week 48, favouring the two-drug regimen although when analysed by baseline ART this was limited to people on a boosted regimen [106]. Results out to week 144 were similar [107].

The SIMPL'HIV study was a randomised trial comparing dolutegravir/emtricitabine and continued standard three-drug regimens [108]. Participants were required to have an undetectable viral load for 6 months prior to study entry, but a single viral load of  $<200$  copies/mL was permitted during this time. After recruitment had commenced, a protocol amendment allowed the recruitment of individuals with a history of transmitted M184V mutation. A total of 188 participants were randomly assigned to treatment and non-inferiority of the two-drug arm was demonstrated at week 48 with a viral load cut-off of  $<100$  copies/mL. Only one participant, assigned to the continued three-drug arm, had a documented M184V mutation. Virological failure was rare, and no new resistance was detected. Of note, dolutegravir/emtricitabine is not available as a fixed-dose combination.

Switching from a boosted PI to dolutegravir in virally suppressed people was investigated in TANGO [105] and SALSA [109]. TANGO excluded people with a history of major NRTI or INSTI resistance and SALSA excluded those who had previously switched therapy for suspected or confirmed virological failure. Both trials recruited people on a variety of regimens, and only 8% of participants in either trial were on a PI at baseline (mainly boosted darunavir); most TANGO participants were on elvitegravir/cobicistat-based ART

and most recruited to SALSA were on an NNRTI (predominantly efavirenz). Both TANGO and SALSA demonstrated non-inferior virological efficacy.

Since the 2022 guidelines, data have emerged related to suppressed switch to dolutegravir/lamivudine in people with historical M184V mutation. Data suggest that, in individuals with virological suppression, detection of M184V many years earlier may not impact virological outcomes, possibly reflecting clearance of the mutation from the HIV archive in individuals with good immune function. Consistent with this, a recent study demonstrated that dolutegravir/lamivudine was an effective switch option in virologically suppressed people with historical M184V but without the mutation detected in proviral HIV DNA at the time of switching [110].

In one small, non-controlled study (that did not undertake proviral DNA sequencing prior to switch), recent plasma detection of M184V increased the risk of virological failure post suppressed switch; by contrast, long-standing (>3 years pre-switch) detection was not associated with a risk of virological rebound [111]. A small retrospective analysis of 22 people with historical M184V demonstrated a median time to clearance from the viral reservoir of 2.5 years, and found that higher nadir CD4 count and lower zenith viral load correlated with faster clearance [112].

In summary, in virally suppressed individuals, historical M184V is likely to show diminishing impact with time since detection (at least 3 years) in people with presumed good immune function during this time (nadir CD4 count >200 cells/mm<sup>3</sup>). Absence of M184V in a current HIV DNA resistance test may provide complementary information, although it cannot guarantee absence of the mutation. Of note, detection of M184I in proviral DNA should be interpreted with caution, as it is highly likely to represent an apolipoprotein B mRNA editing catalytic polypeptide (APOBEC)-context resistance-associated mutation (RAM) and to lack clinical relevance. Currently, we do not recommend the routine use of dolutegravir/lamivudine in people with historical M184V. However, in situations where alternatives are not clinically appropriate, dolutegravir/lamivudine could be considered cautiously on a case-by-case basis.

#### 5.10.5.2 Dolutegravir with rilpivirine

Switching conventional three-drug treatment to dolutegravir with rilpivirine has been evaluated in the identically designed SWORD 1 and 2 open-label, randomised clinical trials [113]. Eligible individuals were required to be receiving first-line or second-line ART. They were also required to have an undetectable viral load for at least 6 months and no viral load measurement of  $\geq 200$  copies/mL in the preceding 6–12 months. Any standard three-drug combination was allowed as a comparator, however participants were excluded if

they had any history of antiretroviral resistance or virological failure. Non-inferiority of the two-drug regimen compared with continued three-drug treatment was demonstrated at week 48.

Drug-related neuropsychiatric adverse events were more common in the dolutegravir/rilpivirine arm, as were headache and diarrhoea. These side effects were responsible for the somewhat larger number of participants who discontinued dolutegravir/rilpivirine (total adverse events leading to discontinuation:  $n=17$  [3%] for dolutegravir/rilpivirine;  $n=3$  [1%] for continued three-drug regimen). There were few virological failures in each arm and the development of only one minor NNRTI mutation in the dolutegravir/rilpivirine arm. Although longer-term follow-up is available in the SWORD studies, randomised comparison was only undertaken until week 48 and therefore longitudinal data for this regimen are limited.

In the open-label WISARD study, virally suppressed people with historical K103N were randomly assigned to continue current ART ( $n=45$ ) or switch to dolutegravir/rilpivirine ( $n=95$ ). Week 48 viral suppression rates were similar [114] but as WISARD was a pilot study and considering the risk of minority variants in the context of acquired NNRTI resistance [115-120], we do not routinely recommend this approach (see Section 7.5.3 First-line treatment failure with NNRTI resistance).

#### 5.10.5.3 Boosted PI with lamivudine

Four randomised studies have compared the use of a boosted PI plus lamivudine versus a conventional three-drug regimen in patients with a suppressed viral load [121-124].

In the DUAL-GESIDA 8014-RIS-EST45 trial, darunavir/ritonavir plus lamivudine was found to be non-inferior to continued darunavir/ritonavir plus two NRTIs in individuals with no history of darunavir or lamivudine resistance [121].

The ATLAS-M trial showed that atazanavir/ritonavir plus lamivudine was non-inferior (and superior in a *post hoc* analysis) to continued atazanavir/ritonavir plus two NRTIs [122].

In the SALT study, switching to atazanavir/ritonavir plus lamivudine was non-inferior to continuing atazanavir/ritonavir plus two NRTIs in individuals suppressed on standard triple ART with no history of virological failure [123].

The OLE study demonstrated that lopinavir/ritonavir plus lamivudine was non-inferior to continued lopinavir/ritonavir plus two NRTIs in individuals with no history of virological failure on, or resistance to, lamivudine or lopinavir [124].

In general, non-PI-based ART is the option of choice but in individuals where a PI-based regimen is preferred, in the absence of hepatitis B co-infection, virological failure or lamivudine resistance, a boosted PI plus lamivudine can be used.

## 5.11 Two-drug injectable regimens

Currently only one long-acting ART regimen is approved: intramuscular cabotegravir/rilpivirine dosed every 8 weeks (Q8W).

### Recommendations

- We recommend that long-acting cabotegravir/rilpivirine can be used in people who:
  - Are motivated to use injectable treatment (Grade 1B) *and*
  - Have been on ART for at least 3–6 months and are virally suppressed typically to <50 copies/mL (Grade 1A) *and*
  - Have no known or suspected NNRTI or INSTI resistance (Grade 1A) *and*
  - Have no history of virological failure on NNRTI- or INSTI-containing ART (Grade 1A) *and*
  - Can commit to 2-monthly attendance for injections (GPP) *and*
  - Have engaged in shared decision-making and are aware of the small risk of virological failure, often with resistance, despite complete adherence and the potential implications for U=U (GPP) *and*
  - Do not have a combination of body mass index (BMI) >30 kg/m<sup>2</sup> and subtype A6\* (Grade 1A) *and*
  - Do not need a tenofovir-containing regimen for the treatment or prevention of hepatitis B (Grade 1A) *and*
  - Are not considered at significant risk of hepatitis B reactivation or re-infection (Grade 1C).

\*Based on a multifactorial analysis of clinical trial data and real-world evidence, a high BMI alone has no impact on efficacy, but we advise caution in people with a high BMI and subtype A6 (see below).

- We recommend that long-acting cabotegravir/rilpivirine can be continued in people who may not meet the criteria above but are already virally suppressed on long-acting cabotegravir/rilpivirine:
  - Via a clinical trial (GPP);
  - As part of a compassionate access or named patient programme (GPP).
- We suggest that long-acting cabotegravir/rilpivirine can be used with caution in people with non-suppressed viral load (Grade 2C) who:
  - Continue to have a detectable viral load on oral ART despite extensive support *and*
  - Are at high risk of disease progression based on CD4 count and/or HIV-related conditions *and*
  - Are able to commit to regular appointments *and*
  - Do not have resistance to cabotegravir and/or rilpivirine *and*
  - Are willing to accept the possibility of resistance emergence and limitation of treatment options.

- We recommend the following viral load monitoring:
  - Two-monthly HIV RNA quantification for the first 6–12 months of injectable therapy (Grade 1B);
  - Thereafter, 4- to 6-monthly HIV RNA quantification in people without indicators of risk\*, taking patient preference into account (GPP).

\*We recommend 2-monthly HIV RNA quantification in the case of one or more of the following: subtype A6, history of viraemia on NNRTIs or INSTIs without resistance, starting long-acting cabotegravir/rilpivirine with detectable or recently detectable viral load, receipt of last injection at the end of the 7-day window period and, potentially, NNRTI polymorphisms (i.e. V106I and V179D/E) that are not recognised rilpivirine RAMs (i.e. L100I, K101E/P, E138A/G/K/Q/R, V179L/F, Y181C/I/V, Y188L, H221Y, F227C/L and M230I/L).

## Rationale

Long-acting cabotegravir/rilpivirine is approved for use in individuals aged 12 years and older who are over 35 kg in weight; this guidance applies to adolescents (aged 16–17 years) and adults. The initial registrational trials, ATLAS [125] and FLAIR [126], compared monthly long-acting cabotegravir/rilpivirine with continued oral therapy in virally suppressed people. Both trials demonstrated non-inferiority of injectable therapy for the primary endpoint of virological failure and key secondary endpoint of virological success. ATLAS-2M compared monthly long-acting cabotegravir/rilpivirine to a 2-monthly dosing schedule, demonstrating non-inferiority to week 152 [127]. Since then the SOLAR study compared continued oral ART with a switch to 2-monthly long-acting cabotegravir/rilpivirine in people virally suppressed on bictegravir/emtricitabine/tenofovir AF for at least 6 months [128]. The injectable regimen was non-inferior to oral therapy at week 48. Finally, in the CARES study, people who were virally suppressed on tenofovir DX with emtricitabine or lamivudine and dolutegravir, efavirenz or nevirapine (74% with a history of NNRTI exposure) were randomly assigned to continue oral ART or switch to 2-monthly long-acting cabotegravir/rilpivirine [129]. At week 48, virological suppression was maintained in 96% of participants on long-acting cabotegravir/rilpivirine versus 97% on oral ART, demonstrating non-inferiority for injectable ART. Of note, nearly half (47%) the participants had purely subtype A1 (based largely on reverse transcriptase sequences and excluding mixed subtypes), but there was a single instance of confirmed virological failure with subtype A1, adding weight to the likelihood that subtype A1 is not predictive of virological failure. It is noteworthy that the summary of product characteristics still lists subtype A6/A1 as a baseline factor associated with higher risk of virological failure, which reflects the way the licensing trials were analysed rather than a clear effect of subtype A1 in these studies. Similarly, at week 96 in the CARES study, 97% of participants in both arms maintained viral suppression with a total of four cases of confirmed virological failure (including two with subtype A1) [130].

HIV RNA quantification was performed at each visit in the ATLAS, FLAIR, ATLAS-2M and SOLAR studies. The CARES study utilised 6-monthly viral load quantification. We suggest that viral load monitoring at all visits is still warranted for the first 6–12 months of injectable therapy. Thereafter we suggest that the frequency of viral load monitoring in individuals judged to be at low risk of virological failure can be reduced to 4-monthly in line with patient choice (recognising that some individuals may prefer more or less frequent monitoring). Prompt recall (within 2 weeks) for repeat viral load testing is required if viral rebound ( $\geq 50$  copies/mL) occurs. Resistance testing should be requested on the confirmatory sample if the viral load remains detectable. More data are needed to inform the management of new-onset, persistent, low-level viraemia ( $>50$  but  $<200$  copies/mL on two or more consecutive samples) during injectable therapy. Pending further evidence, we recommend switching to a higher-barrier (i.e. oral at the time of writing) regimen.

The frequency of viral blip (a single viral load between 50 and 200 copies/mL with adjacent values  $<50$  copies/mL; see Section 7.2 Blips) is similar on injectable cabotegravir/rilpivirine compared to oral ART, and blips are not associated with confirmed virological failure.

The European Medicines Agency granted approval to both the monthly and 2-monthly long-acting cabotegravir/rilpivirine schedules, however the manufacturer is marketing only the 2-monthly option in Europe [131,132].

It is important to note that a small number of participants in clinical trials experience viral rebound despite on-time injections, and most, albeit not all, people experiencing virological failure develop two-class resistance. The risk of viral rebound and resistance is likely to be higher in the context of late or missed injections but data are lacking. In ATLAS-2M, among 522 participants randomly assigned to the Q8W arm, there were 12 cases of confirmed virological failure over 152 weeks (2.3%), of which nine occurred by week 48, one between weeks 48 and 96, and two between weeks 96 and 152 [127]. Lower virological failure rates were observed at year 1 in SOLAR with 3/447 (0.7%) participants experiencing confirmed virological failure [128]. By week 96 there were no cases of confirmed virological failure in the oral ART arm and a total of four in the injectable arm; three had NNRTI and INSTI RAMs and one sample failed to amplify [130]. A systematic review of 33 studies over 24–48 weeks found that virological failure prevalence was 1% in induction-maintenance/suppressed switch studies and 5% in studies switching non-virally suppressed people to long-acting cabotegravir/rilpivirine [133]. Among the small subset of people with virological failure whose samples were genotyped, emergent INSTI resistance was reported in 71%, 61% and 41% in induction-maintenance, suppressed switch and non-virally suppressed switch studies, respectively.

An analysis of a pooled dataset of 1651 participants receiving monthly and 2-monthly long-acting cabotegravir/rilpivirine identified three baseline risk factors for virological failure: rilpivirine RAMs, HIV

subtype A6/A1 and BMI  $\geq 30$  kg/m<sup>2</sup> [134]. The risk of confirmed virological failure was 0.4% (4/970) when none of these three factors was present, 2% (8/404) with a single risk factor (driven mainly by rilpivirine RAMs and subtype A6/A1), 0.5% (1/216) when BMI  $\geq 30$  kg/m<sup>2</sup> was the only risk factor, and 19% (11/57) when two or more risk factors occurred [134]. The lack of impact of a high BMI in isolation is supported by cohort data [135].

Of note, the CARES study recruited virologically suppressed participants with frequent prior exposure to NNRTIs (74%) and INSTIs (92%) but no history of virological failure. The published week 48 analysis of CARES [129] described a high prevalence of RAMs at study entry, including rilpivirine RAMs in 25/200 (13%) participants in the long-acting therapy arm, as determined by sequencing of cellular HIV DNA. Following re-analysis of the baseline data (to account for APOBEC-induced effects), the prevalence of archived rilpivirine RAMs was reduced to 14/208 (7%) for rilpivirine (largely the polymorphism E138A) [130]. Among those with rilpivirine RAMs, 2/14 (14%) experienced confirmed virological failure (both with a BMI  $< 23$  kg/m<sup>2</sup>, one with subtype D and one with subtype A1) [130]. We do not recommend long-acting cabotegravir/rilpivirine in people with known resistance to these drugs.

There were 180/1431 (13%) ATLAS, FLAIR, ATLAS-2M trial participants with subtype A6 and 169/180 (94%) maintained virological suppression over up to 152 weeks. While we generally recommend caution with initiating long-acting cabotegravir/rilpivirine for individuals with subtype A6, where the risk–benefit ratio is favourable, it can be considered as part of shared decision-making.

Initiation of long-acting cabotegravir/rilpivirine should be guided by the treatment and viral load history, alongside available HIV RNA resistance data. There is growing interest in exploring the use of HIV DNA sequencing ('archived resistance testing') in virologically suppressed individuals with incomplete treatment history. Where available, it may complement (not replace) the treatment history. However, archived resistance testing requires cautious interpretation, as it may be misleading by underestimating or overestimating resistance [136].

HIV DNA sequencing may also be used to determine the HIV subtype if not available from previous sequences. Prevalence of A6 is currently low in the UK (<4% among recently acquired HIV infections diagnosed in England in 2020–2021 [137]). In an analysis of more than 2300 people newly diagnosed with HIV in Italy between 2015 and 2021, only 0.3% had subtype A6 virus [138]. Where sequencing is not available, geographical origin of the infection may serve as proxy. A6 is the dominant subtype in countries of the former Soviet Union (Ukraine, Belarus and others) but migration is driving increased prevalence of subtype A6 in other countries including Poland, where A6 was responsible for half of the diagnoses made in

2023–2024 compared to 9% in 2015–2018 [139], and in Denmark where A6, having been detected only sporadically in the past, accounted for 24% of all cases of HIV acquired abroad in 2024 [140].

The available data on long-acting cabotegravir/rilpivirine specifically describe the impact of rilpivirine RAMs (any of L100I, K101E/P, E138A/G/K/Q/R, V179L/F, Y181C/I/V, Y188L, H221Y, F227C/L and M230I/L). Caution is required when considering the use of long-acting cabotegravir/rilpivirine in people with a history of NNRTI failure associated with other NNRTI RAMs (e.g. K103N) as NNRTI failure is often accompanied by emergence of multiple RAMs, some of which may not be detected by routine resistance testing.

There is insufficient evidence to recommend the routine use of therapeutic drug monitoring (TDM) to predict response as there is a lack of evidence for a strong relationship between cabotegravir and rilpivirine concentrations and virological failure [141]; research is ongoing.

### **5.11.1 Hepatitis B reactivation**

At the time of writing, specific BHIVA guidance on hepatitis B reactivation is pending. Once finalised this section will be removed.

Hepatitis B reactivation in people with evidence of past hepatitis B infection is an important consideration when switching hepatitis B-active ART to any non-hepatitis B-active regimen, including long-acting cabotegravir/rilpivirine. A scoping review of trials and case reports revealed variable hepatitis B testing before and after switching to hepatitis B-inactive ART. There were 99 cases of reactivation among 6093 switches (1.6%) and reactivation was typically less common where surface antibody was detectable pre-switch (at least 10 IU/L) [142]. The earliest detection of hepatitis B surface antigen or DNA ranged from 1 to 14 months and acute hepatic flares typically resolved after reintroduction of hepatitis B-active agents, with hepatitis B surface antigen and/or DNA loss documented within 2–5 months. Careful risk–benefit evaluation should be undertaken in individuals with evidence of past hepatitis B infection (positive core antibody). Risk factors for reactivation include [142] (Geretti AM, personal communication): a detectable HIV viral load, low current CD4 count (likely to be  $<350$  cells/mm<sup>3</sup> but can occur at any CD4 count), nadir CD4 count  $<100$  cells/mm<sup>3</sup>, detectable hepatitis B DNA pre-switch, hepatitis B surface antibody  $<10$  IU/L (although levels above this may not be fully protective as antibodies may not be functional and may have reduced neutralising ability in people with HIV), any other cause of immunosuppression, poorly controlled diabetes and advanced chronic kidney disease. In people with risk factors, we suggest routine measurement of hepatitis B surface antigen and hepatitis B DNA screening regardless of alanine transaminase (ALT) level (at least every 6 months; more frequently in people with identified risk factors) or whether there is a rise in ALT ( $>1.5$  times the baseline level). While lamivudine may reduce the risk of hepatitis B reactivation, it is not a preferred strategy and may not abolish risk.

Hepatitis B surface antigen and/or DNA will be detectable before the ALT rises so a robust monitoring plan should reduce the risk of a significant hepatic flare if reactivation does occur. Prompt reintroduction of a recommended hepatitis B-active agent (tenofovir DX, tenofovir AF or entecavir) is recommended where hepatitis B reactivation is detected.

### **5.11.2 Oral lead-in and oral bridging**

Since the original registrational studies, oral lead-in is now optional, supported by the licence [131,132], data from the extension phase of FLAIR [143] and data from SOLAR, where oral lead-in was optional. In the SOLAR study, 61% of participants opted for 'start with injections' [128]. Oral lead-in is not required from a pharmacokinetic perspective unless switching from efavirenz, nevirapine or etravirine (see 6.2.3). We suggest that individuals with a history of tolerability issues on ART or who have never received an NNRTI and/or INSTI may benefit from an oral lead-in period but the decision should be guided by patient preference. Individuals who find it difficult taking tablets may particularly benefit from a direct-to-injectable approach; if NNRTI tolerability is a concern, consider adding an oral NNRTI to an existing higher-barrier oral regimen for a short period (up to 2 weeks).

Oral bridging should be initiated if an individual plans to receive an injection more than 7 days late, in line with the summary of product characteristics [132]. There are no data supporting frequent or regular use of oral bridging so it should be considered an exception.

### **5.11.3 Offering long-acting cabotegravir/rilpivirine**

When offering long-acting cabotegravir/rilpivirine, the discussion should include the following to support informed decision-making:

- The importance of on-time injections (defined as no more than 7 days before or after the target injection date);
- Oral lead-in is optional but may be preferable for people who are concerned about tolerability;
- Oral bridging can be employed if an injection is missed but this should be considered an exception; any clinically appropriate regimen can be used;
- Shared decision-making around the small risk of virological rebound, even when injections are administered on time, and the potential consequences of virological failure, specifically: onward transmission if the viral load rebounds to >200 copies/mL (and especially >1000 copies/mL); emergent resistance; and a possible need to switch to a boosted PI (resistance testing should guide the choice and some individuals may regain suppression on oral INSTI-based regimens);
- The potential advantages of long-acting cabotegravir/rilpivirine;

- Improved treatment satisfaction found in clinical trials;
- Freedom from daily pill-taking;
- Freedom from the daily reminder of living with HIV;
- Maintaining confidentiality at home or when travelling;
- Injection appointments typically take 30–60 minutes;
- Injection-site reactions are common, usually mild and tend to improve with time; uncommonly they result in treatment discontinuation;
- Simple interventions that may reduce the severity of injection-site reaction include simple analgesia, ice packs, ensuring medication and equipment are at room temperature prior to administration, slow injection and gentle exercise within a few hours of injection.

Clear patient information should be provided, alongside support to attend services such as appointment reminders and written or online calendar tools.

#### 5.11.4 Service capacity

The use of long-acting cabotegravir/rilpivirine has implications for HIV services, in terms of staffing and the time required to support people to follow the strict dosing schedules. The impact on services was included in the cost-effectiveness analyses undertaken by national approval bodies; the National Institute for Health and Care Excellence [NICE] technology appraisal estimated 15 minutes of band 5 nurse time [144]. However a service evaluation of 12 UK clinics reported appointment times of 30–60 minutes and although injections were administered by band 5 nurses at 2/12 services, at 10/12 this was undertaken by band 6+ nurses or pharmacists [145]. There is no extra funding to support the additional clinic resources required to implement long-acting treatments. In terms of the possibility of delivering long-acting cabotegravir/rilpivirine beyond the clinic to alleviate capacity issues, the ILANA study ( $n=114$ ) conducted at six clinics in England, with an option of community delivery from month 6, showed excellent adherence to injection schedule when delivered outside of the clinic (at home and in community support organisations). However, community delivery was not popular with participants due to stigma-related concerns (only 27% chose this option) and is unlikely to alleviate capacity issues [146].

It is reasonable for services to prioritise people most in need of injectable ART, who also meet the appropriate criteria, depending on local capacity. It is important to ensure that staff members administering injectable ART are trained in the Z-track injection technique, and that all members of staff are suitably trained to discuss the key data and support people in making decisions about the suitability of long-acting

cabotegravir/rilpivirine for them. We suggest that clinical services develop standard operating procedures to deliver injectable treatment. There should be clear and robust pathways to manage recall, missed appointments, cold chain requirements and the need for observation after injection administration. Individual services that lack the capacity to manage the logistics of injectable delivery should work within their clinical networks to ensure equitable access.

#### **5.11.5 Long-acting cabotegravir/rilpivirine in pregnancy**

There is limited information about the safety and efficacy of injectable treatment in pregnancy, so it is not currently a recommended option. Individuals wishing to conceive should consult their physician and come to a joint decision about initiating or continuing long-acting cabotegravir/rilpivirine. Those becoming pregnant on long-acting cabotegravir/rilpivirine should discuss the best evidence-based approach with their physician. Data are currently limited. Strategies may include continuing long-acting cabotegravir/rilpivirine (possibly with shorter dosing intervals), intensifying therapy or switching to oral ART. For up-to-date advice, see the most recent version of the BHIVA pregnancy guidelines [3].

#### **5.11.6 Prescribing long-acting cabotegravir/rilpivirine in people who are not virally suppressed**

Most of the evidence for long-acting cabotegravir/rilpivirine is in virally suppressed people, reflected in UK guidance/advice [144,147]. However, some individuals who are unable to achieve viral suppression on oral regimens could benefit from long-acting cabotegravir/rilpivirine.

There is increasing cohort experience reporting high rates of viral suppression in people initiating long-acting cabotegravir/rilpivirine with detectable HIV RNA, although reported numbers are mostly small and follow-up relatively short [148-150]. The SPLASH Clinic in San Francisco, which provides care for publicly insured people with high rates of mental health, substance use and housing challenges, started 59 non-virally suppressed people on long-acting cabotegravir/rilpivirine [151]. At week 48, 92% were virally suppressed and five experienced virological failure (three with NNRTI resistance and two with dual-class resistance). In an updated analysis of the Ward 86 cohort of 370 people starting long-acting ART, 130 of whom started with viraemia [152], median time to viral suppression was 32 days and month 6 viral suppression rates were high and similar to rates in those who started long-acting ART when virally suppressed (99% vs 98% respectively).

The LATITUDE study recruited 434 non-virally suppressed adults with adherence challenges and no cabotegravir or rilpivirine resistance. Prior to randomisation, all participants received standard of care oral ART for up to 24 weeks with financial incentives for achieving virological milestones (induction phase). Those

achieving HIV RNA <200 copies/mL ( $n=294$ ) were randomly assigned to continue oral ART or switch to monthly long-acting cabotegravir/rilpivirine for 52 weeks (optional oral lead-in) [153]. Although the primary endpoint (regimen failure, a combination of virological failure and treatment discontinuation) did not meet predefined stopping criteria, secondary endpoints favoured injectable ART; confirmed virological failure occurred in 7% on injectable ART versus 25% on oral ART, and treatment-related failures in 10% versus 26% respectively. These findings led the Data and Safety Monitoring Board to recommend halting randomisation and offering long-acting cabotegravir/rilpivirine to all eligible participants. A US modelling study predicted that immediate implementation of long-acting cabotegravir/rilpivirine in people with persistent viraemia and intermittent engagement could result in better viral suppression and fewer deaths than waiting for more evidence [154].

Additionally, since the last guidelines update, the International Antiviral Society-USA [155], DHHS [31] and EACS [156] have updated their guidelines to permit cautious use of long-acting cabotegravir/rilpivirine in non-virally suppressed people.

It is the opinion of the writing group that injectable cabotegravir/rilpivirine should be available for non-virally suppressed people at high risk of clinical progression where a multidisciplinary team considers it the only reasonable option to achieve viral suppression. The criteria for use of long-acting cabotegravir/rilpivirine are:

- Lack of viral suppression on oral ART despite extensive support;
- At high risk of disease progression based on CD4 count and/or HIV-related conditions;
- Ability to commit to regular appointments;
- Susceptibility of the virus to cabotegravir and rilpivirine;
- Willingness to accept a risk of virological failure and further limitation of treatment options.

Frequent visits for injection administration can provide an opportunity to offer psychosocial and substance use support, where relevant. We suggest that clinics should implement appropriate support systems such as appointment reminders and flexible injection appointments.

If an individual is considered unlikely to be able to access regular injections, whether within an HIV service or through appropriate liaison with other care providers, it may not be in their best interest to initiate injectable ART due to the high risk of emergent resistance in case of treatment discontinuation without switching to oral ART.

It is the view of the writing group that in the context of high viral load (particularly >10,000 copies/mL) high-barrier oral ART (ideally PI-based to avoid emergent INSTI resistance) should be used to reduce the viral load as far as possible before switching to long-acting cabotegravir/rilpivirine. We suggest all efforts are made to ensure that injections are administered on-time and, where administration on the due date is not possible, cabotegravir/rilpivirine is administered earlier in the window for injection, not later.

Of note, the requirement for susceptibility of the virus to cabotegravir and rilpivirine permits the potential use of this regimen in people with NNRTI RAMs that do not impact susceptibility to rilpivirine. However, we advise caution. K103N as transmitted resistance does not usually imply the presence of other transmitted NNRTI RAMs [96,137]. However, acquired NNRTI resistance poses a greater risk as, in addition to high-frequency variants, minority variants are usually selected which may impact rilpivirine susceptibility but escape detection by routine Sanger sequencing [115-120]. Careful risk–benefit evaluation is warranted. Factors to consider include duration of viral replication on the NNRTI (longer duration increases risk), duration of virological suppression since failure of the NNRTI-based regimen (longer duration reduces risk), and nadir and current CD4 counts (lower counts increase risk). The use of long-acting cabotegravir/rilpivirine in people with past or current acquired non-rilpivirine NNRTI RAMs should be limited to individuals who meet the criteria above, or who are already virally suppressed on this regimen (e.g. people who started it through the compassionate access programme). In exceptional circumstances, long-acting cabotegravir/rilpivirine can be considered for virally suppressed people with a history of non-rilpivirine NNRTI RAMs, for whom their current oral ART, and other oral alternatives, are associated with treatment-limiting tolerability, toxicity or drug–drug interaction issues.

## 5.12 PI monotherapy

### Recommendation

- We recommend against the use of PI monotherapy for routine ART (Grade 1A).

### Auditable outcome

- Proportion of individuals on boosted PI monotherapy as an ART maintenance strategy and record of rationale.

### Rationale

No new evidence has been considered for PI monotherapy; detailed guidance can be found in the 2015 BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy [1].

PI monotherapy is associated with a small but significant increased risk of viral rebound compared to triple therapy (relative risk 0.95, 95% CI 0.9–0.99) although this was not associated with incident viral resistance, serious adverse events or compromised treatment options at 3-year follow-up [77,157-170]. We do not recommend PI monotherapy due to the higher risk of virological failure [171,172]. Clinicians might consider PI monotherapy in individuals who are unable to tolerate NRTIs due to toxicities or as a short-term measure to manage or bridge complex clinical scenarios (e.g. stopping certain NNRTI-containing regimens or managing toxicity, or overdose, or acute illness). Where PI monotherapy is considered, darunavir/ritonavir (once or twice daily) or lopinavir/ritonavir (twice daily) should be used but with reintroduction of NRTIs if there is loss of virological control. Atazanavir/ritonavir monotherapy is not recommended because it has been associated with high rates of virological failure [173,174]. PI monotherapy is not recommended in individuals with active hepatitis B co-infection.

## 5.13 References

1. Churchill D, Waters L, Ahmed N *et al.* British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. *HIV Med* 2016; **17 Suppl 4**: s2–s104.
2. Angus B, Brook G, Awosusi F *et al.* *BHIVA guidelines for the routine investigation and monitoring of adult HIV-1 positive individuals 2016 (2019 interim update)*. Available at: <https://www.bhiva.org/monitoring-guidelines> (accessed September 2022).
3. Byrne L, Short C-E, Bamford A *et al.* BHIVA guidelines on the management of HIV in pregnancy and the postpartum period 2025. Available at: <https://bhiva.org/clinical-guideline/pregnancy-guidelines/> (accessed July 2025).
4. Ueaphongsukkit T, Gatechompol S, Avihingsanon A *et al.* Tenofovir alafenamide nephrotoxicity: a case report and literature review. *AIDS Res Ther* 2021; **18**: 53.
5. Figueroa MI, Brites C, Cecchini D *et al.* Efficacy and safety of dual therapy with dolutegravir/lamivudine in treatment-naïve persons with CD4 counts <200/mm<sup>3</sup>: 48 weeks results of the DOLCE Study. Available at: <https://ssrn.com/abstract=5151362> (accessed May 2025).
6. Venter WD, Moorhouse M, Sokhela S *et al.* Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med* 2019; **381**: 803–815.
7. Calmy A, Tovar Sanchez T *et al.*; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. *Lancet HIV* 2020; **7**: e677–e687.
8. Walmsley SL, Antela A, Clumeck N *et al.* Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med* 2013; **369**: 1807–1818.

9. Clotet B, Feinberg J, van Lunzen J *et al.*; ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet* 2014; **383**: 2222–2231.
10. Gallant J, Lazzarin A, Mills A *et al.* Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. *Lancet* 2017; **390**: 2063–2072.
11. Sax PE, DeJesus E, Crofoot G *et al.* Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. *AIDS* 2018; **32**: 1723–1725.
12. Cahn P, Madero JS, Arribas JR *et al.* Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr* 2020; **83**: 310–318.
13. Fichtenbaum CJ, Malvestutto CD, Watanabe MG *et al.*; REPRIEVE Investigators. Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. *Lancet HIV* 2025; **12**: e496–e505.
14. Orkin C, Squires KE, Molina JM *et al.*; DRIVE-AHEAD Study Group. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. *Clin Infect Dis* 2019; **68**: 535–544.
15. Molina JM, Squires K, Sax PE *et al.*; DRIVE-FORWARD trial group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. *Lancet HIV* 2020; **7**: e16–e26.
16. Raffi F, Jaeger H, Quiros-Roldan E *et al.*; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* 2013; **13**: 927–935.
17. Eron JJ, Young B, Cooper DA *et al.* Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet* 2010; **375**: 396–407.
18. Lennox JL, Landovitz RJ, Ribaldo HJ *et al.* Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med* 2014; **161**: 461–471.
19. Costagliola D, Potard V, Lang S *et al.* Is the risk of myocardial infarction in people with human immunodeficiency virus (HIV) associated with atazanavir or darunavir? A nested case-control study within the French Hospital Database on HIV. *J Infect Dis* 2020; **221**: 516–522.
20. Opsomer M, Dimitrova D, Verspeelt J *et al.* Evaluation of cardiovascular disease risk in HIV-1-infected patients treated with darunavir. *Drugs* 2018; **18**: 199–210.
21. Bini T, Mancusi D, Termini R *et al.* Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. *Drug Des Devel Ther* 2019; **13**: 1667–1685.

22. Orrell C, Hagins DP, Belonosova E *et al.*; ARIA study team. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. *Lancet HIV* 2017; **4**: e536–e546.
23. Eron JJ, Orkin C, Gallant J *et al.*; AMBER study group. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. *AIDS* 2018; **32**: 1431–1442.
24. Sax PE, Wohl D, Yin MT *et al.*; GS-US-292-0104/0111 study team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet* 2015; **385**: 2606–2615.
25. DeJesus E, Haas B, Segal-Maurer S *et al.* Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. *AIDS Res Hum Retroviruses* 2018; **34**: 337–342.
26. Dorjee K, Choden T, Baxi SM *et al.* Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies. *Int J Antimicrob Agents* 2018; **52**: 541–553.
27. Wang LH, Begley J, St Claire RL 3rd *et al.* Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. *AIDS Res Hum Retroviruses* 2004; **20**: 1173–1182.
28. Feng JY, Shi J, Schinazi RF, Anderson KS. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. *FASEB J* 1999; **13**: 1511–1517.
29. Drogan D, Rauch P, Hoffmann D *et al.* The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro. *Antiviral Res* 2010; **86**: 312–315.
30. World Health Organization. *Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach*. 2021. Available at: <https://www.who.int/publications/i/item/9789240031593> (accessed September 2022).
31. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines> (accessed July 2025).
32. European AIDS Clinical Society. *Guidelines*. 2021. Available at: [https://www.eacsociety.org/media/final2021eacsguidelinesv11.0\\_oct2021.pdf](https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf) (accessed April 2022).
33. Ford N, Vitoria M, Doherty M, Gray A. Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable? *Curr Opin HIV AIDS* 2017; **12**: 334–338.
34. Rokx C, Gras L, van de Vijver D *et al.*; ATHENA National Observational Cohort Study. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. *HIV Med* 2016; **17**: 571–580.

35. Rokx C, Fibriani A, van de Vijver D *et al.* More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort. *J Int AIDS Soc* 2014; **17 (4 Suppl 3)**: 19491.
36. Pollock K, Stebbing J, Bower M. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity. *J Antimicrob Chemother* 2006; **58**: 227–228.
37. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. *J Antimicrob Chemother* 2008; **62**: 879–888.
38. Hirasaka T, Tadokoro T, Yamamoto Y *et al.* Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. *J Infect Chemother* 2011; **17**: 602–608.
39. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. *Antivir Ther* 2007; **12**: 1075–1085.
40. Sax PE, Tierney C, Collier AC *et al.*; AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *J Infect Dis* 2011; **204**: 1191–1201.
41. Sabin CA, Ryom L, d'Arminio Monforte A *et al.*; D:A:D Study Group. Abacavir use and risk of recurrent myocardial infarction. *AIDS* 2018; **32**: 79–88.
42. Squires K, Kityo C, Hodder S *et al.* Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. *Lancet HIV* 2016; **3**: e410–e420.
43. Ryom L, Mocroft A, Kirk O *et al.*; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. *J Infect Dis* 2013; **207**: 1359–1369.
44. Reyataz Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/49/smpc#gref> (accessed May 2022).
45. Mollan KR, Smurzynski M, Eron JJ *et al.* Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. *Ann Intern Med* 2014; **161**: 1–10.
46. Arenas-Pinto A, Grund B, Sharma S *et al.*; INSIGHT START Study Group. Risk of suicidal behavior with use of efavirenz: results from the strategic timing of antiretroviral treatment trial. *Clin Infect Dis* 2018; **67**: 420–429.
47. Rockstroh JK, Lennox JL, Dejesus E *et al.*; STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. *Clin Infect Dis* 2011; **53**: 807–816.

48. Gatell JM, Morales-Ramirez JO, Hagins DP *et al.* Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. *J Int AIDS Soc* 2014; **17** (4 Suppl 3): 19532.
49. Cohen CJ, Molina JM, Cassetti I *et al.*; ECHO, THRIVE Study Groups. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. *AIDS* 2013; **27**: 939–950.
50. van Lunzen J, Antinori A, Cohen CJ *et al.* Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. *AIDS* 2016; **30**: 251–259.
51. Choi JY, Sungkanuparph S, Anekthananon T *et al.* Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection: a sub-analysis of phase 3 clinical trials. *Infect Chemother* 2016; **48**: 219–224.
52. DeJesus E, Rockstroh JK, Henry K *et al.*; GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. *Lancet* 2012; **379**: 2429–2438.
53. Phanuphak P, Sirivichayakul S, Jiamsakul A *et al.* Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia. *J Acquir Immune Defic Syndr* 2014; **66**: 74–79.
54. UKHIV Drug Resistance Database. *HIV Drug resistance in the UK*. Available at: <http://www.hivrd.org.uk/hiv-drug-resistance-uk> (accessed September 2022).
55. Mbisa JL, Ledesma J, Kirwan P *et al.* Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK. *J Antimicrob Chemother* 2020; **75**: 3311–3318.
56. Hakim JG, Thompson J, Kityo C *et al.*; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. *Lancet Infect Dis* 2018; **18**: 47–57.
57. Boyd MA, Kumarasamy N, Moore CL *et al.*; SECOND-LINE Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. *Lancet* 2013; **381**: 2091–2099.
58. Aboud M, Kaplan R, Lombaard J *et al.* Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. *Lancet Infect Dis* 2019; **19**: 253–264.
59. Paton NI, Musaazi J, Kityo C *et al.*; NADIA Trial Team. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. *Lancet HIV* 2022; **9**: e381–e393.

60. Gregson J, Rhee SY, Datir R *et al.* Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I. *J Infect Dis* 2020; **222**: 1108–1116.
61. Wainberg MA, Moisi D, Oliveira M *et al.* Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. *J Antimicrob Chemother* 2011; **66**: 2346–2349.
62. Fulcher JA, Du Y, Zhang TH *et al.* Emergence of integrase resistance mutations during initial therapy containing dolutegravir. *Clin Infect Dis* 2018; **67**: 791–794.
63. Lübke N, Jensen B, Hüttig F *et al.* Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R. *N Engl J Med* 2019; **381**: 887–889.
64. Huhn GD, Crofoot G, Ramgopal M *et al.* Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study. *Clin Infect Dis* 2020; **71**: 3110–3117.
65. Rolle CP, Berhe M, Singh T *et al.* Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. *AIDS* 2021; **35**: 1957–1965.
66. Bachelard A, Isernia V, Charpentia C *et al.* Efficacy and safety of using bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). *18th European AIDS Conference*. 2021. London, UK. Poster PE2/7.
67. Sedaghat AR, Dinoso JB, Shen L *et al.* Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. *Proc Natl Acad Sci U S A* 2008; **105**: 4832–4837.
68. Halvas EK, Joseph KW, Brand LD *et al.* HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. *Clin Invest* 2020; **130**: 5847–5857.
69. Raffi F, Hanf M, Ferry T *et al.*; Dat’AIDS Study Group. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. *J Antimicrob Chemother* 2017; **72**: 3425–3434.
70. Pyngottu A, Scherrer AU, Kouyos R *et al.*; Swiss HIV Cohort Study. Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatment. *Clin Infect Dis* 2021; **73**: e2134–e2141.
71. Di Biagio A, Rusconi S, Marzocchetti A *et al.*; ARCA Collaborative Group. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. *J Med Virol* 2014; **86**: 1648–1655.
72. Chen S, Han Y, Song X-J *et al.* Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients. *Infect Dis Poverty* 2020; **9**: 75.
73. University of Liverpool. *HIV Drug Interactions*. Available at: <https://www.hiv-druginteractions.org/> (accessed April 2022).

74. Feng Q, Zhou A, Zou H *et al.* Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2019; **366**: 14179.
75. Brady M, Clutterbuck D, Rodger A *et al.* British Association for Sexual Health and HIV/British HIV Association guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2025. Available at: <https://bhiva.org/clinical-guideline/prep-guidelines/> (accessed July 2025).
76. Girometti N, McCormack S, Tittle V *et al.*; 56 Dean Street Collaborative Group. Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes. *AIDS* 2022; **36**: 561–566.
77. Arribas JR, Delgado R, Arranz A *et al.* Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. *J Acquir Immune Defic Syndr* 2009; **51**: 147–152.
78. Derache A, Iwuji CC, Danaviah S *et al.* Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. *J Antimicrob Chemother* 2019; **74**: 473–479.
79. Mills A, Arribas JR, Andrade-Villanueva J *et al.* Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis* 2016; **16**: 43–52.
80. Tybost Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/1277/smpc#gref> (accessed April 2022).
81. Sax PE, DeJesus E, Mills A *et al.*; GS-US-236-0102 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. *Lancet* 2012; **379**: 2439–2448.
82. Post FA, Tebas P, Clarke A *et al.* Brief Report: Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. *J Acquir Immune Defic Syndr* 2017; **74**: 180–184.
83. Ibrahim F, Campbell L, Bailey AC *et al.* Estimated glomerular filtration rate slopes on tenofovir alafenamide. *HIV Med* 2020; **21**: 607–612.
84. Erlandson KM, Carter CC, Melbourne K *et al.* Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. *Clin Infect Dis* 2021; **73**: 1440–1451.
85. Sax PE, Rockstroh JK, Luetkemeyer AF *et al.*; GS-US-380–4030 Investigators. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. *Clin Infect Dis* 2021; **73**: e485–e493.
86. Mallon PW, Brunet L, Hsu RK *et al.* Weight gain before and after switch from TDF to TAF in a U.S. cohort study. *J Int AIDS Soc* 2021; **24**: e25702.

87. Ryom L, Lundgren JD, El-Sadr W *et al.*; D:A:D study group. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. *Lancet HIV* 2018; **5**: e291–e300.
88. Ryom L, Dilling Lundgren J, Reiss P *et al.*; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Use of contemporary protease inhibitors and risk of incident chronic kidney disease in persons with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *J Infect Dis* 2019; **220**: 1629–1634.
89. Vispo E, Barreiro P, Maida I *et al.* Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. *HIV Clin Trials* 2010; **11**: 197–204.
90. Fisher M, Nelson M, Johnson M *et al.* Simplification of PI+RTV+FTC/TDF to E/C/F/TDF maintains HIV suppression and is well tolerated. *HIV Med* 2014; **15 (Suppl 3)**: 114.
91. Arribas JR, Pialoux G, Gathe J *et al.* Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. *Lancet Infect Dis* 2014; **14**: 581–589.
92. Daar ES, DeJesus E, Ruane P *et al.* Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. *Lancet HIV* 2018; **5**: e347–e356.
93. Andreatta K, Willkom M, Martin R *et al.* Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. *J Antimicrob Chemother* 2019; **74**: 3555–3564.
94. Martinez E, Arnaiz JA, Podzamczar D *et al.* Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. *N Engl J Med* 2003; **349**: 1036–1046.
95. Echeverria P, Bonjoch A, Puig J *et al.* Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study. *PLoS One* 2014; **9**: e84676.
96. Porter DP, Toma J, Tan Y *et al.* Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine/emtricitabine/tenofovir disoproxil fumarate in the SPIRIT Study. *HIV Clin Trials* 2016; **17**: 29–37.
97. Palella FJ Jr, Fisher M, Tebas P *et al.* Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. *AIDS* 2014; **28**: 335–344.
98. Johnson M, Kumar P, Molina JM *et al.*; DRIVE-SHIFT Study Group. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. *J Acquir Immune Defic Syndr* 2019; **81**: 463–472.

99. Wong A, Goldstein D, Mallolas J *et al*. Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) in treatment-naïve adults with HIV-1 and transmitted nonnucleoside reverse transcriptase inhibitor resistance mutations. *J Acquir Immune Defic Syndr* 2019; **82**: e47–e49.
100. Waters L, Fisher M, Winston A *et al*. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. *AIDS* 2011; **25**: 65–71.
101. Vera JH, Bracchi M, Alagaratnam J *et al*. Improved central nervous system symptoms in people with HIV without objective neuropsychiatric complaints switching from efavirenz to rilpivirine containing cART. *Brain Sci* 2019; **9**: 195.
102. Pozniak A, Markowitz M, Mills A *et al*. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. *Lancet Infect Dis* 2014; **14**: 590–599.
103. van Wyk J, Ait-Khaled M, Santos J *et al*. Brief Report: Improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide-based 3- or 4-drug regimen to the 2-drug regimen of dolutegravir/lamivudine: The TANGO Study. *J Acquir Immune Defic Syndr* 2021; **87**: 794–800.
104. Hagins D, Mussini C, Zhang F *et al*. Week-48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen: SALSA. *Conference on Retroviruses and Opportunistic Infections*. February 2022. Abstract 603.
105. Van Wyk J, Ajana F, Bisshop F *et al*. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. *Clin Infect Dis* 2020; **71**: 1920–1929.
106. Rockstroh JK, DeJesus E, Henry K *et al*. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. *J Acquir Immune Defic Syndr* 2013; **62**: 483–486.
107. Osiyemi O, De Wit S, Ajana F *et al*. Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial. *Clin Infect Dis* 2022; **75**: 975–986.
108. Sculier D, Wandeler G, Yerly S *et al*. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. *PLoS Med* 2020; **17**: e1003421.
109. Llibre JM, Brites C, Cheng CY *et al*. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial. *Clin Infect Dis* 2022 Mar 2: ciac130.

110. De Miguel R, de Lagarde Sebastian M, Blanco Arévalo JL *et al.* Dolutegravir/lamivudine for maintenance of virological suppression in persons with historical suspected or confirmed resistance to lamivudine: week 48 results of a single-arm, open-label, multicentre, phase IIA clinical trial. *Clin Infect Dis* 2025; ciaf100. doi: 10.1093/cid/ciaf100.

111. Santoro MM, Armenia D, Teyssou E *et al.*; LAMRES Study Group. Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study. *J Glob Antimicrob Resist* 2022; **31**: 52–62.

112. Teyssou E, Soulie C, Fauchois A *et al.* The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type. *J Antimicrob Chemother* 2024; **79**: 1673–1676

113. Llibre JM, Hung CC, Brinson C *et al.* Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet* 2018; **391**: 839–849.

114. Moyle G, Assoumou L, de Castro N *et al.*; NEAT ID Foundation and the WISARD study group. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. *Lancet HIV* 2024; **11**: e156–e166.

115. Minuto JJ, Haubrich R. Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. *Futur HIV Ther* 2008; **2**: 525–537.

116. Metzner K. The significance of minority drug-resistant quasispecies. In: Geretti AM, ed. *Antiretroviral Resistance in Clinical Practice*. London, Mediscript, 2006. Chapter 11.

117. Geretti AM, Fox Z, Johnson JA *et al.* Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *PLoS One* 2013; **8**: e69266.

118. Li JZ, Paredes R, Ribaudó HJ *et al.* Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. *Infect Dis* 2013; **207**: 893–897.

119. Li JZ, Paredes R, Ribaudó HJ *et al.* Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA* 2011; **305**: 1327–1335

120. Cozzi-Lepri A, Noquera-Julian M, Di Giallonardo F *et al.* Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother* 2015; **70**: 930–940.

121. Pulido F, Ribera E, Lagarde M *et al.* Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial. *Clin Infect Dis* 2017; **65**: 2112–2118.

122. Di Giambenedetto S, Fabbiani M, Quiros Roldan E *et al.* Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-

infected patients: 48 week results from a randomized trial (ATLAS-M). *J Antimicrob Chemother* 2017; **72**: 1163–1171.

123. Perez-Molina JA, Rubio R, Rivero A *et al*. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. *Lancet Infect Dis* 2015; **15**: 775–784.

124. Arribas JR, Girard PM, Landman R *et al*. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. *Lancet Infect Dis* 2015; **15**: 785–792.

125. Swindells S, Lutz T, Van Zyl L *et al*. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. *AIDS* 2022; **36**: 185–194.

126. Orkin C, Oka S, Philibert P *et al*. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. *Lancet HIV* 2021; **8**: e185–e196.

127. Overton ET, Richmond G, Rizzardini G *et al*. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. *Clin Infect Dis* 2023; **76**: 1646–1654.

128. Ramgopal MN, Castagna A, Cazanave C *et al*. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. *Lancet HIV* 2023; **10**: e566–e577.

129. Kityo C, Mambule IK, Musaazi J *et al*. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. *Lancet Infect Dis* 2024; **24**: 1083–1092.

130. Kityo C, Mambule IK, Sokhela SM *et al*. Randomized trial of long-acting cabotegravir and rilpivirine in Africa (CARES): week 96 results. *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 202.

131. Rekambys Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/12950/smpc#gref> (accessed July 2025).

132. Vocabria Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/12957/smpc#gref> (accessed July 2025).

133. Perez Navarro A, Nutt CT, Siedner MJ *et al*. Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: a meta-analysis. *Clin Infect Dis* 2024: ciae631.

134. Orkin C, Schapiro JM, Perno CF *et al*. Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. *Clin Infect Dis* 2023; **77**: 1423–1431.

135. Maguire C, Rueve K, Farmer E *et al.* Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine. *Clin Infect Dis* 2024: ciae579.
136. Geretti AM, Blanco JL, Marcelin AG *et al.* HIV DNA sequencing to detect archived antiretroviral drug resistance. *Infect Dis Ther* 2022; **11**: 1793–1803.
137. Geretti AM, Ledesma J, Bibby D *et al.* Trends in transmitted drug resistance among adults with a recently acquired HIV infection. 19th European AIDS Conference 2023. Warsaw, Poland. Abstract 923. Available at: [https://react-profile.org/ebook/EACS-2023\\_Abstracts/392/](https://react-profile.org/ebook/EACS-2023_Abstracts/392/) (accessed July 2025).
138. Fabeni L, Armenia D, Abbate I *et al.*; Italian HIV Drug Resistance Group. HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21. *J Antimicrob Chemother* 2024; **79**: 2152–2162.
139. Załęski A, Lembas A, Dydą T *et al.* Drug resistance mutations (DRMs) for long-acting injectable cabotegravir and rilpivirine (CAB/RPV LAI) in the HIV-1 subtype A6 epidemic in Poland. *Microorganisms* 2025; **13**: 321.
140. Statens Serum Institut. HIV 2023. Available at: <https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/h/hiv-2023> (accessed July 2025).
141. Thoueille P, Saldanha SA, Schaller F *et al.*; Swiss HIV Cohort Study. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. *Lancet Reg Health Eur* 2023; **36**: 100793.
142. Ring K, Orkin C, Parczewski M *et al.* HBV reactivation post-switch to HBV-inactive ART: a scoping review. *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 771.
143. Orkin C, Morell EB, Tan DHS *et al.* Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. *Lancet HIV* 2021; **8**: e668–e678.
144. National Institute for Health and Care Excellence. *Cabotegravir with rilpivirine for treating HIV-1. Technology appraisal guidance [TA757]*. 2022. Available at: <https://www.nice.org.uk/guidance/ta757> (accessed October 2022).
145. Ring K, Smuk M, Shongwe M *et al.* Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net). *HIV Med* 2024; **25**: 1125–1134.
146. Orkin C, Hayes R, Haviland J *et al.* Perspectives of people with HIV on implementing long-acting cabotegravir plus rilpivirine in clinics and community settings in the United Kingdom: results from the antisexist, antiracist, antiageist implementing long-acting novel antiretrovirals study. *Clin Infect Dis* 2025; **80**: 1103–1113.
147. Scottish Medicines Consortium. Cabotegravir 600mg prolonged-release suspension for injection (Vocabria®). Available at <https://scottishmedicines.org.uk/media/6493/cabotegravir-vocabria-final-sept-2021-amended-241121-for-website.pdf> (accessed July 2025).

148. Christopoulos KA, Grochowski J, Mayorga-Munoz F *et al*. First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. *Clin Infect Dis* 2023; **76**: e645–e651.
149. Hsu RK, Sension M, Fusco JS *et al*. 1028. Real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA® Cohort. *Open Forum Infect Dis* 2023; **10** (Suppl 2): ofad500.059. Available at: [https://academic.oup.com/ofid/article/10/Supplement\\_2/ofad500.059/7448451](https://academic.oup.com/ofid/article/10/Supplement_2/ofad500.059/7448451) (accessed July 2025).
150. Colasanti JA, Aldredge A, Carnes LN *et al*. Long-acting injectable art in persons with HIV-1 viremia in the south: a tool to end the epidemic. *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 690.
151. Hickey MD, Gistand N, Grochowski J *et al*. Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir/rilpivirine with initial viremia. *Clin Infect Dis* 2025; **80**: 864–870.
152. Gistand NL, Spinelli M, Heise MJ *et al*. Long-term virologic suppression rates in the ward 86 HIV clinic's long-acting ART program (SPLASH). *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 689.
153. Rana AI, Bao Y, Zheng Lu *et al*. Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359. *Conference on Retroviruses and Opportunistic Infections*. March 2024. Abstract 212.
154. Hu R, Jones M, Pei PP *et al*. Clinical consequences of delaying implementation of LA-ART for PWH with persistent viremia in the US. *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 1360.
155. Sax PE, Thompson MA, Saag MS; IAS-USA Treatment Guidelines Panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV From the IAS-USA Guidelines Panel. *JAMA* 2024; **331**: 1060–1061.
156. European AIDS Clinical Society. EACS Guidelines 2024. Available at: <https://eacs.sanfordguide.com/> (accessed July 2025).
157. Arribas JR, Horban A, Gerstoft J *et al*. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. *AIDS* 2010; **24**: 223–230.
158. Arribas JR, Pulido F, Delgado R *et al*. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). *J Acquir Immune Defic Syndr* 2005; **40**: 280–287.
159. Pulido F, Arribas JR, Delgado R *et al*. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. *AIDS* 2008; **22**: F1–9.
160. Arribas JR, Clumeck N, Nelson M *et al*. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. *HIV Med* 2012; **13**: 398–405.

161. Cahn P, Montaner J, Junod P *et al.* Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. *PLoS One* 2011; **6**: e23726.
162. Gutmann C, Cusini A, Gunthard HF *et al.* Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. *AIDS* 2010; **24**: 2347–2354.
163. Hasson H, Galli L, Gallotta G *et al.* HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfecting patients starting anti-HCV treatment: a randomised pilot study (KaMon study). *New Microbiol* 2012; **35**: 469–474.
164. Katlama C, Valantin MA, Algarte-Genin M *et al.* Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. *AIDS* 2010; **24**: 2365–2374.
165. Mathis S, Khanlari B, Pulido F *et al.* Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. *PLoS One* 2011; **6**: e22003.
166. Meynard JL, Bouteloup V, Landman R *et al.* Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. *J Antimicrob Chemother* 2010; **65**: 2436–2444.
167. Nunes EP, Santini de Oliveira M, Mercon M *et al.* Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). *HIV Clin Trials* 2009; **10**: 368–374.
168. Waters L, Jackson A, Singh K *et al.* The impact of continued ART versus lopinavir/ritonavir monotherapy (mLPV/r) on body fat and bone mineral density (BMD) as measured by DEXA: 48 week results of a randomised study. *XVII International AIDS Conference*. August 2008. Mexico City, Mexico. Abstract CDB0193.
169. Winston A, Fatkenheuer G, Arribas J *et al.* Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. *HIV Clin Trials* 2010; **11**: 163–169.
170. Paton N, Stohr W, Arenas-Pinto A *et al.* The protease inhibitor versus ongoing triple-therapy (PIVOT) trial. *HIV Med* 2014; **15 Suppl 3**: 1.
171. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. *Appl Health Econ Health Policy* 2011; **9**: 217–223.
172. Arribas J, Bernardino J, Hill A *et al.* Effects of switching to PI monotherapy on measures of lipodystrophy: metaanalysis of six randomized HIV clinical trials. *11th International Congress on Drug Therapy in HIV Infection*. November 2012. Abstract P287.
173. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. *J Acquir Immune Defic Syndr* 2007; **44**: 417–422.
174. Vernazza P, Daneel S, Schiffer V *et al.* Risk of CNS compartment failure on PI monotherapy (ATARITMO study). *XVI International AIDS Conference*. August 2006. Toronto, Canada. Abstract WEPE0073.

## 6 Supporting individuals on therapy

### 6.1 Adherence

#### Recommendations

- We recommend that adherence and potential barriers to it are assessed and discussed with people living with HIV whenever ART is discussed, prescribed or dispensed (GPP).
- Detailed adherence discussion is recommended when virological failure occurs (GPP).
- We recommend that adherence support should address both perceptual and practical barriers to adherence (GPP).
- Individuals experiencing difficulties with adherence should be offered additional support from staff within the multidisciplinary team with experience in adherence support and/or from organisations offering peer support (GPP).

#### Auditable outcomes

- Record in medical notes of discussion about and assessment of adherence and potential barriers, both before starting a new ART regimen and while on ART.
- Record in medical notes of the provision or offer of adherence support.

#### Rationale

High levels of adherence are important to achieve and maintain viral suppression; there is a marked reduction in viral suppression for even modern regimens among people reporting lower adherence [1-3]. Data from men enrolled in the Multicenter AIDS Cohort Study demonstrated that suboptimal adherence, in the context of maintained viral suppression, was associated with higher levels of inflammation although there may be additional confounders associated with suboptimal adherence [4].

In the era of recommending that ART is started as soon as someone is ready, there may be less time to prepare individuals for lifelong treatment, so clear and repeated adherence advice is essential. Consultation with members of the multidisciplinary team who have experience in adherence support, such as pharmacists, psychologists and specialist nurses, and/or peer support should be considered for all individuals starting ART, reporting adherence concerns or who have experienced virological failure. In this situation patients will require a discussion to establish possible causes of failure, done in a way not to apportion blame. They may need increased support as they will be concerned about possible resistance and switching therapy.

Non-adherence is best understood as a variable behaviour with intentional and unintentional causes. Most people taking medication are non-adherent some of the time. Unintentional non-adherence is associated with limitations in capacity or resources, which reduce the ability to adhere to the treatment as intended. Intentional non-adherence is the result of a decision informed by beliefs, emotions and preferences [5].

Guidance on the monitoring of adherence to ART is available in the BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals [6]. As people may not raise adherence concerns, adherence should be checked routinely at every clinical visit.

Community advocacy and peer support, including clinic-based peer support, are helpful in supporting an individual's understanding and confidence around treatments. Community organisations in the UK have been instrumental in providing a range of information resources for people living with HIV as well as peer-support services, including published and web-based information materials, telephone advice lines, treatment advocates and peer-support groups, working in collaboration with healthcare professionals.

### 6.1.1 Barriers to adherence

Careful review of factors that impact adherence should be undertaken prior to ART initiation or switch, particularly when switching for virological failure.

Interventions to support adherence should be tailored to address specific relevant perceptual and practical barriers (see Section 6.1.2 Interventions to increase adherence to treatment). A three-step 'perceptions and practicalities approach' [7] may be helpful:

- Identify and address any doubts about personal need for ART;
- Identify and address specific concerns about taking ART;
- Identify and address practical barriers to adherence.

A review of factors associated with ART uptake and adherence in the UK, Canada and Australia showed that beliefs about the necessity, efficacy, convenience and side effects of ART all affect adherence; three main categories of barriers were identified: intrapersonal, interpersonal and extrapersonal [8] (Table 6.1).

**Table 6.1** Categories of barriers to ART uptake and adherence

| Intrapersonal                   | Interpersonal   | Extrapersonal   |
|---------------------------------|---|---|
| Risk of disclosure              | Not being connected to services   | Lack of care coordination   |
| Unwanted reminder of HIV status | Negative perceptions of provider's interpersonal skills, competency and confidentiality | Sociodemographic characteristics (employment, poverty, migration status, age at diagnosis, urban vs rural location, housing, ethnicity and sexuality) |

|   |   |                                     |
|---|---|-------------------------------------|
| Perceived lack of HIV-related illness and negative beliefs about health benefits of ART | Lack of provider recommendation to start/continue ART | Comorbidities and drug interactions |
| Low perceived readiness/self-efficacy around ART adherence                              |   | Drug use                            |
| Mental health symptoms and poor coping skills   |   | Distance from clinic                |
| Lack of knowledge about treatment and care  |   |                                     |

A 2019 web-based survey from 25 countries showed that the commonest reasons for missing ART five times or more within the past month were feeling depressed or overwhelmed, trying to forget about HIV and work-related concerns [9]. Correlates of suboptimal adherence included age under 50 years, education to high school equivalent or less, gastrointestinal side effects and privacy concerns. As people living with HIV age, the risk of multimorbidity increases; a systematic review revealed that, among people experiencing multimorbidity, non-adherence to medication for one condition did not necessarily extend to all conditions and, for example, people with HIV and TB reported higher adherence to medication for both conditions than those with HIV and chronic obstructive pulmonary disease [10]. The same study confirmed earlier findings from studies focused on HIV [11,12] demonstrating that depression is associated with lower adherence, and that stronger belief in medication necessity correlated with better adherence.

#### **6.1.1.1 Depression**

Although depression is consistently associated with lower medication adherence, one study showed that lower rates of viral suppression were mitigated by treatment for depression [13], consistent with an earlier study showing that adherence can be improved by treating depression [14]. We recommend screening for depression prior to ART initiation and regularly thereafter in line with BHIVA monitoring guidelines [6], as well as appropriate pathways for advice, referral and support as required. People living with HIV may benefit from being informed about the support options that are available to them locally, in line with the British Psychological Society/BHIVA/Medical Foundation for AIDS and Sexual Health standards for psychological support for adults living with HIV [15].

#### **6.1.1.2 Alcohol and drug use**

Alcohol use, harmful or otherwise, is associated with lower ART adherence [16,17]. The importance of accurate information provision is highlighted by a study demonstrating that intentional non-adherence may be explained by the inaccurate belief that it is hazardous to drink alcohol when taking medications [18]. Similarly, recreational drug use has a negative impact on adherence and engagement in care [19] and concerns about interactions with HIV medication may drive intentional non-adherence [20]. Injecting drug

use can also be associated with worse HIV treatment outcomes but opioid substitution therapy, and its integration within HIV services, improves adherence, viral suppression and retention in care [21]. We recommend screening for alcohol and drug use prior to ART initiation and regularly thereafter in line with BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals [6], as well as appropriate pathways for advice, referral and support as required.

### 6.1.1.3 Stigma

Stigma is a key factor associated with negative outcomes and the Positive Voices survey showed that one in four people with HIV experienced at least one stigma-related event within healthcare settings [22]. Non-disclosure of HIV status is associated with lower ART adherence [23] and peer support can foster improvements in self-esteem, confidence to share HIV status and ART adherence [22]. People living with HIV should be referred to the BHIVA standards and advised how to raise concerns if they experience stigma during their care [24].

### 6.1.1.4 Socioeconomic status

The ASTRA study revealed that after adjustment for demographic factors, increasing financial hardship and lack of employment, homeownership, university education and a supportive network were associated with higher risk of virological rebound in ART-treated individuals [25]. Services refer individuals living with HIV to social support where necessary.

## 6.1.2 Interventions to increase adherence to treatment

NICE has published detailed guidance on the assessment and support of adherence to medication in people with chronic diseases; key recommendations for adherence support are shown in Box 6.1 [26].

### Box 6.1. Summary of NICE guidance on adherence support [26]

| Assessment  |
|---|
| Recognise that non-adherence is common and that most individuals are non-adherent sometimes. Routinely assess adherence in a non-judgemental way whenever you prescribe, dispense and review medicines. The purpose of assessing adherence is not to monitor individuals but rather to find out whether they need more information and support.   |
| Make it easier for them to report non-adherence by: <ul style="list-style-type: none"> <li>• Asking the question in a way that does not apportion blame;</li> <li>• Explaining why you are asking the question;</li> <li>• Mentioning a specific time period such as ‘in the past week’;</li> <li>• Asking about medicine-taking behaviours such as reducing the dose and stopping and starting medicines.</li> </ul> |

If individuals are not taking their medicines, discuss with them whether this is because of beliefs and concerns or problems related to the medicines (intentional non-adherence) or because of practical problems (unintentional non-adherence).

Find out what form of support they would prefer to increase their adherence to medicines.

### Intervention

Individuals may need support to help them make the most effective use of their medicines (e.g. further information and discussion, or practical changes to the type of medicine or the regimen). Any interventions should address the concerns and needs of each individual. Tailor any intervention to increase adherence to the specific difficulties with adherence the person is experiencing.

Address any beliefs and concerns that result in reduced adherence.

Interventions might include:

- Suggesting that individuals record their medicine taking;
- Encouraging them to monitor their condition;
- Simplifying the dosing regimen;
- Using alternative packaging for the medicine;
- Using a multi-compartment medicines system.

Side effects can be a problem for some. If this is the case you should:

- Discuss how the individual would like to deal with side effects;
- Discuss the benefits, side effects and long-term effects with the individual to allow them to make an informed choice;
- Consider adjusting the dosage;
- Consider switching to another medicine with a different risk of side effects;
- Consider what other strategies might be used (e.g. timing of medicines).

#### 6.1.2.1 Dosing frequency

An overview of systematic reviews of consumer-oriented medication interventions found that simplified dosing regimens improved adherence in the majority of studies in several reviews [27]. A review of adherence interventions for ART included 19 studies (6312 adult individuals). Average adherence was modestly higher with once-daily than twice-daily regimens (weighted mean difference 2.55%, 95% CI 1.23–3.87;  $P=0.0002$ ) but virological suppression was similar. Both adherence and rates of suppression decreased over time, but adherence decreased less with once-daily than twice-daily dosing. Lower pill burden was associated with both better adherence and virological suppression [28]. Of note, this was based on non-randomised comparisons so there is a potential for confounding. NICE [26] reviewed

several randomised controlled trials of interventions to reduce dose frequency and found that adherence may increase with once-daily dosing but not in all studies. Once-daily dosing is a reasonable intervention to reduce unintentional non-adherence to ART but no corresponding impact on virological suppression has been observed.

#### **6.1.2.2 Fixed-dose combinations and single-tablet regimens**

There are several fixed-dose combinations of ARVs, including single-tablet regimens. No meta-analyses on whether fixed-dose combinations or single-tablet regimens improve adherence, compared to the same components with a greater pill burden, have been published on this subject for ART. A meta-analysis of nine randomised controlled trials and cohort studies in a range of diseases found that use of fixed-dose combinations was associated with a significant reduction in the risk of non-adherence; however, in the single randomised controlled trial of treatment for HIV included in the analysis, no significant difference in treatment failure between groups receiving a fixed-dose combination versus non-fixed-dose combination was observed [29]. A meta-analysis of cohort studies found that use of fixed-dose combinations for anti-hypertensive treatment was associated with increased adherence but with no improvement in blood pressure control [30]. A randomised trial conducted in New Zealand showed that fixed-dose combinations resulted in significantly better adherence to primary prevention for CVD [31].

A retrospective study of a pharmacy database found no benefit in persistence on first-line ART for any fixed-dose combination compared to separate agents [32]. In the ECHO and THRIVE studies, a lower virological response rate in individuals with baseline viral load of 100,000–500,000 copies/mL was observed for rilpivirine- versus efavirenz-based regimens when given as separate agents [33]; this finding was not replicated when rilpivirine- and efavirenz-based regimens were formulated as fixed-dose combinations in the preliminary 48-week results from the STaR study [34]. Although the use of fixed-dose combinations may have driven this apparent improvement in performance of rilpivirine, it may also have arisen due to the simpler once-daily regimens in STaR, other methodological differences or by chance.

A potential advantage of single-tablet regimens is that they prevent individuals from preferentially adhering less closely to one component of a regimen than others. A minority of participants in one study did report such 'differential' adherence, but this was not associated with a difference in virological outcomes [35]. Differential adherence was also reported in an Italian observational study; however, the difference was small and may have been confounded by other factors [36].

An observational study of outcomes following a switch from a fixed-dose combination of efavirenz/emtricitabine/tenofovir DF to multi-tablet regimens including swapping emtricitabine for lamivudine demonstrated maintained efficacy, and was safe and lower in cost [37]. A retrospective analysis

of switching from fixed-dose combinations to separate components in the Balearic Islands found lower pharmaceutical cost but higher overall healthcare cost in the first year following the switch [38].

A systematic review and meta-analysis of single-tablet versus multi-tablet regimens demonstrated that single-tablet regimens are associated with significantly higher ART adherence levels at 95% and 90% thresholds. Findings from the systematic review showed that improved adherence results in an increased likelihood of achieving viral suppression in observational settings [39]. A French cohort analysis showed that first-line therapy with single-tablet regimens was associated with a longer time to treatment discontinuation than with multi-tablet regimens but when ART modification for simplification was not considered as a failure, single-tablet and multi-tablet regimens were similar [40].

Disadvantages of single-tablet regimens include cost, limited choice of regimens and the inability to adjust the dose for weight, renal impairment or drug–drug interactions. Although the licences for both lamivudine and emtricitabine as single components and within fixed-dose combination and single-tablet regimen preparations call for renal dose adjustment, there is evidence to support the use of higher doses in renal impairment. With dose adjustment based on eGFR, there is a risk of under dosing, particularly in the presence of drugs that inhibit tubular secretion of creatinine, and subsequent underestimation of eGFR. Studies have demonstrated good tolerability and minimal toxicity resulting from accumulation of either drug [41-46]. These data are limited and any decision to deviate from licensed dosing should be made based on the individual's clinical circumstances including stage of renal failure, modality of renal replacement therapy and ability to manage complex administration including liquid formulations.

In summary, fixed-dose combinations and single-tablet regimens support adherence to treatment, and this may reduce the risk of virological failure. However, the size of this effect is uncertain, and needs to be balanced against the potentially far lower cost of generic ARV agents. When considering the need for a fixed-dose combination or single-tablet regimen, ARV pill burden should be considered in the context of concomitant medication taken for other conditions.

### **6.1.3 Should the choice of first-line ART combination be affected by risk of non-adherence?**

#### **Recommendation**

- Where there is clinical concern that doses may be missed intermittently, there is insufficient evidence to guide specific recommendations about ART choice. However, where there is a risk of frequent treatment interruptions, higher barrier regimens may be associated with less frequent selection for drug resistance (Grade 2C).

## Rationale

Clinicians are poor at predicting adherence to ART [47-50]. The consequences of low adherence depend on drug pharmacokinetics, potency, fitness of resistant strains and genetic barrier to resistance.

There are no data from randomised controlled trials that directly address whether the choice of first-line ART combination should be affected by risk of non-adherence; people likely to be non-adherent may be excluded from such trials. Observational studies often select people living with HIV already established on ART [51,52] where the observed effects of non-adherence on treatment outcome are likely to differ from those in individuals starting ART *de novo*. This selection bias may exclude those who have experienced early virological failure or disease progression (or even death) or have defaulted from care. In addition, most studies predate the use of boosted-PI regimens and INSTIs with high genetic barriers to resistance in first-line therapy [51,53].

Three different outcomes may be considered: virological suppression, selection of drug resistance and effect of pattern of non-adherence.

### 6.1.3.1 Effect of adherence on virological suppression

There are no data from randomised controlled trials that directly address the effect of adherence on virological suppression. Where the impact of adherence on viral suppression is reported, outcomes are usually reported by adherence greater than 95% versus 95% or less, though a cut-off of 90% is used in some studies. The small proportion of people reporting low adherence in first-line trials, the binary adherence thresholds used, and the fact that self-report may not be a fully accurate marker of adherence limit the ability to interpret the impact of adherence on treatment outcomes.

In a randomised controlled trial comparing lopinavir/ritonavir with once-daily darunavir/ritonavir, virological failure was more likely in the lopinavir/ritonavir than the darunavir/ritonavir arm; there were no differences between the two arms when analysing individuals reporting >95% adherence [54].

An association between virological suppression rates and adherence has also been demonstrated in randomised controlled trials of high-genetic barrier INSTI-based regimens.

The GS-1489 and GS-1490 studies evaluated the efficacy of bicitgravir/emtricitabine/tenofovir AF, compared to dolutegravir/abacavir/lamivudine and dolutegravir with emtricitabine/tenofovir AF, respectively, in ART-naïve HIV-positive adults. Subgroup analyses were conducted stratifying subjects by adherence of <95% and ≥95%, based on tablet count. Differences in viral suppression by adherence were not statistically significant between study arms for either study [2,55], but lower virological success rates between the adherence strata for individual regimens indicate that adherence rates influence outcomes for

these high-genetic barrier INSTI-based regimens, as would be expected. Of note, only viral suppression outcomes have been reported by adherence category in these trials; there are no data on whether virological failure rates differ by adherence category and no resistance emergence was described at week 48 or week 96 timepoints.

A pooled *post hoc* analysis of the GEMINI 1 and 2 studies evaluated the impact of treatment adherence on achieving viral load suppression at week 48 with dolutegravir and lamivudine dual therapy compared to dolutegravir with a tenofovir DF/emtricitabine backbone [56]. Analyses were conducted stratifying subjects by adherence of <90% and ≥90%, based on tablet count. The proportion of participants achieving viral suppression at week 48 was lower, and to a similar degree, in both arms among those with <90% adherence compared to those with ≥90% adherence for both treatment regimens [56]. As for the bicitegravir trials outlined above, only viral suppression outcomes have been reported by adherence category in these trials; there are no data on whether virological failure rates differ by adherence category and no resistance emergence was described at week 48 or 96.

Much of the evidence on which adherence advice is based, including that at least 95% adherence is required to maintain viral suppression, was generated in the era of first-generation NNRTIs and unboosted PIs. More recent data suggest that many people will maintain viral suppression at lower levels of adherence. The association between adherence (based on percentage of days covered by ART over the previous 365 days) and viral suppression was examined in a cohort of 765 people [57]. The odds ratio for viral suppression was the same for 80–90% adherence as for >90%; the overall estimated adherence level necessary to achieve viral suppression in 90% of viral load tests was 82% and varied by regimen type. INSTI-, NNRTI- and PI-based regimens achieved 90% viral suppression with adherence levels of 75%, 78% and 89% respectively.

#### **6.1.3.2 Effect of pattern of non-adherence**

The pattern of non-adherence may also be important. A number of small observational studies have examined short, intermittent treatment interruptions (2–7 days) in individuals with prolonged virological suppression. For efavirenz, cycles of 2 days off per week appeared no more likely to result in treatment failure than continuous therapy, as long as the treatment interruption was not prolonged [58,59]. The BREATHER trial investigated a ‘5 days on, 2 days off’ strategy versus continued ART in participants aged 8 to 24 years with viral suppression on efavirenz plus two NRTIs [60]. Non-inferiority was shown for short cycle therapy versus continuous therapy at 48 weeks, with similar resistance and a better safety profile. However, cycles of 7-day or 28-day treatment interruption resulted in failure of efavirenz and selection of resistance [59,61].

In the QUATUOR trial, 647 people on suppressive ART were randomly assigned to intermittent (4 days on, 3 days off) or continuous ART [62]. At week 48, 96% in the intermittent treatment group and 97% in the continuous treatment group maintained viral suppression with virological failure rates of 2% and 1% respectively. Reported treatment satisfaction was significantly higher, and drug costs significantly lower, in the intermittent ART arm but resistance was more frequent: three of six participants who had virological failure developed emergent resistance compared to one of four in the continuous treatment. For boosted PI treatment, average adherence, rather than duration of treatment interruption, was associated with virological response in one study [63].

Although these data may be helpful to reassure people who miss doses occasionally, this is not a strategy to be recommended routinely. However, in specific circumstances, structured intermittent therapy might be deemed an appropriate option, for example where stopping treatment at weekends reduces risk of longer treatment interruptions.

## 6.2 Pharmacology

For managing HIV, as for any long-term condition (and arguably more so due to the consequences of treatment failure), healthcare professionals need to have a clear understanding of the basic principles of pharmacology to ensure effective and appropriate prescribing. We focus on four key areas: drug interactions, stopping therapy, switching therapy and TDM.

### 6.2.1 Drug interactions

#### Recommendations

- Drug histories should be taken at each clinic visit, and a full medication history (including herbal medicines, recreational drugs and other non-prescribed medications) should be taken at least annually (GPP).
- All potential adverse pharmacokinetic interactions between ARV drugs and other concomitant medications should be checked before administration (GPP).
- Wherever feasible, people living with HIV should be counselled about the risks of drug interactions, and advised to use resources such as the University of Liverpool HIV Drug Interactions app (iOS or Android) (GPP).

#### Auditable outcomes

- Record in medical notes of full medication history at least annually.

- Record in medical notes of potential adverse pharmacokinetic interactions between ARV drugs and other concomitant medications.
- Record of communication regarding key drug–drug interactions with GPs and other key healthcare professionals.

### **Rationale**

The importance of eliciting a complete medication history in order to manage potential drug interactions in patients cannot be overemphasised. Drug–drug interactions may involve positive or negative interactions between ARV agents or between ARVs and drugs used to treat other coexistent conditions. A detailed list is beyond the remit of these guidelines but clinically important interactions to consider when co-administering with ARV drugs include interactions with the following drugs: steroids (including topical, inhaled and local injections), quetiapine, acid-reducing agents, methadone, oral contraceptives, anti-epileptics, antidepressants, lipid-lowering agents, certain antimicrobials (e.g. clarithromycin, minocycline and fluconazole), some anti-arrhythmics, anti-TB therapies, anti-cancer drugs, immunosuppressants, phosphodiesterase inhibitors and anti-hepatitis C virus therapies. Most of these interactions can be managed safely (i.e. with/without dosage modification, together with enhanced clinical vigilance) but in some cases (e.g. rifampicin and PIs, proton pump inhibitors and atazanavir, and inhaled fluticasone and ritonavir/cobicistat) the nature of the interaction is such that co-administration must be avoided and alternatives sought.

It is important that education about the risks of drug interactions, including over-the-counter or recreational drugs, should be provided and people living with HIV should be encouraged to discuss the risks with pharmacists or their healthcare professionals before commencing any new drugs, including those prescribed in primary care.

High-risk scenarios for harmful drug–drug interactions are those involving non-oral co-medications (especially steroids that are inhaled or injected locally), or those involving multiple teams (such as is the case with multiple morbidities, or in acutely unwell patients). In these cases, teams may lack full knowledge of medicines and their drug–drug interaction liabilities, and harms may be wrongly attributed to underlying disease. Large surveys have shown that about a third to a quarter of people living with HIV receiving ART are at risk of a clinically significant drug interaction [64-70]. This suggests that safe management of HIV drug interactions is only possible if medication recording is complete, and if physicians are aware of the possibility that an interaction might exist. Incomplete or inaccurate medication recording has resulted from self-medication, between hospital and community health services [71] and within hospital settings particularly

when multiple teams are involved, or when medical records are fragmented (e.g. with separate HIV case notes) [72].

A UK survey found that even when medication recording is complete, physicians were only able to identify correctly one-third of clinically significant interactions involving HIV drugs [69].

In patients who are acutely unwell and medically unstable there are several potential risks and early engagement with specialist pharmacists and use of appropriate resources is advised; risks include:

- Lack of recognition of the interaction potential of rifampicin given outside of TB treatment (e.g. for severe and complex *Staphylococcus* infections);
- The routine prescribing of vitamin supplements in patients with malignancies;
- The routine prescribing of sodium bicarbonate or calcium supplements in patients with renal disease;
- Continuing medications that have potential toxicities and do not contribute significantly to acute management (e.g. statins and acid-reducing agents); temporarily discontinuing such medications should be considered. Hypoalbuminaemia is common in acutely unwell patients and competition for protein binding can result in higher concentrations of free drug and increased risk of toxicity of highly protein-bound drugs. Consideration should be given to this when rationalising treatment;
- Some clinical scenarios may necessitate administration of medication and feeds via enteral tubes, which may further potentiate malabsorption or drug–drug interactions.

#### **6.2.1.1 Specialist advice**

In addition to HIV specialist and local pharmacists, the University of Liverpool's comprehensive HIV drug interaction website [73] is an excellent and highly recommended resource for information relating to potential drug interactions; the website also includes specific resources such as dosing in renal impairment, information on gender-affirming hormones, managing people who cannot take oral medication and considerations for bariatric surgery. Additional information resources include the electronic medicines compendium [74], summaries of product characteristics and medical information departments of pharmaceutical companies.

Communication with GPs and other medical specialists involved in care is fundamental for minimising the risk of adverse drug interactions. All clinic letters should carry as a standard header or footer advice to check for interactions, with links to appropriate resources to address the potential for drug interactions, and should flag particularly important drug–drug interactions if possible. Where drug–drug interactions are identified, there should be appropriate reporting and feedback to the relevant prescribers/teams. Peer support may help individuals understand the need for open and clear discussion with their HIV team about

drug–drug interactions, particularly as people may not feel comfortable telling healthcare professionals about recreational drug use or may not appreciate the potential importance of non-prescribed medication and supplements.

## 6.2.2 Stopping therapy: pharmacological considerations

### Recommendations

- For individuals discontinuing ART containing efavirenz, nevirapine or etravirine in combination with an NRTI backbone, we recommend that all drugs are replaced with a PI (darunavir/ritonavir once daily) for 4 weeks (Grade 1C).
- We strongly recommend against abrupt cessation of long-acting cabotegravir/rilpivirine due to a high risk of resistance emergence (Grade 1D).
- For individuals stopping any other regimen, we recommend that all drugs are stopped simultaneously, and no replacement is required (Grade 1C).

### Rationale

In general, treatment interruptions are not recommended for most individuals. Whatever the reason for stopping ART (e.g. intercurrent illness or individual choice), pharmacological issues must be considered for a clinician to give guidance. The half-life of each drug included in the regimen is critical. There is the potential for monotherapy or dual therapy if ARV drugs with different half-lives are stopped simultaneously.

NRTI and NNRTI resistance mutations have been detected following discontinuation of previously suppressive NRTI plus NNRTI regimens [75] and may have the potential to affect the likelihood of viral resuppression on restarting an NNRTI-based ART regimen. There are limited data on which to base recommendations for how to protect against development of resistance in the period immediately following treatment cessation. Several discontinuation strategies have been proposed [76], and choice is influenced by clinical considerations, individual preferences and pharmacological principles. Options include: (i) simultaneously stopping all drugs in a regimen containing drugs with similar half-lives; (ii) a staggered stop, discontinuing the drug with the longest half-life first in a regimen containing drugs with short and long half-lives; or (iii) replacing all drugs with a drug with a short half-life and high-genetic barrier to resistance (i.e. a PI). There have been no randomised comparisons of these three strategies. However, in one study, fewer emergent resistance mutations were seen in those switching to a PI compared with those undergoing a simultaneous or staggered stop [77]. Therapeutic plasma concentrations of efavirenz can also be detected up to 3 weeks after stopping the drug in some people and thus a staggered stop of 1 week may be inadequate to prevent emergence of NNRTI mutations [77]. The optimal duration of replacement with a PI is not known, but 4 weeks is probably advisable.

The long-acting injectable preparations of cabotegravir and rilpivirine have long pharmacokinetic tails with marked interindividual variability, and subtherapeutic concentrations of drug have been detected for more than a year after the last injection in some individuals [78,79]. This highlights the importance of initiating these preparations in individuals who are likely to remain engaged with care and unlikely to experience treatment interruptions. We strongly recommend against abrupt ART cessation and suggest that a fully active oral regimen is initiated within one dosing interval if stopping an injectable regimen to prevent development of viral rebound and resistance.

### 6.2.3 Switching therapy: pharmacological considerations

#### Recommendations

- Despite the potential for altered concentrations of the replacement drug when switching from efavirenz or nevirapine, in the context of viral suppression we recommend a direct switch without dose adjustment (Grade 1D).
- If switching from etravirine to dolutegravir, we recommend increasing the dolutegravir dose to 50 mg twice daily for the first 14 days (GPP).
- We recommend against omitting the oral lead-in when switching from efavirenz, nevirapine or etravirine to long-acting cabotegravir/rilpivirine (GPP).
- We recommend careful consideration of the impact on concomitant non-ARV medications if switching from a boosted to an unboosted regimen (GPP).

#### Rationale

Switching a component of an ART regimen is frequently considered in people living with HIV to manage drug side effects or address adherence issues. ARVs that either induce or inhibit drug-metabolising enzymes have the potential to affect the plasma concentrations of the new agent. This applies in particular to switching away from NNRTIs. Induction of drug-metabolising enzymes by efavirenz is likely to persist for a period beyond drug cessation. Whether viral load is maximally suppressed should also be considered when planning how to switch away from efavirenz to an alternative agent.

Strategies for switching to an alternative agent where there may be pharmacological consequences are summarised below.

#### 6.2.3.1 Switching from efavirenz (or nevirapine) to alternative oral agents

Efavirenz is classified as a moderate inducer and nevirapine as a weak-to-moderate inducer of cytochrome P45 (CYP)3A and glucuronidation.

It has been shown that switching from efavirenz to etravirine or rilpivirine, or nevirapine to rilpivirine [80], in people living with HIV with an undetectable viral load does not compromise virological responses, as undetectable viral loads were maintained despite the transitional lower drug plasma concentrations post-switch [81,82]. It has also been shown that increasing the dosage of maraviroc to 600 mg twice daily for 7 days following the switch from efavirenz overcomes the persistence of efavirenz post-switch induction and contributes to maintaining an undetectable viral load [83]. A transient decrease in doravirine [84] and elvitegravir [85] concentrations was observed following switching from efavirenz but in the context of viral suppression the significance of this remains unknown. There is some impact of a direct switch from efavirenz on raltegravir [86] and dolutegravir [87] pharmacokinetics, and some impact of a direct switch from nevirapine on dolutegravir pharmacokinetics [88] but these are not considered clinically important and no dose adjustment is recommended.

Hence, we have taken the view that (where specific data on switching are lacking) unless there is evidence of a major risk of toxicity or failure when switching from a moderate inhibitor or inducer, a straightforward substitution should be presumed to be reasonable. However, if switching away from efavirenz is undertaken when viral load is likely to still be detectable, substitution with a boosted PI in preference to a within-class switch is advised.

### **6.2.3.2 Switching from etravirine to alternative oral agents**

Modern regimens are associated with higher inhibitory quotients, which provide greater resilience against short-term falls in plasma drug concentrations.

Etravirine is a potent inducer of CYP3A and glucuronidation, reducing dolutegravir exposure by 71% (in the absence of any protective effect of a concomitant boosted PI) [89] but raltegravir exposure by only 10% [90]. Therefore, we recommend a straightforward substitution of etravirine with raltegravir, and a doubling of dolutegravir to 50 mg twice daily for the first 14 days after stopping etravirine, especially in people with a detectable viral load.

Data on switching from etravirine to other core agents, including elvitegravir/cobicistat, doravirine or bictegravir, are not available. It is expected that such switches would result in significantly lowered concentrations for the first 14 days. Because dose increment is not an option for these regimens, we recommend switching directly in people with an undetectable viral load, and then monitoring viral load.

### **6.2.3.3 Switching from efavirenz, etravirine or nevirapine to long-acting cabotegravir/rilpivirine Recommendations**

- We recommend against omitting the oral lead-in (in the absence of pharmacokinetic data) when switching from efavirenz or etravirine (GPP). An oral lead-in period of 4 weeks is recommended for patients switching from efavirenz/etravirine (GPP), comprising:
  - Oral cabotegravir and higher-dose oral rilpivirine (50 mg) for 2 weeks followed by 2 weeks of standard dosing *or*
  - Standard-dose oral cabotegravir and rilpivirine with additional two-NRTI cover from tenofovir DF (or tenofovir AF) plus emtricitabine or lamivudine.
- Although no significant drug–drug interaction is anticipated, we also recommend a 4-week oral cabotegravir/rilpivirine lead-in period when switching from nevirapine (GPP).

Efavirenz and etravirine are examples of moderate enzyme inducers and, as noted above, nevirapine is a weak-to-moderate inducer of CYP3A. Residual induction (persisting for up to 2 weeks after their discontinuation) may decrease concentrations of rilpivirine (more so than cabotegravir) which also has a low-genetic barrier to resistance. Additionally, following intramuscular administration (in the absence of oral cabotegravir/rilpivirine lead-in) it takes several months for steady-state levels of these agents to be reached. The majority of participants in ATLAS and ATLAS-2M [91,92] switched from NNRTI-containing regimens (most commonly efavirenz: 32% and 39% in ATLAS and ATLAS-2M respectively) where the dose of oral rilpivirine was not increased. Additionally, pooled pharmacokinetic analyses from SWORD-1 and SWORD-2 [93] suggested that rilpivirine trough concentrations were comparable to historical controls at weeks 4, 24 and 48 following switch. Although no significant drug–drug interaction is anticipated [80], we include switch from nevirapine in our recommendations. Collectively these considerations have informed our recommendations for managing a switch to long-acting cabotegravir/rilpivirine from regimens containing efavirenz, etravirine and nevirapine.

#### **6.2.3.4 Switching from a boosted PI to any regimen**

The virological, tolerability and toxicity-associated benefits of switching away from a boosted PI have been demonstrated in a number of studies, and switching away from a PI is now more common due to evolving evidence to support the use of high-genetic barrier INSTI-based regimens in treatment-experienced individuals. Removal of a pharmacokinetic enhancer from a regimen often results in alteration of levels of concomitant non-ARV drugs and subsequent toxicity or reduction in efficacy, and close monitoring and dose adjustment may be required particularly in the case of agents that have a narrow therapeutic index. Taking a thorough drug history in advance of the switch is essential, and cross-disciplinary communication is key in managing such modifications.

## 6.2.4 TDM

### Recommendations

- We recommend against the non-selective use of TDM (GPP).
- TDM may be of clinical value in specific populations (e.g. children and pregnant women) or selected clinical scenarios (e.g. malabsorption, drug interactions and suspected non-adherence to therapy) (Grade 2C).

### Rationale

TDM has been shown to be valuable in optimising the management of certain individuals; however, the general utility of this test in those receiving ART has been poorly assessed. With the marked improvement in tolerability of modern ARV regimens, which are associated with higher therapeutic indices and inhibitory quotients, the role of TDM in clinical management has also evolved in the context of selected groups and clinical situations. A Cochrane review of randomised controlled trials [94] suggested little value of TDM when used unselectively. However, TDM may inform the management of vulnerable populations or complex clinical situations.

#### 6.2.4.1 Monitoring adherence

While detection of drug at therapeutic or even high plasma concentrations does not exclude low adherence, absence of measurable drug, or presence of very low drug levels, strongly suggests lack of medication intake, particularly in the absence of evidence of significant malabsorption. Here, TDM should rarely be interpreted in isolation, but rather integrated with reported adherence, virological rebound, particularly in the absence of any resistance mutations, and other features in the history that suggest risk of low treatment adherence.

#### 6.2.4.2 Optimising treatment in specific populations

TDM may have a role in optimising therapy in specific populations (e.g. children, pregnant women [95] and individuals with extremes of BMI) or in specific clinical situations (e.g. liver and renal impairment, treatment failure, foreseen and unanticipated drug interactions, malabsorption, suspected non-adherence and unlicensed once-daily dosing regimens). Higher concentrations of PIs have been observed in ageing populations, and evidence of ARV toxicity resulting from drug accumulation due to altered drug pharmacokinetics is a concern [6,96,97]. Although TDM may be beneficial in ageing populations, further evidence for its role in routine management is needed; in the absence of further data, management should be guided by virological control, signs and symptoms of toxicity and the need to optimise ART. In scenarios in which TDM is used to guide dosing, the aim is either to optimise dosing based on known efficacy or toxicity

cut-offs or to achieve the range of plasma concentrations observed in pharmacokinetic studies at licensed treatment doses.

#### 6.2.4.3 Managing drug interactions

Where the ARV drug has the potential to be adversely affected by another drug, and the combination is unavoidable, TDM may be used either to manage the interaction or to discount a significant interaction in a particular individual.

#### 6.2.4.4 Other situations

Knowledge of plasma drug concentrations may be clinically useful when evaluating whether there is scope for treatment simplification, or for confirming or refuting impaired drug absorption as a reason for virological failure.

As for all other investigations, it is essential that TDM is undertaken correctly, especially with regard to timing (i.e. when steady state has been achieved). A consensus has been reached for defining targets [98] for many ARVs. With many newer agents, evidence for a defined minimum target for efficacy is either weak or lacking, and evidence for an upper toxicity cut-off for most ARVs is lacking.

## 6.3 References

1. Cahn P, Madero JS, Arribas JR *et al.* Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naïve adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr* 2020; **83**: 310–318.
2. Gallant J, Lazzarin A, Mills A *et al.* Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. *Lancet* 2017; **390**: 2063–2072.
3. Sax PE, DeJesus E, Crofoot G *et al.* Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. *AIDS* 2018; **32**: 1723–1725.
4. Castillo-Mancilla JR, Brown TT, Erlandson KM *et al.* Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. *Clin Infect Dis* 2016; **63**: 1661–1667.
5. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. *J Psychosom Res* 2008; **64**: 41–46.
- 6.. Angus B, Brook G, Awosusi F *et al.* BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals 2016 (2019 interim update). Available at: <https://www.bhiva.org/monitoring-guidelines> (accessed July 2022).

7. Horne R, Chapman SC, Parham R *et al*. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. *PLoS One* 2013; **8**: e80633.
8. Bolsewicz K, Debattista J, Valley A *et al*. Factors associated with antiretroviral treatment uptake and adherence: a review. Perspectives from Australia, Canada, and the United Kingdom. *AIDS Care* 2015; **27**: 1429–1438.
9. de Los Rios P, Okoli C, Puneekar Y *et al*. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. *Prev Med* 2020; **139**: 106182.
10. Foley L, Larkin J, Lombard-Vance R *et al*. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. *BMJ Open* 2021; **11**: e044987.
11. Kacanek D, Jacobson DL, Spiegelman D *et al*. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. *J Acquir Immune Defic Syndr* 2010; **53**: 266–272.
12. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. *J Acquir Immune Defic Syndr* 2011; **58**: 181–187.
13. Lesko CR, Hutton HE, Fojo AT *et al*. Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014-2019. *AIDS* 2021; **35**: 2017–2024.
14. Yun LW, Maravi M, Kobayashi JS *et al*. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. *J Acquir Immune Defic Syndr* 2005; **38**: 432–438.
15. British Psychological Society, British HIV Association, Medical Foundation for AIDS and Sexual Health. *Standards for psychological support for adults living with HIV*. MedFASH; 2011. Available at: [www.bhiva.org/StandardsForPsychologicalSupport.aspx](http://www.bhiva.org/StandardsForPsychologicalSupport.aspx) (accessed July 2022).
16. Sheinfil AZ, Foley JD, Moskal D *et al*. Daily associations between alcohol consumption and antiretroviral therapy (ART) adherence among HIV-positive men who have sex with men. *AIDS Behav* 2022; **26**: 3153–3163.
17. Rose AL, Belus JM, Ma T *et al*. The relationship between harmful alcohol use and antiretroviral non-adherence in people accessing HIV treatment in Cape Town, South Africa: an event-level analysis. *AIDS Behav* 2022; **26**: 2055–2066.
18. Kalichman SC, Eaton LA, Kalichman MO. Believing that it is hazardous to mix alcohol with medicines predicts intentional non-adherence to antiretrovirals. *J Acquir Immune Defic Syndr* 2022; **90**: 208–213.
19. Castro-Granell V, Garin N, Jaén Á *et al*. Recreational drug use in people living with HIV in Spain: factors associated with drug use and the impact on clinical outcomes. *AIDS Behav* 2021; **25**: 3883–3897.
20. Fuster-RuizdeApodaca MJ, Castro-Granell V, Laguía A *et al*. Drug use and antiretroviral therapy (ART) interactions: a qualitative study to explore the knowledge, beliefs, adherence, and quality of life of people living with HIV taking ART and illicit drugs. *AIDS Res Ther* 2020; **17**: 24.

21. Low AJ, Mburu G, Welton NJ *et al.* Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. *Clin Infect Dis* 2016; **63**: 1094–1104.
22. Wiginton JM, Maksut JL, Murray SM *et al.* Brief Report: HIV-related healthcare stigma/discrimination and unmet needs among persons living with HIV in England and Wales. *Prev Med Rep* 2021; **24**: 101580.
23. Daskalopoulou M, Lampe FC, Sherr L *et al.*; ASTRA Study Group. Non-disclosure of HIV status and associations with psychological factors, ART non-adherence, and viral load non-suppression among people living with HIV in the UK. *AIDS Behav* 2017; **21**: 184–195.
24. British HIV Association. *Standards of Care for people living with HIV*. 2018. Available at: <https://standards.bhiva.org/file/5ee25266705ef/Your-Guide-To-BHIVA-Standards-of-Care.pdf> (accessed October 2022).
25. Burch LS, Smith CJ, Anderson J *et al.* Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. *Lancet Public Health* 2016; **1**: e26–e36.
26. National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline 76 (CG76). 2009. Available at: <http://guidance.nice.org.uk/CG76> (accessed March 2022).
27. Nieuwlaat R, Wilczynski N, Navarro T *et al.* Interventions for enhancing medication adherence. *Cochrane Database Syst Rev* 2014; **11**: CD000011.
28. Nachega JB, Parienti JJ, Uthman OA *et al.* Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. *Clin Infect Dis* 2014; **58**: 1297–1307.
29. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med* 2007; **120**: 713–719.
30. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension* 2010; **55**: 399–407.
31. Selak V, Elley CR, Bullen C *et al.* Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. *BMJ* 2014; **348**: g3318.
32. Juday T, Grimm K, Zoe-Powers A *et al.* A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. *AIDS Care* 2011; **23**: 1154–1162.
33. Cohen CJ, Molina JM, Cassetti I *et al.* Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. *AIDS* 2013; **27**: 939–950.
34. Porter DP, Kulkarni R, Fralich T *et al.* Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). *J Acquir Immune Defic Syndr* 2014; **65**: 318–326.

35. Gardner EM, Sharma S, Peng G *et al.* Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. *AIDS* 2008; **22**: 75–82.
36. Fabbiani, M., Zaccarelli, M., Grima, P *et al.* Single tablet regimens are associated with reduced efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. *BMC Infect Dis* 2014; **14**, 26.
37. Engsig FN, Gerstoft J, Helleberg M *et al.* Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen. *J Acquir Immune Defic Syndr* 2014; **66**: 407–413.
38. Homar F, Lozano V, Martinez-Gomez J *et al.* Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. *Health Econ Rev* 2012; **2**: 16.
39. Altice F, Evuarherhe O, Shina S *et al.* Adherence to HIV treatment regimens: systematic literature review and meta-analysis. *Patient Prefer Adherence* 2019; **13**: 475–490.
40. Cotte L, Ferry T, Pugliese P *et al.* Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy—results from a large French multicenter cohort study. *PLoS One* 2017; **12**: e0170661.
41. Fischetti B, Shah K, Taft DR *et al.* Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. *Open Forum Infect Dis* 2018; **5**: ofy225.
42. Mounzer K, Brunet L, Wyatt CM *et al.* To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. *AIDS* 2021; **35**: 1201–1208.
43. Pozniak A, Arribas JR, Gathe J *et al.* Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. *J Acquir Immune Defic Syndr* 2016; **71**: 530–537.
44. Eron JJ Jr, Lelievre JD, Kalayjian R *et al.* Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. *Lancet HIV* 2018; **6**: e15–e24.
45. Michienzi SM, Schriever CA, Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. *Int J STD AIDS* 2019; **30**: 181–187.
46. Tan M, Johnston S, Nicholls J, Gompels M. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients? *HIV Med* 2019; **20**: 634–637.
47. Gross R, Bilker WB, Friedman HM *et al.* Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. *AIDS* 2002; **16**: 1835–1837.
48. Bangsberg DR, Hecht FM, Clague H *et al.* Provider assessment of adherence to HIV antiretroviral therapy. *J Acquir Immune Defic Syndr* 2001; **26**: 435–442.

49. Miller LG, Liu H, Hays RD *et al.* How well do clinicians estimate patients' adherence to combination antiretroviral therapy? *J Gen Intern Med* 2002; **17**: 1–11.
50. Clyne W, McLachlan S, Mshelia C *et al.* "My patients are better than yours": optimistic bias about patients' medication adherence by European health care professionals. *Patient Prefer Adherence* 2016; **10**: 1937–1944.
51. Bangsberg DR, Acosta EP, Gupta R *et al.* Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virologic fitness. *AIDS* 2006; **20**: 223–231.
52. Maggiolo F, Airoldi M, Kleinloog HD *et al.* Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. *HIV Clin Trials* 2007; **8**: 282–292.
53. Trotta MP, Ammassari A, Cozzi-Lepri A *et al.* Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. *AIDS* 2003; **17**: 1099–1102.
54. Nelson M, Girard PM, Demasi R *et al.* Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. *J Antimicrob Chemother* 2010; **65**: 1505–1509.
55. Sax PE, Pozniak A, Montes ML *et al.* Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet* 2017; **390**: 2073–2082.
56. Ait-Khaled M, Sierra Madero J, Estrada V *et al.* Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. *HIV Res Clin Pract* 2021; **23**: 9–14.
57. Byrd KK, Hou JG, Hazen R *et al.*; Patient-Centered HIV Care Model Team. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. *J Acquir Immune Defic Syndr* 2019; **82**: 245–251.
58. Cohen CJ, Colson AE, Sheble-Hall AG *et al.* Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. *HIV Clin Trials* 2007; **8**: 19–23.
59. Reynolds SJ, Kityo C, Hallahan CW *et al.* A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. *PLoS One* 2010; **5**: e10307.
60. BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. *Lancet HIV* 2016; **3**: e421–e430.
61. Dybul M, Nies-Kraske E, Daucher M *et al.* Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. *J Infect Dis* 2003; **188**: 388–396.

62. Landman R, de Truchis P, Assoumou L *et al.*; ANRS 170 QUATUOR study group. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. *Lancet HIV* 2022; **9**: e79–e90.
63. Parienti JJ, Ragland K, Lucht F *et al.* Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. *Clin Infect Dis* 2010; **50**: 1192–1197.
64. Okoli C, Schwenk A, Radford M *et al.* Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database. *HIV Med* 2020; **21**: 471–480.
65. Deutschmann E, Bucher HC, Jaeckel S *et al.*; Swiss HIV Cohort Study. Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors. *Clin Infect Dis* 2021; **73**: e2145–e2152.
66. López-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan Á *et al.* Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study. *Clin Infect Dis* 2020; **71**: 353–362.
67. Molas E, Luque S, Retamero A *et al.* Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a multidisciplinary team. *HIV Clin Trials* 2018; **19**: 1–7.
68. Demessine L, Peyro-Saint-Paul L, Gardner EM *et al.* Risk and cost associated with drug-drug interactions among aging HIV patients receiving combined antiretroviral therapy in France. *Open Forum Infect Dis* 2019; **6**: ofz051.
69. Evans-Jones JG, Cottle LE, Back DJ *et al.* Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. *Clin Infect Dis* 2010; **50**: 1419–1421.
70. Marzolini C, Elzi L, Gibbons S *et al.* Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. *Antivir Ther* 2010; **15**: 413–423.
71. de Maat MM, Frankfort SV, Mathot RA *et al.* Discrepancies between medical and pharmacy records for patients on anti-HIV drugs. *Ann Pharmacother* 2002; **36**: 410–415.
72. Seden K, Mathew T, Bradley M *et al.* Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system? *Int J STD AIDS* 2012; **23**: 99–104.
73. University of Liverpool. *HIV Drug Interactions*. Available at: [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) (accessed September 2022).
74. The electronic medicines compendium. *Latest medicine updates*. Available at: [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc) (accessed September 2022).
75. Fox Z, Phillips A, Cohen C *et al.* Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. *AIDS* 2008; **22**: 2279–2289.
76. Taylor S, Boffito M, Khoo S *et al.* Stopping antiretroviral therapy. *AIDS* 2007; **21**: 1673–1682.

77. Taylor S, Jayasuriya A, Fisher M *et al.* Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. *J Antimicrob Chemother* 2012; **67**: 675–680.
78. Spreen W, Min S, Ford SL *et al.* Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. *HIV Clin Trials* 2013; **14**: 192–203.
79. Verloes R, Deleu S, Niemeijer N *et al.* Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. *HIV Med* 2015; **16**: 477–484.
80. Allavena C, Dailly E, Reliquet V *et al.* Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. *J Antimicrob Chemother* 2014; **69**: 2804–2808.
81. Waters L, Fisher M, Winston A *et al.* A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. *AIDS* 2011; **25**: 65–71.
82. Crauwels H, Vingerhoets J, Ryan R *et al.* Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. *Antivir Ther* 2012; **17**: 439–446.
83. Waters L, Jackson A, Else L *et al.* Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. *Antivir Ther* 2015; **20**: 157–163.
84. Greaves W, Wan H, Yee KL *et al.* Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. *Antimicrob Agents Chemother* 2019; **63**: e01298-19.
85. Ramanathan S, Custodio JM, Wei X *et al.* Pharmacokinetics of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate after switch from efavirenz/emtricitabine/tenofovir disoproxil fumarate in healthy subjects. *J Acquir Immune Defic Syndr* 2016; **72**: 281–288.
86. Iwamoto M, Wenning LA, Petry AS *et al.* Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. *Antimicrob Agents Chemother* 2008; **52**: 4338–4343.
87. Generaux G, Song I, Bowers G, Piscitelli S. A mechanistic SimCYP simulation evaluating dolutegravir and efavirenz pharmacokinetics following a switch from once-daily efavirenz to once-daily dolutegravir. *15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy*. May 2014. Washington DC, USA. Abstract P\_36.
88. Dailly E, Allavena C, Gregoire M *et al.* Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. *J Antimicrob Chemother* 2015; **70**: 3307–3310.
89. Song I, Borland J, Min S *et al.* Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. *Antimicrob Agents Chemother* 2011; **55**: 3517–3521.
90. Ford SL, Gould E, Chen S *et al.* Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744. *Antimicrob Agents Chemother* 2013; **57**: 277–280.

91. Swindells S, Lutz T, Van Zyl L *et al*. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. *AIDS* 2022; **36**: 185–194.
92. Jaeger H, Overton ET, Richmond G *et al*. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. *Lancet HIV* 2021; **8**: e679–e689.
93. Adkison K, Kahl L, Blair E *et al*. Pharmacokinetics of dolutegravir and rilpivirine after switching to the two-drug regimen from an efavirenz- or nevirapine-based antiretroviral regimen: SWORD-1 & -2 pooled PK analysis. *18th International Workshop on Clinical Pharmacology of Antiviral Therapy*. June 2017. Chicago, IL, USA.
94. Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. *Cochrane Database Syst Rev* 2009; Cd007268.
95. Andany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. *Drugs* 2013; **73**: 229–247.
96. Winston A, Jose S, Gibbons S *et al*. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. *J Antimicrob Chemother* 2013; **68**: 1354–1359.
97. Avihingsanon A, Kerr SJ, Punyawudho B *et al*. Short communication: aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. *AIDS Res Hum Retroviruses* 2013; **29**: 1541–1546.
98. La Porte C, Back D, Blaschke T *et al*. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. *Rev Antivir Ther* 2006; **3**: 4–14.

## 7 Managing virological failure

### 7.1 Introduction

Detailed guidance on HIV viral load, resistance and genotypic tropism testing can be found in the BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals [1].

The following recommendations concern the management of people living with HIV experiencing virological failure on ART. Populations experiencing virological failure will include those with no or limited HIV drug resistance, those with more extensive resistance or historical virological failure on NRTIs, NNRTIs, PIs and/or INSTIs and those with limited treatment options. For the assessment and evaluation of evidence, priority questions were agreed and outcomes were ranked as critical, important and not important by members of the writing group. For individuals with no or limited HIV drug resistance, the following were ranked as critical outcomes: viral suppression to <50 copies/mL at 48 weeks, development of resistance and discontinuation due to clinical and laboratory adverse events. For individuals with three-class failure/few therapeutic options, clinical progression, median CD4 cell count change at 48 weeks and development of new resistance were ranked as critical outcomes. Treatments were compared where data were available and differences in outcomes assessed. For this update of the guidelines, the benefit of including NRTIs in the context of virological failure/resistance was examined.

In the UK, the cumulative virological failure rate after 4 years on first-line therapy was estimated to be 8%, 12% and 25%, respectively, for NNRTI-, INSTI- and PI-based regimens [2]. As baseline genotypic testing of reverse transcriptase and protease (not integrase at the time of writing) is now performed routinely and is recommended practice, detection of resistance at virological failure is rarely a result of TDR and failure to adapt first-line treatment [3,4].

The general principles for the management of individuals experiencing virological failure are outlined in Boxes 7.1 and 7.2 (all GPPs). Details of typical patterns of HIV drug resistance found in individuals with a history of or presenting with virological failure are outlined in Box 7.3.

#### **Definitions (in the context of continued ART without changes):**

**Virological suppression:** achieving and maintaining a viral load below the lower limit of detection of the assay being used (may vary between centres).

**Virological failure:** incomplete virological response after commencing treatment or evidence of confirmed virological rebound to >200 copies/mL.

**Incomplete virological response:** viral load >200 copies/mL in two consecutive tests after 24 weeks without ever achieving an undetectable viral load. The baseline viral load and regimen should be taken into consideration as some regimens will take longer than others to suppress HIV RNA levels. In individuals with a high baseline viral load (i.e. >100,000 copies/mL) it may take longer for viral load to fall below the limit of detection; by contrast, individuals treated with an INSTI are more likely to experience a more rapid reduction in viral load.

**Virological rebound:** failure to maintain viral load below the limit of detection on two or more consecutive tests.

**Low-level viraemia:** a confirmed viral load between 50 and 200 copies/mL.

**Viral blip:** after virological suppression, a single viral load between 50 and 200 copies/mL followed by an undetectable result.

### **Auditable outcomes**

- Record in medical notes of resistance result at baseline (HIV diagnosis) or at ART initiation (if former not available) and at first viral load >200 copies/mL after prior virological suppression (or less if successful genotyping) and/or before switch.
- Record in medical notes of adherence assessment and tolerability/toxicity to ART in individuals experiencing virological failure or repeated viral blips.
- Proportion of individuals experiencing virological failure on current ART regimen.
- Proportion of individuals experiencing virological failure switched to a new suppressive regimen within 6 months.
- Proportion of individuals on ART with previously documented HIV drug resistance who now have an undetectable viral load.
- Record of individuals with multi-class virological failure with or without multi-class resistance being discussed within a multidisciplinary team and/or referred for expert advice.

## **7.2 Blips**

### **Recommendation**

- In individuals on ART, a single viral load of 50–200 copies/mL preceded and followed by an undetectable viral load is usually not a cause for clinical concern (GPP). It should necessitate clinical

vigilance, adherence reinforcement, a search for possible interactions and repeat testing within 2–6 weeks depending on ARV regimen.

## Rationale

Optimal HIV control is ordinarily reflected by complete virological suppression with an undetectable viral load. A viral blip is variably defined but for the purposes of these guidelines the definition that has been adopted is a detectable viral load between 50 and 200 copies/mL, which is preceded and followed by an undetectable result without any change of therapy. Blips occur frequently. One study reported a median value of 79 copies/mL and, when real and not due to laboratory variability, blips are short-lived (median 2.5 days, range 2–11.5 days) [5-7]. Many individuals have at least one blip at some time [8] and most studies have found no relationship between isolated blips and adverse outcomes such as virological failure or emergent resistance [5,9,10]. However some studies have shown an association between blips and future virological failure [6,11].

There is a correlation between level of first detectable viral load and subsequent virological rebound [8,12]. One retrospective study of more than 3000 individuals found virological failure (defined as consecutive HIV viral load >50 copies/mL measured at least 30 days apart, or any viral load >1000 copies/mL) in 26%; 14% of rebounds were preceded by transient HIV viral load of 50–999 copies/mL but, critically, only transient HIV viral load >500 copies/mL correlated with rebound in multivariable analyses [12]. This is consistent with findings from other studies (see Section 7.3 Low-level viraemia on ART).

Viral load assay variation and laboratory processing artefacts account for many blips (i.e. no 'true' increase in viral replication), which partly explains why blips do not appear to compromise long-term outcomes [9,13,14]. Most individuals with short-lived increases in HIV viral load to <200 copies/mL can be reassured that such events are relatively common and unlikely to presage failure. However, those with sustained low-level increases in viral load (see Section 7.3 Low-level viraemia on ART) run a higher risk of virological failure. In keeping with the DHSS guidance [15], in these guidelines we define virological failure as a confirmed viral load >200 copies/mL, a threshold that eliminates most cases of viral blips.

A detectable viral load should prompt a review of adherence (and reiteration of the importance of full adherence), as well a search for any tolerability/toxicity issues, drug–drug and drug–food interactions and evidence of archived resistance. A viral load of 50–200 copies/mL preceded and followed by an undetectable viral load should not be a cause of clinical concern. In the context of repeated blips or persistent low-level viraemia, genotypic resistance testing is recommended [11,16].

## 7.3 Low-level viraemia on ART

### Recommendations

- We recommend that in the context of low-level viraemia or repeated viral blips, resistance testing should be attempted (Grade 1D).
- We recommend that in the context of low-level viraemia or repeated blips a high genetic barrier regimen should be used (GPP).

### Rationale

Low-level viraemia is observed in up to 8% of individuals [17] and, when compared to viral suppression to <50 copies/mL, is associated with an increased risk of virological failure and resistance [6,18,19]. The likelihood of resuppression after low-level viraemia is greater for lower magnitudes of viraemia [20]. Indeed it is uncertain whether viraemia <200 copies/mL always confers independent risks as viraemia at this level may reflect assay variation. Low-level viraemia is associated with resistance (37% in one study [19]) that may be associated with the magnitude of viraemia; in one analysis, maximum viral load was higher in those who developed resistance (368 vs 143 copies/mL;  $P=0.008$ ). In cohort studies [18] and clinical trials [19], individuals on boosted PI-based ART were more likely to experience detectable viraemia than those on an NNRTI-based regimen. Many individuals with low-level viraemia have low or undetectable plasma drug levels in untimed samples underscoring the importance of assessing adherence [21]; however, we do not recommend routine TDM in this context (see Section 6.2.4 TDM). Low-level viraemia is also associated with immune activation [10]. Low-level antigenic exposure differentially affects T cell activation and HIV-specific T cell response.

Resistance testing should be considered, where feasible, in all cases of low-level viraemia (viraemia between 50 and 200 copies/mL) on treatment. Where resistance is detected, regimens should be modified appropriately. In the absence of clear data, it is the view of the writing group that persistent low-level viraemia or recurrent blips on a low-genetic barrier regimen (including NNRTI-based or first-generation INSTI-based therapy), even in the absence of detectable resistance, warrants prompt regimen change to a high-genetic barrier three-drug regimen [22,23]. Of note, intensifying ART in the context of low-level viraemia or recurrent blips is not usually effective. Further evaluation should follow as outlined in Box 7.1.

Increasingly, viral load assays have quantification cut-offs lower than 50 copies/mL. Thus, individuals may have persistent viraemia >20 or >40 copies/mL but <50 copies/mL, depending on the assay used. Rates of this 'very low-level' viraemia are unclear. Several studies have evaluated the risk of virological rebound to >50 copies/mL in individuals with detectable viraemia <50 copies/mL; results are conflicting [24-26]. In one study, subjects were stratified based on the Abbott RealTime Assay into viral load 40-49 copies/mL,

<40 copies/mL with RNA detected and <40 copies/mL with no RNA detected [25]. It was found that compared to individuals with viral load <40 copies/mL and no detected RNA, viraemia of 40–49 copies/mL increased the risk of rebound to >50 copies/mL by 4.67-fold while a detectable RNA at <40 copies/mL increased the risk by 1.97-fold. The risk of rebound to >400 copies/mL was increased by 6.91-fold and 2.88-fold, respectively. Other studies have found increased risk of rebound to >50, >200 and >400 copies/mL but, importantly, not  $\geq 1000$  copies/mL [27]. The majority of the rebounds to >200 copies/mL were blips and resistance rarely emerged [27], making the significance of these events unclear.

In the absence of clear data, it is the view of the writing group that, having assessed factors outlined in Box 7.1, no treatment modification is required for individuals with detectable viraemia below 50 copies/mL.

## 7.4 Virological failure on ART

### Recommendation

- We recommend that a single viral load of >200 copies/mL is investigated further, including a rapid re-test with/without genotypic resistance testing, as it may be indicative of virological failure (Grade 1C).

### Rationale

In the UK, among drug-experienced individuals who experience virological failure, approximately 70% have no major resistance mutations on genotypic resistance testing [28]. Confirmation of virological failure at any stage should lead to the practice shown in Box 7.1. This situation is likely to cause anxiety for the individual involved and support should be offered while the factors associated with virological failure are evaluated and further investigations are undertaken (see also Section 6 Supporting individuals on therapy).

**Box 7.1.** Best practice for the management of individuals with suspected or confirmed virological failure (all GPPs)

- Factors affecting adherence and drug exposure, including tolerability/toxicity issues, drug–drug /drug–food interactions, ARV potency, significant renal/liver disease and mental health/drug dependency problems should be evaluated.
- Resistance testing should be performed while on failing therapy or within 2–4 weeks of discontinuation.
- Past ART and resistance tests should be reviewed for archived mutations.
- Tropism testing should be performed if maraviroc is being considered.
- Intensification with a single additional active ARV is not recommended.

- Once virological failure is confirmed and preferably after a resistance test result is available, the regimen should be changed as soon as possible to avoid accumulation of resistance mutations.
- When switching regimens, factors such as drug–drug interactions and patient characteristics such as hepatitis B virus status should be considered. Where necessary, drugs that are active against hepatitis B should be continued.

The choice of the new ART regimen will primarily depend on the results of resistance testing, prior treatment history and the individual’s preference. Additional considerations include the results of tropism and HLA-B\*5701 testing, drug–drug and drug–food interactions, comorbidities and future therapy options. The goal of the new combination is to re-establish a viral load <50 copies/mL.

**Box 7.2.** Best practice for the management of individuals with multi-class virological failure (all GPPs)

- In individuals with ongoing viraemia and with few options to construct a fully suppressive regimen, referral for specialist advice and/or discussion in a multidisciplinary team ‘virtual’ clinic is imperative.
- In those with significant resistance, include at least two and preferably three fully active agents with at least one active boosted PI (preferably ritonavir- or cobicistat-boosted darunavir) and one agent with a novel mechanism of action (these may include INSTIs, CCR5 antagonists, molecules targeting glycoprotein 120 [gp120; fostemsavir], monoclonal antibodies targeting CD4 [ibalizumab], capsid inhibitors [lenacapavir], the fusion inhibitor T-20 or other investigational agents).
- Treatment interruption is not recommended.

**Box 7.3.** Typical resistance patterns on virological failure

- No resistance (wild-type virus).
- Lamivudine/emtricitabine resistance (M184V/I) (following any first-line therapy, including tenofovir DF/emtricitabine or abacavir/lamivudine).
- NNRTI resistance (e.g. K103N, Y181C/I/V or E138K) and/or lamivudine/emtricitabine resistance (following first-line therapy with an NNRTI-based regimen, including tenofovir DF/emtricitabine or abacavir/lamivudine).

- INSTI resistance (e.g. Y143C/R, Q148R/H or N155H) and/or lamivudine/emtricitabine resistance (following first-line therapy with raltegravir- or elvitegravir-based regimens, including tenofovir DF/emtricitabine or abacavir/lamivudine).
- Extended reverse transcriptase resistance (e.g. K65R/L74V or TAMs) (following suboptimal regimens and/or in individuals with more extensive NRTI-based drug history associated with virological failure).
- Three-class resistance (usually NRTI, NNRTI and PI) (following multiple failing regimens).
- Limited therapeutic options (following multiple failing regimens, including INSTIs and CCR5 antagonists).

## 7.5 Individuals with no or limited drug resistance

### Recommendations

- We recommend that factors associated with suboptimal adherence are considered for individuals experiencing virological failure on first-line ART with wild-type virus at baseline and without emergent resistance mutations at failure (GPP).
- If the current regimen is well tolerated and there are no concerning drug–drug interactions, it may be reasonable to continue the same regimen (GPP).
- If there are tolerability issues or significant drug–drug interactions, a switch in regimen should be considered (GPP).
- We suggest in exceptional circumstances that long-acting cabotegravir/rilpivirine can be used in non-virally suppressed people (see Section 5.11.5 Long-acting cabotegravir/rilpivirine in pregnancy) (Grade 2C).

### Rationale

#### 7.5.1 PI-based and INSTI-based regimens in people with NRTI resistance

Most studies investigating treatment strategies in people with NRTI resistance have been undertaken in the context of first-line virological failure on a two NRTI plus NNRTI regimen. The clinical importance of historical resistance in virally suppressed people is less clear.

Although there are a number of potential options for second-line therapy in people with NRTI resistance, evidence supports one of three strategies:

- Dolutegravir plus two NRTIs. In the DAWNING study [29], people who experienced virological failure while on a first-line NNRTI-based regimen were randomly assigned to receive either a boosted PI (lopinavir/ritonavir) or dolutegravir; in addition two NRTIs were given, one of which had to be fully active based on resistance testing. The study was stopped after an interim analysis showed that the dolutegravir arm was superior to the lopinavir/ritonavir arm.

In the NADIA study [30], patients who experienced virological failure while on a first-line regimen of tenofovir DF plus lamivudine or emtricitabine plus an NNRTI were randomly assigned to receive either darunavir/ritonavir or dolutegravir; in addition, patients were randomly assigned to receive either zidovudine or tenofovir DF in combination with lamivudine. Dolutegravir was found to be as effective as the boosted PI. Tenofovir DF was non-inferior to zidovudine at week 48 and superior by week 96, showing that recycling tenofovir in this context was superior to switching to zidovudine. There was a high prevalence of NRTI RAMs including M184V/I (86%) and K65R/N (50%), and a smaller subset with one or more TAMs at baseline. Of note, K65R typically occurred alongside M184V/I, a combination that virologically attenuates tenofovir resistance and causes hypersusceptibility to zidovudine. There is therefore limited evidence to support a two NRTI plus PI or second-generation INSTI regimen in the context of isolated K65R/N. Dolutegravir may be preferable to a boosted PI in terms of tolerability and fewer potential drug–drug interactions. However it is worth noting that in the NADIA study, although there was no difference in the rates of virological failure between the two arms, four people in the dolutegravir arm developed dolutegravir resistance by week 48 and nine by week 96, associated with poor adherence, compared to none in the darunavir/ritonavir arm.

In the VISEND study, adults living with HIV with virological failure on tenofovir DF/lamivudine and an NNRTI (efavirenz or nevirapine) had favourable outcomes in terms of virological responses when switched to dolutegravir with either tenofovir AF/emtricitabine or tenofovir DF/lamivudine compared to those switched to the standard-of-care second-line boosted PI-based regimen with either lopinavir/ritonavir or atazanavir/ritonavir [31].

Further evidence for use of dolutegravir in individuals taking second-line therapy comes from the Second-line Switch to Dolutegravir (2SD) study [32]. This study evaluated the efficacy and safety of switching virally suppressed adults from a regimen containing a second-line ritonavir-boosted PI to a dolutegravir-containing regimen, without prior resistance testing. Eligible participants were adults who were virally suppressed (plasma viral load <50 copies/mL) on a second-line regimen of a ritonavir-boosted PI plus two NRTIs for at least 24 weeks, without prior INSTI exposure. At week 48, switching to

a dolutegravir-containing regimen was found to be non-inferior to remaining on the boosted PI regimen.

Although bictegravir may have similar activity after first-line NNRTI failure, there have been no large clinical trials to demonstrate this in the context of detectable viraemia. First-line and suppressed switch trials have demonstrated efficacy when switching to bictegravir/tenofovir AF/emtricitabine in the presence of historical NRTI mutations detected on genotypic RNA [33,34] and proviral DNA sequencing [35]. It should be noted that the clinical implication of resistance mutations detected in proviral DNA alone is uncertain.

- A boosted PI plus two NRTIs. In addition to the NADIA study described above, three large randomised controlled trials [36-38] explored different strategies following first-line virological failure including a boosted PI plus NRTIs or a boosted PI plus raltegravir. These studies demonstrated non-inferiority between the two strategies described and, interestingly, showed that NRTIs retained substantial virological activity. There are no direct comparisons of the boosted PIs among individuals starting second-line treatment after experiencing virological failure on an NNRTI-based regimen. **Darunavir is the preferred PI but, depending on tolerability (e.g. darunavir-related rash), lopinavir or atazanavir can be used.**
- A boosted PI plus an INSTI. As described above, an NRTI-free regimen of raltegravir with a boosted PI has been found to be as efficacious as a boosted PI regimen with at least two new or recycled NRTIs [36-38].

**In the D<sup>2</sup>EFT study, people on failing first-line NNRTI-based therapy were randomly assigned to boosted darunavir plus two NRTIs, dolutegravir plus tenofovir DX with lamivudine or emtricitabine, or an NRTI-free option of boosted darunavir plus dolutegravir [39]. Most participants were on efavirenz with a tenofovir DX plus lamivudine or emtricitabine backbone at study entry and most (77%) participants randomly assigned to boosted darunavir plus two NRTIs received a zidovudine plus lamivudine backbone in line with standard-of-care guidelines. In terms of baseline resistance, 93% had virus with high-level resistance to at least one NRTI: lamivudine/emtricitabine (87–90%) or tenofovir (21–23%). Less than 30% of participants had virus that was considered fully susceptible to tenofovir but isolated K65R/N was unlikely (not reported separately) based on the high rates of M184V/I. Both dolutegravir arms achieved numerically higher virological suppression rates compared to boosted darunavir plus two NRTIs but this was statically significant for the NRTI-free arm only: efficacy difference 8.6% (95% CI 1.7–15.5; *P*=0.016) compared to 6.7% (95% CI –1.2 to 14.4; *P*=0.093) when comparing dolutegravir plus two NRTIs with boosted darunavir plus two NRTIs.**

In the context of NRTI resistance with no evidence of INSTI or PI resistance, it is the opinion of the writing group that a combination of tenofovir plus emtricitabine or lamivudine with a second-generation INSTI or boosted darunavir can be used with the following NRTI RAMs or mutation combinations:

- Isolated M184V/I;
- K65R/N (or K70E/G) plus M184V/I;
- L74V +/- M184V/I;
- A maximum of two TAMs plus M184V/I.

We advise caution, and consideration of including active agents from classes other than NRTIs, where combinations of TAMs +/- M84V/I are predicted to confer intermediate or greater loss of susceptibility to tenofovir.

Of note, although an isolated K65R mutation (without M184V/I) is uncommon, it is associated with poor virological response to tenofovir intensification [40]. As susceptibility to both tenofovir and emtricitabine/lamivudine is reduced, a regimen including a higher-barrier agent and an additional fully active agent is recommended, including the option of boosted darunavir plus dolutegravir, as supported by the results of the D<sup>2</sup>EFT study [39].

The French ANRS cohort analysed outcomes among 636 people switching to bictegravir/emtricitabine/tenofovir AF of whom 147 (23%) had pre-existing resistance mutations, none affecting bictegravir or dolutegravir [41]: 36% had isolated M184V/I, 20%/25% had M184V/I with one to two/three or more TAMs, respectively, 8% had three or more TAMs alone, 3% had M184V/I + K65R +/- one to two TAMs and 3% had M184V/I + Q151M + three or more TAMs. None had isolated K65R. Among those virally suppressed at switch to bictegravir/emtricitabine/tenofovir AF, 96% maintained viral suppression at month 12 with no difference by presence or absence of pre-existing resistance mutations. However, among those who were not virally suppressed at switch to bictegravir/emtricitabine/tenofovir AF, the rate of month 12 viral suppression was lower among those with pre-existing resistance mutations compared to those with none (60% versus 75%, respectively).

The PIBIK study [42] evaluated outcomes in participants on boosted PI-based ART with various historical genotypic patterns including M184V/I, up to two TAMs and other NRTI RAMs (e.g. L74I/V and K70E/G/Q, but excluding K65R/N/E, T69ins and Q151M), and no integrase resistance. Of 72 participants:

- Thirty-one had one TAM ± M184V/I ± one NRTI RAM;
- Twenty-one had M184V/I alone;
- Fifteen had two TAMs ± M184V/I ± one NRTI RAM;

- Five had M184V/I + one NRTI RAM.

Participants were randomly assigned to switch to bictegravir/emtricitabine/tenofovir AF immediately or after 24 weeks. At week 24, proportions maintaining virological suppression were 33/33 (100%) on bictegravir/emtricitabine/tenofovir AF versus 38/39 (97.4%) on a boosted PI (difference 2.6%; 95% CI -2.4% to 7.5%). Virological responses were maintained at week 48, supporting the use of bictegravir/emtricitabine/tenofovir AF in virologically suppressed individuals with a relatively limited NRTI resistance history.

### 7.5.2 First-line treatment failure with no resistance

Seventy percent of individuals have wild-type virus despite failure of therapy [43-49]. Failure is usually attributable to poor treatment adherence with drug levels that are both insufficient to maintain viral load suppression and inadequate to select out viral mutations associated with drug resistance detectable on standard tests. Factors affecting adherence such as tolerability/toxicity issues, regimen convenience, drug–food interactions and mental health/drug dependency problems should be fully evaluated and where possible corrected before initiation of the new regimen. Additional adherence support should be considered with careful discussion with the individual. TDM may be of benefit to confirm low/absent therapeutic drug levels and to enable targeted discussion (see Section 6.2.4 TDM).

The absence of detectable resistance mutations does not exclude the presence of mutations in minor virus populations, especially with the NNRTIs [9,10,50]. This may increase the likelihood of subsequent failure if the same first-line drugs, or drugs in the same class, are prescribed [51,52]. Nevertheless, testing for minority resistance requires a specialist test and expert interpretation by a virologist is essential. There is no indication for routine testing for minority species for individuals with wild-type virus and failed therapy.

Following the development of virological failure, or persistent low-level viraemia, on either an NNRTI or first-generation INSTI-based ART regimen with two NRTIs and when no resistance mutations are detected, switching to a regimen with a higher-genetic barrier (such as a boosted PI or dolutegravir or bictegravir) may be optimal. This should lead to virological suppression, and is least likely to select emergent resistance. Restarting the previous failing regimen is an alternative option, especially where poor adherence has been identified as the likely cause and has been addressed. However, the individual should be monitored carefully and repeat viral load testing performed after approximately 4 weeks. If there is an inadequate virological response, resistance testing should be performed to detect any archived resistance. Switching to an NNRTI- or INSTI-based ART regimen is another option but must be individualised, including consideration of history of virological failure. In deciding which option to use, knowledge of the likely cause of virological failure

(especially detailed reasons for poor adherence) is important. In an NNRTI/two-NRTI regimen, when all three agents have been stopped, the prevalence of NNRTI resistance is 12–16% depending on whether there is a simultaneous or staggered interruption [53,54].

In exceptional circumstances, long-acting cabotegravir/rilpivirine may be used in non-virally suppressed people (see Section 5.11.5 Prescribing long-acting cabotegravir/rilpivirine in people who are not virally suppressed).

### 7.5.3 First-line treatment failure with NNRTI resistance

Up to two-thirds of people living with HIV with virological failure on an NNRTI/two-NRTI ART combination harbour viruses with NNRTI resistance mutations and at least half have NRTI resistance mutations at 48 weeks [46-49,55]; with increasing time, accumulation of resistance mutations may compromise second-line regimens [56]. The finding of associated NRTI resistance is more frequent in individuals on a thymidine analogue backbone than in those on a non-thymidine analogue backbone.

In people with acquired NNRTI resistance, we do not recommend relying on an NNRTI as the core agent. Although transmitted NNRTI resistance (e.g. K103N) does not usually imply the presence of other transmitted NNRTI RAMs [57,58], acquired NNRTI resistance poses a greater risk; in addition to high-frequency variants, minority variants are usually selected which may further impact NNRTI susceptibility but escape detection by routine Sanger sequencing [59-64]. If considering the use of an NNRTI in the context of acquired NNRTI resistance, careful risk–benefit evaluation is warranted. Factors to consider include duration of viral replication on the NNRTI (longer duration increases risk), duration of virological suppression since failure of the NNRTI-based regimen (longer duration reduces risk) and nadir and current CD4 count (lower counts increase risk).

Sequencing to two NRTIs plus etravirine after virological failure on an efavirenz- or nevirapine-based regimen is not recommended [65] and, by extrapolation, we do not recommend switching to two NRTIs plus rilpivirine or doravirine. However, limited observational data suggest that virologically suppressed individuals with historical NNRTI resistance mutations (median time since last detection 12 years [IQR 5–17 years]) may maintain virological suppression over 48 and 96 weeks after switching to various doravirine-based ART regimens [66]. Among 11 individuals with historical doravirine RAMs switching to tenofovir DF/lamivudine/doravirine, all maintained virological suppression. Of note, only two retained doravirine resistance at the time of switching as determined by HIV DNA sequencing. DRIVE-BEYOND investigated the safety and efficacy of tenofovir DF/lamivudine/doravirine in 10 people with transmitted, not acquired, single NNRTI mutations (eight with K103N and two with G190A) in whom viral suppression was maintained [67].

In the absence of clinical trials investigating optimal therapy after virological failure on doravirine- or rilpivirine-containing therapy, we recommend sequencing to a second-generation INSTI or a PI-based regimen. Switching to a first-generation INSTI (raltegravir or elvitegravir) or maraviroc with two active NRTIs is not recommended if there are historical or existing reverse transcriptase mutations and these regimens should be used with caution if there has been previous virological failure on an NRTI-containing regimen [68]. In the context of isolated acquired NNRTI resistance where NRTI resistance is unlikely (e.g. single unplanned treatment interruption of NNRTI-based ART), two NRTIs with a fully active first-generation INSTI or maraviroc could be used with caution if a PI or second-generation INSTI is not clinically appropriate.

#### **7.5.4 First-line treatment failure on a ritonavir-boosted PI-based two-NRTI regimen with or without PI resistance**

Less than 1% of individuals with virological failure harbour viruses with primary PI mutations and 10–20% have NRTI mutations at 48 weeks, with 75% having wild-type virus [43,46-48,69,70]. For those whose regimens fail with limited or no resistance and where adherence is a concern, remaining on the same regimen may be a reasonable approach but with close monitoring and adherence support. However, the individual should be monitored carefully and repeat viral load testing performed after approximately 4 weeks. If there is inadequate virological response, resistance testing should be performed to detect any additional archived resistance. There are currently limited data regarding the efficacy of switching to another boosted PI-, NNRTI-, INSTI- or maraviroc-based regimen and again the decision should be individualised. Options include switching to a different boosted PI (darunavir/ritonavir is preferred unless resistance is likely), a second-generation INSTI-based regimen or a different PI plus an INSTI. However, switching to a first-generation INSTI, maraviroc or an NNRTI for a person with historical or existing reverse transcriptase mutations is not recommended because of an increased risk of virological failure and further emergence of resistance [68].

#### **7.5.5 First-line treatment failure with first- and second-generation INSTI-based resistance**

In studies of naïve subjects developing virological failure on raltegravir- or elvitegravir-containing regimens, up to 50% have been found to harbour viruses with primary integrase mutations and 25% have NRTI mutations at 48 weeks; approximately 50% have wild-type virus [45,55,69,71]. By contrast, resistance is extremely rare in studies in treatment-naïve individuals with dolutegravir or bicitegravir/two-NRTI-based regimens with no emergent resistance to bicitegravir/emtricitabine/tenofovir AF, or dolutegravir plus emtricitabine/tenofovir AF to week 144 and only two cases of emergent M184V on dolutegravir/abacavir/lamivudine within the randomised phase of GS-1489 [72-74]. Again, there are no existing clinical trial data to guide treatment decisions in the context of first-line INSTI failure but sequencing to a new regimen that

includes a boosted PI is unlikely to lead to further emergent resistance and may be an option. Data from the VIKING-3 study in individuals with pre-existing integrase mutations after failure on raltegravir or elvitegravir in the context of three-class resistance and with optimisation of the background regimen to include dolutegravir have shown that over 50% achieve a viral load <50 copies/mL [75] but, despite this, there are no data to support sequencing to dolutegravir after first-line failure. If considering the use of dolutegravir following virological failure with resistance to raltegravir or elvitegravir, twice daily dolutegravir is recommended. There are no data on the efficacy of bictegravir in patients who experience virological failure on a first-generation INSTI.

Switching to an NNRTI or maraviroc with two active NRTIs is an option but is also not recommended in a person with historical or existing reverse transcriptase mutations or previous virological failure on an NRTI-containing regimen.

Individuals experiencing virological failure on raltegravir or elvitegravir should switch to a new regimen as soon as possible to reduce the risk of accumulating resistance mutations that may affect susceptibility to dolutegravir (or bictegravir) where success of response has been linked to the profile and number of resistance mutations.

## 7.6 Individuals with multi-class virological failure with or without extensive drug resistance

### Recommendations

- We recommend discussion within a multidisciplinary team or referral for expert advice for individuals with persistent viraemia and with limited options to construct a fully suppressive regimen (GPP).
- We recommend that all past and current genotypic resistance test results and treatment history are reviewed in order to guide therapy decisions (GPP).
- We recommend that individuals with extensive drug resistance are switched to a new ART regimen containing at least two and preferably three fully active agents (Grade 1C).
- We suggest that consideration on an individual basis should be given to whether inclusion of NRTIs with predicted reduced activity on genotypic testing will provide additional antiviral activity (Grade 2A).
- Where there is extensive drug resistance, we recommend consideration of agents with novel mechanisms of action if available (Grade 2B).
- We recommend consideration of clinical trials or expanded access programmes to facilitate the previous recommendation (GPP).
- We recommend that all individuals receive intensive adherence support at the start and at regular intervals to support them on their new ART combination (GPP).

## Rationale

Until relatively recently, limited treatment options have been available for people living with HIV who have had virological failure with the three original classes of HIV ARV drugs (NRTIs, NNRTIs and PIs) and developed triple-class resistance. Most of these individuals have received prior suboptimal ARV treatment, often from the combination ART era in the mid-1990s, or have experienced adherence difficulties to multiple regimens and have accumulated resistance. However, with the introduction of INSTIs, particularly second-generation drugs, and newer inhibitors of reverse transcriptase and protease with enhanced activity against resistant virus as well as agents active through novel sites of action, even people with multi-class resistance can expect to achieve high levels of viral suppression [76,77].

However, despite improvements in treatments, viral load cannot be suppressed in some individuals. In most, this is a result of poor adherence but some individuals do have extensive drug resistance with minimal treatment options and achieving viral suppression becomes increasingly difficult. The benefit of using resistance testing to guide ART choice for third-line regimens was demonstrated in ACTG A5288 [78].

A non-inferiority trial comparing dolutegravir with raltegravir as the comparator included individuals with triple-class experience but who were naïve to INSTIs and had at least two-class resistance and at least one fully active drug as optimised background therapy [79]. Overall, once-daily dolutegravir was superior to raltegravir at 48 weeks in achieving a viral load <50 copies/mL. However, there was no benefit in individuals who had not received darunavir/ritonavir or had no primary darunavir mutations.

This supports the use of at least two and preferably three of the above agents in a new regimen; with this strategy, the goal of an undetectable viral load is achievable in most adherent individuals with multi-regimen failure.

Recently, drugs with novel mechanisms of action have become licensed in the UK. These drugs include the first-in-class CD4 post-attachment inhibitor ibalizumab [80] and the gp120-directed attachment inhibitor fostemsavir [81]. The capsid maturation inhibitor lenacapavir [82] has shown encouraging results in combination with other ARVs in heavily treatment-experienced patients and is also in late-stage development [83].

A priority issue addressed by the writing group was the net contribution of recycling NRTIs in the context of virological failure and existing or potential reverse transcriptase mutations. In two studies including individuals previously naïve to ART for whom an NNRTI/two-NRTI regimen subsequently failed [36,37], a ritonavir-boosted PI regimen with at least two new or recycled NRTIs was no less efficacious than an NRTI-sparing regimen combining raltegravir with a boosted PI. Even in the presence of limited or no predicted

activity on the basis of genotypic assay, NRTIs retained substantial virological activity equivalent to that of raltegravir without evidence of increased toxicity and therefore may allow deferral of the introduction of drugs known to be active. However, NRTI inclusion was demonstrated to achieve improved virological control over ritonavir-boosted PI monotherapy up to 96 weeks [37]. Maintenance of NRTIs even in the presence of extensive NRTI resistance is also supported by findings from both the DAWNING [29] and NADIA [30] studies. In particular, the NADIA study demonstrated that tenofovir DF can be recycled following virological failure on a first-line tenofovir DF-containing NNRTI-based regimen [30].

Once virological suppression has been achieved, the advantage of retaining NRTIs where partial or complete resistance is demonstrated is uncertain. A small randomised open study of 90 virologically suppressed individuals evaluated the safety of withdrawing NRTIs compared to a control arm of maintaining them in the context of partial NRTI activity and the presence of at least two fully active remaining drugs in the regimen. No significant difference in virological failure between the arms was observed up to 48 weeks although there were three cases of virological failure in the simplification arm and none in the NRTI control arm [84].

A further study included individuals who had triple-class failure and/or resistance when randomisation to the new regimen was based on treatment history, tropism testing and resistance profiles including a choice of NRTIs [85]. Following randomisation, subjects received the chosen regimen with or without the NRTIs. The results demonstrated that omitting NRTIs was non-inferior to their inclusion. Of note, subjects in this study received an average of three active drugs and therefore the lack of NRTI benefit is not altogether surprising.

An additional uncertainty has been whether maintaining lamivudine/emtricitabine provides clinical benefit through the replication deficit provided by the M184V mutation combined with the residual antiviral activity of lamivudine/emtricitabine [86,87]. Studies using lamivudine monotherapy for individuals developing therapy failure have shown that those harbouring M184V who continue on lamivudine maintain lower viral loads, have smaller declines in CD4 cell count, and rarely develop new reverse transcriptase mutations [88-90]. In addition, the presence of M184V mutation enhances *in vitro* susceptibility to tenofovir DF and this translates into a significant HIV RNA response in clinical trials of tenofovir DF intensification [91,92]. Moreover, continuing lamivudine in conjunction with boosted PI therapy in second-line ART was associated with a high rate of success, despite the presence of M184V, when compared with boosted PI monotherapy [93]. It is the recommendation of the writing group that maintenance of lamivudine/emtricitabine should be considered even in the presence of M184V.

For those drugs with a novel mode of action (fusion inhibitors and CCR5 antagonists), the absence of previous exposure indicates susceptibility, although maraviroc is only active against CCR5-tropic virus. For darunavir, tipranavir and etravirine, the number and type of mutations inform the degree to which these

drugs are active [94-96]. The potential for drug–drug interactions is also important. Etravirine can be paired with darunavir/ritonavir (but not tipranavir/ritonavir or dolutegravir), and maraviroc dosing is variable depending on the other drugs in the new regimen.

Some individuals can have a successfully suppressive fully active three-drug regimen constructed without a boosted PI [97]. Nevertheless, where feasible, a boosted PI such as darunavir/ritonavir should be included because of its protective effect on emergent resistance to the other drugs in the regimen.

Darunavir/ritonavir can be given as 800/100 mg once daily in treatment-experienced individuals without darunavir RAMs [98].

The same principles regarding reviewing adherence, tolerability/toxicity issues, drug–drug and drug–food interactions, and mental health/drug dependency problems apply (see Box 7.1). Additional adherence support is important in these individuals as the reason triple-class failure has occurred often relates to past poor adherence. Additionally, the pill burden is increased and therefore careful discussion is important.

## 7.7 Individuals with limited or no therapeutic options when a fully viral suppressive regimen cannot be constructed

### Recommendations

- We recommend accessing newer agents through research trials, expanded access and named individual programmes (GPP).
- We suggest that consideration, on an individual basis, should be given to whether inclusion of NRTIs with reduced activity on genotypic testing will provide additional antiviral activity; this may be the case where it is difficult to construct a regimen with fully active drugs including a boosted PI (Grade 2A).
- We recommend against discontinuing or interrupting ART (Grade 1B).
- We recommend against adding a single, fully active ARV because of the risk of further resistance (Grade 1D).
- We recommend against the use of maraviroc to increase the CD4 cell count where there is evidence for X4- or dual-tropic virus (Grade 1C).
- We recommend that in the context of triple-class failure and raltegravir-/elvitegravir-selected integrase resistance, twice-daily dolutegravir should be included as part of a new regimen where there is at least one fully active agent in the background regimen (Grade 1C).

## Rationale

The use of currently available ARV drugs has resulted in a dramatic decline in the number of patients who have limited or no therapeutic options because of multi-class resistance or failure.

There is evidence from cohort studies that continuing therapy, even in the presence of viraemia and the absence of CD4 cell count increases, reduces the risk of disease progression [99,100] whereas interruption may lead to a rapid fall in CD4 cell count and a rise in viral load [101,102]. Evidence from other studies suggests continued immunological and clinical benefits if the HIV RNA level is maintained below approximately 10,000–20,000 copies/mL [103]. Hence, if the CD4 cell count is well maintained (>200 cells/mm<sup>3</sup>), there is an argument to continue the failing regimen and not change treatment until investigational agents are available to create a suppressive regimen. However, the potential benefit must be balanced against the ongoing risk of accumulating additional resistance mutations and the regimen should be maintained for the shortest period possible [104,105].

In general, adding a single, fully active ARV to a failing regimen is not recommended because of the risk of rapid development of resistance. However, in individuals with a high likelihood of clinical progression (e.g. CD4 count <100 cells/mm<sup>3</sup>) and limited drug options, adding a single drug may reduce the risk of immediate clinical progression, because even transient decreases in HIV RNA and/or transient increases in CD4 cell counts have been associated with clinical benefits [106].

Several studies and an early meta-analysis suggested that CCR5 receptor antagonists were associated with significant gains in CD4 cell counts even in the presence of C-X-C chemokine receptor type 4 tropic virus. By contrast, in a meta-analysis, CCR5 receptor antagonists were not significantly associated with increases in CD4 cell count compared with other new drugs ( $P=0.22$ ) [107].

VIKING-3 [75] was a study in individuals who had received either raltegravir or elvitegravir and had integrase resistance with the majority having additional triple-class resistance, and where there was at least one fully active agent to use in the optimised background regimen. Dolutegravir 50 mg twice daily was added to the failing regimen; by day 8 and at the time of switching to an optimised background regimen, the mean drop in viral load was  $\log_{10}$  1.43. By week 24, 69% of participants had achieved a viral load <50 copies/mL. Response was associated with dolutegravir susceptibility and was most reduced in those with Q148 with at least two additional resistance mutations.

Ibalizumab is an injectable monoclonal antibody that is able to bind CD4 at a site that does not prevent its physiological function but is able to prevent HIV attachment. It is FDA approved for treatment of multidrug-resistant HIV. In the pivotal clinical study [80], a single-arm, open-label Phase 3 trial in which ibalizumab was

added to a failing regimen as a single agent, mean CD4 count was 150 cells/mm<sup>3</sup> and median viral load was 4.5 log<sub>10</sub> copies/mL in participants at baseline. At week 25, the treated individuals had achieved a drop of 1.6 log<sub>10</sub> copies/mL in viral load from baseline, with 50% below 200 copies/mL. The most common side effect was diarrhoea (in 20%). Among 10 individuals with virological failure, nine had evidence of virus that had reduced susceptibility to drug at failure compared to the baseline sample, indicating emergent resistance.

Fostemsavir is a prodrug of temsavir, an attachment inhibitor targeting HIV envelope (Env) gp120, that is independent of X4/R5 preference of Env. The randomised, placebo-controlled, Phase 3 BRIGHT study [81] enrolled 272 heavily experienced patients (viral load >400 copies/mL at screening) with fostemsavir or placebo added to the failing regimen. Fostemsavir was very well tolerated. After day 8, response rate was 54% in the fostemsavir group versus 38% in the placebo group. Further analyses demonstrate that certain env amino acid substitutions may be associated with reduced drug susceptibility. Fostemsavir is a possible candidate drug for use with at least one other fully active agent. Treatment-emergent mutations occurred in almost half of patients with virological failure following fostemsavir treatment.

The capsid inhibitor lenacapavir was studied in injectable form in a recent small randomised study ( $n=36$ ) in heavily treatment-experienced patients with three-class resistance and viral load >400 copies/mL [83]. In this study lenacapavir was added to an optimised background regimen, and participants (median 24 years since HIV diagnosis) had received a median of 11 previous agents. The favourable pharmacokinetic properties of lenacapavir allow for 6-monthly subcutaneous dosing and there are plans for daily and weekly oral formulations. The drug targets a highly conserved region in p24, and therefore all subtypes appear susceptible.

Where lenacapavir is not available, and there are no other fully active drugs, we previously recommended the use of both fostemsavir and ibalizumab in combination (expert opinion). However, ibalizumab was withdrawn from the European market in January 2023 [108] and can be accessed only via a named patient programme importing the product at high cost from the USA (via email to: [trogarzo@WEPclinical.com](mailto:trogarzo@WEPclinical.com)), which will not be routinely reimbursed through usual routes. Considering this, where a fully active new drug is essential, we advise that all efforts are made to access lenacapavir to be combined with optimised background therapy including, where necessary, other long-acting injectable drugs or fostemsavir.

Finally, where feasible, people living with HIV should be given the opportunity to enrol in research studies or expanded access programmes evaluating investigational new drugs. Drugs developed for, and used in, other settings (such as pegylated interferon) that have been incidentally demonstrated to decrease viral load should not be used without discussion with experienced HIV physicians in a multidisciplinary team because data are either too limited or contradictory.

## 7.8 References

1. Angus B, Brook G, Awosusi F *et al*. BHIVA guidelines for the routine investigation and monitoring of adult HIV-1 positive individuals 2016 (2019 interim update). Available at: <https://www.bhiva.org/monitoring-guidelines> (accessed September 2022).
2. El Bouzidi K, Jose S, Phillips AN *et al*. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. *AIDS* 2020; **34**: 1823–1831.
3. Wittkop L, Gunthard HF, de Wolf F *et al*. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis* 2011; **11**: 363–371.
4. Kuritzkes DR, Lalama CM, Ribaldo HJ *et al*. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. *J Infect Dis* 2008; **197**: 867–870.
5. Havlir DV, Bassett R, Levitan D *et al*. Prevalence and predictive value of intermittent viremia with combination HIV therapy. *JAMA* 2001; **286**: 171–179.
6. Greub G, Cozzi-Lepri A, Ledergerber B *et al*. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. *AIDS* 2002; **16**: 1967–1969.
7. Nettles RE, Kieffer TL. Update on HIV-1 viral load blips. *Curr Opin HIV AIDS* 2006; **1**: 157–161.
8. Garcia-Gasco P, Maida I, Blanco F *et al*. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. *J Antimicrob Chemother* 2008; **61**: 699–704.
9. Nettles RE, Kieffer TL, Kwon P *et al*. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. *JAMA* 2005; **293**: 817–829.
10. Karlsson AC, Younger SR, Martin JN *et al*. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. *AIDS* 2004; **18**: 981–989.
11. Easterbrook PJ, Ives N, Waters A *et al*. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. *AIDS* 2002; **16**: 1521–1527.
12. Grennan JT, Loutfy MR, Su D *et al*. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. *J Infect Dis* 2012; **205**: 1230–1238.
13. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. *J Acquir Immune Defic Syndr* 2009; **51**: 3–6.
14. Stosor V, Palella FJ Jr, Berzins B *et al*. Transient viremia in HIV-infected patients and use of plasma preparation tubes. *Clin Infect Dis* 2005; **41**: 1671–1674.

15. US Department of Health and Human Services. *Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV*. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines> (accessed April 2022).
16. Pozniak A, Gupta RK, Pillay D *et al*. Causes and consequences of incomplete HIV RNA suppression in clinical trials. *HIV Clin Trials* 2009; **10**: 289–298.
17. Cohen C. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. *HIV Clin Trials* 2009; **10**: 116–124.
18. Geretti AM, Smith C, Haberl A *et al*. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. *Antivir Ther* 2008; **13**: 927–936.
19. Taiwo B, Gallien S, Aga E *et al*. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. *J Infect Dis* 2011; **204**: 515–520.
20. Staszewski S, Sabin C, Dauer B *et al*. Definition of loss of virological response in trials of antiretroviral drugs. *AIDS* 2003; **17**: 1997–1998.
21. Gonzalez-Serna A, Swenson LC, Watson B *et al*. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. *Clin Microbiol Infect* 2016; **22**: 1004.e9–1004.e16.
22. Prosperi MC, Mackie N, Di Giambenedetto S *et al*. Detection of drug resistance mutations at low plasma HIV1 RNA load in a European multicentre cohort study. *J Antimicrob Chemother* 2011; **66**: 1886–1896.
23. Gallien S, Delaugerre C, Charreau I *et al*. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. *AIDS* 2011; **25**: 665–669.
24. Maggiolo F, Callegaro A, Cologni G *et al*. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. *J Acquir Immune Defic Syndr* 2012; **60**: 473–482.
25. Doyle T, Smith C, Vitiello P *et al*. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. *Clin Infect Dis* 2012; **54**: 724–732.
26. Alvarez Estevez M, Chueca Porcuna N, Guillot Suay V *et al*. Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter. *J Clin Microbiol* 2013; **51**: 1555–1557.
27. Henrich TJ, Wood BR, Kuritzkes DR. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. *PLoS One* 2012; **7**: e50065.
28. Dolling D, Nelson M, Schwenk A *et al*. Rapid increase in the frequency of wild type HIV-1 drug resistance reports among ART-experienced patients in the UK. *Conference on Retroviruses and Opportunistic Infections*. March 2013. Atlanta, GA, USA. Abstract 594.
29. Aboud M, Kaplan R, Lombaard J *et al*. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. *Lancet* 2019; **19**: 253–264.

30. Paton NI, Musaazi J, Kityo C *et al.*; NADIA Trial Team. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. *Lancet HIV* 2022; **9**: e381–e393.
31. Mulenga LB, Fwoloshi S, Mweemba A *et al.* Dolutegravir with recycled NRTIs is noninferior to PI-based ART: VISEND trial. *Conference on Retroviruses and Opportunistic Infections*. February 2022. Abstract 135.
32. Ombajo LA, Penner J, Nkuranga J *et al.* Randomized trial of switching treatment-experienced adults from PI/r to DTG. *Conference on Retroviruses and Opportunistic Infections*. February 2022. Abstract 136.
33. Acosta RK, Willkom M, Andreatta K *et al.* Switching to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. *J Acquir Immune Defic Syndr* 2020; **85**: 363–371.
34. Hagins D, Kumar P, Saag M *et al.*; BRAAVE2020 Investigators. Switching to bicitegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study. *J Acquir Immune Defic Syndr* 2021; **88**: 86–95.
35. Andreatta K, Willkom M, Martin R *et al.* Switching to bicitegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. *J Antimicrob Chemother* 2019; **74**: 3555–3564.
36. Boyd MA, Kumarasamy N, Moore CL *et al.* Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. *Lancet* 2013; **381**: 2091–2099.
37. Paton NI, Kityo C, Hoppe A *et al.* Assessment of second-line antiretroviral regimens for HIV therapy in Africa. *N Engl J Med* 2014; **371**: 234–247.
38. Amin J, Boyd MA, Kumarasamy N *et al.* Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. *PLoS One* 2015; **10**: e0118228.
39. D<sup>2</sup>EFT Study Group. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D<sup>2</sup>EFT): an open-label, randomised, phase 3b/4 trial. *Lancet HIV* 2024; **11**: e436–e448.
40. Miller MD, Margot N, Lu B *et al.* Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. *J Infect Dis* 2004; **189**: 837–846.
41. Peyrouny-Mazeau A, Leleux O, Bellecave P *et al.* Predictive factors of virological failure after switching to B/F/TAF (ANRS-CO3-AquiVIH-NA). *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 696.
42. Iwuji C, Waters L, Milinkovic A *et al.* Outcomes of switching from protease inhibitor-based antiretroviral therapy to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with

nucleos(t)ide analogue resistance - a phase IV randomised, open-label study (PIBIK study). *Virology* 2025; **22**: 33.

43. Ortiz R, DeJesus E, Khanlou H *et al*. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. *AIDS* 2008; **22**: 1389–1397.
44. Molina JM, Andrade-Villanueva J, Echevarria J *et al*. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV1-infected patients: 48 week efficacy and safety results of the CASTLE study. *Lancet* 2008; **372**: 646–655.
45. Lennox JL, DeJesus E, Lazzarin A *et al*. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet* 2009; **374**: 796–806.
46. Riddler SA, Haubrich R, DiRienzo AG *et al*. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med* 2008; **358**: 2095–2106.
47. Daar ES, Tierney C, Fischl MA *et al*. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. *Ann Intern Med* 2011; **154**: 445–456.
48. Soriano V, Arasteh K, Migrone H *et al*. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. *Antivir Ther* 2011; **16**: 339–348.
49. Rimsky L, Vingerhoets J, Van Eygen V *et al*. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. *J Acquir Immune Defic Syndr* 2012; **59**: 39–46.
50. Roche Diagnostics Ltd. Cobas® HIV-1 Test. 2022. Available at: <https://diagnostics.roche.com/gb/en/products/params/cobas-hiv-1-test.html> (accessed September 2022).
51. Li JZ, Paredes R, Ribaldo HJ *et al*. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA* 2011; **305**: 1327–1335.
52. Paredes R, Lalama CM, Ribaldo HJ *et al*. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. *J Infect Dis* 2010; **201**: 662–671.
53. Geretti AM, Fox Z, Johnson JA *et al*. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *PLoS One* 2013; **8**: e69266.
54. Cambiano V, Castro H, Chadwick D *et al*. Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. *Conference on Retroviruses and Opportunistic Infections*. March 2014. Boston, MA, USA. Abstract 593.
55. Sax P, DeJesus E, Mills A *et al*. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus coformulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. *Lancet* 2012; **379**: 2439–2448.

56. Cozzi-Lepri A, Paredes, Phillips AN *et al*. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI\*. *HIV Med* 2012; **13**: 62–72.
57. Geretti AM, Ledesma J, Bibby D *et al*. Trends in transmitted drug resistance among adults with a recently acquired HIV infection. 19th European AIDS Conference 2023. Warsaw, Poland. Abstract 923. Available at: [https://react-profile.org/ebook/EACS-2023\\_Abstracts/392/](https://react-profile.org/ebook/EACS-2023_Abstracts/392/) (accessed July 2025).
58. Porter DP, Toma J, Tan Y *et al*. Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine/emtricitabine/tenofovir disoproxil fumarate in the SPIRIT Study. *HIV Clin Trials* 2016; **17**: 29–37.
59. Minuto JJ, Haubrich R. Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. *Futur HIV Ther* 2008; **2**: 525–537.
60. Metzner K. The significance of minority drug-resistant quasispecies. In: Geretti AM, ed. *Antiretroviral Resistance in Clinical Practice*. London, Mediscript, 2006. Chapter 11.
61. Geretti AM, Fox Z, Johnson JA *et al*. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *PLoS One* 2013; **8**: e69266.
62. Li JZ, Paredes R, Ribaldo HJ *et al*. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. *Infect Dis* 2013; **207**: 893–897.
63. Li JZ, Paredes R, Ribaldo HJ *et al*. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA* 2011; **305**: 1327–1335.
64. Cozzi-Lepri A, Noquera-Julian M, Di Giallonardo F *et al*. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother* 2015; **70**: 930–940.
65. Ruxrungtham K, Pedro RJ, Latiff GH *et al*. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. *HIV Med* 2008; **9**: 883–896.
66. Abdi B, Saliba A, Wirden M *et al*. No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens. *Conference on Retroviruses and Opportunistic Infections*. March 2025. Abstract 734.
67. Wong A, Goldstein D, Mallolas J *et al*. Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) in treatment-naïve HIV-1 infected adults with transmitted non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. *J Acquir Immune Defic Syndr* 2019; **82**: e47–e49.
68. Eron JJ, Young B, Cooper DA *et al*. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet* 2010; **375**: 396–407.

69. Dejesus E, Rockstroh J, Henry K *et al.* Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. *Lancet* 2012; **379**: 2429–2438.
70. Molina JM, Andrade-Villanueva J, Echevarria J *et al.* Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr* 2010; **53**: 323–332.
71. Eron JJ Jr, Rockstroh JK, Reynes J *et al.* Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. *Lancet Infect Dis* 2011; **11**: 907–915.
72. Walmsley SL, Antela A, Clumeck N *et al.* Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med* 2013; **369**: 1807–1818.
73. Clotet B, Feinberg J, van Lunzen J *et al.* Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet* 2014; **383**: 2222–2231.
74. Raffi F, Rachlis A, Stellbrink HJ *et al.* Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. *Lancet* 2013; **381**: 735–743.
75. Castagna A, Maggiolo F, Penco G *et al.* Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. *J Infect Dis* 2014; **210**: 354–362.
76. Yazdanpanah Y, Fagard C, Descamps D *et al.* High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. *Clin Infect Dis* 2009; **49**: 1441–1449.
77. Wittkop L, Breilh D, Da Silva D *et al.* Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. *J Antimicrob Chemother* 2009; **63**: 1251–1255.
78. Grinsztejn B, Hughes MD, Ritz J *et al.*; A5288 Team. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. *Lancet HIV* 2019; **6**: e588–e600.
79. Cahn P, Pozniak AL, Mingrone H *et al.* Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet* 2013; **382**: 700–708.
80. Emu B, Fessel J, Schrader S *et al.* Phase 3 study of ibalizumab for multidrug-resistant HIV-1. *N Engl J Med* 2018; **379**: 645–654.
81. Kozal M, Aberg J, Pialoux G *et al.* Fostemsavir in adults with multidrug-resistant HIV-1 infection. *N Engl J Med* 2020; **382**: 1232–1243.

82. Link JO, Rhee MS, Tse WC *et al.* Clinical targeting of HIV capsid protein with a long-acting small molecule. *Nature* 2020; **584**: 614–618.
83. Ogbuagu O, Segal-Maurer S, Brinson C *et al.* Long-acting lenacapavir in people with multidrug resistant HIV-1: week 52 results. *Conference on Retroviruses and Opportunistic Infections*. February 2022. Abstract 491.
84. Llibre J, Alvarez H, Antela A *et al.* Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. *J Antimicrob Chemother* 2016; **71**: 1346–1351.
85. Gandhi RT, Tashima KT, Smeaton LM *et al.* Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS). *J Infect Dis* 2020; **221**: 1407–1415.
86. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. *Science* 1995; **269**: 696–699.
87. Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. *Antimicrob Agents Chemother* 2003; **47**: 747–754.
88. Eron JJ, Benoit SL, Jemsek J *et al.* Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. *N Engl J Med* 1995; **333**: 1662–1669.
89. Gianotti N, Tiberi S, Menzo S *et al.* HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. *J Med Virol* 2008; **80**: 201–208.
90. Castagna A, Danise A, Menzo S *et al.* Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). *AIDS* 2006; **20**: 795–803.
91. Wainberg MA, Miller MD, Quan Y *et al.* In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. *Antivir Ther* 1999; **4**: 87–94.
92. Miller MD, Margot N, Lu B *et al.* Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. *J Infect Dis* 2004; **189**: 837–846.
93. Ciaffi L, Koulla-Shiro S, Sawadogo AB *et al.* Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. *Lancet HIV* 2017; **4**: e384–e392.
94. Vingerhoets J, Peeters M, Azijn H *et al.* An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET -1 and DUET 2 clinical trial data. *XVII International Drug Resistance Workshop*. June 2008. Sitges, Spain. Abstract 24.
95. Lambert-Niclot S, Flandre P, Canestri A *et al.* Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. *Antimicrob Agents Chemother* 2008; **52**: 491–496.

96. Schapiro JM, Scherer J, Boucher CA *et al.* Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. *Antivir Ther* 2010; **15**: 1011–1019.
97. Nozza S, Galli L, Visco F *et al.* Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. *AIDS* 2010; **24**: 924–928.
98. Cahn P, Fourie J, Grinsztejn B *et al.* Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. *AIDS* 2011; **25**: 929–939.
99. Miller V, Sabin C, Hertogs K *et al.* Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. *AIDS* 2000; **14**: 2857–2867.
100. Raffanti SP, Fusco JS, Sherrill BH *et al.* Effect of persistent moderate viremia on disease progression during HIV therapy. *J Acquir Immune Defic Syndr* 2004; **37**: 1147–1154.
101. Deeks SG, Wrin T, Liegler T *et al.* Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med* 2001; **344**: 472–480.
102. Lawrence J, Mayers DL, Hullsiek KH *et al.* Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. *N Engl J Med* 2003; **349**: 837–846.
103. Ledergerber B, Lundgren JD, Walker AS *et al.* Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet* 2004; **364**: 51–62.
104. Kristiansen TB, Pedersen AG, Eugen-Olsen J *et al.* Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. *Scand J Infect Dis* 2005; **37**: 890–901.
105. Hatano H, Hunt P, Weidler J *et al.* Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. *Clin Infect Dis* 2006; **43**: 1329–1336.
106. Murray JS, Elashoff MR, Iacono-Connors LC *et al.* The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. *AIDS* 1999; **13**: 797–804.
107. Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. *HIV Med* 2012; **13**: 148–155.

108. European Medicines Agency. Trogarzo. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/trogarzo> (accessed July 2025).

## 8 Specific populations

This section provides guidance and recommendations for the treatment of specific populations with HIV.

Although individuals with many conditions (for example diabetes, cancer or chronic obstructive pulmonary disease) could be interpreted as being ‘special populations’, these have not been included because, beyond the universal recommendation to check for drug–drug interactions, there are no specific ART recommendations.

**Hepatitis B or C/HIV co-infection:** guidance and recommendations regarding prescribing ART in individuals with HIV co-infected with hepatitis B or hepatitis C can be found in the BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 (<https://www.bhiva.org/hepatitis-guidelines>).

**HIV-related cancers:** details about HIV-related cancers and prescribing ART for people with HIV and these cancers can be found in recent European guidelines (see [www.bhiva.org/guidelines](http://www.bhiva.org/guidelines)).

**TB/HIV co-infection:** guidance and recommendations regarding prescribing ART in individuals with HIV co-infected with TB can be found in the BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (<https://www.bhiva.org/TB-guidelines>).

### 8.1 Adolescents

The WHO definition of adolescents includes all young people aged between 10 and 19 years, and young adults aged between 20 and 24 years [1]. For the purposes of these guidelines, we will consider adolescents living with HIV by route of transmission: perinatally acquired HIV (PaHIV) and behaviourally acquired HIV (BaHIV).

For young people 18 to 24 years of age with BaHIV, the management of their HIV disease and associated considerations should be in accordance with BHIVA guidance for adults. The management of adolescents <16 years of age within paediatric care should be in accordance with the Children’s HIV Association (CHIVA) guidelines [2] and the EACS guidelines (paediatric section) [3]. There are no randomised controlled trial data on long-term complications of PaHIV and ART exposure during physical development, although observational cohort data are becoming increasingly available and the following recommendations are based on a pragmatic approach and good clinical practice. As for all people living with HIV, any newly diagnosed adolescent or young person should be carefully counselled and offered ART as soon as possible, ideally as close to the time of diagnosis as appropriate.

### **8.1.1 Management of HIV, ART and sexual and reproductive health specifically for young adults and adolescents living with HIV**

For this specific population, ART should be prescribed in accordance with BHIVA guidance for adults and directed by HIV genotype, anticipated drug side effects and any co-infection and comorbidity. Where alternatives exist, drugs with known association with adverse bone health should be avoided until peak bone mass accrual is achieved, typically at 25 years of age [4].

#### **Recommendation**

- We recommend avoiding tenofovir DF in adolescents and young adults under the age of 25 years, prior to peak bone mass accrual (Grade 2B).

### **8.1.2 Youth-focused HIV and sexual and reproductive health services**

Young adults and adolescents represent a uniquely vulnerable group with poorer health outcomes compared to younger children and older adults living with the same condition. This is a feature of lifestyle, adolescent behaviour, lack of engagement in healthcare services and primary care and often lack of social support. As such, any service providing care for young adults and adolescents living with HIV must offer appropriate youth-friendly services, with an open-door policy, non-judgemental care provision, opening hours consistent with educational commitments and access to peer support and mental health and reproductive and sexual health services [5]. For young women on boosted PI or efavirenz-based regimens, contraceptive choices will need to be adapted accordingly based on drug–drug interactions [6]; this is particularly relevant to this group as over-the-counter post-coital contraception is now available and may be impacted by drug–drug interactions with ART.

### **8.1.3 UK Epidemiology for young adults and adolescents living with HIV**

Public Health England (PHE) surveillance data have revealed that 10% (315/3165) of all new HIV diagnoses in 2019 were in young people aged 15–24 years, which is a 50% reduction from 2015 [7]. Overall, 231/315 (73%) were male, and the median CD4 count was 423 cells/mm<sup>3</sup> at diagnosis with one-third presenting with a CD4 count <350 cells/mm<sup>3</sup>. An additional 80 young adults and adolescents presented for care having previously been diagnosed abroad. Routes of transmission were sex between men (*n*=222), heterosexual contact (*n*=85), perinatal infection (*n*=34), intravenous drug use (*n*=7) and unknown/other (*n*=47). In total 2313 young people aged 15–24 years were accessing HIV care during 2019, representing 2.4% (2313/98,552) of people seen for HIV care in the UK [7]. Of those accessing care, 97% were receiving ART and five young people died.

With ART, the significant fall in HIV-associated morbidity and mortality for children with PaHIV has resulted in increasing numbers entering adolescence and transitioning towards adult services [8-10]. Over 95% of children diagnosed in the UK and reported to the Integrated Screening Outcomes Surveillance Service (ISOSS) were followed prospectively in the Collaborative HIV Paediatric Study (CHIPS) [11]. Data to the end of March 2021 show that 1381/2212 (62%) young people ever reported to CHIPS have now transitioned from paediatric to adult HIV care services, with an average of 100 young people transferring each year over the last 5 years at a median age of 18 years [11]. From January 2022, CHIPS reporting has been replaced by quarterly reporting to the Children's HIV and AIDS Reporting System (CHARS) within ISOSS (<https://www.ucl.ac.uk/chars/>).

#### **8.1.4 Transition of clinical care from paediatric to adult services: a process for young adults and adolescents with PaHIV**

##### **Recommendations**

- We recommend a robust transition process that includes a written pathway and a designated lead for transitional care within each trust to ensure that linkage of care is maintained following transition to adult services (GPP).
- We suggest that young adults continue in specialised services until 23–25 years of age and then transition to adult care (GPP).

##### **Auditable outcome**

- Percentage engaged in adult care 1, 3 and 5 years after the final paediatric appointment.

Transfer to adult services had been associated with increased disease-related morbidity and mortality for a wide range of chronic conditions of childhood prompting the National Service Framework 2004 to set standards for the healthcare of young people [12]. Subsequently multiple bodies including NICE and the Royal College of Paediatrics and Child Health have produced a wealth of resources to guide the development of transitional care services [13,14]. Transition is defined as 'a planned, purposeful, process resulting in the point of transfer to adult services'. Several different transition models have been described; the key to a successful transition is communication, forward planning and maintaining a young person-centred approach [15]. HIV-specific transitional care guidance is available through CHIVA and included within the CHIVA Standards [16]. Evidence suggests that a well-managed transition process can have a positive impact on health and wellbeing as young people enter adult services [17,18].

### 8.1.5 Cognitive and mental health impact of HIV in young adults and adolescents with PaHIV

#### Recommendation

- Optimising virological control with further investigation and referral to expert HIV neurology clinics for symptomatic individuals is recommended (GPP).

The cognitive impact of living with PaHIV throughout the period of brain development is highly variable with a small proportion having significant learning disabilities and/or hypertonic diplegia, the legacy of infantile HIV encephalopathy, impacting on independent living. However a larger proportion present with poorer school performance and working memory and executive functioning difficulties, compared to the age-matched general population, although these issues may not be entirely HIV related as some studies suggest a similar pattern in their HIV-exposed uninfected siblings [19-21]. Data suggest that more than two-thirds of treatment-naïve young adults and adolescents with PaHIV meet criteria for a diagnosis of HIV-associated cognitive disorders, with the most common deficits being in memory and fine motor skills [22]. Services need to take into account the potential impact of learning impairment on the ability of young people to negotiate healthcare services including attendance, adherence to ART and quality of life including mental health.

Mental health diagnoses are rising in youth populations and whereas rates of anxiety, depression and substance use in PaHIV and BaHIV appear broadly similar to rates in HIV-exposed uninfected populations, there is a consistent association between mental health diagnoses and poor adherence to ART [23-27]. Emerging data suggest that rates of psychosis are significantly higher in young adults and adolescents with PaHIV than the age-matched general population, although this may in part be driven by traditional risk factors of adverse childhood experiences, migration, ethnicity and poverty [28]. Addressing mental health issues through integrated HIV and mental health services is necessary to optimise quality of life and ART adherence.

### 8.1.6 ART

#### 8.1.6.1 Adherence

#### Recommendation

- We suggest that ideally ART should be started with a once-daily regimen with a low pill burden and a high-genetic barrier to resistance based on a second-generation INSTI plus two NRTIs (GPP).

Poorer adherence to ART is reported with increasing age in childhood, as well as in young people with BaHIV, when compared to older adults [8-10]. PHE data for 2019 demonstrate reduced rates of viral suppression (<200 copies/mL) in those aged 15–24 years versus overall rates of viral suppression for those on ART

(91% vs 97%) and even lower rates for those with PaHIV (89%) [29]. For young people with PaHIV, poor adherence in paediatric care predicts new AIDS diagnoses and mortality following transition to adult care [30-32]. Young adults and adolescents therefore require additional multi-agency adherence support and consideration of novel therapeutic approaches such as long-acting injectable ART [32,33]. There are no specific data to demonstrate better virological suppression with different ART regimens in young adults and adolescents.

Second-generation INSTI-based regimens are the recommended first-line therapy for younger adolescents in the 2021 EACS guidelines [3].

### **8.1.6.2 Resistance**

Within the UK paediatric cohort, while half of the adolescents with PaHIV are triple-class experienced, rates of triple class resistance are relatively low, ranging from 6–12% [7,9,30]. Decisions regarding the optimal regimen for young adults and adolescents require an individualised approach considering archived resistance, predicted adherence, substance use and mental health.

### **8.1.6.3 Long-term outcomes for young adults and adolescents with PaHIV**

Despite advances in ART, mortality for young adults and adolescents with PaHIV is more than 10-fold higher than the age-matched UK population [9,30,34]. Almost 1 in 10 young people experienced a new AIDS diagnosis and/or death within a median of 3 years post-transition to adult care [30]. Almost all deaths were due to HIV and associated with prolonged poor adherence to ART but not due to multidrug-resistant untreatable virus. Emerging data suggest a 10-fold higher risk of malignancy when compared to age-matched population data, driven by lymphomas [34,35]. In addition to addressing traditional risk factors, including by optimising human papillomavirus and hepatitis B virus vaccination, clinical vigilance for early diagnosis is recommended.

Bone health is adversely affected both in young adults and adolescents with BaHIV and in those with PaHIV, with growth stunting and delayed puberty also affecting the latter group [36,37]. In addition to addressing additional risk factors we recommend, where alternatives exist, avoidance of drugs with known association with adverse bone health until peak bone mass accrual is achieved (see 8.6.1 above) [4]. FRAX scores are only validated from 40 years of age so dual-energy X-ray absorptiometry (DEXA) scanning should be considered for young adults and adolescents with additional risk factors such as prolonged viraemia, reduced mobility, abnormal BMI, growth stunting and recreational/prescription steroid use with referral to dietetic/endocrinology services where appropriate.

### 8.1.6.4 Clinical monitoring for young adults and adolescents

#### Recommendations

- We suggest regular rigorous monitoring for hepatic malignancy for adolescents and young adults living with HIV and co-infected with hepatitis B and C (Grade 1C).
- We suggest a high index of suspicion to exclude cervical, anal and vulval intraepithelial neoplasia and lymphoma (Grade 1C).
- We suggest reviewing bone health including DEXA scanning where clinically indicated (Grade 1C).
- We suggest increasing viral load monitoring for pregnant women with PaHIV. Increasing numbers of young adults and adolescents are having children of their own and, although HIV transmission rates in infants are reassuringly low, women with PaHIV are more likely to have detectable viraemia at the time of the birth than women with BaHIV [38] (Grade 1C).
- We suggest early specialist referral for those struggling to conceive irrespective of age due to preliminary data suggesting a possible reduction in fertility [39] (Grade 1C).

## 8.2 Bone disease

### 8.2.1 What to start

#### Recommendation

- We recommend against the use of tenofovir DF in individuals with osteoporosis, severe osteopenia ( $T < -2.0$ ), a history of fragility fracture, a 10-year probability of a major osteoporotic fracture  $>5\%$  and/or a 10-year probability of a hip fracture  $>1\%$  (Grade 1D).

#### Auditable outcome

- Number/proportion of individuals aged  $>60$  years who continue to receive tenofovir DF without a DEXA assessment of BMD, and a record of the rationale.

#### Rationale

Since the 2022 guidelines, we have amended the bone criteria for avoiding the use of tenofovir DF to permit more flexible clinical decision-making.

Several randomised controlled clinical trials comparing tenofovir DF-containing and tenofovir DF-sparing regimens in ART-naïve individuals have reported greater reductions in BMD in the tenofovir DF arms. A study comparing abacavir/lamivudine versus tenofovir DF/emtricitabine (each with efavirenz) reported greater reductions in BMD at the lumbar spine ( $-1.6\%$  vs  $-2.4\%$ ) and the hip ( $-1.9\%$  vs  $-3.6\%$ ), and greater proportions of participants with  $>6\%$  BMD reductions ( $3-6\%$  vs  $13-15\%$ ) in the tenofovir DF-containing arm

at week 48 [40]. Another study comparing abacavir/lamivudine versus tenofovir DF/emtricitabine (each with efavirenz or atazanavir/ritonavir) reported BMD reductions of  $-1.3\%$  versus  $-3.3\%$  at the lumbar spine and  $-2.6\%$  and  $-4.0\%$  at the hip at week 96 [41]. Greater reductions in BMD have also been reported in a study comparing tenofovir AF versus tenofovir DF (each with emtricitabine/elvitegravir/cobicistat):  $-0.9\%$  versus  $-3.0\%$  at the lumbar spine and  $-0.8\%$  versus  $-3.4\%$  at the hip at 96 weeks [42]. A further study of tenofovir AF versus tenofovir DF (each with emtricitabine/darunavir/cobicistat) reported greater BMD reductions in the tenofovir DF arm at the lumbar spine ( $+0.21\%$  vs  $-2.73\%$ ) and hip ( $-0.68$  vs  $-2.38\%$ ) at 48 weeks [43]. A meta-analysis of studies in ART-naïve individuals found that the proportion of individuals on tenofovir AF-containing versus tenofovir DF-containing regimens who experienced greater than 3% reduction in BMD was 26.7% versus 47.0% at the lumbar spine, and 16.3% versus 50.1% at the hip [44]. No differences in the incidence of fractures have been reported in these studies of relatively short duration, and no differences in BMD at the lumbar spine or hip have been reported in a trial that compared abacavir/lamivudine versus tenofovir AF/emtricitabine (each with bictegravir) up to 144 weeks [45]. Altogether, these data support the use of tenofovir AF/emtricitabine and abacavir/lamivudine in preference to tenofovir DF/emtricitabine as part of initial regimens for people living with HIV who have osteoporosis, severe osteopenia and/or high fracture risk.

Clinical trial data on the effects of PIs on BMD in treatment-naïve individuals are relatively sparse. A study comparing BMD at the spine and hip in individuals randomly assigned to efavirenz or atazanavir/ritonavir (each with abacavir/lamivudine or tenofovir DF/emtricitabine) reported significantly greater reductions in BMD at the spine ( $-0.8\%$  vs  $-2.0\%$  with abacavir/lamivudine;  $-2.5\%$  vs  $-4.4\%$  with tenofovir DF/emtricitabine), but not at the hip ( $-2.5\%$  vs  $-2.7\%$  with abacavir/lamivudine;  $-3.8\%$  vs  $-4.4\%$  with tenofovir DF/emtricitabine), with atazanavir/ritonavir [41]. When analysed together with two other ACTG studies, randomisation to ritonavir-boosted PIs resulted in a 0.8% greater reduction in total BMD [46]. Greater reductions in BMD at 96 weeks were reported for PIs (atazanavir/ritonavir or darunavir/ritonavir) versus raltegravir (each with tenofovir DF/emtricitabine):  $-3.8\%$  versus  $1.8\%$  at the lumbar spine and  $-3.7\%$  versus  $-2.4\%$  at the hip [47]. It is possible that increased tenofovir concentrations, as occur when tenofovir DF is co-administered with boosted PIs, may account for these differential effects on BMD. There are no data for boosted PIs versus unboosted third agents in regimens containing tenofovir AF/emtricitabine, and insufficient data to make firm recommendations regarding the third agent in terms of their effect on BMD.

## 8.2.2 Switching treatment

### Recommendation

- We recommend against continued use of tenofovir DF in individuals with osteoporosis, severe osteopenia ( $T < -2.0$ ), a history of fragility fracture, a 10-year probability of a major osteoporotic fracture  $>5\%$  and/or a 10-year probability of a hip fracture  $>1\%$  (Grade 1D).

### Rationale

Since the 2022 guidelines, we have amended the bone criteria for avoiding the use of tenofovir DF to permit more flexible clinical decision-making.

In randomised controlled clinical trials of individuals who were virologically suppressed on ART including older people with HIV, switching from a tenofovir DF-containing to a tenofovir AF-containing regimen resulted in improvements in BMD at the lumbar spine (1.5–2.2%) and the hip (1.3–1.9%) [48-51]. Similar results have been obtained with switches to abacavir [52], raltegravir [53], dolutegravir/rilpivirine [54] or darunavir/ritonavir monotherapy [55]. No changes in BMD at the lumbar spine and hip were observed in individuals switching from abacavir/lamivudine to tenofovir AF/emtricitabine [56]. In cohort studies, tenofovir DF has been associated with low BMD and bone loss [57-60], and a modest (8–13%) increased incidence of fracture in some studies [61,62] but not in others [63], and switching away from tenofovir DF has been associated with increases in BMD at the lumbar spine to levels approaching those in people without HIV, suggesting the potential for reversal of tenofovir DF-associated BMD reductions in people living with HIV [64].

Although cohort studies have also identified an association between exposure to PIs and reductions in BMD [57,60] and an improvement in spine BMD in individuals who discontinued PIs [65], there are no data from ART switch studies to suggest that PI discontinuation improves BMD, and no consistent association between PI use and fracture has been observed [61-63]. An association between PIs and avascular necrosis was reported in a meta-analysis of four case–control studies [66] but not confirmed in the EuroSIDA study [62].

## 8.3 Cardiovascular and metabolic disease

### 8.3.1 Cardiovascular considerations

#### Recommendations

In individuals with high CVD risk:

- We recommend avoiding lopinavir/ritonavir-based regimens (Grade 1C).
- If a boosted PI is the desired option, an atazanavir-based regimen may have advantages over a darunavir-based regimen (GPP).

## Rationale

CVD has been recognised for many years as a significant contributor to morbidity and mortality in people living with HIV. The prevalence of CVD is high in people living with HIV with the onset at a younger age than in the HIV-negative population. A recent meta-analysis which included over 700,000 people living with HIV estimated a relative risk of CVD of 2.16 in people living with HIV compared to those without HIV [67].

For the purposes of these guidelines, an elevated CVD risk is defined as: established atherosclerotic CVD; diabetes mellitus type 1 over the age of 40 years; an eGFR of <60 mL/min/1.73 m<sup>2</sup> and/or albuminuria; familial hypercholesterolaemia; and/or a high calculated CVD risk (>10% over 10 years) estimated in line with BHIVA monitoring guidelines [68,69].

In some studies, specific ARV agents have been associated with CVD. Current abacavir use has been associated with myocardial infarction risk in multiple observational studies [70], leading to our recommendation of alternative ARV options for individuals with established or risk factors for CVD. **Most recently, prior/current use of abacavir was associated with a 1.62-/1.41-fold increased risk of incident major adverse cardiovascular events in the REPRIEVE trial in participants with low-to-moderate estimated CVD risk [71].** Cumulative exposure to several of the PIs has been associated with increased risk of myocardial infarction, including more recently darunavir [72]. Such effects have not been observed to date with boosted or unboosted atazanavir [73-75]. Other cohorts have failed to show an association between darunavir exposure and CVD [76,77]. The RESPOND cohort demonstrated an increased risk of CVD in the first 24 months of INSTI exposure which decreased thereafter to levels similar to those observed among people never exposed to INSTI-based ART [78]. People at high CVD risk were more likely to start an INSTI; channelling bias and residual confounding could account for at least some of the observed difference. Of note, the effect was relatively short term and the study was not powered to investigate the impact of individual INSTI agents. At the time of writing, the mechanism for increased CVD risk on INSTI-based ART, if the association is real, is unclear. A US cohort did not show an association between CVD events and INSTI use, and indeed demonstrated that INSTIs were associated with a lower risk of CVD compared to non-INSTI-based ART [79]. There is insufficient evidence at present to recommend avoiding INSTIs in people with, or at high risk of, CVD. The NNRTIs efavirenz and nevirapine were not associated with myocardial infarction risk in a large cohort [80] but there are insufficient data to draw a similar conclusion for rilpivirine or doravirine.

While CVD concerns exist for specific ARV drugs and classes, these concerns are clearly outweighed by the enormously beneficial effects of ART and viral suppression on reducing the overall incidence of CVD, with studies reporting a substantial reduction in risk of myocardial infarction in those virally suppressed [81].

The previous advice to adjust estimated CVD risk by a factor of 1.6 for people living with HIV has been removed based on limited evidence. CVD risk assessment will be included in the next update of the BHIVA monitoring guidelines. It is important to acknowledge that standard tools, such as QRISK, may underestimate CVD risk for some populations, including people living with HIV, as acknowledged by the NICE guidelines for estimating CVD risk [68]. We suggest assessing individuals on a case-by-case basis, considering HIV-specific CVD risk tools, and that clinical judgement should be applied when interpreting risk assessment scores [68,82].

Since 2023, statins have been advised for all people living with HIV aged 40 years or older, regardless of CVD risk [83].

### 8.3.2 Lipid considerations

#### Recommendation

- We recommend that the adverse effects on lipid parameters should be considered when selecting ART (GPP).

#### Rationale

The following ARV drugs are associated with dyslipidaemia:

- Boosted PIs
- Efavirenz
- Elvitegravir/cobicistat

Tenofovir DF is associated with an improved lipid profile.

For many years, dyslipidaemia has been associated with both HIV disease and ART. Boosted PIs and the boosted INSTI elvitegravir affect serum lipid concentrations as does the NNRTI efavirenz [84].

Conversely, the NRTI tenofovir DF was associated with beneficial effects on overall lipid profiles in healthy volunteer studies [85], when used for PrEP [86] and compared to the NRTIs abacavir [87] and tenofovir AF [88] in randomised trials. Switch from tenofovir DF to tenofovir AF was associated with a slight deterioration in some lipid parameters in both randomised trials [89] and cohort studies [90-92] with preservation of total:HDL-cholesterol ratio. Lipid changes in the GS-1489 study were similar in the abacavir/lamivudine/dolutegravir and tenofovir AF/emtricitabine/bictegravir arms suggesting that tenofovir AF has a similar impact on lipids as abacavir [93]. There is insufficient evidence to suggest that overall CVD risk profile differs between tenofovir DF and tenofovir AF [94].

### 8.3.3 Weight gain considerations

#### Recommendation

- We recommend that the impact of weight gain should be considered when selecting ART (GPP).

#### Auditable outcome

- Proportion of individuals with a documented discussion on weight gain when selecting a new ART regimen.

#### Rationale

In recent studies, the following ARV drugs have been associated with greater weight gain compared to comparator agents:

- Tenofovir AF compared to tenofovir DF or abacavir
- INSTI-containing regimens compared to NNRTI- or boosted PI-based regimens

Recently, in ART-naïve individuals, the initiation of INSTI-containing ART has been associated with greater weight gain than with the initiation of NNRTI- or boosted-PI-containing regimens [95-97]. In a recent pooled analysis of eight randomised controlled trials of around 5000 people with HIV initiating ART, those commencing an INSTI-containing regimen were more likely to have experienced significant weight gain after 2 years with the greatest effects observed with bictegravir and dolutegravir [98]. A similar pooled analysis of 12 suppressed switch trials reported that moderate post-switch weight gain was frequently observed and associated with younger age and lower baseline BMI; switch from efavirenz or rilpivirine to elvitegravir/cobicistat and tenofovir DF to tenofovir AF were associated with greatest risk of weight gain and switch from abacavir to tenofovir AF was associated with less weight gain than switch from tenofovir DF [99].

Tenofovir AF has also been associated with greater weight gain when compared to tenofovir DF in first-line studies, most markedly in black women [95]. Additionally, switching from tenofovir DF to tenofovir AF was associated with a weight gain of approximately 2 kg at 1 year in two large cohorts [92,100] and a randomised trial [101]. This may, in part, be explained by the abrogation of weight loss observed on tenofovir DF, best demonstrated in PrEP trials [102], though this is non-progressive and typically less than 1 kg. Efavirenz has also been associated with relative weight loss which appears to be related to drug exposure [103]. Data from a randomised trial in pregnant women showed that weight gain was less than recommended in pregnancy but closest to normal for tenofovir AF/emtricitabine/dolutegravir compared to tenofovir DF/emtricitabine/dolutegravir and tenofovir DF/emtricitabine/efavirenz [95,104].

The mechanisms underlying this weight gain remain unclear and the clinical implications of ART-associated weight change are uncertain. People living with HIV should be advised that annual weight gain in the region of 0.5 kg is typical in the general population. People starting ART for the first time should be advised that they may experience additional early weight gain as part of their return to health. Among the combinations recommended for initial therapy in Section 5.1 there is insufficient evidence to recommend a particular strategy based on potential for weight gain.

There is no evidence at present to support switching ART to manage weight gain. The Do-IT trial recently demonstrated no significant difference in weight change among individuals on tenofovir AF/emtricitabine and a second-generation INSTI who continued the same regimen, switched to tenofovir AF/emtricitabine plus doravirine or switched to tenofovir DX/emtricitabine plus doravirine [105]. After an informed discussion with a healthcare professional, if an individual wishes to start or switch ART based on potential for weight change, this should be in the context of the relative wider advantages and disadvantages of the alternative versus commencing ART recommended for most people living with HIV.

Where individuals on ART are concerned about weight gain, they should be offered general lifestyle advice and signposting or referral to specialist services in line with local, regional and national guidelines. They should be advised that if a drug is associated with weight gain, stopping that drug may not result in weight loss.

## 8.4 Chronic kidney disease

### 8.4.1 What to start

#### Recommendations

- We recommend darunavir/ritonavir or darunavir/cobicistat in individuals with an eGFR of <60 mL/min/1.73 m<sup>2</sup> if a PI is required (Grade 1C).
- We recommend tenofovir AF in individuals with an eGFR of 30–60 mL/min/1.73 m<sup>2</sup> who require tenofovir (Grade 1B).

#### Auditable outcome

- Number/proportion of individuals with CKD (eGFR <60 mL/min/1.73 m<sup>2</sup> or protein/creatinine ratio >50 mg/mmol) who are maintained on ART regimens containing tenofovir DF, atazanavir or lopinavir, and a record of the rationale.

## Rationale

There are no data from randomised controlled trials to inform ART decisions in individuals with CKD. Observational data suggest that kidney function improves in those with impaired kidney function following initiation of ART [106,107]. Renal impairment and proteinuria are powerful predictors of kidney disease progression [108-110]. Therefore, ART with nephrotoxic potential (tenofovir DF [111-114], lopinavir/ritonavir [115] and atazanavir [115,116]) is best avoided in individuals with an eGFR of (or approaching)  $<60$  mL/min/1.73 m<sup>2</sup>, or moderate-to-severe proteinuria (urine protein-to-creatinine ratio  $>50$  mg/mmol or urine albumin-to-creatinine ratio  $>30$  mg/mmol).

The use of tenofovir DF and tenofovir AF (each co-administered with emtricitabine, elvitegravir and cobicistat) has been compared in two randomised controlled clinical trials of ART-naïve persons with eGFR  $>50$  mL/min/1.73 m<sup>2</sup>. At 3 years, there were significantly more renal discontinuations in the tenofovir DF arm (12 vs 0;  $P<0.001$ ) [117].

The relative safety of tenofovir AF has also been demonstrated in individuals with CKD (eGFR 30–70 mL/min/1.73 m<sup>2</sup>), with marked reductions in tubular proteinuria within days of switching from tenofovir DF to tenofovir AF, and stable eGFR over 96 weeks [118].

### 8.4.2 Need to switch

#### Recommendation

- We recommend against continued use of tenofovir DF, lopinavir/ritonavir or atazanavir in individuals with worsening renal function who have developed or are approaching an eGFR of  $<60$  mL/min/1.73 m<sup>2</sup> or who have developed moderate-to-severe proteinuria, if acceptable alternatives are available (Grade 1C).

#### Rationale

Tenofovir DF may cause renal tubular injury and proximal tubulopathy [114,119]. Tenofovir DF has been associated with eGFR decline, CKD and proteinuria in cohort studies [115,116,120], and discontinuation of tenofovir DF with improved kidney function [121,122]. Tenofovir AF has an improved renal safety profile, with stable eGFR patterns in those with renal impairment (eGFR 30–70 mL/min/1.73 m<sup>2</sup>) [118], reductions in (tubular) proteinuria [118,123] and a lower incidence of renal discontinuations and no reported cases of proximal tubulopathy in clinical trials [123]. Tenofovir AF had no effect on tubular biomarkers or BMD in a prospective study of individuals with a history of proximal tubulopathy on tenofovir DF, and no recurrent cases of proximal tubulopathy were observed over 96 weeks [124].

Atazanavir may cause kidney stones or tubulo-interstitial nephritis [113,125-128]. Atazanavir and lopinavir/ritonavir, but not darunavir, have been associated with CKD and eGFR decline in cohort studies [115,129,130], and switching from atazanavir or lopinavir/ritonavir to darunavir has been associated with improved renal function [131].

The optimal treatments for people with severe CKD (stage 4 CKD: eGFR 15–29 mL/min/1.73 m<sup>2</sup>) and end-stage kidney disease (ESKD; dialysis or transplantation) remain to be defined [132]. In individuals with stage 4 CKD, tenofovir AF (25 mg) results in 5- to 6-fold higher tenofovir exposures as compared to individuals with normal kidney function (similar to tenofovir exposures with tenofovir DF as part of unboosted regimens in people with normal kidney function) [133]. If tenofovir AF is required to suppress HIV and/or hepatitis B in people with severe CKD, an unboosted third agent together with tenofovir AF/emtricitabine (10/200 mg once daily) could be considered with careful monitoring for worsening kidney function and proximal tubulopathy, although there are no data to support such a strategy.

Transplantation is the preferred treatment modality for ESKD [134]. Hence, ART regimens for people with ESKD should be optimised for the post-transplant setting in which impaired renal function, eGFR decline, proteinuria, acute kidney injury and drug–drug interactions between ART and calcineurin inhibitors (tacrolimus and ciclosporin) are common [132]. Tenofovir AF/emtricitabine/elvitegravir/cobicistat (administered once daily; *n*=55) and tenofovir AF/emtricitabine/bictegravir (once daily; *n*=10) are the only ART regimens that have been formally studied in people on dialysis [135,136]. Although most participants maintained viral suppression on these regimens, tenofovir exposures were almost 30-fold and 2- to 4-fold higher than those achieved with tenofovir AF and tenofovir DF, respectively, in people with normal kidney function; the effects of these high exposures on residual kidney function and bone are unknown. For people on dialysis, we recommend the use of ART regimens that are optimised for use in kidney transplantation; such regimens should not include cobicistat or ritonavir, and tenofovir AF should be avoided unless individuals are hepatitis B surface antigen positive or require tenofovir to maintain viral suppression.

The advent of two-drug regimens such as dolutegravir/lamivudine and dolutegravir/rilpivirine has provided more options to manage HIV in the setting of renal impairment and/or moderate-to-severe proteinuria. However, experience with these regimens is still limited [137].

Of note, the renal prescribing advice for many ARVs is based on creatine clearance estimated by the Cockcroft–Gault equation. We advise following local guidelines when making decisions about ART prescribing.

### 8.4.3 Dose adjustment of ART in the setting of renal impairment

#### Recommendation

- We suggest that lamivudine and emtricitabine are dose adjusted in people with a confirmed eGFR of  $<30$  mL/min/1.73 m<sup>2</sup> (GPP).

#### Rationale

All currently licensed NRTIs (except abacavir) are renally cleared [138]. Hence, exposures of most NRTIs increase in renal impairment, and progressive dose reductions are recommended as renal function declines [139]. As HIV treatment guidelines evolved, dose reductions have remained relevant for a few ARVs, most notably emtricitabine, lamivudine and tenofovir. Full-dose (200 mg daily) emtricitabine has been studied in people with renal impairment (eGFR 30–70 mL/min/1.73 m<sup>2</sup>) and in people on dialysis; although plasma exposures were predictably elevated, no toxicity signal was detected [135,140]. The same is probably true for lamivudine: full-dose (300 mg daily) lamivudine appears to be safe in people with eGFR  $>30$  mL/min/1.73 m<sup>2</sup> [141,142], and 100–150 mg daily in those on haemodialysis [141]. These data provide support for continued use of fixed-dose, emtricitabine- or lamivudine-containing ART combinations in individuals with mild-to-moderate renal impairment. Clinicians need to avoid unnecessary dose reduction of emtricitabine or lamivudine where these agents are co-administered with dolutegravir or other agents that have major effects on tubular creatinine secretion (which leads to overestimation of the severity of renal impairment) [138]. As described above (see Section 8.2.2 Switching treatment), tenofovir DF should be avoided in people with eGFR  $<60$  mL/min/1.73 m<sup>2</sup> or rapid eGFR decline, and tenofovir AF should be avoided in those with eGFR  $<30$  mL/min/1.73 m<sup>2</sup>. Intermittent dosing is well established for tenofovir DF in those with eGFR  $<50$  mL/min/1.73 m<sup>2</sup> [139]; there are no data for intermittent dosing of tenofovir AF.

### 8.4.4 Assessment of renal function in the presence of agents that reduce creatinine clearance

#### Recommendations

- We suggest that repeat and additional measures of kidney function (eGFR and urine protein-to-creatinine ratio) are obtained if large reductions in eGFR are observed following the introduction of drugs that inhibit tubular creatinine secretion (GPP).
- We suggest that an alternative estimate of eGFR (e.g. based on cystatin C) is obtained in individuals in whom reductions in creatinine-based eGFR on drugs that inhibit tubular creatinine secretion may affect decisions about dose reduction or substitution of medications (GPP).

**Rationale**

Several ARV drugs, including dolutegravir, bictegravir, raltegravir, doravirine, rilpivirine, ritonavir and cobicistat, inhibit tubular secretion of creatinine, resulting in modest elevations of serum creatinine concentrations. These benign effects are mediated by inhibition of creatinine transporters on the apical or basolateral membrane of the tubular cells and are not accompanied by new-onset or worsening proteinuria, haematuria or glycosuria. Moreover, the inhibitory effects on creatinine secretion are fully established by 2–4 weeks, and reversible upon discontinuation of the relevant agent(s) [138]. The increase in serum creatinine concentrations affects eGFR or creatinine clearance; large reductions in eGFR may be observed in people with normal renal function [143]. If this benign effect of these ARV drugs is not recognised, tenofovir toxicity may be inadvertently diagnosed or renally cleared medications inadvertently dose reduced. Repeat and/or alternative measures of renal function (e.g. cystatin C and urinalysis) can help to distinguish benign effects of ART on creatinine secretion from renal injury [143].

## 8.5 Chronic liver disease

**Recommendation**

- People found to have non-alcoholic fatty liver disease (NAFLD) should be actively involved in the choice of ART to attempt to minimise the risks not only of progression of liver disease and CVD but also of weight gain and diabetes (GPP).

**Auditable outcome**

- Proportion of people with chronic liver disease for whom there is a documented discussion of the risks and benefits of continuing the current ART regimen.

**Rationale**

Chronic liver disease remains relatively common in people living with HIV. While co-infection with hepatitis B and C and related liver fibrosis remain challenges, progress in therapy of viral hepatitis means that alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) are increasingly important.

For patients being considered for hepatitis C virus therapy, drug–drug interactions need to be considered and there are some contraindicated combinations of hepatitis C and HIV therapy (particularly with PI-based hepatitis C therapy). Clinicians should consult specialist guidelines and refer to the dedicated pages of the Liverpool website [144].

Alterations to drug choice and dosing of ART regimens may be required in the setting of liver fibrosis. Dose adjustments are not usually required in those with mild fibrosis alone, but in the setting of cirrhosis, specific

guidelines [3] should be consulted. Evidence is limited for many settings and TDM may be helpful where there is clinical uncertainty.

In the setting of NAFLD, both an individual's liver health and their overall CVD risk profile and weight need to be considered when selecting ART. While some agents (e.g. INSTIs) are associated with more favourable lipid profiles and may be preferred in the setting of advanced liver disease, they may also be associated with weight gain that could impact liver health.

## 8.6 Cognitive impairment associated with HIV

### 8.6.1 Introduction

With the widespread use of effective combination ART, the incidence of severe HIV-associated cerebral disease has declined dramatically [145]; however, more subtle forms of brain disease, known as HIV-associated cognitive disorders, are reported to remain prevalent [146]. This cognitive deficit may present with a wide spectrum of clinical symptoms and typically includes patterns involving ineffective learning and difficulties in decision-making or executive function, rather than pure difficulties in formulating new memory (i.e. the cortical defect typical of Alzheimer's disease [147]).

Studies describing prevalence of HIV-associated cognitive impairment vary depending on definitions used and populations studied [148-150]. Cohorts including only aviraemic and symptomatic subjects suggest the prevalence of cognitive impairment to be between 6% and 19% [149,151-153]. Risk factors for the development of cognitive disorders are poorly understood and are likely to be multifactorial including both HIV disease-related factors [154,155] and concomitant non-HIV-related factors, particularly multimorbidity and polypharmacy associated with ageing [156-160]. Although it is possible that the choice of combination ART that subjects receive may influence cognitive function, this is a controversial area without definitive evidence. The following recommendations apply to individuals with symptomatic HIV-associated cognitive disorders.

### 8.6.2 When to start ART

#### Recommendation

- Along with the general recommendation to offer ART to all persons with HIV, we recommend that symptomatic HIV-associated cognitive disorders is considered a further indication to commence ART (Grade 1C).

## Rationale

Current evidence suggests that cognitive function improves after commencing ART for the first time [161] in both cognitively symptomatic [162] and asymptomatic [163] subjects. However, these studies have been undertaken in individuals with other indications to commence ART, in general with CD4 cell counts <350 cells/mm<sup>3</sup>. A neurology substudy of START did not demonstrate cognitive benefits in patients immediately commencing ART; however, potential benefits may have been confounded by the high rates of efavirenz-based ART [164]. Early ART after HIV acquisition may be associated with lower rates of cognitive impairment that are comparable to rates in HIV-negative populations [165,166]. For vulnerable individuals, the possible advantages to brain health of successful early HIV suppression must be balanced against ensuring ART adherence, a key determinant of long-term cognitive outcomes.

### 8.6.3 What to start

#### Recommendations

- We recommend that individuals with HIV-associated cognitive disorders start standard three-drug combination ART regimens (Grade 1C).
- We recommend avoiding efavirenz-containing regimens in individuals with HIV-associated cognitive disorders (Grade 1C).

#### Auditable outcome

- Proportion of individuals with HIV-associated cognitive disorders commencing an ART regimen recommended as initial treatment for most people living with HIV.

## Rationale

### 8.6.3.1 Including zidovudine in a regimen

During the earlier years of ART, clear benefits on cerebral function of individual ARV drugs such as high-dose zidovudine were reported [167] and the benefits of combination therapy overall described [161], however data are sparse regarding any differences in these benefits between individual agents or combinations. Within cohort studies, the use of NRTIs within ART regimens has been associated with a reduced risk of severe HIV-associated dementia [168] compared to the use of other regimens; however, the confounders of a cohort study limit the interpretation of these data. The improvements in cognitive function observed with zidovudine monotherapy [167] and the greater improvements in cognitive function observed with a zidovudine-containing quadruple NRTI regimen compared to other ART regimens [169] raise the possibility of selecting a zidovudine-containing regimen in subjects with cognitive impairment. Conversely, a lack of

comparator data for zidovudine monotherapy, and potential toxicities arising from zidovudine use, may limit the relevance of these data [170].

### **8.6.3.2 Clinical penetration effectiveness score**

Attempts have been made to establish a relationship between cognitive function and CNS ARV drug delivery based on an ARV scoring system known as the clinical penetration effectiveness (CPE) score [171]. The CPE score aims to rationally rank the cerebral effects of individual ARV agents. However, the system is predominantly based on pharmacokinetic modelling rather than pharmacodynamic endpoints such as data describing changes in cognitive function. Studies that have assessed the correlation between the CPE scores of ART regimens and cognitive function report conflicting findings with some cohorts showing a positive association [172,173] whereas other cohorts describe a negative association [174,175]. In a small prospective study, no differences in cognitive outcomes were observed in subjects randomly assigned to higher CPE score-containing ART regimens compared to standard therapies [152]. Given these factors, the CPE score should not influence therapeutic decisions in subjects with cognitive impairment commencing ART.

### **8.6.3.3 Neurotoxicities of ARVs**

Although early neuropsychiatric side effects are widely recognised and common with efavirenz-containing therapy, recent reports have highlighted concerns regarding poorer cognitive function being associated with efavirenz-containing regimens. In one cohort study, poorer cognitive function was found to be associated with current efavirenz use [176]. Two randomised controlled studies have assessed the cognitive effects of efavirenz [169,177]. In one small study, improvements in cognitive function were poorer in those allocated to efavirenz-containing therapy [169] and in a large study, the time to development of cognitive impairment was reduced in subjects allocated to efavirenz-containing therapy [177]. ARV switch studies have reported improvement in CNS symptomatology when modifying therapy to non-efavirenz-containing regimens [178,179]. We recommend avoiding efavirenz in individuals with baseline cognitive impairment or mental health issues or concerns, and switching individuals who develop symptoms while on efavirenz-containing regimens.

Post-licensing cohort studies of INSTIs have reported neuropsychiatric side effects in specific at-risk populations (such as older individuals or those with pre-existing mental health morbidity) which may have been missing from the original licensing trials [180]. Neurotoxicities associated with INSTIs are predominantly reported as insomnia and anxiety rather than cognitive impairment. At present, there are insufficient data to support avoiding INSTI-based regimens in individuals with symptomatic cognitive

disorders, particularly given the high efficacy and low pill burden of many modern regimens, however vigilance is advised.

#### **8.6.4 Simplification strategies**

##### **Recommendation**

- We recommend avoiding dual therapy regimens in individuals with HIV-associated cognitive disorders (Grade 1C).

##### **Rationale**

Novel ARV strategies, particularly dual therapy with INSTIs or PIs, continue to be of interest given the potential for reduced long-term toxicities. Concerns have been raised regarding the cerebral effects of both PI monotherapy [181] and dual therapies [182].

Such concerns are based on the hypothesis that novel strategies comprise only one or two effective ARV agents that may not adequately suppress ongoing HIV replication in sanctuary sites such as the CNS [171]. Isolated cases describing the evolution of CNS disease in previously stable people living with HIV receiving PI monotherapy have been reported [183]. In the PIVOT study, the largest study of PI monotherapy, no differences in parameters of cognitive function were noted over 5 years of follow-up in subjects randomly assigned to continue standard therapy versus commence PI monotherapy [184]. Similarly reassuring data were reported during shorter follow-up of PI dual therapy [185,186]. However, all PI monotherapy studies recruited low numbers of neurologically symptomatic subjects. Subsequent, large cross-sectional and prospective studies of aviraemic individuals found an association between HIV CSF escape and PI use [187,188]. However, the prevalence of CSF escape was low and did not correlate with cognitive function at the single timepoint of analysis [187].

In a retrospective cohort study of aviraemic individuals at high risk or with symptoms of cognitive impairment, no differences in CSF escape or cognitive function were identified between individuals receiving a range of dual therapy regimens compared to those receiving standard triple therapy [189]. However INSTI-containing regimens were predominantly used in the small and heterogenous dual therapy group.

There are few data describing efficacy and safety of modern dual regimens in the CNS. In one open-label study, virologically suppressed individuals switching to dolutegravir-based dual therapy experienced more neuropsychiatric adverse events leading to discontinuation compared to those receiving standard triple therapy [190]. In another open-label switch study, discontinuation rates were comparable between dolutegravir-based dual therapy and triple therapy arms despite higher rates of insomnia reported in the dual therapy group [191]. No cognitive adverse events were identified in the first 48 weeks of either study

and the populations studied were relatively young with a median age of less than 50 years. Randomised controlled clinical trials to study long-term safety and efficacy of simplified regimens in the CNS and other compartments in naïve and experienced patients are awaited.

Long-acting injectable therapies represent a particularly attractive treatment for those individuals at risk of or with established cognitive impairment by removing the daily pill burden. In the only available study of injectable therapy in virologically suppressed individuals, who also had no history of treatment failure, no significant neuropsychiatric or cognitive adverse events were reported in either injectable or oral therapy arms [192].

### **8.6.5 Continuing or worsening cognitive impairment despite ART**

#### **Recommendations**

Best practice management should include (GPP):

- Reassessment and management of confounding conditions.
- Assessment and genotyping of CSF HIV RNA.
- Modifications to ART based on paired plasma and CSF genotypic results in subjects with detectable CSF HIV RNA.

#### **Rationale**

Several randomised controlled studies, assessing both intensification of ART with new ARV agents [152,193] and with adjunctive therapies [194-197] have been published. Unfortunately, none of these studies describes improvements in cognition subsequent to the study interventions. In one small, randomised, open-label pilot trial of symptomatic patients, switching from a dolutegravir-containing to elvitegravir-containing regimen improved neuropsychiatric and cognitive outcomes [198]. However, there are insufficient data to recommend switching between INSTIs in individuals who develop cognitive symptoms while on INSTI-containing triple therapy regimens. No benefit on cognitive function have been observed in a study assessing ART intensification with maraviroc and/or dolutegravir (NCT02519777) [199]. Without evidence-based interventions, a best-practice approach based on the current literature is outlined. As HIV-associated cognitive disorders are diagnoses of exclusion, re-evaluation of subjects with ongoing cognitive impairment despite ART for confounding conditions is recommended, with expert input from other clinical specialties such as psychiatry, neurology and neuropsychology and where possible from an HIV neurology service. Given the presence of non-infectious comorbidities reported to be a risk factor for cognitive impairment [156], such conditions should be optimally managed.

Assessment of CSF HIV RNA and genotypic analysis of CSF RNA may be useful tools in the management of people with ongoing cognitive impairment for two reasons. First, data from cohorts of untreated people living with HIV would suggest that CSF HIV RNA levels are higher in those with HIV-associated dementia and cognitive decline [200-202] and therefore suppression of CSF HIV RNA may be beneficial for cognitive function. Secondly, in people with ongoing cognitive impairment, higher degrees of genetic diversity between HIV viral strains in the CSF and plasma compartment may exist [203], even in those with undetectable plasma HIV RNA [204,205]. Therefore, assessment for CSF HIV resistance is justified in order to tailor ART. Management should also involve consideration of any potential toxicities and side effects of ARV drugs. For instance, a trial of switching from an efavirenz-containing to an alternative regimen may be considered along with any potential disadvantages of treatment modifications as outlined above.

## 8.7 Later life and ageing with HIV

### 8.7.1 Introduction

People with HIV are not only living into older age but older people are also acquiring HIV as they maintain sexually active lifestyles. The proportion of people living with HIV in the UK aged  $\geq 50$  years has more than doubled in the last decade. In 2019, 43% of adults (aged  $>15$  years) seen for HIV care in the UK were aged  $\geq 50$  years, compared with 21% in 2010 [206]. Older people living with HIV are more likely to experience comorbidities and be receiving non-ARV medication. In addition, increased age may be associated with a higher prevalence of mental health issues, social isolation and financial challenges; HIV-treating clinicians should be mindful of these factors and familiar with appropriate sources of support.

### 8.7.2 When to start ART

#### Recommendation

- We recommend that standard criteria are used to determine when to commence ART in older people with HIV (Grade 1C).

#### Rationale

The following factors should be specifically considered.

##### 8.7.2.1 Rate of CD4 cell count decline

Older age has been found to be strongly associated with faster CD4 cell count declines [207-209]. An analysis from the COHERE dataset demonstrated that older age was significantly associated with higher viral load, which is in turn associated with CD4 cell count decline [210,211]. As such, older individuals with a high CD4

cell count may experience more rapid decline, therefore older age may be considered an additional factor when deciding how quickly to commence ART at high CD4 strata.

#### **8.7.2.2 Absolute risk of disease progression at a given CD4 cell count**

The absolute risk of disease progression is significantly higher for a given CD4 cell count in older people, which is an important factor to consider when counselling older individuals about starting ART.

#### **8.7.2.3 CD4 cell count recovery on commencing ART**

CD4 cell count recovery on commencing ART may be limited in the older person [210,212], possibly due to age-associated effects on thymic function or lower baseline CD4 cell count [210,213,214]. Some studies suggest that this is a short-term phenomenon attenuated with longer duration of ART [215] and others suggest that CD4 cell count recovery and virological suppression are not affected by age [216,217].

#### **8.7.2.4 Non-infectious comorbidities**

Individuals living with HIV may experience a higher rate of age-related conditions than the general population. While increased frailty has been observed in ART-naïve individuals, and ART may limit this accelerated ageing, long-term ART exposure may also contribute to certain phenotypes associated with comorbidities, including fat changes, atherosclerosis and sarcopenia [218].

### **8.7.3 What to start**

#### **Recommendation**

- We recommend that standard ART regimens are commenced in older people with HIV (Grade 1C).

#### **Auditable outcome**

- Proportion of older people with HIV commencing an ART regimen recommended as initial treatment for most people living with HIV.

#### **Rationale**

The factors below should be specifically considered when commencing therapy in older people living with HIV.

#### **8.7.3.1 Non-infectious comorbidities**

Non-infectious comorbidities are more prevalent in older individuals and are reported to occur more frequently and at a younger age in people with HIV compared to matched control populations [219]. The possibility of end-organ disease should be considered when tailoring ART for older individuals.

### 8.7.3.2 Concomitant medication

The use of concomitant medication, both over-the-counter preparations and prescription medication, is highly prevalent in older people living with HIV [220]. Consideration of drug–drug interactions with concomitant medications is required when commencing ART in older people with HIV.

### 8.7.3.3 Clinical pharmacology and ageing

All aspects of drug pharmacology, namely absorption, metabolism, distribution and elimination, are reported to change with age. Specifically, for the currently available ARV drugs, effects on hepatic metabolism and elimination may be relevant [221]. Regarding hepatic metabolism, CYP3A4 activity may wane with age and therefore, for drugs metabolised via this pathway, plasma exposure may increase with age. In pharmacokinetic studies, exposure of the boosted-PIs has been reported to increase with age [222], with these effects not reported with other classes such as the INSTIs [223]. Although theoretically this could lead to increased toxicity in older people living with HIV, this has not been reported in clinical practice. Regarding elimination, renal elimination of drugs reduces with increasing age. Pharmacokinetic studies have described increased exposure of tenofovir DF in older compared to younger people living with HIV, which was thought to be due to reduced renal clearance [224]. Again, there is a theoretical risk of increased toxicity as a result of higher drug exposure.

## 8.8 Mental health

### Recommendations

- We recommend that efavirenz-containing regimens should be avoided in individuals with a current or past history of depression, psychosis, suicidal ideation or attempted suicide, or at risk of self-harm (Grade 1C).
- We recommend that INSTI-containing regimens should be used with caution in patients with a pre-existing history of any psychiatric illness including depression (GPP).

### Rationale

The summary of product characteristics for efavirenz cautions that ‘patients with a prior history of psychiatric disorders appear to be at greater risk of serious psychiatric adverse reactions’ with a 2% risk of both severe depression and suicidal ideation [225]. In view of this warning, studies exploring efavirenz and risk of depression or suicide are inevitably subject to confounding by indication because individuals most at risk will not have been prescribed efavirenz or entered into randomised controlled trials where one of the arms included efavirenz.

A meta-analysis of four ACTG randomised controlled trials with efavirenz in one arm included 5000 people living with HIV [226]. 'Suicidality' was defined as suicidal ideation or attempted or completed suicide. The incidence of suicidality was 8/1000 PY with efavirenz versus 4/1000 PY without (HR 2.3;  $P=0.006$ ); rates of attempted or completed suicide were 3/1000 PY versus 1/1000 PY respectively (HR 2.6;  $P=0.065$ ) (eight suicides on efavirenz vs one on comparator regimens). In a secondary analysis of time to suicidal ideation, attempted or completed suicide, or death attributed to substance abuse, homicide or accident (to capture possible under-reporting of suicide) rates were 9/1000 PY and 5/1000 PY on efavirenz and comparator regimens respectively (HR 2.06;  $P=0.007$ ). Incidence of suicidality did not change during the period of follow-up indicating that risk could emerge at any time.

A small Spanish cohort study found no association between depression or suicide attempts and efavirenz but the overall event rate was unusually low and the proportion of those with depression prescribed efavirenz was half that in the main cohort suggesting significant confounding by indication (i.e. less use of efavirenz where there was a concern about mental health) [227]. No association was found in the D:A:D cohort study between efavirenz use and suicide as a reported cause of death, possibly for similar confounding reasons [228].

A retrospective analysis using data from the US FDA Adverse Event Reporting System (i.e. post-marketing surveillance data of spontaneous adverse event reports from people living with HIV and healthcare workers) explored the ratio of observed to expected numbers of suicidality events (O/E ratio) for a variety of drugs [229]. Such data are inevitably subject to reporting biases that make them difficult to interpret. The authors concluded that there was no association between efavirenz exposure and suicidality because the O/E ratio did not exceed the arbitrarily predefined threshold of 2, whereas it did for other drugs with a known suicide risk (e.g. fluoxetine). Nevertheless, the O/E ratio for efavirenz was significantly higher than for other ARVs, which is consistent with an increased risk for this drug.

Completed suicide ranks among the most adverse possible effects of any treatment. Unfortunately, depression is under-recognised by people living with HIV and poorly elicited by healthcare workers [230]. The above data support a precautionary stance of avoiding efavirenz in those with a current or past history of depression or suicidality.

Neuropsychiatric side effects, including insomnia, anxiety and worsening depressive symptoms, have been reported for all INSTIs, particularly in patients with pre-existing psychiatric illness [231]. However high-quality data directly comparing incidence of neuropsychiatric side effects between third agents in non-trial populations are lacking and definitions of side effects between studies are heterogenous. The summary of product characteristics for raltegravir states that raltegravir should be used with caution in individuals with a

pre-existing history of psychiatric illness [232]. We recommend caution when using all INSTIs in individuals with a history of psychiatric illness including depression. However, INSTIs have outperformed other classes of ARV agents in clinical trials from an efficacy perspective; they are associated with fewer drug interactions than some alternatives and are the recommended therapy for most individuals living with HIV. Therefore, at present, we do not recommend avoidance of this class. Rather, we recommend that this risk of effects on mood or suicidal behaviour should be carefully considered in those individuals most at risk with monitoring for neuropsychiatric side effects.

## 8.9 Transgender people

### Recommendations

- Transgender people living with HIV may be impacted disproportionately by some of the key considerations around ART choice (e.g. drug–drug interactions, mental health concerns, stigma, CVD and low BMD); holistic assessment is advised when selecting optimal ART (GPP).
- We recommend that clinics collect accurate data on gender identity so that data on the outcomes and experiences of transgender people living with HIV can be used to better tailor services (GPP).
- We recommend individualised interpretation of gender-influenced laboratory and other assessments that may impact ART choice (GPP).

### Auditable outcomes

- Percentage of people living with HIV who are transgender, non-binary or identify with a different gender than that given at birth who are on ART with an undetectable viral load.
- Percentage of people living with HIV who are transgender, non-binary or identify with a different gender than that given at birth who have documented hormone therapy (name, dose, frequency) and a drug interaction review (mainly but not only between hormones and ARVs).

### Rationale

Transgender is defined by the Office for National Statistics as an umbrella term for people whose gender identity is different from the sex assigned at birth [233]. Of note the Equality Act 2010 includes identifying as transgender as a protected characteristic [234].

It is important for HIV care providers to gain understanding and support the specific care needs of transgender people. Transgender populations are at higher risk of HIV acquisition [235] and are impacted disproportionately by factors that may impact adherence and drug toxicity, and therefore ART choice.

There are no robust data on the number of people in the UK who identify as transgender though the Government offers a ‘tentative estimate’ of 200,000 to 500,000 individuals [236]. Government data demonstrate lower quality of life scores among people in the lesbian, gay, bisexual and transgender (LGBT) community in general, and scores are particularly low for those who identify as transgender [237].

Importantly, HIV prevalence among transgender and gender-diverse people in England has been reported to be relatively low compared with international estimates [238]. However, estimates of undiagnosed HIV prevalence among transgender populations are high compared with cisgender populations and structural barriers may prevent transgender people from HIV testing [239].

Individual assessment of current and future health needs is of the utmost importance for transgender people. For example, understanding pregnancy plans, need for cervical screening and access to interventions such as human papilloma virus vaccination can help ensure transgender people receive optimal care.

### **8.9.1 Accessing care**

In England, between 2017 and 2020, 4–6% of individuals newly diagnosed with HIV were transgender or gender diverse people of whom more than 96% were initiated on ART [240].

Transgender people may experience numerous barriers to successful engagement with HIV care services [241,242].

A Stonewall survey revealed that 41% of transgender men and women had experienced a hate crime or incident because of their gender identity [236]. They also reported that 25% of transgender people had experienced homelessness at some point in their lives. A Government led national LGBT survey found similar results, with 67% of transgender respondents saying they had avoided being open about their gender identity for fear of a negative reaction from others [236].

Transgender people may avoid the healthcare system due to stigma and past negative experiences (e.g. being called the wrong name or pronoun, being verbally harassed, asked invasive questions about being transgender, or having to educate their providers about transgender people) [243].

We recommend ensuring that registration forms and electronic medical records are inclusive of transgender and gender non-binary identities (e.g. record both current gender identity and gender assigned at birth) (GPP):

- All people should be asked for their chosen name and pronouns, and these should be used consistently when speaking to or about the person, regardless of legal name.

- Training for staff and brochures, and other materials that meet the specific needs of transgender people living with HIV, should be available.

### **8.9.2 Peer support**

Peer navigation has been found to improve the likelihood of durable viral suppression among key populations, including among transgender women [244]. Research with youth and adults suggests that having visible transgender staff in the clinical environment also facilitates engagement in care.

### **8.9.3 ART outcomes**

For the reasons outlined above, transgender people may be particularly affected by adherence challenges.

Some studies have shown that transgender women living with HIV are less likely than cisgender men to receive ART, be adherent to ART, and achieve viral suppression [243,245].

### **8.9.4 Drug–drug interactions**

Gender-affirming hormone therapy (GAHT) may have drug–drug interactions with some ARVs. The University of Liverpool website has a specific prescribing resource on interactions with GAHT [246].

GAHT may be a greater priority than HIV treatment [247] and fear of drug–drug interactions between ART and GAHT is common among transgender people [247]. Ensuring that people taking GAHT, or planning to, are provided with clear, accurate information about any potential interactions with ART may help address these concerns. Clinicians should reassure patients taking or intending to take GAHT that ART can and will be tailored to avoid or manage interactions and that GAHT can be continued on ART.

### **8.9.5 CVD risk**

Elevated CVD risk in transgender individuals can be due to both traditional risk factors and to hormone use. Rates of tobacco use are higher among transgender people [248], and transgender women have a higher risk of venous thromboembolism and ischaemic stroke, associated with the use of oestrogens [249]. Oestrogens may cause an increase in triglycerides and high-density lipoprotein (HDL) levels and a decrease in low-density lipoprotein (LDL) levels, whereas exogenous testosterone was reported to increase levels of LDL and decrease levels of HDL [249].

Specific guidance for estimating CVD risk for transgender people is lacking and evidence is required. Clinicians should take CVD risk into consideration when selecting ART regimens and GAHT regimens.

Clinicians are advised to use the risk calculator for the sex at birth, affirmed gender, or an average of the two, considering the age at which the individual started using hormones, and the amount of time that a patient has been on GAHT [250].

### **8.9.6 Bone health**

Bone metabolism is influenced by sex hormones. Current recommendations for osteoporosis screening are based on age and sex and have not been studied in transgender populations, which include people who have used hormone therapy and/or undergone surgical gender affirmation.

Studies investigating BMD changes in transgender women have shown inconsistent results, with the use of oestrogens being associated with both increases and decreases in BMD [251]. The risk of osteoporosis increases after gonadectomy for both transgender men and transgender women, especially if GAHT regimens are stopped. Consequently, early DEXA screening in this setting should be considered.

When using the FRAX score, which requires a sex designation, expert consensus is that assigned birth sex should be used, because transgender people who initiate hormones in early adulthood have generally already achieved peak bone mass [252].

### **8.9.7 Renal function**

GAHT may affect eGFR that relies on serum creatinine due to changes in muscle mass. Creatinine-based eGFR calculations may therefore overestimate eGFR in transgender women on GAHT or underestimate eGFR in transgender men on GHAT. Cystatin C-based or isotopic eGFR calculations may be preferred, if available, for patients with marginal renal function.

There are conflicting data regarding use of identified gender versus sex at birth in eGFR calculators with some studies suggesting sex at birth yields more accurate results, other studies showing identified gender to be more accurate, and one study suggesting identified gender should be used where an individual has been on GAHT for at least 6 months [253]. In the absence of definitive research, we advise individualised assessment, careful monitoring of trends and urine markers of renal impairment, and conservative interpretation of results that might impact ART choice.

## 8.10 Women

### 8.10.1 Introduction

The following guidance considers issues concerning the initiation and choice of ART for women with HIV who are not currently pregnant **or planning to conceive**. For guidance on the management of pregnancy in women with HIV **and what to start in those planning to conceive**, please refer to the BHIVA guidelines on the management of HIV in pregnancy and the postpartum period [254]. Specific data on ART in women other than in pregnancy are limited. Available data are largely from meta-analyses or *post hoc* analyses or derived from cohort studies. Most of the randomised clinical trial data on ART are from studies that have enrolled mainly men. If randomised controlled trials do enrol women, the numbers are often too small to draw significant sex-based conclusions. Approximately one-third of people diagnosed with, and accessing care, for HIV in the UK are women [255]. The majority are of childbearing age but the age range is increasing, adding the complexity of menopause and its sequelae to the management of women with HIV. Many women with HIV in the UK are of African heritage and face overlapping challenges to their health and wellbeing [256]. Women's experience of HIV reflects multiple social and cultural influences, which when combined with sex-specific biological factors influence individual responses to HIV.

### 8.10.2 What to start

#### Recommendations

- There are insufficient data to support specific recommendations for non-pregnant women with HIV. We therefore recommend that therapy-naïve women with HIV start ART as per general guidelines (Grade 1A).
- We recommend that both women with HIV of childbearing potential and healthcare professionals who prescribe ART are familiar with the benefits and risks of ARV agents for the health of the woman as well as for **safety at conception and during pregnancy** (GPP).
- We recommend that potential pharmacokinetic interactions between ARV drugs, hormonal contraceptive agents and hormone-replacement therapy are considered before administration (GPP).

#### Rationale

##### 8.10.2.1 Efficacy

There are few data to guide prescribing of initial ART specifically for women as no randomised controlled trial in people living with HIV starting ART has been powered to detect sex-based differences in efficacy. From the limited data available, virological outcomes within clinical trial settings generally appear to be no

different between men and women. WAVES was a women-only randomised controlled trial that demonstrated superiority of tenofovir DF/emtricitabine/elvitegravir/cobicistat over tenofovir DF/emtricitabine plus atazanavir/ritonavir; this was driven predominantly by more adverse event discontinuations in the atazanavir arm [257]. Following on from this study, women in the tenofovir DF/emtricitabine plus atazanavir/ritonavir arm were further randomly assigned to receive either tenofovir AF/emtricitabine/elvitegravir/cobicistat or remain on their current regimen. Virological suppression was maintained in 94% of women who switched and 87% of women who remained on the tenofovir DF/emtricitabine/atazanavir/ritonavir arm (difference 7.5%, 95% CI -1.2% to 19.4%), thus showing non-inferiority in the tenofovir AF arm [258].

A meta-analysis of FDA registrational randomised controlled trials analysed data from 20,328 individuals with HIV participating in 40 trials investigating 16 ARV agents. Overall, 20% of study participants were women and there were no clinically or statistically significant differences in week 48 virological outcomes between men and women [259].

In a study comparing atazanavir/ritonavir and efavirenz in 1857 ART-naïve individuals of whom 17% were women, female sex was associated with increased virological failure on atazanavir/ritonavir compared with efavirenz [260]. No difference was seen with efavirenz between men and women. The efficacy and tolerability of raltegravir were similar in men and women at 48 weeks in one cohort of treatment-naïve and treatment-experienced individuals [261]. First-line rilpivirine-based ART showed no difference in rates of virological suppression at 48 and 96 weeks between men and women, but the number of women included was low and the study was not designed to investigate sex differences [262]. Cohort studies in the UK have reported similar virological outcomes during the first year of treatment in heterosexual men and women [263]. An Italian cohort study reported no significant effect of sex on clinical progression or the risk of developing a clinical event [264]. Data from Spain, which included both treatment-naïve and treatment-experienced women, showed similar virological responses compared to men [265].

#### **8.10.2.2 Toxicity, discontinuation and adherence**

Several studies have suggested that sex may influence the frequency, presentation and severity of selected ART-related adverse events. Although data are limited, there is evidence that the pharmacokinetic parameters of some ARV drugs may differ between men and women because of factors such as body weight, plasma volume, plasma protein levels, CYP450 activity and drug transporter function [266,267]. Adverse events and treatment discontinuations within ART clinical trials and cohort studies published between 2002 and 2007 have been systematically reviewed [268]. It was found that the overall event rate is often the same but the adverse event profile may be different. Women were reported to be more likely than men to experience ART-related lipodystrophy, rash and nausea, and to discontinue therapy [268]. Data from the

USA have shown that women are more likely than men to discontinue ART because of poor adherence, dermatological symptoms, neurological reasons, constitutional symptoms and concurrent medical conditions [267]. UK cohort data showed that 11.4% of men compared with 19.3% of women discontinued treatment in the first year of ART (adjusted relative hazard 0.72, 95% CI 0.63–0.83;  $P=0.0001$ ) [263]. CNS side effects of varying severity can occur with efavirenz, particularly at the initiation of therapy. This may be partly explained by the greater efavirenz exposure associated with a CYP2B6 variant, more commonly found in Africans and African Americans [269]. In the UK population, this is of particular relevance to women with HIV, the majority of whom are of African heritage.

Compared with men with HIV, women are more likely to experience an increase in central fat with ART [270]. A retrospective study of over 1000 women followed up in the Women's Interagency HIV study from 2006 to 2011 compared virologically suppressed women who switched to a regimen containing an INSTI compared to those who did not. Overall, 73% were overweight or obese but a significant increase in glycated haemoglobin ( $P\leq 0.0318$ ) and systolic ( $P\leq 0.0191$ ) and diastolic ( $P\leq 0.0121$ ) blood pressure were seen in those who switched to an INSTI-containing regimen [271]. The ADVANCE trial compared tenofovir AF/emtricitabine/dolutegravir with tenofovir DF/emtricitabine/dolutegravir and tenofovir DF/emtricitabine/efavirenz. Significantly more weight gain was seen in women compared with men and larger increases in weight in both men and women were seen in the dolutegravir combined with tenofovir AF arm [272].

Women have an increased risk of osteopenia/osteoporosis, especially after menopause, and this risk may be exacerbated by HIV and ART [273]. At present, these observed differences do not require women-specific recommendations. A systematic review of studies on sex and ART adherence published between 2000 and 2011 in resource-rich countries concluded that overall reported adherence is lower in women than men [274]. However, of over 1000 studies initially identified for review, only 44 had adequate data on sex to allow any comparisons to be made. The authors identified specific factors for lower adherence in women: depression, lack of supportive interpersonal relationships, young age, drug and alcohol use, black ethnicity, ART with six or more pills per day, higher numbers of children, self-perception of abdominal fat gain, sleep disturbances and increased levels of distress.

### **8.10.2.3 Fetal safety**

All women of childbearing potential should be offered reproductive health counselling including advice around conception, prevention of vertical transmission and contraception as a component of routine medical care. For guidance, refer to the BHIVA guidelines on the management of HIV in pregnancy and the postpartum period [254].

#### **8.10.2.4 Hormone interactions**

Significant pharmacokinetic and pharmacodynamic interactions have been reported between ARV drugs and hormonal agents and these should be taken into consideration when selecting an ART regimen for women using hormonal contraception and hormone-replacement therapy. We suggest prescribers refer to the summary of product characteristics for individual drugs or the University of Liverpool HIV drug interactions website [6], or seek specialist pharmacy advice within their unit/network.

#### **8.10.2.5 Menopause**

As the average age of the female population living with HIV increases, more women with HIV reach menopause. The menopause raises a number of issues for women with HIV including menopausal symptoms, drug interactions with hormone-replacement therapy and increased risk of comorbidities such as CVD and osteoporosis. Although data are limited, there is no evidence that menopause has a direct effect on ART efficacy. A subanalysis of responses to ART among a small number of treatment-naïve premenopausal and postmenopausal women in a US study found no significant differences in the immunological and virological responses between the two groups [275].

#### **8.10.3 Women living with HIV experiencing virological failure**

There is very little evidence to guide prescribing ART in women with HIV experiencing virological failure on ART, with women accounting for approximately 10% of those recruited in most studies. One study investigating darunavir/ritonavir in ART-experienced individuals recruited a large proportion of women and was powered to show a difference in virological efficacy between men and women; this study showed higher discontinuation rates among women than men, with nausea being cited as a particular problem, but overall there was no difference in virological efficacy [276]. A further study has reported similar efficacy and tolerability of raltegravir in ART-experienced women with HIV [261]. In women with HIV experiencing virological failure on ART, the same principles of management and recommendations apply as for men with HIV experiencing virological failure.

#### **8.10.4 Psychosocial issues**

Women living with HIV often experience additional vulnerability factors (psychological and social) that can affect access to and engagement with care as well as adherence and treatment outcomes. Such factors include HIV-related stigma, low socioeconomic status, culturally defined gender roles and high levels of intimate partner violence. There are higher levels of mental health problems, particularly depression and post-traumatic stress disorder, in women living with HIV compared with the general population, which can

also adversely affect outcomes. These issues need to be recognised and identified by healthcare professionals and effective interventions offered, in particular psychosocial and peer support.

## 8.11 References

1. World Health Organization. *Adolescent health*. 2021. Available at: [www.who.int/topics/adolescent\\_health/en/](http://www.who.int/topics/adolescent_health/en/) (accessed July 2021).
2. Children's HIV Association. *Enhancing the health and social wellbeing of children and young people living with HIV. Guidelines*. 2021. Available at: <https://www.chiva.org.uk/infoprofessionals/guidelines/> (accessed August 2021).
3. European AIDS Clinical Society. *Guidelines version 11.0*. October 2021. [https://www.eacsociety.org/media/final2021eacsguidelinesv11.0\\_oct2021.pdf](https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf) (accessed April 2022).
4. NHS England. *Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents*. 2017. Available at: <https://www.england.nhs.uk/wp-content/uploads/2017/03/f03-taf-policy.pdf> (accessed July 2021).
5. You're Welcome Pilot 2017. *Refreshed standards for piloting*. Available at: <https://www.healthylondon.org/wp-content/uploads/2018/07/Youre-Welcome-standards.pdf> (accessed October 2022).
6. University of Liverpool. *HIV Drug Interactions*. Available at: [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) (accessed April 2022).
7. Public Health England. *HIV annual data tables*. 2020. Available at: <https://www.gov.uk/government/statistics/hiv-annual-data-tables> (accessed July 2021).
8. Collins IJ, Foster C, Tostevin A *et al.*; on behalf of the Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Clinical status of adolescents with perinatal HIV at transfer to adult care in the UK/Ireland. *Clin Infect Dis* 2017; **64**: 1105–1112.
9. Chappell E, Lyall H, Riordan A *et al.*; on behalf of the Collaborative HIV Paediatric Study (CHIPS) Steering Committee. The cascade of care for children and adolescents with HIV in the UK and Ireland, 2010 to 2016. *J Int AIDS Soc* 2019; **22**: e25379.
10. Judd A, Collins IJ, Parrott F *et al.* Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. *J Int AIDS Soc* 2017; **20 Suppl 3**: 21577.
11. Collaborative HIV Paediatric Study (CHIPS). *Summary data to the end of March 2021*. 2021. Available at: <http://www.chipscohort.ac.uk/patients/summary-data/> (accessed July 2021).
12. Department of Health. *National service framework: children, young people and maternity services*. 2004. Available at: <https://www.gov.uk/government/publications/national-service-framework-children-young-people-and-maternity-services> (accessed August 2021).

13. National Institute of Health and Care Excellence. Transition from children's to adults' services for young people using health or social care services. NICE Guideline [NG43]. 2016. Available at: <https://www.nice.org.uk/guidance/ng43> (accessed July 2021).
14. Royal College of Paediatrics and Child Health. Transition to adult services. Available at: <https://www.rcpch.ac.uk/resources/transition-adult-services> (accessed July 2021).
15. Foster C, Fidler S. Optimising HIV transition services for young adults. *Curr Opin Infect Dis* 2018; **31**: 33–38.
16. Foster C. CHIVA Guidance on transition for adolescents living with HIV. 2021. Available at: [https://www.chiva.org.uk/files/6916/3541/0779/CHIVA\\_Transition\\_Guidelines\\_2021.pdf](https://www.chiva.org.uk/files/6916/3541/0779/CHIVA_Transition_Guidelines_2021.pdf) (accessed April 2022).
17. Lam PK, Fidler S, Foster C. Transition experiences in perinatally and behaviourally acquired HIV-1 infection; same, same but different? *J Int AIDS Soc* 2017; **20 Suppl 3**: 21506.
18. Kim S, Kim SH, McDonald S *et al.* Transition to adult services - a positive step. *AIDS Care* 2017; **29**: 885–889.
19. Willen EJ, Cuadra A, Arheart KL *et al.* Young adults perinatally infected with HIV perform more poorly on measures of executive functioning and motor speed than ethnically matched healthy controls. *AIDS Care* 2017; **29**: 387–393.
20. Hoare J, Heany SJ, Fouche JP *et al.* Initiation of antiretroviral therapy after the critical neuronal developmental period of the second postnatal year affects white matter microstructure in adolescents living with HIV. *J Neurovirol* 2019; **25**: 254–262.
21. Judd A, Le Prevost M, Melvin D *et al.*; Adolescents and Adults Living with Perinatal HIV (AALPHI) Steering Committee. Cognitive function in young persons with and without perinatal HIV in the AALPHI cohort in England: role of non-HIV related factors. *Clin Infect Dis* 2016; **63**: 1380–1387.
22. Nichols SL, Bethel J, Garvie PA *et al.* Neurocognitive functioning in antiretroviral therapy-naive youth with behaviorally acquired human immunodeficiency virus. *J Adolesc Health* 2013; **53**: 763–771.
23. Abrams EJ, Mellins CA, Bucek A *et al.* Behavioral health and adult milestones in young adults with perinatal HIV infection or exposure. *Pediatrics* 2018; **142**: e20180938.
24. Evangeli M. Mental health and substance use in HIV-infected adolescents. *Curr Opin HIV AIDS* 2018; **13**: 204–211.
25. Hall CDX, Morgan E, Bundy C *et al.* Substance use predicts sustained viral suppression in a community cohort of sexual and gender minority youth living with HIV. *AIDS Behav* 2021; **25**: 3303–3315.
26. Le Prevost M, Arenas-Pinto A, Melvin D *et al.*; Adolescents and Adults Living with Perinatal HIV (AALPHI) Steering Committee. Anxiety and depression symptoms in young people with perinatally acquired HIV and HIV affected young people in England. *AIDS Care* 2018; **30**: 1040–1049.
27. Copelyn J, Thompson LC, Le Prevost M *et al.*; Adolescents and Adults Living with Perinatal HIV (AALPHI) Steering Committee. Self-harm in young people with perinatal HIV and HIV negative young people in England: cross sectional analysis. *BMC Public Health* 2019; **19**: 1165.

28. Mallik I, Pasvol T, Frize G *et al.* Psychotic disorders in young adults with perinatally acquired HIV: a UK case series. *Psychol Med* 2022; **52**: 2263–2269.
29. Public Health England. *Trends in HIV testing, new diagnoses and people receiving HIV-related care in the United Kingdom: data to the end of December 2019*. 2020. Available at: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/959330/hpr2020\\_hiv19.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959330/hpr2020_hiv19.pdf) (accessed July 2021).
30. Asad H, Collins IJ, Goodall R *et al.*; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK. *HIV Med* 2021; **22**: 631–640.
31. Foster C, Ayers S, Mcdonald S *et al.* Clinical outcomes post transition to adult services in young adults with perinatally acquired HIV infection: mortality, retention in care and viral suppression. *AIDS* 2020; **34**: 261–266.
32. Judd A, Melvin D, Thompson LC *et al.* Factors associated with nonadherence to antiretroviral therapy among young people living with perinatally acquired HIV in England. *J Assoc Nurses AIDS Care* 2020; **31**: 574–586.
33. Foster C, Ayers S, Fidler S. Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness. *Ther Adv Infect Dis* 2020; **7**: 2049936120920177.
34. Chhabra S, Fidler S, Ayers S *et al.* Malignancy and all-cause mortality; incidence in adolescents and young adults living with perinatally acquired HIV. *J Virus Erad* 2020; **6**: 30–33.
35. Eades CP, Herbert SA, Edwards SG *et al.* High rate of lymphoma among a UK cohort of adolescents with vertically acquired HIV-1 infection transitioning to adult care in the era of antiretroviral therapy. *AIDS* 2016; **30**: 153–156.
36. Mulligan K, Harris DR, Emmanuel P *et al.*; ATN 021 Protocol team. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. *Clin Infect Dis* 2012; **55**: 461–468.
37. Jacobson D, Liu JZ, Lindsey JC *et al.* Immune markers and their association with bone density in children, adolescents, and young adults with perinatally acquired HIV. *AIDS Res Hum Retroviruses* 2021; **37**: 122–129.
38. Byrne L, Sconza R, Foster C *et al.* Pregnancy incidence and outcomes in women with perinatal HIV infection. *AIDS* 2017; **31**: 1745–1754.
39. Pasvol TJ, Teh J, Balfoussia D *et al.* Outcomes of fertility investigations in a cohort of adults with perinatally acquired HIV-1 infection: a UK cross-sectional observational study. *AIDS* 2021; **35**: 343–345.
40. Stellbrink HJ, Orkin C, Arribas JR *et al.* Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. *Clin Infect Dis* 2010; **51**: 963–972.
41. McComsey GA, Kitch D, Daar ES *et al.* Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with

efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. *J Infect Dis* 2011; **203**: 1791–1801.

42. Wohl D, Oka S, Clumeck N *et al*. Brief Report: A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. *J Acquir Immune Defic Syndr* 2016; **72**: 58–64.

43. Eron JJ, Orkin C, Gallant J *et al*. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. *AIDS* 2018; **32**: 1431–1442.

44. Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. *Medicine (Baltimore)* 2016; **95**: e5146.

45. Orkin C, DeJesus E, Sax PE *et al*. Fixed-dose combination bicitegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. *Lancet HIV* 2020; **7**: e389–e400.

46. Grant PM, Kitch D, McComsey GA *et al*. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. *Clin Infect Dis* 2013; **57**: 1483–1488.

47. Brown TT, Moser C, Currier JS *et al*. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. *J Infect Dis* 2015; **212**: 1241–1249.

48. Hagins D, Orkin C, Daar ES *et al*. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. *HIV Med* 2018; **19**: 724–733.

49. Orkin C, Molina JM, Negredo E *et al*. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. *Lancet HIV* 2018; **5**: e23–e34.

50. Raffi F, Orkin C, Clarke A *et al*. Brief Report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. *J Acquir Immune Defic Syndr* 2017; **75**: 226–231.

51. Maggiolo F, Rizzardini G, Raffi F *et al*. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. *Lancet HIV* 2019; **6**: e655–e666.

52. Ibrahim F, Samarawickrama A, Hamzah L *et al*. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG. *HIV Med* 2021; **22**: 83–91.

53. Bloch M, Tong WW, Hoy J *et al*. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. *HIV Med* 2014; **15**: 373–380.

54. McComsey GA, Lupo S, Parks D *et al.* Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. *AIDS* 2018; **32**: 477–485.
55. Hamzah L, Tiraboschi JM, Iveson H *et al.* Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS). *Antivir Ther* 2016; **21**: 287–296.
56. Winston A, Post FA, DeJesus E *et al.* Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. *Lancet HIV* 2018; **5**: e162–e171.
57. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. *J Acquir Immune Defic Syndr* 2008; **49**: 298–308.
58. Bonjoch A, Figueras M, Estany C *et al.* High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. *AIDS* 2010; **24**: 2827–2833.
59. Mary-Krause M, Viard JP, Ename-Mkoumazok B *et al.* Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. *J Clin Densitom* 2012; **15**: 422–433.
60. Yin MT, Zhang CA, McMahon DJ *et al.* Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. *J Clin Endocrinol Metab* 2012; **97**: 554–562.
61. Bedimo R, Maalouf NM, Zhang S *et al.* Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. *AIDS* 2012; **26**: 825–831.
62. Borges AH, Hoy J, Florence E *et al.* Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. *Clin Infect Dis* 2017; **64**: 1413–1421.
63. Costagliola D, Potard V, Lang S *et al.* Impact of antiretroviral drugs on fracture risk in HIV-infected individuals: a case-control study nested within the French Hospital Database on HIV (FHDH-ANRS CO4). *J Acquir Immune Defic Syndr* 2019; **80**: 214–223.
64. McGinty T, Tinago W, Landay A *et al.* Bone density in ART treated HIV+ and HIV– subjects in follow up; HIV UPBEAT results. *Conference on Retroviruses and Opportunistic Infections*. March 2020. Boston, MA, USA. Abstract 695.
65. Kinai E, Nishijima T, Mizushima D *et al.* Long-term use of protease inhibitors is associated with bone mineral density loss. *AIDS Res Hum Retroviruses* 2014; **30**: 553–559.
66. Permpalung N, Ungprasert P, Summachiwakij S *et al.* Protease inhibitors and avascular necrosis: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2014; **44**: 93–95.
67. Shah ASV, Stelzle D, Lee KK *et al.* Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. *Circulation* 2018; **138**: 1100–1112.

68. National Institute for Health and Care Excellence. *Cardiovascular disease: risk assessment and reduction, including lipid modification*. Clinical guideline [CG181]. 2014. Available at: <https://www.nice.org.uk/guidance/cg181> (accessed July 2021).
69. Angus B, Brook G, Awosusi F *et al*. BHIVA guidelines for the routine investigation and monitoring of adult HIV-1 positive individuals 2016 (2019 interim update). Available at: <https://www.bhiva.org/monitoring-guidelines> (accessed September 2022).
70. Sabin CA, Worm SW, Weber R *et al*. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet* 2008; **371**: 1417–1426.
71. Fichtenbaum CJ, Malvestutto CD, Watanabe MG *et al*.; REPRIEVE Investigators. Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. *Lancet HIV* 2025; **12**: e496–e505
72. Ryom L, Lundgren JD, El-Sadr W *et al*. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. *Lancet HIV* 2018; **5**: e291–e300.
73. Costagliola D, Potard V, Lang S *et al*. Is the risk of myocardial infarction in people with human immunodeficiency virus (HIV) associated with atazanavir or darunavir? A nested case-control study within the French Hospital Database on HIV. *J Infect Dis* 2020; **221**: 516–522.
74. LaFleur J, Bress AP, Rosenblatt L *et al*. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. *AIDS* 2017; **31**: 2095–2106.
75. Monforte A, Reiss P, Ryom L *et al*. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. *AIDS* 2013; **27**: 407–415.
76. Opsomer M, Dimitrova D, Verspeelt J *et al*. Evaluation of cardiovascular disease risk in HIV-1-infected patients treated with Darunavir. *Drugs R D* 2018; **18**: 199–210.
77. Antinori A, Rusconi S, Gianotti N *et al*. Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. *Drug Des Devel Ther* 2019; **13**: 1667–1685.
78. Neesgaard B, Greenberg L, Miró JM *et al*. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. *Lancet HIV* 2022; **9**: e474–e485.
79. O'Halloran JA, Sahrman J, Butler AM *et al*. Brief Report: Integrase strand transfer inhibitors are associated with lower risk of incident cardiovascular disease in people living with HIV. *J Acquir Immune Defic Syndr* 2020; **84**: 396–399.
80. Worm W, Sabin C, Weber R *et al*. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis* 2010; **201**: 318–330.
81. Freiberg MS, Chang CC, Kuller LH *et al*. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med* 2013; **173**: 614–622.

82. Healthcare Improvement Scotland. Risk estimation and the prevention of cardiovascular disease (SIGN 149). 2017. Available at: <https://www.sign.ac.uk/media/1085/sign149.pdf> (accessed May 2023).

83. Waters L, Gilleece Y, Alagaratnam J *et al*. BHIVA rapid guidance on the use of statins for primary prevention of cardiovascular disease in people living with HIV. Available at: <https://bhiva.org/wp-content/uploads/2024/10/BHIVA-rapid-guidance-on-the-use-of-statins.pdf> (accessed July 2025).

84. Nguyen A, Calmy A, Delhumeau C *et al*. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). *AIDS* 2011; **25**: 1481–1487.

85. Randell PA, Jackson AG, Zhong L *et al*. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. *Antivir Ther* 2010; **15**: 227–233.

86. Glidden DV, Mulligan K, McMahan V *et al*. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. *Clin Infect Dis* 2018; **67**: 411–419.

87. Sax PE, Tierney C, Collier AC *et al*. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *J Infect Dis* 2011; **204**: 1191–1201.

88. Sax PE, Wohl D, Yin MT *et al*. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet* 2015; **385**: 2606–2615.

89. Hagins D, Orkin C, Daar ES *et al*. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. *HIV Med* 2018; **19**: 724–733.

90. Lacey A, Savinelli S, Barco EA *et al*. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. *AIDS* 2020; **34**: 1161–1170.

91. Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. *AIDS* 2019; **33**: 2387–2391.

92. Surial B, Mugglin C, Calmy A *et al*. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. *Ann Intern Med* 2021; **174**: 758–767.

93. Gallant J, Lazzarin A, Mills A *et al*. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. *Lancet* 2017; **390**: 2063–2072.

94. Huhn GD, Shamblaw DJ, Baril JG *et al*. Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate. *Open Forum Infect Dis* 2020; **7**: ofz472.

95. Venter WDF, Moorhouse M, Sokhela S *et al*. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med* 2019; **381**: 803–815.

96. Bhagwat P, Ofotokun I, McComsey GA *et al*. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. *Open Forum Infect Dis* 2018; **5**: ofy201.

97. Bernardino JI, Mocroft A, Wallet C *et al.* Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: a substudy of the NEAT001/ANRS143 randomised trial. *PLoS One* 2019; **14**: e0209911.
98. Sax PE, Erlandson KM, Lake JE *et al.* Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. *Clin Infect Dis* 2020; **71**: 1379–1389.
99. Erlandson KM, Carter CC, Melbourne K *et al.* Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. *Clin Infect Dis* 2021; **73**: 1440–1451.
100. Mallon PW, Brunet L, Hsu RK *et al.* Weight gain before and after switch from TDF to TAF in a U.S. cohort study. *J Int AIDS Soc* 2021; **24**: e25702.
101. Acosta RK, Willkom M, Andreatta K *et al.* Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. *J Acquir Immune Defic Syndr* 2020; **85**: 363–371.
102. Mayer KH, Molina JM, Thompson MA *et al.* Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet* 2020; **396**: 239–254.
103. Griesel R, Maartens G, Chirehwa M *et al.* CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz. *Clin Infect Dis* 2021; **73**: e3902–e3909.
104. Caniglia EC, Shapiro R, Diseko M *et al.* Weight gain during pregnancy among women initiating dolutegravir in Botswana. *EClinicalMedicine* 2020; **29–30**: 100615.
105. Koethe J, Lake J, Kantor A *et al.* A5391: a randomized multicenter 3-arm controlled trial for people with obesity on integrase inhibitors and tenofovir alafenamide switching to doravirine, with or without tenofovir disoproxil fumarate (The DO-IT Trial). 13th International AIDS Society Conference on HIV Science, Kigali. July 2025. Abstract OAB0206LB.
106. Reid A, Stohr W, Walker AS *et al.* Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. *Clin Infect Dis* 2008; **46**: 1271–1281.
107. Kalayjian RC, Franceschini N, Gupta SK *et al.* Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. *AIDS* 2008; **22**: 481–487.
108. Ibrahim F, Hamzah L, Jones R *et al.* Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. *Am J Kidney Dis* 2012; **60**: 539–547.
109. Ryom L, Mocroft A, Kirk O *et al.* Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. *AIDS* 2014; **28**: 187–199.
110. Jotwani V, Li Y, Grunfeld C *et al.* Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. *Am J Kidney Dis* 2012; **59**: 628–635.

111. Woodward CL, Hall AM, Williams IG *et al.* Tenofovir associated renal and bone toxicity. *HIV Med* 2009; **10**: 482–487.
112. Zimmermann AE, Pizzoferrato T, Bedford J *et al.* Tenofovir associated acute and chronic kidney disease: a case of multiple drug interactions. *Clin Infect Dis* 2006; **42**: 283–290.
113. Schmid S, Opravil M, Moddel M *et al.* Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. *Virchows Arch* 2007; **450**: 665–670.
114. Hamzah L, Booth JW, Jose S *et al.* Renal tubular disease in the era of combination antiretroviral therapy. *AIDS* 2015; **29**: 1831–1836.
115. Mocroft A, Lundgren JD, Ross M *et al.* Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. *Lancet HIV* 2016; **3**: e23–32.
116. Scherzer R, Estrella M, Li Y *et al.* Association of tenofovir exposure with kidney disease risk in HIV infection. *AIDS* 2012; **26**: 867–875.
117. Arribas JR, Thompson M, Sax PE *et al.* Brief Report: Randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. *J Acquir Immune Defic Syndr* 2017; **75**: 211–218.
118. Post FA, Tebas P, Clarke A *et al.* Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. *J Acquir Immune Defic Syndr* 2017; **74**: 180–184.
119. Hamzah L, Jose S, Booth JW *et al.* Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. *J Infect* 2017; **74**: 492–500.
120. Kalayjian RC, Lau B, Mehekano RN *et al.* Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. *AIDS* 2012; **26**: 1907–1915.
121. Jose S, Hamzah L, Campbell LJ *et al.* Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. *J Infect Dis* 2014; **210**: 363–373.
122. Ibrahim F, Campbell L, Bailey AC *et al.* Estimated glomerular filtration rate slopes on tenofovir alafenamide. *HIV Med* 2020; **21**: 607–612.
123. Gupta SK, Post FA, Arribas JR *et al.* Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. *AIDS* 2019; **33**: 1455–1465.
124. Campbell L, Barbini B, Burling K *et al.* Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil fumarate. *J Acquir Immune Defic Syndr* 2021; **88**: 214–219.

125. Rockwood N, Mandalia S, Bower M *et al.* Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. *AIDS* 2011; **25**: 1671–1673.
126. Couzigou C, Daudon M, Meynard JL *et al.* Urolithiasis in HIV-positive patients treated with atazanavir. *Clin Infect Dis* 2007; **45**: e105–108.
127. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F *et al.* Complicated atazanavir-associated cholelithiasis: a report of 14 cases. *Clin Infect Dis* 2012; **55**: 1270–1272.
128. Hamada Y, Nishijima T, Watanabe K *et al.* High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. *Clin Infect Dis* 2012; **55**: 1262–1269.
129. Ryom L, Dilling Lundgren J, Reiss P *et al.*; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Use of contemporary protease inhibitors and risk of incident chronic kidney disease in persons with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *J Infect Dis* 2019; **220**: 1629–1634.
130. Kooij KW, Vogt L, Wit F *et al.* Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. *J Infect Dis* 2017; **216**: 622–631.
131. Jose S, Nelson M, Phillips A *et al.* Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. *AIDS* 2017; **31**: 485–492.
132. Hamzah L, Jones R, Post FA. Optimizing antiretroviral regimens in chronic kidney disease. *Curr Opin Infect Dis* 2019; **32**: 1–7.
133. Custodio JM, Fordyce M, Garner W *et al.* Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. *Antimicrob Agents Chemother* 2016; **60**: 5135–5140.
134. Gathogo E, Jose S, Jones R *et al.* End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study. *J Acquir Immune Defic Syndr* 2014; **67**: 177–180.
135. Eron JJ Jr, Lelievre JD, Kalayjian R *et al.* Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. *Lancet HIV* 2018; **6**: e15–e24.
136. Eron JJ, Wilkin A, Ramgopal M *et al.* 1002. A daily single tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically-suppressed adults living with HIV and end stage renal disease on chronic hemodialysis. *Open Forum Infect Dis* 2020; **7 Suppl 1**: S529–S530.
137. Casado JL, Monsalvo M, Vizcarra P *et al.* Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. *HIV Med* 2019; **20**: 648–656.
138. Yombi JC, Pozniak A, Boffito M *et al.* Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. *AIDS* 2014; **28**: 621–632.

139. Yombi JC, Jones R, Pozniak A *et al.* Monitoring of kidney function in HIV-positive patients. *HIV Med* 2015; **16**: 457–467.
140. Pozniak A, Arribas JR, Gathe J *et al.* Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. *J Acquir Immune Defic Syndr* 2016; **71**: 530–537.
141. Fischetti B, Shah K, Taft DR *et al.* Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. *Open Forum Infect Dis* 2018; **5**: ofy225.
142. Ross LL, Walker AS, Lou Y *et al.* Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs  $\geq 50$  mL/min. *PLoS One* 2019; **14**: e0225199.
143. Post FA, Hamzah L. Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all? *Antivir Ther* 2020; **25**: 241–243.
144. University of Liverpool. *HEP Drug Interactions*. Available at: [www.hep-druginteractions.org](http://www.hep-druginteractions.org) (accessed June 2022).
145. Dore GJ, Correll PK, Li Y *et al.* Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. *AIDS* 1999; **13**: 1249–1253.
146. Antinori A, Arendt G, Becker JT *et al.* Updated research nosology for HIV-associated neurocognitive disorders. *Neurology* 2007; **69**: 1789–1799.
147. Valcour V, Paul R, Chiao S *et al.* Screening for cognitive impairment in human immunodeficiency virus. *Clin Infect Dis* 2011; **53**: 836–842.
148. Heaton RK, Clifford DB, Franklin DR Jr *et al.* HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology* 2011; **75**: 2087–2096.
149. Underwood J, De Francesco D, James H Cole JH *et al.*; COMorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study Group. Validation of a novel multivariate method of defining HIV-associated cognitive impairment. *Open Forum Infect Dis* 2019; **6**: ofz198.
150. Wei J, Hou J, Su B *et al.* The prevalence of Frascati-criteria-based HIV-associated neurocognitive disorder (HAND) in HIV-infected adults: a systematic review and meta-analysis. *Front Neurol* 2020; **11**: 581346.
151. Simioni S, Cavassini M, Annoni JM *et al.* Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. *AIDS* 2010; **24**: 1243–1250.
152. Ellis RJ, Letendre S, Vaida F *et al.* Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. *Clin Infect Dis* 2014; **58**: 1015–1022.
153. Su T, Schouten J, Geurtsen GJ *et al.*: AGEHIV Cohort Study Group. Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection. *AIDS* 2015; **29**: 547–557.

154. Ellis RJ, Badiee J, Vaida F *et al.* CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *AIDS* 2011; **25**: 1747–1751.
155. Goodkin K, Miller EN, Cox C *et al.*; Multicenter AIDS Cohort Study. Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study. *Lancet HIV* 2017; **4**: e411–e422.
156. Wright EJ, Grund B, Robertson K *et al.* Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. *Neurology* 2011; **75**: 864–873.
157. Guaraldi G, Malagoli A, Calcagno A *et al.* The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. *BMC Geriatr* 2018; **18**: 99.
158. Rubin LH, Radtke KK, Eum S *et al.* Cognitive burden of common non-antiretroviral medications in HIV-infected women. *J Acquir Immune Defic Syndr* 2018; **79**: 83–91.
159. De Francesco D, Underwood J, Bagkeris E *et al.*; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study. Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls. *HIV Med* 2019; **20**: 274–285.
160. Hosaka KRJ, Greene M, Premeaux TA *et al.* Geriatric syndromes in older adults living with HIV and cognitive impairment. *J Am Geriatr Soc* 2019; **67**: 1913–1916.
161. Al-Khindi T, Zakzanis KK, van Gorp WG. Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature. *J Int Neuropsychol Soc* 2011; **17**: 956–969.
162. Cysique LA, Vaida F, Letendre S *et al.* Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. *Neurology* 2009; **73**: 342–348.
163. Winston A, Puls R, Kerr SJ *et al.* Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. *HIV Med* 2012; **13**: 245–251
163. Wright EJ, Grund B, Robertson KR *et al.*; INSIGHT START Neurology Substudy Group. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. *AIDS* 2018; **32**: 985–997.
165. Crum-Cianflone NF, Moore DJ, Letendre S *et al.* Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. *Neurology* 2013; **80**: 371–379.
166. Evering TH, Applebaum A, La Mar M *et al.* Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection. *AIDS* 2016; **30**: 203–210.
167. Schmitt FA, Bigley JW, McKinnis R *et al.* Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. *N Engl J Med* 1988; **319**: 1573–1578.
168. d'Arminio Monforte A, Cinque P, Mocroft A *et al.* Changing incidence of central nervous system diseases in the EuroSIDA cohort. *Ann Neurol* 2004; **55**: 320–328.

169. Winston A, Duncombe C, Li PC *et al.* Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. *Clin Infect Dis* 2010; **50**: 920–929.
170. Schweinsburg BC, Taylor MJ, Alhassoon OM *et al.* Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. *J Neurovirol* 2005; **11**: 356–364.
171. Letendre S, Marquie-Beck J, Capparelli E *et al.* Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. *Arch Neurol* 2008; **65**: 65–70.
172. Tozzi V, Balestra P, Salvatori MF *et al.* Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. *J Acquir Immune Defic Syndr* 2009; **52**: 56–63.
173. Smurzynski M, Wu K, Letendre S *et al.* Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. *AIDS* 2011; **25**: 357–365.
174. Marra CM, Zhao Y, Clifford DB *et al.* Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. *AIDS* 2009; **23**: 1359–1366.
175. Ashraf T, Robillard K, Chan GN, Bendayan R. Role of CNS transporters in the pharmacotherapy of HIV-1 associated neurological disorders. *Curr Pharm Des* 2014; **20**: 1543–1563.
176. Ciccarelli N, Fabbiani M, Di Giambenedetto S *et al.* Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. *Neurology* 2011; **76**: 1403–1409.
177. Zhang F, Mu W, Heaton R *et al.* Randomized clinical trial of antiretroviral therapy for prevention of HAND. *Conference on Retroviruses and Opportunistic Infections* February 2015. Seattle, WA, USA. Abstract 56.
178. Waters L, Fisher M, Winston A *et al.* A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. *AIDS* 2011; **25**: 65–71.
179. Mills AM, Cohen C, Dejesus E *et al.* Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. *HIV Clin Trials* 2013; **14**: 216–223.
180. Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. *Curr Opin HIV AIDS* 2018; **13**: 102–111.
181. Perez-Valero I, Bayon C, Cambron I *et al.* Protease inhibitor monotherapy and the CNS: peace of mind? *J Antimicrob Chemother* 2011; **66**: 1954–1962.
182. Mangioni D, Muscatello A, Sabbatini F *et al.* A case of CSF viral escape on dual antiretroviral regimen: worth the risk? *Clin Infect Dis* 2014; **59**: 1655–1656.

183. Katlama C, Valantin MA, Algarte-Genin M *et al.* Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. *AIDS* 2010; **24**: 2365–2374.
184. Paton NI, Stöhr W, Arenas-Pinto A *et al.*; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. *Lancet HIV* 2015; **2**: e417–e426.
185. Mondì A, Fabbiani M, Ciccarelli N *et al.* Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. *J Antimicrob Chemother* 2015; **70**: 1843–1849.
186. Pérez-Valero I, Pasquau J, Rubio R *et al.*; GESIDA 7011 Study Group members. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. *J Antimicrob Chemother* 2018; **73**: 2444–2451.
187. Pérez-Valero I, Ellis R, Heaton R *et al.* Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. *AIDS* 2019; **33**: 475–481.
188. Mukerji SS, Misra V, Lorenz DR *et al.* Impact of antiretroviral regimens on cerebrospinal fluid viral escape in a prospective multicohort study of antiretroviral therapy-experienced human immunodeficiency virus-1-infected adults in the United States. *Clin Infect Dis* 2018; **67**: 1182–1190.
189. Trunfio M, Ruggie W, Mighetto L *et al.* Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. *AIDS* 2020; **34**: 1899–1906.
190. van Wyk J, Ajana F, Bisshop F *et al.* Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. *Clin Infect Dis* 2020; **71**: 1920–1929.
191. Sculier D, Wandeler G, Yerly S *et al.*; Swiss HIV Cohort Study (SHCS). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. *PLoS Med* 2020; **17**: e1003421.
192. Swindells S, Andrade-Villanueva J-F, Richmond GJ *et al.* Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. *N Engl J Med* 2020; **382**: 1112–1123.
193. Brew BJ, Halman M, Catalan J *et al.* Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. *PLoS Clin Trials* 2007; **2**: e13.
194. Schifitto G, Navia BA, Yiannoutsos CT *et al.* Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. *AIDS* 2007; **21**: 1877–1886.
195. Schifitto G, Yiannoutsos CT, Ernst T *et al.* Selegiline and oxidative stress in HIV-associated cognitive impairment. *Neurology* 2009; **73**: 1975–1981.
196. Schifitto G, Zhong J, Gill D *et al.* Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. *J Neurovirol* 2009; **15**: 176–186.

197. Schifitto G, Peterson DR, Zhong J *et al.* Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. *Neurology* 2006; **66**: 919–921.
198. Perez Valero I, Cabello A, Ryan P *et al.* Randomized trial evaluating the neurotoxicity of dolutegravir/abacavir/lamivudine and its reversibility after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: GESIDA 9016. *Open Forum Infect Dis* 2020; **7**: ofaa482.
199. ClinicalTrials.gov. *Integrase and maraviroc intensification in neurocognitive dysfunction (InMIND)*. Available at: <https://clinicaltrials.gov/ct2/show/NCT02519777> (accessed July 2021).
200. Ho DD, Rota TR, Schooley RT *et al.* Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. *N Engl J Med* 1985; **313**: 1493–1497.
201. Sonnerborg AB, Ehrnst AC, Bergdahl SK *et al.* HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. *AIDS* 1988; **2**: 89–93.
202. Rawson T, Muir D, Mackie NE *et al.* Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. *J Infect* 2012; **65**: 239–245.
203. Soulie C, Fourati S, Lambert-Niclot S *et al.* HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. *AIDS* 2010; **24**: 2412–2414.
204. Canestri A, Lescure FX, Jaureguierry S *et al.* Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. *Clin Infect Dis* 2010; **50**: 773–778.
205. Grant I, Franklin DR Jr, Deutsch R *et al.* Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. *Neurology* 2014; **82**: 2055–2062.
206. Public Health England. *HIV annual data tables*. 2020. Available at: <https://www.gov.uk/government/statistics/hiv-annual-data-tables> (accessed July 2021).
207. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. *AIDS Res Ther* 2007; **4**: 11.
208. Touloumi G, Hatzakis A, Rosenberg PS *et al.* Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Multicenter Hemophilia Cohort Study. *AIDS* 1998; **12**: 1691–1697.
209. Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe in EuroCoord. Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. *AIDS* 2014; **28**: 1351–1356.
210. Grabar S, Kousignian I, Sobel A *et al.* Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. *AIDS* 2004; **18**: 2029–2038.

211. Sabin CA, Smith CJ, d'Arminio Monforte A, *et al.*; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Response to combination antiretroviral therapy: variation by age. *AIDS* 2008; **22**: 1463–1473.
212. Manfredi R, Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. *AIDS* 2000; **14**: 1475–1477.
213. Douek DC, McFarland RD, Keiser PH *et al.* Changes in thymic function with age and during the treatment of HIV infection. *Nature* 1998; **396**: 690–695.
214. Nogueras M, Navarro G, Anton E *et al.* Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. *BMC Infect Dis* 2006; **6**: 159.
215. Silverberg MJ, Leyden W, Horberg MA *et al.* Older age and the response to and tolerability of antiretroviral therapy. *Arch Intern Med* 2007; **167**: 684–691.
216. Tumbarello M, Rabagliati R, de Gaetano Donati K *et al.* Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. *BMC Infect Dis* 2004; **4**: 46.
217. Wellons MF, Sanders L, Edwards LJ *et al.* HIV infection: treatment outcomes in older and younger adults. *J Am Geriatr Soc* 2002; **50**: 603–607.
218. Guaraldi G, Prakash M, Moecklinghoff C, Stellbrink HJ. Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. *AIDS Rev* 2014; **16**: 75–89.
219. Schouten J, Wit FW, Stolte IG *et al.* Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEHIV cohort study. *Clin Infect Dis* 2014; **59**: 1787–1797.
220. Marzolini C, Back D, Weber R *et al.* Ageing with HIV: medication use and risk for potential drug-drug interactions. *J Antimicrob Chemother* 2011; **66**: 2107–2111.
221. Winston A, Underwood J. Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection. *Curr Opin Infect Dis* 2015; **28**: 17–22.
222. Winston A, Jose S, Gibbons S *et al.* Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. *J Antimicrob Chemother* 2013; **68**: 1354–1359.
223. Vera JH, Jackson A, Dickinson L *et al.* The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. *HIV Clin Trials* 2015; **16**: 39–42.
224. Baxi SM, Greenblatt RM, Bacchetti P *et al.* Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. *AIDS* 2014; **28**: 59–66.
225. Sustiva Summary of Product Characteristics. 2015. Available at: [www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000249/WC500058311.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000249/WC500058311.pdf) (accessed July 2021).

226. Mollan KR, Smurzynski M, Eron JJ *et al.* Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. *Ann Intern Med* 2014; **161**: 1–10.
227. Gutierrez F, Garcia L, Padilla S *et al.* Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. *HIV Med* 2014; **15**: 213–223.
228. Smith C, Ryom L, d'Arminio Monforte A *et al.* Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. *J Int AIDS Soc* 2014; **17 Suppl 3**: 19512.
229. Napoli AA, Wood JJ, Coumbis JJ *et al.* No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. *J Int AIDS Soc* 2014; **17**: 19214.
230. National Institute for Health and Care Excellence. *Depression in adults: recognition and management*. Clinical guideline [CG90]. 2009. Available at: <https://www.nice.org.uk/guidance/cg90> (accessed July 2021).
231. Cuzin L, Pugliese P, Katlama C *et al.*; Dat' AIDS Study Group. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. *J Antimicrob Chemother* 2019; **74**: 754–760.
232. Isentress Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/8436/smpc> (accessed June 2022).
233. Office for National Statistics. What is the difference between sex and gender? Available at: <https://www.ons.gov.uk/economy/environmentalaccounts/articles/whatisdifferencetwensexandgender/2019-02-21#:~:text=Transgender,-Transgender%20or%20trans&text=%E2%80%9CA%20person%20has%20the%20protected,or%20other%20at%20tributes%20of%20sex.%E2%80%9D> (accessed April 2022).
234. The National Archives. *Equality Act 2010*. Available at: <https://www.legislation.gov.uk/ukpga/2010/15/contents> (accessed April 2022)
235. Becasen JS, Denard CL, Mullins MM *et al.* Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. *Am J Public Health* 2019; **109**: e1–e8.
236. Government Equalities Office. *Trans people in the UK*. Available at: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/721642/GEO-LGBT-factsheet.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/721642/GEO-LGBT-factsheet.pdf) (accessed April 2022).
237. Government Equalities Office. *National LGBT survey 2018*. Available at: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/722314/GEO-LGBT-Survey-Report.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/722314/GEO-LGBT-Survey-Report.pdf) (accessed April 2022).
238. Kirwan P, Hibbert M, Kall M *et al.* HIV prevalence and HIV clinical outcomes of transgender and gender-diverse people in England. *HIV Med* 2021; **22**: 131–139.
239. Baral SD, Poteat T, Stromdahl S *et al.* Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; **13**: 214–222.

240. UK Health Security Agency. *Key populations HIV data tables*. No. 2: 2021. Available at: <https://www.gov.uk/government/statistics/hiv-annual-data-tables> (accessed June 2022).
241. Poteat T, Hanna DB, Rebeiro PF *et al*. Characterizing the HIV care continuum among transgender women and cisgender women and men in clinical care: a retrospective time-series analysis. *Clin Infect Dis* 2020; **70**: 1131–1138.
242. Kalichman SC, Hernandez D, Finneran S *et al*. Transgender women and HIV-related health disparities: falling off the HIV treatment cascade. *Sex Health* 2017; **14**: 469–476.
243. Poteat T, German D, Kerrigan D. Managing uncertainty: a grounded theory of stigma in transgender health care encounters. *Soc Sci Med* 2013; **84** :22–29.
244. Cunningham WE, Weiss RE, Nakazono T *et al*. Effectiveness of a peer navigation intervention to sustain viral suppression among HIV-positive men and transgender women released from jail: the LINK LA randomized clinical trial. *JAMA Intern Med* 2018; **178**: 542–553.
245. Beckwith CG, Kuo I, Fredericksen RJ *et al*. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: data from the Seek, Test, Treat, and Retain Harmonization Initiative. *PLoS One* 2018; **13**: e0197730.
246. University of Liverpool. *HIV Drug Interactions*. Available at: [www.hiv-druginteractions.org/prescribing\\_resources/hiv-guidance-gender](http://www.hiv-druginteractions.org/prescribing_resources/hiv-guidance-gender) (accessed October 2022).
247. Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. *Ann Behav Med* 2014; **47**: 5–16.
248. Buchting FO, Emory KT, Scout *et al*. Transgender use of cigarettes, cigars, and e-cigarettes in a national study. *Am J Prev Med* 2017; **53**: e1–e7.
249. Connelly PJ, Marie Freel E, Perry C *et al*. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. *Hypertension* 2019; **74**: 1266–1274.
250. University of California, San Francisco. *Transgender care. Cardiovascular disease*. Available at: <https://transcare.ucsf.edu/guidelines/cardiovascular> (accessed June 2022).
251. Figuera TM, Ziegelmann PK, Rasia da Silva T, Spritzer PM. Bone mass effects of cross-sex hormone therapy in transgender people: updated systematic review and meta-analysis. *J Endocr Soc* 2019; **3**: 943–964.
252. University of California, San Francisco. *Transgender care. Bone health and osteoporosis*. Available at: <https://transcare.ucsf.edu/guidelines/bone-health-and-osteoporosis> (accessed June 2022).
253. Jue JS, Mikhail D, González J, Alameddine M. Assessment of renal function in transgender patients with kidney disease. *Can J Kidney Health Dis* 2021; **8**: 20543581211020168.
254. Byrne L, Short C-E, Bamford A *et al*. BHIVA guidelines on the management of HIV in pregnancy and the postpartum period 2025. Available at: <https://bhiva.org/clinical-guideline/pregnancy-guidelines/> (accessed July 2025).

255. Public Health England. *HIV in the United Kingdom: Towards zero HIV transmissions by 2030*. 2019. Available at: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/858559/HIV\\_in\\_the\\_UK\\_2019\\_towards\\_zero\\_HIV\\_transmissions\\_by\\_2030.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/858559/HIV_in_the_UK_2019_towards_zero_HIV_transmissions_by_2030.pdf) (accessed July 2021).
256. Doyal L. Challenges in researching life with HIV/AIDS: an intersectional analysis of black African migrants in London. *Cult Health Sex* 2009; **11**: 173–188.
257. Squires K, Kityo C, Hodder S *et al*. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. *Lancet HIV* 2016; **3**: e410–e420.
258. Hodder S, Squires K, Kityo C *et al*. Efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women. *J Acquir Immune Defic Syndr* 2018; **78**: 209–213.
259. Soon GG, Min M, Struble KA *et al*. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008). *AIDS Patient Care STDS* 2012; **26**: 444–453.
260. Smith KY, Tierney C, Mollan K *et al*. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. *Clin Infect Dis* 2014; **58**: 555–563.
261. Squires KE, Bekker LG, Eron JJ *et al*. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. *AIDS Res Hum Retroviruses* 2013; **29**: 859–870.
262. Cohen CJ, Molina JM, Cassetti I *et al*.; ECHO, THRIVE study groups. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. *AIDS* 2013; **27**: 939–950.
263. Barber TJ, Geretti AM, Anderson J *et al*. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. *Antivir Ther* 2011; **16**: 805–814.
264. Murri R, Lepri AC, Phillips AN *et al*. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. *J Acquir Immune Defic Syndr* 2003; **34**: 184–190.
265. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. *AIDS* 2007; **21**: 835–843.
266. Kempf MC, Pisu M, Dumcheva A *et al*. Gender differences in discontinuation of antiretroviral treatment regimens. *J Acquir Immune Defic Syndr* 2009; **52**: 336–341.
267. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. *Genit Med* 2007; **4**: 106–119.
268. Nicastrì E, Leone S, Angeletti C *et al*. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. *J Antimicrob Chemother* 2007; **60**: 724–732.

269. Haas DW, Ribaud HJ, Kim RB *et al.* Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. *AIDS* 2004; **18**: 2391–2400.
270. Galli M, Veglia F, Angarano G *et al.* Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. *J Acquir Immune Defic Syndr* 2003; **34**: 58–61.
271. Summers NA, Lahiri CD, Angert CD *et al.* Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. *J Acquir Immune Defic Syndr* 2020; **85**: 355–362.
272. Venter W, Sokhela S, Simmons B *et al.* Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV* 2020, **7**: e666–e676.
273. Brown TT, Qaqish RB. Response to Berg *et al.* 'Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review'. *AIDS* 2007; **21**: 1830–1831.
274. Puskas CM, Forrest JI, Parashar S *et al.* Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. *Curr HIV/AIDS Rep* 2011; **8**: 277–287.
275. Patterson KB, Cohn SE, Uyanik J *et al.* Treatment responses in antiretroviral treatment-naïve premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. *Clin Infect Dis* 2009; **49**: 473–476.
276. Currier J, Averitt Bridge D, Hagins D *et al.* Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. *Ann Intern Med* 2010; **153**: 349–357.

## 9 Acknowledgements

The writing group thanks Prof Esteban Martinez, Hospital Clínic & University of Barcelona, Spain, and Dr Mark O'Reilly, Prahran Market Clinic, Victoria, Australia, for peer review of the guidelines. Particular thanks to Dr Catherine Nieman Sims for her tireless patience and hard work as BHIVA guidelines coordinator.

## 10 List of abbreviations

|        |   |
|--------|---|
| ALT    | Alanine transaminase                                |
| APOBEC | Apolipoprotein B mRNA editing catalytic polypeptide |
| APR    | Antiretroviral Pregnancy Registry                   |
| ART    | Antiretroviral therapy                              |
| ARV    | Antiretroviral                                      |
| BaHIV  | Behaviourally acquired HIV                          |
| BASHH  | British Association for Sexual Health and HIV       |
| BHIVA  | British HIV Association                             |
| BMD    | Bone mineral density                                |
| BMI    | Body mass index                                     |
| CHARS  | Children’s HIV and AIDS Reporting System            |
| CHIPS  | Collaborative HIV Paediatric Study                  |
| CHIVA  | Children’s HIV Association                          |
| CI     | Confidence interval                                 |
| CKD    | Chronic kidney disease                              |
| CNS    | Central nervous system                              |
| CPE    | clinical penetration effectiveness                  |
| CSF    | Cerebrospinal fluid                                 |
| CVD    | Cardiovascular disease                              |
| CYP    | Cytochrome P45                                      |
| DEXA   | Dual-energy X-ray absorptiometry                    |
| DHHS   | Department of Health and Human Services             |
| EACS   | European AIDS Clinical Society                      |
| eGFR   | Estimated glomerular filtration rate                |
| Env    | HIV envelope  |
| ESKD   | End-stage kidney disease                            |
| GAHT   | Gender-affirming hormone therapy                    |

|           |   |
|-----------|---|
| GP        | General practitioner  |
| GPP       | Good practice point   |
| GRADE     | Grading of Recommendations Assessment, Development and Evaluation |
| HDL       | High-density lipoprotein  |
| HIV       | Human immunodeficiency virus                                      |
| HR        | Hazard ratio  |
| HTLV      | T-cell lymphotropic virus   |
| INSTI     | Integrase inhibitor   |
| IQR       | Interquartile range   |
| ISOSS     | Integrated Screening Outcomes Surveillance Service                |
| LDL       | Low-density lipoprotein   |
| LGBT      | Lesbian, gay, bisexual and transgender                            |
| MSM       | Men who have sex with men   |
| NAFLD     | Non-alcoholic fatty liver disease                                 |
| NICE      | National Institute for Health and Care Excellence                 |
| NNRTI     | Non-nucleoside reverse transcriptase inhibitor                    |
| NRTI      | Nucleoside reverse transcriptase inhibitor                        |
| O/E ratio | Ratio of observed to expected numbers of suicidality events       |
| OR        | Odds ratio  |
| PaHIV     | Perinatally acquired HIV  |
| PHE       | Public Health England   |
| PHI       | Primary HIV infection   |
| PI        | Protease inhibitor  |
| PrEP      | Pre-exposure prophylaxis  |
| PY        | Patient-years   |
| RAM       | Resistance-associated mutation                                    |
| SIGN      | Scottish Intercollegiate Guidelines Network                       |
| TAM       | Thymidine analogue mutation                                       |
| TB        | Tuberculosis  |

|              |                               |
|--------------|-------------------------------|
| TDR          | Transmitted drug resistance   |
| Tenofovir AF | Tenofovir alafenamide         |
| Tenofovir DF | Tenofovir disoproxil fumarate |
| Tenofovir DX | Tenofovir disoproxil          |
| UK-CAB       | UK Community Advisory Board   |
| U=U          | Undetectable=untransmittable  |
| WHO          | World Health Organization     |

## 11 List of appendices

The appendices can be found on the BHIVA website ([www.bhiva.org/HIV-1-treatment-guidelines](http://www.bhiva.org/HIV-1-treatment-guidelines)):

Appendix 1 Summary of the modified GRADE system

Appendix 2 PICO questions and search strategies

Appendix 3 Grade tables